SOUTH-SOUTH TRADE PROMOTION PROGRAMME …s3.amazonaws.com/zanran_storage/ · SOUTH-SOUTH TRADE PROMOTION PROGRAMME INDIA ... presented in a report according to the broad outline given

SOUTH-SOUTH TRADE PROMOTION PROGRAMME

INDIA

SUPPLY AND DEMAND SURVEY ON PHARMACEUTICALS AND NATURAL PRODUCTS

June 2004

India Trade Promotion Organization (ITPO) Pragati Bhawan Pragati Maidan New Dehli - India Tel: 9111-337 1540 Fax: 9111-331 8142

Supply and demand survey on pharmaceuticals and natural products - India

- ii -

The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the International Trade Centre (ITC) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. While every effort has been made to verify the information contained in this document, ITC cannot accept any responsibility for any errors that it may contain.

This report has not been formally edited by the International Trade Centre (ITC).


- iii -

Table of content

Page Notes iv I. INTRODUCTION 1 A. Background 1 B. Products coverage 1 II. INDIAN DRUGS AND PHARMACEUTICAL INDUSTRY: AN

OVERVIEW 23

A. Highlights of the industry 23 B. Indian healthcare sector 25 III. PRODUCTION 27 IV. RESEARCH AND DEVELOPMENT 29 V. DOMESTIC MARKET 34 VI. EXPORTS 40 VII. IMPORTS 44 VIII. DRUGS POLICIES AND LAWS 46 IX. MARKET PROSPECT 56


- iv -

Page List of tables 1. A brief 252. Production of bulk drugs of selected companies in the organized sector 273. Prodution of bulk drugs (specific items) 284. R&D expenditure 295. Financial performance of top 10 Indian pharma companies 346. Top 10 therapeutic groups in India in 2000 357. Exports of drugs and pharmaceuticals from India 408. Top 15 countries of exports of drugs and pharmaceuticals from India 429. Imports of bulk drugs and formulations for the last few years 4410. Annual drug expenditure per capita in US$ in various countries 5711. Leading pharma markets 6212. Top 10 pharma companies in the world 63 Annexes I. Production of bulk drugs (specific items) of selected companies in the

organized sector 67

II. Company/product profile forms 71III. Statistics from the Department of Commerce 177


- v -

NOTES The following abbreviations are used: CDRI Central Drug Research Institute

DPCO Drugs Price Control Order

DPEA Drug Price Equalisation Account

EMRs Exclusive Marketing Rights

GATT General Agreement on Tariffs and Trade

GMP Good Manufacturing Practices

IDPL Indian Drugs & Pharmaceuticals Ltd

ITC International Trade Centre

ITPO India Trade Promotion Organization

NDDS Novel Drug Delivery Systems

NPPA National Pharmaceuticals Pricing Authority

NPM Net Profit Margin

OPM Operating Profit Margin

PC Packing Charge

PL Process Loss

R&D Research & Development

SIL Special Import Licence

WHO World Health Organization

WTO World Trade Organization


- 1 -

I. INTRODUCTION

A. Background The Indian Pharmaceutical industry, which is considered to be a highly knowledge based industry has moved through several phases, largely inline with the Government Policy. It has commendable past, commencing with repacking and preparation of formulations from imported bulk drugs. From a mere processing industry, India’s pharmaceutical industry is today highly sophisticated possessing advanced manufacturing technology, modern equipment and stringent quality control. It has shown tremendous progress in terms of infrastructure development, technology base and wide range of production. From being a major importer of bulk drugs and formulations, the Indian pharmaceutical industry has today become a net exporter of pharmaceutical products. The International Trade Centre (ITC) is organizing “AsiaHealthCare 2004” - a buyers/sellers meeting on pharmaceuticals and natural products (14-16 July 2004) in Singapore. The product sectors include active ingredients and starting materials, formulations, biotech and natural products. In preparation of the meeting, it was decided to carry out a supply and demand survey in India in order to capture the import requirements on the one hand and the export capacities on the other. The India Trade Promotion Organisation (ITPO) has been designated as the national cooperating institution for carrying out the supply and demand study for drugs and pharmaceutical industry in India. Accordingly, a study was undertaken on a subcontract basis by the focal institution in India. The study identified specific products of drugs and pharmaceuticals having potential in the participating countries and involved preparation of detailed company and product profiles for dissemination among prospective importers. The study aims at identifying specific products of drugs and pharmaceuticals having potential in specific markets and providing comprehensive information on market opportunities for the participating countries. The findings have been presented in a report according to the broad outline given by ITC.

B. Products coverage The study covers all the major products under drugs and pharmaceuticals as given below: Sl.NO. HS code Commodity

1. 30011001 *PANCREATIN & DRIED PWDR OF PANCREAS

2. 30011009 *OTHR GLNDS/ORGNS DRIED W/N PWDRD

3. 30012001 *LIQUID EXTRACTS OF LIVER

4. 30012002 *LIVER EXTRACTS DRY

5. 30012003 *HEPARIN

6. 30012004 *SNAKE VENOM


- 2 -

Sl.NO. HS code Commodity

7. 30012009 *OTHR EXTRACTS OF GLANDS OR OTHR ORGANS OR OF THEIR SECRETIONS

8. 30019000 *HEPARIN SLTS OTHR HUMAN/ANML SUBSTNS FBR THRUPTC/PROPHYLACTIC USE NES

9. 30021001 *BLOOD PLASMA

10. 30021002 *DIPTHERIA ANTISERA

11. 30021003 *TETANUS ANTISERA

12. 30021005 *SNAKE VENOM ANTISERA

13. 30021006 *HUMAN GAMMA GLOBULIN

14. 30021007 *AGLUTINATING OR BLOOD SERA OF COW-CALF ETC

15. 30021009 *ANTI BACTERIAL SERUMS & ANTI SERUM NES

16. 30022001 *VACCINES FOR CHOLERA

17. 30022002 *VACCINES FR DPTHRA(DPTHRA TXD-FT,APT ETC

18. 30022003 *VACCINES FOR POLIO

19. 30022004 *MIXED VACCINES FR T.A.B. OR T.A.B.C.

20. 30022005 *VCCNS FR TTNS(TTNS TXD-FT,APT,PTAH ETC)

21. 30022006 *VACCINES FOR TUBERCULINS(B.C.G.)

22. 30022008 *MIXED VACCINES FOR DPT-TRIPLE ANTI GEN

23. 30022011 VACCINES FOR CHOLERA AND TYPHOID

24. 30022012 VACCINES FOR HEPATITIS

25. 30022013 VCCNS FOR TETANUS

26. 30022014 VACCINES FOR POLIO

27. 30022015 VACCINES FOR TUBERCULINS(B.C.G.)

28. 30022016 ANTI RABIES VACCINE

29. 30022019 OTHER SINGLE VACCINE

30. 30023000 VACCINES FOR VETERINARY MADICINE

31. 30029001 *TOXINS

32. 30029002 *MICROBIAL CULTURES

33. 30029009 *OTHER BACTERIOLOGICAL PRODUCTS

34. 30029019 *OTHR CULTURES OF MICROORGANISMS ETC

35. 30031000 MDCMNTS CNTNG PNCLNS/THR DRVTVS WITH A/PNCLNC ACD STRCTRE,STRPTMCNS/THR DRVTS

36. 30032000 MEDICAMENTS CONT. OTHER ANTI-BIOTICS

37. 30032005 *AMIKACIN


- 3 -


38. 30032019 *OTHERS ANTIBIOTICS (OTHER THAN HEADING NO. 300310 )

39. 30033100 MEDICAMENTS CONTAINING INSULIN

40. 30033900 OTHER MEDICAMENTS CONTAINING HORMONES OR OTHER PRODUCT OF HDNG 2937 EXCL ANTIBIOTIC

41. 30034000 MDCMNTS CONT. ALKLDS/THR DRVTVS BUT NOT/ HORMNS/OTHR PRDTCS OF HDNG NO. 29.37/ANTBT

42. 30039001 *AYURVEDIC & UNANI MEDICINES

43. 30039002 *HOMOEOPATHIC MEDICINE

44. 30039014 MEDICANTS OF HOMOEOPATHIC SYSTEM

45. 30039027 *GRIPE WATER

46. 30039033 CALCIUM SENNOSIDE

47. 30039034 ANAESTHETIC AGENTS USED IN HUMAN OR VETERINARY MEDICINE OR SURGERY

48. 30039038 *MENTHOL CRYSTAL

49. 30039043 *MLK OF MAGNESIA

50. 30039074 *BOVINE ALBUMIN AND DRUGS OF ANIMAL ORIGIN

51. 30039078 *MEDICINAL CASTOR OIL B.P.

52. 30039081 *MERBROMIN N.F.12(MERCUROCHROME)

53. 30039082 *CALCIUM SENNOSIDE

54. 30039084 *ALUMINIUM HYDROXIDE GEL

55. 30039085 *LIGNOCAINE /LIDICAINE

56. 30039087 *OTHER ANAESTHETIC AGENTS LIKE KETAMINE, HALOTHINE,THIOPENTANE

57. 30039088 *ISAFGUL HUSK AND PHYLLIUN HUSK PREPN.

58. 30039091 *CETRIMIDE (SAVLON)

59. 30039092 *CHLOROXYLENOLS (DETTOL)

60. 30039099 *OTHER MEDICAMENTS NOT PUT UP IN MEASURED DOSES OR IN PACKING

61. 30041001 *STRPTMYCN & ITS SLTS IN CPSLS INJCTNS ETC

62. 30041002 *PENICILLIN IN CAPSULES, INJECTIONS ETC.

63. 30041003 *AMPICILLINE IN CAPSULES, INJECTIONS ETC.

64. 30041004 *AMOXYCYLLIN IN CAPSULES, INJECTIONS ETC.

65. 30041005 *CLOXACILLIN IN CAPSULES, INJECTIONS ETC.

66. 30041006 *AMCLOS IN CAPSULES INJECTIONS ETC.

67. 30041007 *AMPICILLIN WITH SULBACTUM FORMULATIONS


- 4 -


68. 30041008 *AMOXYCILLIN WITH CLAVULANIC ACID & PROBENICID PREPNS.

69. 30041011 *BECAMPICILLIN

70. 30041013 *PEFLOXACIN

71. 30041014 *OFLOXACIN

72. 30041015 *LOMEFLOXACIN

73. 30041016 *ENROFLOXACIN

74. 30041017 *GEMFIBROZIL

75. 30041019 *OTHERS

76. 30042001 *CHLORMPHENICOL CAPSULES, INJECTIONS ETC.

77. 30042002 *TETRACYLINE IN CAPSULES, INJECTIONS, OINTMENTS ETC.

78. 30042003 *ERYTHROMYCIN IN CAPSULES,INJECTIONS, OINTMENTS ETC.

79. 30042005 *OTHER FORMULATIONS CONTAINING TETRACYCLIN DERIVATIVES (EG. OXYTETRACYCLINE,MINOCY- CLINE) IN CAPSULES,INJECTIONS,OINMENT ETC.

80. 30042007 *RIFMPICINE - FORMULATIONS, IN CSPSULES ETC

81. 30042008 *CEPHALEXIN - FORMULATIONS THEREOF, IN CAPSULES ETC.

82. 30042011 CEFAZOLIN

83. 30042012 CEPHALEXIN - FORMULATIONS THEREOF, IN CAPSULES ETC.

84. 30042013 CIPROFLOXACINE- IN CAPSUL,TBLTS FORM ETC

85. 30042014 CEFOXITIN

86. 30042017 *KANAMYCIN AND ITS SALTS

87. 30042018 *CEFACLOR AND ITS SALTS

88. 30042021 *CEFUROXIME AND ITS SALTS

89. 30042022 *CEFTAZIDIME AND ITS SALTS

90. 30042023 *CEFTIZOXIME AND ITS SALTS

91. 30042024 *CEFIXIME AND ITS SALTS

92. 30042026 *AMIKACIN AND ITS SALTS

93. 30042027 *NEOMYCIN AND ITS SALTS

94. 30042028 *POLYMIXIN !B! AND ITS SALTS

95. 30042031 NORFLOXACIN

96. 30042032 NALIDIXIC ACID


- 5 -


97. 30042033 CIPROFLOXACIN (FLUOROQUINOLONES)

98. 30042034 OFLOXACIN

99. 30042039 OTHER FLUOROQUINOLONES

100. 30043103 *INSULIN (HUMAN) INJECTION

101. 30043104 *INSULIN (BOVINE/PORK) INJECTION

102. 30043109 *INSULIN IN OTHER FORMS

103. 30043200 MEDICAMENTS CONTAINING CORTICOSTEROID HORMONES, THEIR DERVATIVE&STRUCTURAL ANALG

104. 30043901 *FORMULTNS FOR PITUITRY HORMNS INJCTNS ETC PUT UP FOR RETAIL SALE

105. 30043902 *PREDNISOLONE TABLETS,INJECTIONS ETC.

106. 30043903 *DXAMTASNE TBLTS ETC INCL EYE/EAR DROPS ETC

107. 30043904 *DANAZOL TABLETS, INJECTIONS ETC.

108. 30043905 *OTHER PROGESTOGENS & OESTOGEN N.E.S. (PROGESTERONE MEDROXY PROGESTERONE SALTS)

109. 30043906 *GONADOTROPHINS-HUMAN FOLLICLE STIMULATING HRMNS & LUTE/NS/NG HRMNS FRMLNS IN PWDR

110. 30043907 *CREAM,DROPS ETC FOR LOCAL ACTION ON EYE/ EAR NOSE & ORPHARYNX CONTNG STEROIDS SUCH/AS BETAMETHASONE HYDROCORTISOME ETC.

111. 30043911 PITUITARY HORMONES

112. 30043912 PREDNISOLONE

113. 30043913 DEXAMETHASONE

114. 30043915 *STANOZOLOL-FORMULATIONS THEREOF IN TABLETS ETC.

115. 30043917 *ETHINYLOESTRADIOL-FORMULATIONS THEREOF IN TABLETS ETC.

116. 30043918 *LYNESTRENOL - FORMULATIONS THEREOF IN TABLETS, INJECTIONS ETC.

117. 30043922 LUTEINISING HORMONE

118. 30043924 *CLOBETASOLE-FORMULATIONS THEREOF

119. 30043925 *FLUCINOLONE-FORMULATIONS THEREOF IN TABLETS, INJECTIONS ETC.

120. 30043926 *TRIAMCINOLONE - FORMULATIONS THEREOF IN TABLETS, INJECTIONS ETC.

121. 30043927 *CLOSTEBOL - FORMULATIONS THEREOF IN TABLETS, CAPSULES ETC.

122. 30043928 *FLUTICASONE - FORMULATIONS THEREOF IN TABLETS, CAPSULES ETC.


- 6 -


123. 30043933 *OXYTOCIN-FORMULATIONS THEREOF

124. 30043934 *CHLORPROPAMIDE- FORMULATIONS THEREOF

125. 30043935 *TOLBUTAMIDE - FORMULATIONS THEREOF

126. 30043936 *PHENFORMIN; METFORMIN -FORMULATIONS THEREOF

127. 30043939 *OTHER HORMONES FORMULASTIONS

128. 30044001 *FORMULATIONS OF ATROPIN SULPHATE,ATROPIN METHONITRATE ETC.IN TABLETS,EYE DROPS, OINTMENS ETC.

129. 30044002 *FORMULATIONS OF CAFFEIN & ITS SALTS

130. 30044005 *FORMULATIONS OF EPHEDRINE & PSEUDOEPHEDRINE IN TABLETS, EXPECTORANT PREPN.

131. 30044007 *FORMULATIONS OF ERGOTPREPARATA, ERGOTAMINE & METHYL ERGOMETRINE IN TABLETS,INJECTIONS ETC.(E.G.METHYL ERGOMET

132. 30044013 *FORMULATIONS OF PAPAVERINE HYDROCHLORIDE

133. 30044015 *FORMULATIONS OF RESERPINE & OTHER RAUWOL FIA ALKALOIDS IN TABLETS ETC.

134. 30044017 *FORMULATIONS OF BROMOHEXIN WITH DEXTROMETHORPHAN, PHENYL PROPANALOMINE, DYPHENHYDRAMINE IN EXPECTORANT PREPN.

135. 30044018 *THEOPHYLLINE, AMINO PHYLLINE & ETOPHYLLINEFORMULATIONS LIKE TABLETS,SYRUP ETC.

136. 30044019 *FRMLTNS OF OTHR VGTBL ALKLDS & ITS DRVTVS

137. 30044021 *ISOPRENALINE-FORMULATIONS THEREOF IN TABLETS, INJECTION ETC.

138. 30044022 *TRIPOLINE-FORMULATIONS THEREOF

139. 30044023 *PHENIRAMINE MALEATE (AVIL) - FORMULATIONS THEREOF IN TABLETS, OINTMENTS ETC.

140. 30044024 *TERBUTALINE - FORMULATIONS THEREOF IN INJECTIONS ETC.

141. 30044025 *LORATADINE -FORMULATIONS THEREOF

142. 30044026 *CETIRAZINE-FORMULATIONS THEREOF

143. 30044027 *TERFENADINE-FORMULATIONS THEREOF

144. 30044028 *ASTEMIZOLE-FORMULATIONS THEREOF

145. 30044031 *TIMOLOL MALEATE-FORMULATIONS THEREOF

146. 30044033 *ACETAZOLAMIDE -FORMULASTIONS THEREOF

147. 30044039 *OTHERS


- 7 -


148. 30045001 *APPETITE STIMULANTS BASED ON CIPROHEPTADINE, AMINO ACIDS ETC.

149. 30045002 *IRN PRPRTNS OF FRRS FUMRT/FRS SLFT/FRC AMNM/CTRT/FRS GLUCNT HIMGLBN OTHR IRN COMPOUNDS

150. 30045003 *MINERAL & PARENTERAL NUTRITIONAL SPPLMNTS/CONTNG CALSIUM SLTS WTH VTMN IN TABLTS ETC

151. 30045004 *TABLETS, CAPSULES, SYRUP ETC OF VITAMIN A INCLD) EXCEPT SALVES OINIMNTS & VACCINES

152. 30045005 *TABLETS, CAPSULES ETC OF VITAMIN "B" GROUP

153. 30045006 *VITAMIN "C" IN TABLETS, SYRUP ETC SALVES OINTMENTS & VACCINES

154. 30045007 *VITAMIN 'D' IN TABLETS, CAPSULES, SYRUP ET

155. 30045008 *MULTIVITAMINS CONTAINING VITAMIN A, B-GR. C,D OR NY TWO OF THESE IN TABS, CAPS, INJECTIBLES, ETC

156. 30045012 *VITAMIN E IN CAPS.TABS, SYRUP ETC

157. 30045013 *OTHER AMINO ACID/ PROTEIN PREPN. WITH / WITHOUT VITAMINS, SPIRULINA & THE LIKE.

158. 30045014 *TONICS, BASED ON VITAMINS GLYCEROPHOS PHATES, GINSENG PREPN.

159. 30045016 *FOLIC ACID AND NIACINAMIDE (VITAMIN"B9") IN TABLETS AND OTHER FORMULATIONS WITH /WITHOUT OTHER ADDITIVES.

160. 30045017 *HEPATO BILARY PREPARATIONS LIKE - L ASPERTATE.

161. 30045019 *OTHERS PUT UP FOR RETAIL SALE

162. 30049001 *AYURVEDIC & UNANI MEDCNS

163. 30049002 *HOMEOPATHIC MEDICINE

164. 30049003 *ANLGN (NVLGN BRLGN) IN TBLTS SYRP INJECTN ETC WTH/WTHOUT OTHR CMPND LIKE PARACETAMOLE.E.G.PRCTML

165. 30049004 *ACTYL SLCYLC ACD (ASPRN) IN TBLTS & OTHR FORMULATIONS OF ASPRIN

166. 30049005 *PARACETAMOL PANDOL ETC IN TBLTS SYRUP ETC

167. 30049006 *OTHER ANALGESICS,ANTIPYRETIES, (NAPROXEN, MEFANAMIC ACID ETC.) IN TABLETSSYRUP,CAPSULES , INJECTIONS ETC.

168. 30049007 *IBUPROFEN WTH/WTHOUT OTHR CMPND IN TABS ETC

169. 30049008 *OXYPHN/PHENYL BUTAZON IN TBS, CPSLS ETC


- 8 -


170. 30049011 MEDICAMENTS OF AYURVEDIC SYSTEM

171. 30049012 MEDICAMENTS OF UNANI SYSTEM

172. 30049013 MEDICAMENTS OF SIDDHA SYSTEM

173. 30049014 HOMEOPATHIC MEDICINE

174. 30049015 MEDICAMENTS OF BIO-CHEMIC SYSTEM

175. 30049016 *TRIMETHOPRIM - FRMLTNS THROF IN TBLTS ETC

176. 30049017 *SULPHAMETHOXAZOLE & TRIMETHOPRIM/(CO- TRI MOXAZOLE) IN TABLETS, SYRUP ETC

177. 30049018 *CEFADR0XYL IN CAPSULES,INJECTI0NS ETC.

178. 30049021 ANTHELMINTICS AND PREPARATIONS THEREOF

179. 30049022 METRONIDAZOLE-FORMULATIONS SINGLE AND IN COMBINATION WITH FURAZOLIDONE & DILOXANIDE FUROATE.

180. 30049023 TINIDAZOLE - FORMULATIONS INCLUDING COMBINATION FORMULATIONS WITH DILOXA NIDE FUROATE/FURAZOLIDONE/ANTIBACTERIALS L

181. 30049024 SECNIDAZOLE

182. 30049025 DILUXAMIDE FUROATE

183. 30049026 SODIUM STIBOGLUCONATE

184. 30049027 PENTAMIDINE

185. 30049028 *OTHER ANTI-TUBERCULOUS FORMULATIONS- IN TABLETS ETC. OF PYRAZINAMIDE, THIACETAZONE, ISONIAZIDE, ETC. (EXCLUDING REFAMPICIN)

186. 30049031 PROMETHAZINE, CHLORPHENIRAMINE, ASTEMIZOLE AND CETEIRIZINE

187. 30049032 SODIUM BICARBONAT, MAGNSM HYDROXID, MAGNSMCARBONAT, MAGNSIUM TRISILICAT, ALUMINIUM HYDROXIDE GEL, MAGALDARATE & COMB. THEREOF

188. 30049034 OMEPRAZOLE AND LANSOPRAZOLE

189. 30049035 DICYCLOMINE, METOCLOPRAMIDE AND DEXAME THASONE AND ONDANSETRON

190. 30049036 CHENODIOL AND URSODIOL

191. 30049037 *ALUMINIUM HYDROXIDE GEL IN TBLTS, LQD ETC WTH MAG HYDRX & MG TRISILICTE ETC IN TABLTS LIQUID ETC

192. 30049038 *OTHER ANTACID ETC.

193. 30049041 CYCLOPHOSPHAMIDE

194. 30049042 METHOTREXATE, 5-FLUOROURACIL (5-FU) AND FTORAFUR

195. 30049043 BINCRISTINE AND VINBLASTINE


- 9 -


196. 30049044 PACLITAXEL AND DOCETAXEL

197. 30049045 ETOPOSIDE

198. 30049046 ACTINOMYCIN D DACTINOMYCIN AND DOXORUBICIN

199. 30049047 L-ASPARAGINASE, CISPLATIN AND CARBOPLATIN

200. 30049048 TAMOXIFEN

201. 30049051 ISONIAZID

202. 30049052 RIFAMPICIN

203. 30049053 PYRAZINAMIDE AND ETHAMBUTOL

204. 30049054 STREPTOMYCIN

205. 30049055 DAPSONE (DDS), ACEDAPSONE (DADDS), SOLOPSONE AND CLOFAZIMINE

206. 30049056 CHLOROQUINE, AMODIAQUINE, MEFLOQUINE, QUININE, CHLOROGUAMIDE, PYRIMETHAMINE

207. 30049057 OTHER ANTITUBERCULAR DRUGS

208. 30049058 OTHER ANTILEPROTIC DRUGS

209. 30049061 ANALGIN WITH OR WITHOUT OTHER COMPOUNDS SUCH AS PARACETAMOL

210. 30049062 ACETYL SALICYLIC ACID (ASPIRIN) AND FORMULATIONS THEREOF

211. 30049063 IBUPROFEN WITH OR WITHOUT PARACETAMOL OR OTHER COMPOUNDS

212. 30049064 OXYPHEN BUTAZONE, PHENYL BUTAZONE AND FORMULATIONS THEREOF

213. 30049065 INDOMETHACIN

214. 30049066 MEPHENAMIC ACID, DACTOFENAC SODIUM, PIROXICAM, TENOXICAM AND MELOXICAM

215. 30049067 KETOROLAC, NIMESULIDE, NABUMETONE AND NEFOPAM

216. 30049072 VERAPAMIL, NIFEDIPINE, AMLODIPINE AND LACIDIPINE

217. 30049073 LOSARTAN

218. 30049074 PROPRANOLOL, METOPROLOL, ATENOLOL AND LABETALOL

219. 30049075 PRAZOSIN, TERAZOSIN, PHENTOLAMINE AND PHENOXYBENZAMINE

220. 30049076 CLONIDINE, METHYLDOPA

221. 30049077 HYDRALAZINE, MINOXIDIL AND DIAZOXIDE

222. 30049078 *OTHER SALINE WATER


- 10 -


223. 30049081 PHENOBARBITONE, MEPHOBARBITONE, PRIMIDONE, PHENYTOIN, CARBAMAZPIN, ETHOSUCIMID, VALPORICACID, DIAZEPA, LAMOTRIGIN, GABAPENTIN ETC

224. 30049082 OTHER ANTIEPILEPTIC DRUGS

225. 30049083 SULPHA DRUGS NOT ELSEWHERE SPECIFIED

226. 30049084 PREPARATIONS OF ENZYMES

227. 30049085 VETERINARY MEDICINAL PREPARATIONS N.E.S.

228. 30049086 ORAL REHYDRATION SALTS

229. 30049087 ANTIBACTERIAL FORMULATIONS, N.E.S.

230. 30049091 SALBUTAMOL, TERBUTALINE, EPHEDRINE, SALMETEROL AND METHYL XANTHIMES

231. 30049092 PLASMA EXPANDERS

232. 30049093 CHLOROPHENIRAMINE MALEATE, WITH OR WITHOUTOTHER COMPOUNDS (EXCL. STERIODS & ALKALOIDS)

233. 30049094 THEOPHYLLINE, AMINOPHYLLINE AND OTHER BRONCHO DILATORS

234. 30049095 CARCINO-CHEMOTHERAPEUTIC DRUGS N.E.S.

235. 30049096 *CLOTRIMAZOLE - FORMULATIONS THEREOF

236. 30049097 *SINVASTATIN; LOVASTATIN, ATORVASTATIN.

237. 30049099 OTHER MEDCNE PUT UP FOR RETAIL SALE N.E.S

238. 30051001 *ADHESIVE GAUZE BANDAGE

239. 30051002 *ADHESIVE TAPE (MEDICINAL)

240. 30051003 *PLASTER OF PARIS (SURGICAL)

241. 30051009 *OTHER BANDAGES

242. 30059001 *COTTON WOOL MEDICATED

243. 30059002 *POULTICE OF KAOLIN

244. 30059003 *MEDICATED LINT

245. 30059004 *BANDAGES WITHOUT ADHESIVE LAYER

246. 30061001 *STERILE SURGCL CATGUT,SMLR MTRLS & STRLE TISSUE ADHSVS FOR SURGICAL WOUND CLOSURE

247. 30061002 *STERILE LAMINARIA & LAMINARIA TENTS.& STRILE ABSRBBLE SURGCL/DENTAL HAEMOSTATICS

248. 30062000 BLOOD-GROUPING REAGENTS


- 11 -


249. 30063000 OPACIFYING PRPNS FR X-RAY EXAMS; DIAGNOSTIC REAGNTS DSGND TO BE ADMNSTRD TO PATIENT BE ADMINISTERED TO THE PATIENT

250. 30064000 DENTAL CEMENTS AND OTHR DENTAL FILLINGS BONE RECONSTRUCTION CEMENTS

251. 30065000 FIRST-AID BOXES AND KITS

252. 30066000 *CHMCL CONTRACEPTIVE PRPNS BASED ON HORMONES/SPERMICIDES


1. 290110 SATURATED ACYCLIC HYDROCARBONS

2. 290121 UNSATURATED ETHYLENE

3. 290122 UNSATURATED PROPENE (PROPYLENE)

4. 290123 UNSTRD BUTENE (BUTYLENE)& ISOMERS THEREOF

5. 290124 UNSTRD BUTS-1 3-DIENE AND ISOPRENE

6. 290129 OTHER ACYCLIC HYDROCARBONS

7. 290211 CYCLOHEXANE

8. 290219 OTHER CYCLANES,CYCLENES & CYCLOTERPENES

9. 290220 BENZENE

10. 290230 TOLUENE

11. 290241 O-XYLENE

12. 290242 M-XYLENE

13. 290243 P-XYLENE

14. 290244 MIXED XYLENE ISOMERS

15. 290250 STYRENE

16. 290260 ETHYLBENZENE

17. 290290 OTHER CYCLIC HYDROCARBONS

18. 290311 SATURATED CHLOROMTHN (MTHYL CHLRD) & CHLOROETHANE (ETHYL CHLORIDE)

19. 290312 DICHLOROMETHANE (METHYLENE CHLORIDE)

20. 290313 CHLOROFORM (TRICHLOROMETHANE)

21. 290314 CARBON TETRACHLORIDE

22. 290315 1,2 DICHLOROMETHANE (CETHYLNE DICHLORIDE)


- 12 -

Sl.NO. HS

code Commodity

23. 290316 *1,2-DICHLOROPROPANE (PROPYLENE DICHLORIDE) AND DICHLOROBUTANES,SATURATED

24. 290319 OTHER CHLOROMETHANE & CHLOROETHANE

25. 290321 VINYL CHLORIDE (CHLOROETHYLENE),UNSTRTD

26. 290322 TRICHLOROETHYLENE,UNSATURATED

27. 290323 TETRACHLOROETHANE (PERCHLOROETHYLENE ) , UNSATRTD

28. 290329 OTHER UNSATURATED CHLORINATED DERIVATIVES OF ACYCLIC HYDROCARBONS

29. 290330 FLUORNTD, BRMNTD/IODINATED DERIVATIVES OF ACYCLIC HYDROCARBONS

30. 290341 TRICHLORO FLUORO METHANE

31. 290342 DICHLORO DIFLUORO ETHANE

32. 290343 TRICHLORO TRIFLUORO ETHANE

33. 290344 DICHLORO TETRA FLUORO ETHANE AND CHLORO PENTA FLUORO ETHANE

34. 290345 OTHER DERIVATIVES PERHALOGENATED ONLY WITH FLUORINE & CHLORINE

35. 290346 BROMO CHLORO DIFLUORO METHANE, BROMO TRI FLUORO METHANE & DIBROMOTETRA FLUOROETHANE

36. 290347 OTHER PERHALOGENATED DERIVATIVES

37. 290349 OTHERDICHLOROTETRAFLUOROETHANE ETC

38. 290351 1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE

39. 290359 OTHR HALOGNTD DRVTVS OF CYCLANIC, CYCLENIC

40. 290361 CHLOROBENZENE O-DICHLOROBENZENE AND P-DICHLOROBENZENE

41. 290362 HEXACHLOROBENZENE&DDT(1,1,1-TRICHLORO-2, 2-BIS (P-CHLOROPHENYL) ETHANE)

42. 290369 OTHR HALGNTD DRVTVS OF ARMTC HYDROCARBON

43. 290410 DRVTVS CNTNG ONLY SULPHO GROUPS, THEIR SALTS AND ETHYL ESTERS

44. 290420 DRVTVS CNTNG ONLY NITRO/NITROSO GRPS

45. 290490 OTHR SULPHONTD NITRTD/NITRSTD DRVTVS

46. 290511 SATURATED METHANOL (METHYL ALCOHOL)

47. 290512 SATURATED PROPAN-1OL (PROPYL ALCOHOL) AND PROPAN-2-OL (ISOPROPYL ALCOHOL)

48. 290513 SATURATED BUTAN-1-OL (N-BUTYL ALCOHOL)


- 13 -

Sl.NO. HS code

Commodity

49. 290514 OTHER SATURATED BUTANOLS

50. 290515 SATURTD PENTANOL(AMYL ALCHL) & SMRS THEROF

51. 290516 SATRTD OCTNL (OCTYL ALCHL)& ISMRS THEREOF

52. 290517 SATRTD DDCAN-1-OL (LRYL-ALCHL) HXADECAN-1-OL (CETYL ALCHL)&OCTDECN-1-OL(STRYL ALCHL)

53. 290519 OTHR SATURTED MONOHYDYDRIC ALCHOL

54. 290522 UNSATURATD ACYCLIC TERPENE ALCOHOLS

55. 290529 OTHER UNSATURATED MONOHYDRIC ALCOHOLS

56. 290531 ETHYLENE GLYCOL (ETHANEDIOL)

57. 290532 PRPPYLENE GLYCOL (PROPANE-1,2-DIOL)

58. 290539 OTHER DIOLS

59. 290541 2-ETHYL-2-(HYDROXYMETHYL)PROPANE-1, 3-DIOL (TRIMETHY-LOLPROPANE)

60. 290542 PENTAERYTHRITOL

61. 290543 MANNITOL

62. 290544 D-GLUCITOL (SORBITOL)

63. 290545 GLYCEROL

64. 290549 OTHER POLYHYDRIC ALCOHOLS

65. 290550 *HALGNTD, SLPHNTD NITRTD/NITRSTD DERIVATIVES OF ACYCLIC ALCOHOLS

66. 290611 MENTHOL

67. 290612 CYCLHXNL MTHYLCYCLHXNLS&DIMTHYL CYCLHXNLS

68. 290613 STEROLS AND INOSITOLS

69. 290614 TERPINEOLS

70. 290619 OTHR CYCLNIC, CYCLENIC/CYCLOTRPNC ALCHLS

71. 290621 BENZYL ALCOHOL

72. 290629 OTHER AROMATIC ALCOHOL

73. 290711 PHENOL (HYDROXYBENZENE) AND ITS SALTS

74. 290712 CRESOLS AND THEIR SALTS

75. 290713 OCTYLPHNL NONYLPHNL & THR ISOMERS,SALTS

76. 290714 XYLENOLS AND THEIR SALTS

77. 290715 NAPHTHOLS AND THEIR SALTS

78. 290719 OTHER MONOPHENOLS

79. 290721 RESORCINOL AND ITS SALTS


- 14 -

Sl.NO. HS code

Commodity

80. 290722 HYDROQUINONE (QUINOL) AND ITS SALTS

81. 290723 4,4-ISOPROPYLIDENEPHNL (BISPHNL A, DIPHENYLOLPROPANE) AND ITS SALTS

82. 290729 OTHER POLYPHENOLS

83. 290730 *PHENOL-ALCOHOLS

84. 290810 DRIVS CNTNG ONLYHALOGEN SUBSTITUENTS AND THEIR SALTS

85. 290820 DRVOVS CNTNG OLLYSULPHO GROUPS, THEIR SALTS & ESTERS

86. 290890 OTHR HLGNTD SLPHNTD NITRTD/NITRSTD DRVTVS OF PHENOLS/PHENOL-ALCOHOLS

87. 290911 DIETHYL ETHER

88. 290919 OTHR ACYCLIC ETHRS & THR HALGNTD, SLPHNTD NITRATED OR NITROSATED DERIVATIVES

89. 290920 CYCLANIC, CYCLENIC/CYCLTRPENC ETHRS & THIR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTS

90. 290930 ARMTC ETHRS & THR HALGNTD SLPHNTD NITRATED OR NITROSATED DERIVATIVES

91. 290941 2,2-OXYDIETHANOL (DIETHYLENE GLYCOL, DIGOL)

92. 290942 MONOMTHYL ETHRS OF ETHYLENE GLYCOL OR OF DIETHYLENE GLYCOL

93. 290943 MONOBUTYL ETHERS OF ETHYLENE GLYCOL OR OF DIETHYLENE GLYCOL

94. 290944 OTHER MONOALKYL ETHERS OF ETHYLENE GLYCOL OR OF DIETHYLENE GLYCOL

95. 290949 OTHR ETHR-ALCHLS & THR HALGNTD SLPHNTD NITRATED OR NITROSATED DERIVATIVES

96. 290950 ETHR-PHNLS, ETHR-ALCHL-PHNLS & THR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS

97. 290960 ALCHL PEROXIDES, ETHR PEROXIDES, KETONE PEROXIDES & THR HALGNTD SLPHNTD NITRATED OR NITROSATED DERIVATIVES

98. 291010 OXIRANE (ETHYLENE OXIDE)

99. 291020 METHYLOXIRANE (PROPYLENE OXIDE)

100. 291030 1-CHLORO-2,3-EPOXYPRPNE(EPICHLOROPHYDRIN)

101. 291090 OTHER EPOXIDES,EPOXY ALCHLS ETC

102. 291100 ACTLS&HEMIACTLS W/N WTH OTHR OXYGN ENCTN &THR HALGNTD SLPHNTD NITRTD/INTRSTD DRVTVS

103. 291211 METHANAL (FORMALDEHYDE)

104. 291212 ETHANAL (ACETALDEHYDE)


- 15 -

Sl.NO. HS code

Commodity

105. 291213 BUTANOL (BUTYRALDEHYDE, NORMAL ISOMER)

106. 291219 OTHR ACYCLIC ALDHYDS WTHOUT OXYGEN FNCTN

107. 291221 BENZALDEHYDE

108. 291229 OTHR CYCLC ALDHYDS WTHOUT OTHR OXYGN FNCTN

109. 291230 ALDEHYDE-ALCOHOLS

110. 291241 VANILLIN (4-HYDROXY-3METHOXY BENZALDEHYDE)

111. 291242 ETHYLVANILIN (3-ETHOXY-4-HYDROXYBNZLDHYD)

112. 291249 OTHR ALDHYD-ETHR, ALDHYD-PHNL& OTHR ALDHYD

113. 291250 CYCLIC POLYMERSOF ALDEHYDES

114. 291260 PARA FORMALDEHYDE

115. 291300 HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS OF PRODUCTS OF HEADING NO. 2912

116. 291411 ACETONE

117. 291412 BUTANONE (METHYL ETHYL KETONE)

118. 291413 4-MTHYLPENTAN-2-ONE (MTHYL ISOBTYL KETONE)

119. 291419 OTHR ACYLC KETONES WTHOUT OTHR OXYGN FNCTN

120. 291421 CAMPHOR

121. 291422 CYCLOHEXANONE AND METHYL CYCLOHEXANONES

122. 291423 IONONES AND METHYLIONONES

123. 291429 OTHER CYCLANIC CYCLENIC/CYCLOTRPNC KETONES WITHOUT OTHER OXYGEN FUNCTION

124. 291431 PHENYLACETONE

125. 291439 OTHR ARMTC KETONES WTHOUT OTHR OXYGEN FUNCTION

126. 291440 KETONE-ALCOHOLS & KETONE ALDEHYDES

127. 291450 KETONE-PHNLS & KETONS WTHOTHR OXYGN FNCTN

128. 291461 ANTHRAQUINONE

129. 291469 OTHER QUINONES

130. 291470 HALGNTD,SULPHNTD,NITRTD/NITROSTD DRVTVS OF KETOKES AND QUINONES

131. 291511 FORMIC ACID

132. 291512 SALTS OF FORMIC ACID

133. 291513 ESTERS OF FORMIC ACID

134. 291521 ACETIC ACID

135. 291522 SODIUM ACETATE


- 16 -

Sl.NO. HS code

Commodity

136. 291523 COBALT ACETATES

137. 291524 ACETIC ANHYDRIDE

138. 291529 OTHR ACETIC ACID & ITS SLTS

139. 291531 ETHYL ACETATE

140. 291532 VINYL ACETATE

141. 291533 N-BUTYL ACETATE

142. 291534 ISOBUTYL ACETATE

143. 291535 2-ETHOXYETHYL ACETATE

144. 291539 OTHER ESTERS OF ACETIC ACID

145. 291540 MONO-DI/TRCHLRACTC ACD,THR SLTS & ESTRS

146. 291550 PROPIONIC ACID ITS SALTS AND ESTERS

147. 291560 BUTYRIC ACDS,VALERIC ACDS THR SLTS & ESTRS

148. 291570 PALMTC ACID,STEARIC ACID THR SLTS & ESTRS

149. 291590 OTHR SATRTD ACYLC, MNOCRBOXYLC ACDS & THR ANHYDRDS, HALDS, PEROXDS, PEROXY ACIDS & THR HALGNTD SLPHNTD NITRTD & NITRSTD DRVTVS

150. 291611 ACRYLIC ACID AND ITS SALTS

151. 291612 ESTERS OF ACRYLIC ACID

152. 291613 METHACRYLIC ACID AND ITS SALTS

153. 291614 ESTERS OF METHACRYLIC ACID

154. 291615 OLEIC LINOLC/LINOLNC ACDS,THR SLTS & ESTRS

155. 291619 OTHR UNSATRTD ACYCLC, MONOCRBOXYLC ACDS, THR ANHYDRDS, HALIDES ETC THR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS

156. 291620 CYCLANIC, CYCLENIC/CYCLOTRPNC MONOCRBOXYLC ACIDS, THEIR ANHYDRDS, HALIDES PEROXIDES PEROXYACIDS AND THEIR DERIVATATIVES

157. 291631 BENZOIC ACID ITS SALTS AND ESTERS

158. 291632 BENZYL PEROXYD & BENZOYL CHLRD

159. 291634 PHENYLACETIC ACID & ITS SALTS

160. 291635 ESTERS OF PHENYL ACETIC ACID

161. 291639 OTHR ARMTC MONOCRBOXYLC ACDS,THR ANHYDRDS HALIDES,PEROXIDES,PEROXYACIDS & THR DRVTVS

162. 291711 OXALIC ACID ITS SALTS AND ESTERS

163. 291712 ADIPIC ACID ITS SALTS AND ESTERS

164. 291713 AZELAIC ACID, SEBACIC ACID THR SLTS & ESTRS


- 17 -

Sl.NO. HS code

Commodity

165. 291714 MALEIC ANHYDRIDE

166. 291719 OTHR ACYLC PLYCRBOXYLC ACDS THR ANHYDRDS HALIDES, PEROXIDES, PEROXYACDS & THR DRVTVS

167. 291720 CYCLANIC, CYCLENIC/CYCLOTRPNC PLYCRBOXYLC ACIDS THR ANHYDRDS HALIDES PEROXIDES PEROXYACIDS AND THEIR DERIVATIVES

168. 291731 DIBUTYL ORTHOPHTHALATES

169. 291732 DIOCTYL ORTHOPHTHALATES

170. 291733 DINONYL OR DIDECYL ORTHOPHTHALATES

171. 291734 OTHER ESTERS OF ORTHOPHTHALIC ACID

172. 291735 PHTHALIC ANHYDRIDE

173. 291736 TEREPHTHALIC ACID AND ITS SALTS

174. 291737 DIMETHYL TEREPHTHALATE

175. 291739 OTHR ARMTC PLYCRBOXYLC ACIDS THR ANHYDRDS HALIDES PEROXIDES PEROXYACDS & THR DRVTVS

176. 291811 LACTIC ACID ITS SALTS AND ESTERS

177. 291812 TARTARIC ACID

178. 291813 SALTS AND ESTERS OF TARTARIC ACID

179. 291814 CITRIC ACID

180. 291815 SALTS AND ESTERS OF CITRIC ACID

181. 291816 GLUCONIC ACID ITS SALTS AND ESTERS

182. 291817 *PHENYLGLYCOLIC ACID (MANDELIC ACID) ITS SALTS AND ESTERS

183. 291819 OTHR CRBOXYLIC ACIDS WTH ALCHL FNCTN BUT WTHOUT OTHR OXYGN FNCTN THR ANHYDRDS HALIDES PEROXIDES PEROXYACIDS & THR DRVTVS

184. 291821 SALICYLIC ACID AND ITS SALTS

185. 291822 0-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS

186. 291823 OTHR ESTERS OF SALICYLIC ACID & THR SALTS

187. 291829 OTHR CABOXYLIC ACIDS WTH PHNL FNCTN BUT WTHOUT OTHR OXYGN FNCTN THR ANHYDRDS HALIDES PEROXIDES PEROXACIDS & THR DRVTVS

188. 291830 CRBXYLC ACIDS WTH ALDHYD/KETONE FNCTN BUT WTHOUT OTHR OXYGN FNCTN THR ANHYDRDS HALDS PEROXIDES PEROXYACIDS & THR DRVTVS


- 18 -

Sl.NO. HS

code Commodity

189. 291890 OTHR CRBOXYLC ACDS WTH ADDTNL OXYGN FNCTN THR ANHYDRDS HALIDES PEROXIDES & PEROXY ACIDS THR HALGNTD SLPHNTD NITRTD DRVTS

190. 291900 PHSPHRC ESTRS & THR SLTS INCL LACTOPHSPHTSTHR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS

191. 292010 THIOPHSPHRC ESTRS (PHOSPHOROTHIOATES) & THEIR SALTS THEIR HALGNTD SLPHNTD NITRATED OR NITROSATED DERIVATIVES

192. 292090 OTR ESTERS OF OTR INORGNC ACDS;THRSLTS ETC

193. 292111 MTHYLAMINE DI-OR TRIMTHYL AMINE & THR SLTS

194. 292112 DIETHYLAMINE AND ITS SALTS

195. 292119 OTHR ACYCLIC MONOAMINES & THEIR DEVIVATIVES SALTS THEREOF

196. 292121 ETHYLENEDIAMINE AND ITS SALTS

197. 292122 HEXAMETHYLENEDIAMINE AND ITS SALTS

198. 292129 OTHR ACYLC PLYAMINS THR DRVTVS SLTS THREOF

199. 292130 CYCLANIC CYCLENIC/CYCLOTRPNC MONO-OR POLYAMINS & THR DRVTVS; SLTS THEREOF

200. 292141 ANILINE AND ITS SALTS

201. 292142 ANILINE DERIVATIVES AND THEIR SALTS

202. 292143 TOLUIDINES AND THEIR DRVTVS SLTS THEREOF

203. 292144 DIPHNYLAMINE & ITS DRVTVS SLTS THEREOF

204. 292145 1-NAPHTHYLAMINE 2-NAPHTHYLAMINE AND THEIR DERIVATIVES; SALTS THEREOF

205. 292149 OTHR ARMTC MONO AMNS & THR DRVTVS AND SLTS

206. 292151 O-M-P-PHENYLENEDIAMINE DIAMINOTOLUENE AND THEIR DRVTVS SALTS THEREOF

207. 292159 OTHR ARMTC PLYAMNS & THR DRVTVS & SLTS

208. 292211 MONOETHANOLAMINE AND ITS SALTS

209. 292212 DIETHANOLAMINE AND ITS SALTS

210. 292213 TRIETHANOLAMINE AND ITS SALTS

211. 292219 OTHER OXYGEN-FUNCTION AMINO-ALCOHOLS

212. 292221 AMNOHYDRXYNPHTHLENESLPHNC ACDS & THR SLTS

213. 292222 ANISIDINES DIANISIDINES PHNTDNS & THR SLTS


- 19 -

Sl.NO. HS

code Commodity

214. 292229 OTHR AMINO-NAPTHLS & OTHR AMINO-PHNLS THR ETHRS & ESTRS OTHR THN THOSE CNTNG MORE THN ONE KND OF EXYGN FNCTN SLTS THEREOF

215. 292230 *AMINO-ALDHYDS AMINO-KETONS & AMINO-QUINONSOTHER THAN THOSE CNTNG MORE THAN ONE KND OF OXYGEN FUNCTION; SALTS THEREOF

216. 292241 LYSINE AND ITS ESTERS SALTS THEREOF

217. 292242 GLUTAMIC ACID AND ITS SALTS

218. 292243 ANTHRANILIC ACID AND ITS SALTS

219. 292249 OTHR AMINO ACIDS & THR ESTRS OTHR THN THOSE CONTAING MOT THN ONE KND OF OXYGEN FUNCTION,SALTS THEREOF

220. 292250 AMINO-ALCHL-PHNLS AMINO-ACID PHNLS & OTHR AMINO-COMPOUNDS WITH OXYGEN FUNCTION

221. 292310 CHOLINE AND ITS SALTS

222. 292320 LECITHINS AND OTHER PHOSPHOAMINOLIPIDS

223. 292390 OTHER QUATERNARY AMMONIUM SALTS & HYDROXDELECITHINS & OTHR PHOSPHOAMINOLIPIDS

224. 292410 *ACYLC AMIDES (INCL ACYLC CARBAMATES) & THER DERIVATIVES SALTS THEREOF

225. 292421 UREINES & THEIR DERIVATIVES SALTS THEREOF

226. 292429 OTHR CYCLC AMIDES (INCL CYCLC CRBAMATES) & THEIR DERIVATIVES & SALTS THEREOF

227. 292511 SACCHARIN AND ITS SALTS

228. 292519 OTHR IMIDES & THR DRVTVS SLTS THEREOF

229. 292520 IMINES & THR DRVTVS SLTS THEREOF

230. 292610 ACRYLONITRILE

231. 292620 1-CYANOGUANIDINE (DICYANDIAMIDE)

232. 292690 OTHR NITRILE-FUNCTION COMPOUNDS

233. 292700 DIAZO-AZO-OR AZOXY-COMPOUNDS

234. 292800 ORGNC DRVTVS OF HYDRAZINE/OF HYDROXYLAMINE

235. 292910 ISOCYANATES

236. 292990 OTHR CMPNDS WITH OTHER NITROGEN FUNCTION

237. 293010 DITHIOCARBONATES (XANTHATES)

238. 293020 THIOCARBAMATES AND DITHIOCARBAMATES

239. 293030 THIURAM MONO-,DI-OR TETRASULPHIDES


- 20 -

Sl.NO. HS code

Commodity

240. 293040 METHIONINE

241. 293090 OTHER ORGANO-SULPHUR COMPOUNDS

242. 293100 OTHER ORGANO-INORGANIC COMPOUNDS

243. 293211 TETRAHYDROFURAN

244. 293212 2-FURALDEHYDE(FURFURALDEHYDE)

245. 293213 FURFURYL ALCHL & TETRAHYDROFURFURYL ALCHL

246. 293219 OTHR CMPNDS CNTNG AN UNFUSED FURANRING (WHETHER OR NOT HNDRGNTD) IN THE STRUCTURE

247. 293221 COUMARIN, MTHYLCOUMRN & EHYLCOUMRN-LACTONES

248. 293229 OTHR LACTONES

249. 293291 IS0SAFR0LE

250. 293299 OTHER HETEROCYCLIC COMPNDS WITH OXYGEN HETERO -ATOM/S)

251. 293311 PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES

252. 293319 OTHR HTRCYCLC CMPNDS CNTNG AN UNFUSED PYRZL RING (W/N HYDRGNTD) IN THE STRUCTURE

253. 293321 HYDANTOIN AND ITS DERIVATIVES

254. 293329 OTHR CMPNDS CNTNG AN UNFUSED IMIDAZOLE RING(W/N HYDROGENATED) IN THE STRUCTURE

255. 293331 PYRIDINE AND ITS SALTS

256. 293332 PIPERIDINE AND ITS SALTS

257. 293339 OTHR CMPNDS CNTNG AN UNFUSED PYRDN RING(W/N HYDRGNTD) IN THE STRUCTURE

258. 293340 *HTRCYCLE CMPNDS CNTNG A GUINOLINE OR ISOQUINOLINE RING-SYSTEM (WHETHER OR NOT HYDROGENATED) NOT FURTHER FUSED

259. 293351 *MALONYLURES (BARBITURIC ACID) AND ITS DERIVATIVES SALTS THEREOF

260. 293359 OTHER MTRCYCLC CMPNDS CNTNG A PYRIMIDINE RING (W/N HYDRGNTD)/PIPERAZINE RING IN THESTRUCTURE

261. 293361 MELAMINE

262. 293369 OTHR CMPNDS CNTNG AN UNFUSED TRIAZINE RING(W/N HYDROGENATED) IN THE STRUCTURE

263. 293371 6-HEXANELACTAM (EPSILON-CAPROLACTAM)

264. 293379 OTHER LACTAMS

265. 293390 *OTHR HTRCYLC CMPNDS WTH NTRGN HTR-ATM(S) HTR-ATM(S)ONLY;NUCLEIC ACIDS & THR SLTS


- 21 -

Sl.NO. HS code

Commodity

266. 293410 CMPNDS CNTNG AN UNFUSED THIAZOLE RING (W/N HYDROGENATED) IN THE STRUCTURE

267. 293420 CMPNDS CNTNG A BENZOTHIAZONE RING-SYSTEM (W/N HYDRGNTD) NT FRTHR FUSED

268. 293430 CMPNDS CNTNG A PHENOTHIAZINE RING-SYSTEM (W/N HYDRGNTD) NT FRTHR FUSED

269. 293490 *OTHER

270. 293500 SULPHONAMIDES

271. 293610 UNMIXED PROVITAMINS

272. 293621 VITAMINS A AND THEIR DERIVATIVES

273. 293622 VITAMIN B1 AND ITS DERIVATIVES


275. 293624 D-OR DL-PANTOTHENIC ACID (VITAMIN B3 OR VITAMIN B5) AND ITS DERIVATIVES

276. 293625 VITAMIN B6 & ITS DRVTS


278. 293627 VITAMIN C (ASCORBIC ACID) & ITS DRVTVS

279. 293628 VITAMIN E AND ITS DERIVATIVES

280. 293629 OTHER VITAMINS AND THER DERIVATIVES

281. 293690 OTHER VIT & PROVIT INCL NATURAL CONCENTRTS

282. 293710 *PITUITARY (ANTRR)/SMLR HRMNS & THR DRVTVS

283. 293721 CORTISONE, HYDROCORTISONE, PREDNISONE (DEHY-DROCORTISONE) AND FREDNISOLONE AND PRDNSLN (DEHYDROHYDROCORTISONE)

284. 293722 HALGNTD DRVTVS OF CORTI COSTEROIDAL

285. 293729 OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES

286. 293791 *INSULIN AND ITS SALTS

287. 293792 *OESTROGENS AND PROGESTOGENS

288. 293799 *OTHR HRMNS & THR DRVTVS;OTHR STEROIDS USED PRIMARILY AS HORMONES

289. 293810 RUTOSIDE (RUTIN) AND ITS DERIVATIVES

290. 293890 OTHR GLYCOSIDES NATRL/RPRDCD BY SYNTHSIS &THR SLTS ETHRS ESTRS AND OTHR DRVTVS

291. 293910 *ALKLDS OF OPIUM & THR DRVTVS SLTS THEREOF

292. 293921 QUININE AND ITS SALTS

293. 293929 OTHR ALKLDS OF CINCHONA & THR DRVTVS AND SLTS THEREOF


- 22 -

Sl.NO. HS code

Commodity

294. 293930 CAFFEINE AND ITS SALTS

295. 293941 EPHIDRINES AND THER SLTS

296. 293942 PSEUDO EPHEDRINE (INN) AND ITS SALTS

297. 293949 OTHER EPHEDRIVES AND THR SALTS

298. 293950 *THEOPHYLLINE AND AMINOPHYLLINE (THEOPHYLLINE-ETHYLENEDIAMINE) AND THEIR DERIVATIVES SALTS THEREOF

299. 293961 ERGOMETRINE (INN) AND ITS SALTS

300. 293963 LYSERGIC ACID AND ITS SALTS

301. 293969 OTHER ALKALOIDS OF RYE ERGOT & DRVTVS

302. 293970 *NICOTINE AND ITS SALTS

303. 293990 *OTHR VEG ALKLDS THR DRVTVS; SLTS THEROF ETC

304. 294000 SUGRS CHMCLY PURE OTHR THN SUCROSE LACTOSEMALTOSE ETC SUGR ETHRS & SUGRESTRS & THR SLTS BESIDES HDG NO. 2937 2938 OR 2939

305. 294110 PENICILLINS & THR DRVTVS WTH A PENICILLANIC ACID STRUCTURE SLTS THEREOF

306. 294120 STREPTOMYCINS & THR DRVTVS SLTS THEREOF

307. 294130 TETRACYCLINES & THR DRVTVS SLTS THEREOF

308. 294140 CHLORAMPHENICOL & ITS DRVTVS SLTS THEREOF

309. 294150 ERTHROMYCIN & ITS DRVTVS SLTS THEREOF

310. 294190 OTHER ANTIBIOTICS

311. 294200 OTHER ORGANIC COMPOUNDS


- 23 -

II. INDIAN DRUGS AND PHARMACEUTICAL INDUSTRY: AN OVERVIEW

The pharmaceutical industry is a lifeline industry for any country, and it can be said that its performance reflects the health of the labour force of the economy. It plays a very crucial role in building a strong human capital of a country, and is equally essential for economic growth and development. The achievements of the Indian pharmaceutical industry during the last three decades are spectacular by any standards. From a mere processing industry, India’s pharmaceutical industry is today highly sophisticated possessing advanced manufacturing technology, modern equipment and stringent quality control. It has shown tremendous progress in terms of infrastructure development, technology base and wide range of production. From being a major importer of bulk drugs and formulations, the Indian pharmaceutical industry has today become a net exporter of pharmaceutical products. Indian pharma sector has moved on to become a net foreign exchange earner. The industry has the capacity to face multiple challenges on account of liberalization of Indian economy, globalization of world economy, to meet obligations under WTO agreements, its switching over to product patent in 2005 from reverse engineering (process patent), which has helped the industry to grow tremendously and has made its place in the world export market. With the increased availability and access of medicines and health care facilities, life expectancy has risen in India from 41 years in 1960s to the level of 61.1 years on an average during 1993-1997 and 63 years as on today. Rapid growth in the pharmaceutical sector since 1970 has largely been the result of change of product to process patent in the Indian Patents Act, 1970. This proved a boon for the drug industry and its growth started picking up by about 19% per annum as against the global market growth of 6 to 7%. Even by 2005, drugs with annual sale of over US$ 30 billions are to go off patent. Indian pharma companies can make full advantage of the situation.

A. Highlights of the industry • Out of about 470 bulk drugs used in India, all the essential bulk drugs, i.e. 350, which

constitutes 90% of all the bulk drugs are produced in India;

• 60,000 finished formulations, which constitute 90% of all the formulations, which is sufficient for domestic requirement are also made indigenously. These formulations are like Anti-TB, Antibiotics, Pain killers, cardiac drugs, etc.;

• Production of pharmaceuticals is worth Rs.200,000 million for domestic use (production in terms of value – bulk drugs and formulations);

• Production on Bulk Drugs and formulations in terms of value as on 2003-04 was estimated at 77,790 million and Rs. 276,920 million respectively against Rs.500 million and Rs.2500 million for the period 1970-71;


- 24 -

• The market is growing at the rate of 9 to 10%. Pharma growth in the year 2002-03 was 11.8% for the period April – June 2002 against growth of 7.9% for the same period in the year 2001;

• Indian pharma is 100% generic and will remain 99% generic in 2005. Nearly 95% of the domestic demand for pharmaceutical is met through indigenous production;

• These are self-achievements by the national sector without any financial or technological assistance from the developed world;

• Total production in value constitutes about 1.3% of the world market and 8% in terms of volume;

• Prices of drugs in India are much lower than the world market price (about 1/6th of average world market prices);

• 5th largest producer after USA, Japan, Europe and China;

• The Indian pharmaceutical industry, today, ranks among the top-15-drug manufacturing countries in the world;

• Have 250 large units and 3000 medium/SSI manufacturing units in the organized sector;

• 1000 bulk drug manufacturers;

• 200 units with WHO GMP approved facilities;

• Over 30 units have approved facilities of US FDA/TGA/MCA;

• In regard to quality India stands at par with the world market and Indian products are widely accepted even in countries like USA, who has become bigger market than India for Ranbaxy and Dr. Reddy’s;

• Budgetary allocation as a percentage of Central budget comes to 1.3%;

• Per capita expense of medicines comes to Rs.160;

• Indian healthcare sector is largely in private hands. Government both at Centre and State are minor players. Healthcare expenses is 1.7% against estimate fixed by the WHO of 10%;

• Medicines reach only 28% of the population;

• Tremendous changes have taken place in health indicators, i.e. life expectancy, birth rate, death rate, infant mortality;

• India with 17% of world population, its share in the sales of medicines (value wise) is only 1.1%;

• Total employment in the industry: Direct – 500,000 Indirect- 2,400,000

• Exports: US$ 2.4 billion, Imports: US$ 0.7 billion. The industry is a net foreign exchange earner.


- 25 -

B. Indian healthcare sector Table 1. A brief Number of Pharma Units 23,790 Large Units 250 Size of the Pharma Market US$ 3.1 billion Average Annual Growth Rate 17% No. of Bulk Drugs Produced More than 400 Production US$ 2.9 million Capital Investment US$ 0.8 billion Industry Turnover US$ 4.3 billion R&D Expenditure US$ 0.13 billion No.of Bulk Drugs Reserved for Public Sector Undertakings

5

No. of Drugs Under Price Control 69 Number of Doctors 489,189 Number of Nurses 559,896 Number of Hospitals 13,692 Number of Hospital Beds 596,203 No. of Primary Health Centres 21,854 Number of Medical Colleges 161 Annual out turn of Doctors 17,000 Current Life Expectancy 63 years

Pharmaceuticals sector is a continuous growth industry, immune to recession and commodity cycles. With rising population, new disease incidence and resurgence of certain diseases, new practices in healthcare, the industry continues to grow. The sector is strong technologically and the following form the basis of the technological strengths of the Indian pharmaceutical industry:

1. Self-reliance displayed by the production of 70% of bulk drugs and almost the entire requirement of formulations within the country;

2. Low cost of production;

3. Low R&D costs;

4. Innovative Scientific manpower;

5. Strength of National Laboratories;

6. Increasing balance of trade in pharma sector.


- 26 -

1. Investment Keeping in view the need to encourage more investment in this important sector to achieve the future demands likely to be placed on it in order to meet the growing needs of the country as well as to promote exports, it is proposed to treat the entire drugs and pharmaceutical sector as a high priority industry for the purpose of permitting foreign investment. It is also proposed to treat companies with foreign equity upto 51% on par with wholly Indian companies. It may also be mentioned that at present companies with foreign equity upto 40% are already enjoying this facility and, in the circumstances mentioned above there is no need to place any fresh curbs on their activities. Similarly, it is felt that automatic approval for foreign technology agreements can be permitted for all items in the drugs and pharmaceuticals sector to encourage the introduction of newer and more efficient technologies, subject to their fulfilling the standard conditions laid down in the industrial policy. However, keeping in mind the levels of technology already available in the country, it is necessary to consider proposals involving foreign equity participation above 51% on merits of each case.


- 27 -

III. PRODUCTION

The Indian parmaceutical idustry manufactures bulk drugs belonging to several major therapeutic groups requiring various manufacturing processes and has developed excellent facilities for production of all dosage forms like tablets, capsules, liquids, orals and injectables, etc. This achievement is strengthened by an assurance with regard to quality of the products. Over the last several years, policy inputs have been directed towards promoting the growth of the industry and in helping it to achieve a broad base in terms of the range of products and technologies needed to produce them from as basic a stage as possible. The results have been very encouraging. There are about 250 large units and about 23,790 medium/small scale units in operation that form the core of the industry (including five Central Public Sector Units). These units produce the complete range of formulations i.e. medicines ready for consumption by patients and about 350 bulk drugs i.e. chemicals having therapeutic value and used for production of formulations. Today, India is in a position to meet 70% of the country’s requirement of bulk drugs and almost all the demands for formulations. The setting up of Pencillin factory at Pimpri, Pune in the early 1950’s and the construction of Indian Drugs & Pharmaceuticals Ltd. (IDPL) plants at Rishikesh and Hyderabad in 1960’s are important milestones in the history of the pharmaceuticals Industry in the country and public sector investment in the pharmaceuticals industry in the initial stages played the role of a catalyst in the development of the industry over the last three decades. From the above Table it may be observed that the average growth rate of production of bulk drugs during the last few years was over 19 % while, in case of formulations, the average growth rate was about 15 % during the period under reference. Table 2 given below describes the details of actual bulk drug production during the years 1999-00 to 2001-02 as under: Table 2. Production of bulk drugs of selected companies in the organized sector (Quantity in MT)

Name of the Bulk Drugs 1999-00 2000-01 2001-02 ANAESTHETICS 35.67 51.63 56.00 ANALGESICS & ANTIPYRETIC 3044.28 3790.00 2998.63 ANTI ASTHAMATICS 445.74 565.19 467.53 ANTIBIOTICS 2269.47 2351.82 2222.75 PENCILLINS 7583.34 7583.43 8242.96 ANTI DIABETICS 138.59 124.04 128.22 ANTI DYSENTRY DRUGS 1496.67 1435.88 1756.69 ANTI HISTAMINS 55.74 45.30 43.50 ANTI LEPROTICS 0.72 - - ANTI T B DRUGS 1136.05 884.86 827.36 CARDIOVASCULAR DRUGS 11.35 19.73 14.78 CNS STIMULANTS 37.12 81.42 30.87 CORTICOSTERIOIDS 6.17 7.33 6.95 DIURETICS 16.16 69.85 59.93 GASTRO INTESTINAL 391.06 739.50 797.79 OTHER ANTI BACTERIALS 443.89 374.65 512.54 SULPHA DRUGS 777.53 274.24 17.67 TRANQUILIZERS & SEDATIVES 37.94 35.19 15.94 VITAMINS 1182.34 1490.67 1374.95

Source: IDMA 42nd Annual Publication 2004


- 28 -

From the above Table it may be observed that the average growth rate of production of bulk drugs during the last few years was over 19 % while, in case of formulations, the average growth rate was about 15 % during the period under reference. Table 3. given below describes the details of bulk drug production during the years 1992-93 to 1997-98 as under: Table 3. Production of bulk drugs (Specific items) (Quantity in tonnes) S.No. Drugs 1994-95 1995-96 1996-97 1997-98 1. Pencillin (mnu) 906 790.8 620.4 354 2. Tetracycline 405.1 282.6 225.7 184 3. Analgin 8.7 5.9 3 2 4. Sulpha drugs 2616 2223 2173 66 5. Vitamin A (mnu) 93.6 90 54 26.7 6. Trimeth Oprin 250.1 260.1 247.9 44 7. Chloromphenical 40.8 39.6 40.8 152 8. Streptomycin 127.4 130.8 128.4 361 9. Ampicillin 273 316.2 35.1 704 10. Metramedozol 553.6 499.5 609.2 518 11. Chloroquine & its salts 311.9 248.8 260.8 247.6 12. Vitamin C 777.4 665.2 639 607

The above data shows that the Drugs & Pharmaceuticals sector has continued to maintain steady growth in terms of production. Several proposals for foreign collaboration for joint ventures, research and developments, establishing new undertakings/expansion of existing units (manufacture of new articles in the existing units) have been received. Following delicensing of the pharmaceuticals industry, a number of IEMs for manufacture of various bulk drugs/drug intermediates/formulations were received. The major items covered in IEM include various bulk drugs, intravenous fluids, formulations etc. The following drugs are reserved for exclusive manufacture by the small scale units: Niacinamide

Paracetamol

Glycero Phosphates Nicotinic Acid


- 29 -

IV. RESEARCH AND DEVELOPMENT

The total R&D expenditure in India today amounts to $2.5 billion. It stands at a low 0.8% compared to 2.5% in USA and Japan. The total R&D expenditure in the pharmaceuticals sector is around $52 million. Table 4. R&D Expenditure (Rs Million) 1994-95 1400 1995-96 1600 1996-97 1850 1997-98 2200 1998-99 2600 1999-00 3200 2000-01 3700 2002-03 5500 2003-04 6600 R&D Expenditure as % of sales during 2003-04 2%

Source:Organisation of pharmaceuticals producers of India) To be globally viable in R&D, high-level expertise and adequate human resources as also modern facilities in specified areas of drug developments are required. A Government of India programme supports, besides new drugs development projects, creation of facilities essential for new drugs development. 1. R&D expenditure as % of sale Torrent Pharma 11.25 (March 1999) Wockhardt 10.79 (June 1998) Lupin Labs 3.19 (June 1999) Dr. Reddy’s Labs 2.49 (March 1999) Ranbaxy 4.3 (December 1998) Cipla 4.02 (March 1999) To be globally viable in R&D, high level expertise and adequate human resources as also modern facilities in specified areas of drug developments are required. A Govt of India programme supports, besides new drugs development projects, creation of facilities essential for new drugs development. Accordingly, facilities that were needed urgently and that would need to be created namely (a) DHA gyrase screening facility; (b) Quantity – Structure – Activity – Relationship (QSAR) facility; (c) Immunomodulators �eager�l and screening and (d) Pharmacological testing were identified. There is a proposal to set up an R&D Cell in the Department of Chemicals and Petrochemicals. Recently, the Union Chemicals and Fertilizers Ministry considered allowing Foreign Investment into the pharmaceutical sector to give a boost to R&D in the country. Accordingly, research centres would be set up in partnership with the chemical laboratories, and if domestic companies entered into agreements with foreign companies to finance R&D, joint patents could be held and


- 30 -

the returns split. The government was also willing to give multinational companies the same concessions as those offered to domestic firms for R&D as long as they were willing to invest in R&D facilities in the country. 2. Institutions engaging in R&D (a) Academic There is a virtual lack of high quality R&D being undertaken at the moment in India. Universities in India seem to be caught in a bureaucratic trap, neither receiving much funding, nor motivated to finish ongoing projects quickly. The R&D undertaken here is negligible if one considers R&D as a whole. If corporates are encouraged to invest in R&D through patent protection, universities will be able to contribute more effectively. e.g. Vaccine for Hepatitis-B developed with Osmania University some years back. (b) Research institutes • Council for Scientific & Industrial Research (CSIR) This is an autonomous R&D organisation providing scientific industrial research for India’s economic growth and human welfare. It has 40 laboratories and 80 field centres covering fundamental and applied R&D in all areas of R&D except atomic research. CSIR has contributed to innovative process technology, and its efforts in discovering and developing new molecules as drugs have met with limited success, considering the techno-economic level of the domestic industry. Now CSIR has to shift from making clever process routes for generic drugs into a few exclusive products of its own. It will have to do this by developing state-of-the-art expertise and facilities for new drug design such as molecular �eager�l, combinatorial chemistry, computer graphics. It will search for new seeds from bioactive molecules based on plant sources, for which India has rich traditions. Some projects undertaken:

- Development of anti filarials; - Development of fast acting antimalarials for cerebral malaria; - Development of new drugs for Cardiovascular, Central Nervous System and other

disorders; - Chemistry and Biology of Peptides and Nucleic Acids (CDRI).

• Central Drug Research Institute (CDRI) Seeks to develop new drugs, immunodiagnostics and vaccines, contraceptive agents and devices, basic biomedical studies to understand the disease process, and dissemination of information in the field of drug research, development and production. Its focus is on developing new drugs for tropical diseases (malaria, filariasis), cardiovascular and CNS disorders. (c) Companies’ R&D projects (completed and on-going) • Ranbaxy tying with Bayer for exclusive marketing rights in India for ciprofloxacin, in return

for development and worldwide marketing by Bayer, which has already paid Ranbaxy $ 10 million upfront;


- 31 -

• Dabur has got permission to conduct phase 1 clinical trials for an anti-cancer molecule, the first NCE developed by Dabur Research Foundation to reach the clinical stage. Dabur has incorporated a wholly-owned subsidiary in the UK to manufacture and market anti-cancer drugs;

• Nicholas Healthcare has tied up with Hoechst Marion Roussel for R&D, in the latter’s prestigious center in India;

• Ranbaxy has held talks with US MNC Pfizer for collaboration in R&D. Ranbaxy is also holding discussions with Pfizer and other MNCs for licensing of its new prostate molecule;

• Cipla’s R&D focus is NDDS, chiral synthesis and generics. In the pipeline is an NDDS for omeprazole, besides chiral drugs for salbutamol and corticosteroids;

• Sun Pharmaceuticals is all set to cash in on prospective abbreviated new drug application (ANDA) filings of the Detroit-based Caraco Pharma, in which it holds 45% stake.

3. Future trends • Innovation, not original research alone;

• MNCs will make an aggressive bid for the Indian market, as India moves towards TRIPS, and international companies register their new drugs for patenting after 10 years;

• Smaller companies which had benefited from the protective regime so far, may be forced to become contracting units, or close shop;

• Generics will have a huge demand, with needs from developing world to be addressed;

• Increasing R&D costs will lead to more consolidation among international companies. Within 5 years, the top ten pharma companies will control over 60% of the world market;

• International companies could set up their own R&D labs in India and develop drugs for tropical diseases;

• The next big lifestyle drug (i.e Viagra) has been discovered;

• Innovations in R&D process such as genomics and combinatorial chemistry. To make the jump from process R&D to basic research, post 2005, many Indian companies will find discovery research beyond their monetary means. One way out is to adopt analogue research as a stepping stone between the two. • Analogue research:

Analogues are modifications of original molecules and are basically superior versions of existing drugs. This is a potent weapon for the Indian Industry, since most Indian companies have good synthesis skills. E.g. Dr. Reddy’s has already licensed two anti-diabetic molecules for clinical development to Novo Nordisk of Denmark.


- 32 -

• Novel Drug Delivery Systems (NDDS): Development of new ways of delivering medications to patients. E.g. Ranbaxy entered into a deal with Bayer of Germany to sell and market Ranbaxy’s ciprofloxacin NDDS (a one-tablet a day dosage, instead of the previous two-tablets a day). Cipla’s NDDS for omeprazole will further prove India’s R&D abilities. • Genetics research: This aims at determining the links between genes and disease conditions. The ongoing mapping of the entire human DNA code, is known as the human Genome Sciences Inc., and was launched in 1990. By 2005, scientists expect to locate the positions of the 100,000 genes on human chromosomes and sequence the base pairs. By doing so, scientists can understand the faulty genes which cause diseases such as Alzheimer’s and schizophrenia, and most important, develop specific drugs designed in accordance to that gene’s structure. This kind of research would eliminate the need for the laborious basic research. Other kinds of activities Indian companies could undertake, post-WTO, are: • In-licensing alliances: Indian companies are using these to access international baskets. E.g. Nicholas Piramal launched 16 products to fight cancer, epilepsy, AIDS through a tie-up with Swiss firm Roche, from its stable of products. • Co-marketing alliances: Both partners market the same molecule using distinct brand names, in order to increase the market and the awareness of a particular brand. E.g. Ranbaxy teamed up with Cipla for carvedilol. • Generics market: In the next 10 years, an estimated 60 major pharmaceutical products with sales (while under patent) in excess of $40 billion will lose patent protection, or go off-patent (see Annexure 5 for a list of drugs going off-patent by 2008). This means there is a huge generics market waiting to be captured, especially with the US importing over 70% of its generic drugs, India could be a key player, with companies such as Sun Pharmaceuticals, Wockhardt, and Dr. Reddy’s preparing for this explosion. E.g. Ranbaxy has already received US FDA approval for ranitidine (an anti-ulcer drug) and cefadroxil hemihydrate (an anti-infective). • Herbal remedies: The herbal markets in Europe and Japan are $6500 million and $2500 million respectively, compared to Rs. 6500 million for the Indian market. Indian companies have plenty of opportunities in this field, especially since India is the land of traditional medicinal systems such as Ayurveda.


- 33 -

• Outsourcing: Contract research for developing manufacturing processes for newer drugs. R&D eats up more than half the 20-year exclusivity period granted to patented drugs. Manufacturing of the drug may lead to bottlenecks caused by infrastructure problems, etc. Hence a company may decide to outsource production of that drug to another country, instead of creating a manufacturing base from scratch for that particular drug, eating precious time remain from the exclusivity period. And with India no longer being able to make and sell products patented by others, post 2005, contract manufacturing seems to be a viable alternative, with outsourcing by global majors making up a staggering $73 billion. India is an attractive, low-cost manufacturing base. E.g. Smithkline Beecham setting up a US$ 50 million manufacturing unit at Sonepat in Haryana, for the company’s global requirements of OTC products.


- 34 -

V. DOMESTIC MARKET The domestic pharmaceutical industry output exceeds Rs125 billion. Of this around 83% is formulations and 17% is bulk drugs. 1. Bulk drugs Over 60% of India’s bulk drugs production is exported. The balance is sold locally to other formulators. However, many of the MNCs affiliates/ subsidiaries in India import bulk drugs from the parent company and formulate it for local markets. Also, local players who export formulations avail of duty free imports of bulk drugs. Hence, there is a significant quantum of bulk drug imports, to the tune of Rs10 billion. Exports are mainly to developing countries in case of under patent drugs and to the developed nations in case of generics. 2. Formulations More than 85% of the formulation production in the country is sold in the domestic market. India is largely self sufficient in case of formulations. Some life saving, new generation under-patent formulations continue to be imported, especially by MNCs which then market them in India. Overall, the size of the domestic formulations market is around Rs90bn and it is growing at 15-16% pa. Formulation exports are largely to developing nations like China, South Africa, CIS etc. Indian pharmaceutical industry will have a dozen corporates with an annual turnover of Rs. 10,000 million by the end of 2005 at the current rate of growth. Seven Indian pharmaceutical companies have reportedly had more than Rs.10,000 million sales for the last two years now. These seven companies are Ranbaxy, Cipla, Dr. Reddy’s, Nicholas Piramal, Lupin, Cadila Healthcare and Aurobindo. The five companies expected to join the league of Rs.10,000 million group are Wockhardt, Sun Pharma, Ochid,Alkem Labs and Cadila Pharma. Among these, Alkem and Cadila Pharma are closely held companies and not listed in stock exchanges. Financial Performance of top 10 Indian Pharma Companies is tabulated below: Table 5. Financial performance of top 10 Indian pharma companies ( Rs. Million ) Sales Net Profit OPM (%) NPM(%) Companies 2003-04 2002-03 2003-04 2002-03 2003-04 2002-03 2003-04 2002-03 Ranbaxy 34,650 30,387 7,945 6,236 27.9 25.7 22.9 20.5Cipla 20,600 15,728 3,138 2,477 21.9 21.8 15.2 15.7Dr Reddy’s Lab.

20,573 18,106 3,123 3,649 23.6 27.1 15.2 20.1

Nicholas 14,347 11,361 1,880 1,181 17.8 17.1 13.1 10.4Aurobindo 13,040 11,904 1,211 1,031 17.5 17.3 9.3 8.7Lupin 12,323 10,085 951 731 22.7 18.4 7.7 7.2Cadila 11,723 10,282 1,428 766 21.2 18.7 12.2 7.4Sun Pharma 9,347 8,587 2,804 2,314 34.0 31.7 30.0 26.9Wockhardt 7,658 7,416 1,334 1,088 20.8 18.9 17.4 14.7Orchid 7,134 5,414 310 195 21.1 20.2 4.3 3.6

Source: Pharmabiz, Volume IV No.22 Note : OPM: Operating Profit Margin, NPM: Net Profit Margin


- 35 -

Traditional Pharma companies in the country are actively considering making bulk drugs business as one of their revenue models and are exploring the possibilities of buying out API manufacturing facilities from existing players or setting up fresh facilities. Pharma analysts claim that about 10 % of the country’s pharma companies are reemphasising upon bulk drug manufacturing. As several drugs would go off patent in the next 2-3 years, the global market for bulk drugs is expected to reach about US$ 85 billion. Indian companies are eyeing this market. As the IPR scenario in India will become stricter after 2005, more MNCs would contract out manufacture of bulk drugs to Indian companies. Indian companies can provide technologically intensive, non-infringing processes of manufacturing at one-fifth of the cost to these companies. The new interest of the pharma companies comes after success demonstrated by traditional contract manufacturers like Suven, Shasun, Divis Labs, Dishman Pharma, Jubilant Organosys and Hikal. The export market of these companies is growing at about 20 % annually. 3. Market size: major therapeutic segments Pharmaceutical usage pattern in India is pre-dominantly for acute therapies. Top 10 Therapeutic Groups in India are given below: Table 6. Top 10 therapeutic groups in India in 2000 Therapeutic Group Market Share (%)

1. Systemic Antibiotics/Antibacterials 19.42. Vitamins,Tonics, Mineral supplements 7.63. Anti-Inflamatory 5.44. Cough & cold preparations 5.35. Antacids 4.46. Cardiac Therapy 3.87. Anti-diabetics 3.08. Anti-anemics 2.89. Hypotensives 2.610. Anti-tuberculars 2.4

(a) Analgesics and anti-pyretics

Most of the popular drugs like Aspirin, Analgin and Paracetamol are off-patent. Yet, DPCO coverage is high hence, margins are low. In case of formulations, including OTC brands and anti-spasmodic combinations, the market size is around Rs4bn and is growing 17-18% yoy. But, a large number of local players result in keen competition while sales are driven by volumes. Major players in formulations are Burroughs Wellcome, SmithKline Beecham, Hoechst and Wockhardt. Paracetamol and Analgin formulations also have large export markets.


- 36 -

(b) Antacids and anti-ulcerants

This segment has large number of new under-patent molecules, due to ongoing R&D on developing more effective ways to combat acidity/ ulcers. DPCO coverage is high as it encompasses the major drug Ranitidine. But, as this globally popular anti-ulcer drug has gone off-patent in Jul ’97, there are good export opportunities. The domestic formulations market for antacids is estimated to be Rs1.8bn, growing 8-9% yoy. Major players are Knoll and Parke Davis. For anti-ulcer formulations, market size is Rs2.3bn growing at 17-18% yoy, with major growth in Omeprazole based formulations. Major players are Glaxo, Cadila, Ranbaxy, Dr Reddy’s Labs etc. (c) Antibiotics The earlier generation drug groups such as Penicillins (eg Amoxycillin) and Macrolides (eg Erythromycin) have mostly gone off-patent. Newer generation groups like Quinolones (eg Ciprofloxacin) and Cephalosporins (eg Ceftriaxone) are still largely under patent. DPCO mostly encompasses the latest generation drugs. Penicillin-G, itself an antibiotic drug, is a common intermediate for many other antibiotics. Total domestic formulations market is estimated to be Rs 21.6bn and is growing at 13.5% yoy. Of this, 27% is accounted by semi-synthetic Penicillins. The fastest growing major subgroup is Cephalosporins at 23.9% yoy. Major players are Glaxo, Ranbaxy, Cipla, Hoechst, Alembic, Burroughs Wellcome, Ambalal Sarabhai etc. Antibiotics also have a large export market, especially off-patent drugs like Amoxycillin, Ampicillin, Sulphamethoxazole and Cephalexin. Cephalosporins which will be going off-patent in near future, has a high export potential. (d) Anti-tuberculosis All popularly used drugs are off-patent. DPCO continues to cover the main drug Rifampicin. The dominant player in both bulk drugs and formulations is Lupin. The domestic formulations market is estimated to be Rs2.9bn, growing 11% yoy. Other major players are Hindustan Ciba and Cadila. MNCs like Glaxo and Hoechst are increasing their presence in this segment. Export opportunities may grow manifold if the spread of AIDS leads to large scale resurgence of TB in developed nations. (e) Anti-parasitic and anti-fungal Most of the popular drugs are off-patent. Relatively low DPCO coverage. Under DPCO ’95, some drugs have been excluded but no new additions have taken place. The domestic formulations market is estimated to be Rs3.9bn and growing at 19-20% yoy. Of this the lion’s share of 60% is contributed by anti-protozoal formulations. Major players in this segment are Rhone Poulenc, SmithKline Beecham Pharma, Ranbaxy, and Cipla. In anti-fungal formulations, main players are Bayer, Fulford, Glaxo etc. Overall, in this segment, presence of a multitude of players keeps margins low. Exports are mainly to other developing nations.


- 37 -

(f) Cardiac therapy Most of the drugs popularly used in India are off-patent. DPCO coverage is also low. Domestic formulations market size, estimated to be Rs5.6bn is growing 17-18% pa. The leading players are mostly local companies like Sun Pharma, Torrent, Cadila, ICI etc. Share of MNCs is relatively low. With increasing level of heart trouble is on the rise. Also, cardiac care is a long-term therapy, providing a good market for the players. (g) Corticosteroids All drugs popularly used in India are off-patent. Though some major drugs were excluded under DPCO ’95, it still encompasses key drugs Betamethasone and Dexamethasone. In case of bulk drugs, there are few local players and imports are high. The domestic formulations market is estimated to be Rs3.6bn, growing 16.5%yoy. Of this, around 58% are topical formulations. Major players are Glaxo, Crosslands, Wyeth, Fulford, Merind. Etc. MNCs have been dominating but now local players are increasing their presence. (h) NSAIDs, anti-rheumatic All major drugs used in India are off-patent yet DPCO coverage is high especially due to inclusion of major drug Ibuprofen under price control. However, DPCO ’95 excluded another major drug Diclofenac Sodium. The domestic formulations market is estimated to be Rs5.2bn, growing at 15%yoy. The growth is again hampered by DPCO coverage, while sales are largely driven by volumes. Major players are MNCs like Knoll, Roussel, Hind Ciba, Pfizer etc. Local players have higher presence in topical formulations. A large global market for NSAIDs makes Ibuprofen the top pharma product exported from India. But, even here multiple players keep margins low. (i) Respiratory system Patent coverage is very low. Also, as DPCO has excluded most popular anti-cough drugs, there have been price hikes and high sales growth. The domestic cough & cold formulations market is estimated to be Rs 5.6bn, growing 24.5% yoy. Of this 75% are anti-cough preparations, wherein major players are MNCs like Pfizer, Parke Davis, Rhone Poulenc. In anti-cold formulations, key players are Burroughs, Alembic etc. The anti-asthmatics market is Rs2bn, growing 15.5% yoy. The dominant leader here is Cipla. (j) Vitamins Vitamins are mostly used in case of deficiencies in India. Globally, the trend is towards imbibing them as a tonic. So, if such a fad catches on, the Rs5.7bn domestic market growing 14% yoy, would notch good growth in future. All drugs are off-patent but DPCO coverage is very high. Leading players are MNCs like E-Merck, Pfizer, Glaxo, Abbott etc. Local players have very poor presence in the segment, probably deterred by the high DPCO coverage which limits margins.


- 38 -

(k) Other therapeutic segments This covers segments like Anti-anaemic, Anti-diabetes, Anti-emetic, Anti-histamine, Anti-malarial, CNS & Psychiatric therapy, Gyneacologicals, Nutrients & Mineral Supplements. The major group is Psychiatric products which has a Rs3.7bn market, growing 11.5% yoy. All other groups range between Rs1-2bn in size. 4. OTC market In India, the access of medicines is poor as modern medicines reach only 30% of the population mostly in urban areas. The World OTC market is estimated as US$ 49.8 billion with a growth rate of 3 %. The OTC market in Europe is quite sizeable at US$ 15.3 billion with 4% growth rate. The OTC market in USA is estimated at US$ 17.6 billion with a growth rate of 2%. In North America one-forth of the medicines marketed can be attributed to OTC category. The OTC market in Far East is around US$ 2.7 billion. The OTC market I India is US$ 560 million. As the OTC market in India is underdeveloped, there is a huge potential for growth of OTC market I India. A committee has been formed to support and assist promotion of responsible self medication and growth of OTC market in India. 5. Biotechnology in India - Changing landscape The total biotechnology market in India was estimated at US$ 1 Billion in 1998, of which 60% is pharmaceuticals. It is projected to grow to US$ 2.5 Billion in future. The impact of biotechnology in India so far has been restricted to pharmaceuticals and agrochemicals. Several new entrepreneurs have entered the fields, the number has grown from 10 in 1993 to 210 in 2002 with about INR 300 million of venture capital funding available to the sector. Some companies have already started making a mark in the international biotech market with their vaccines. India has developed core competency in some areas such as its capacity in handling sterile fermentation processes, skills in handling microbes and animal cells, capacity in downstream processing and isolation methods, skills in extraction and isolation of plant and animal products, competence in plant and animal breeding and infrastructure in fabricating bio-reactors. The Department of Biotechnology has begun a major drive to develop vaccines against cholera, typhoid, malaria, HIV, Japanese encephalitis and rabies. All of these vaccines are in fairly advanced stages of research. Currently in India, eight units have taken steps to produce recombinant deoxyribonucleic acid (r-DNA) products in the healthcare area. Recently, three Indian companies launched the recombinant hepatitis B vaccine. Several r-DNA products, such as strepto-kinase, granulocyte colony stimulating factor (G-CSF), erythropoietin, insulin, epidermal growth factor and interferon, are being developed by Indian companies. The US based Genome International Corporation will be setting up a US$ 5 Million genome project in Chennai. The project Genome Technologies India Ltd. Aims to establish a genome-sequencing centre for contract sequencing of genomes and a computation and data interpretation facility. The biotech market in India can be expected to grow to US$ 5 billion by 2005 by which time a product patent regime will be in place. Indian companies can maximize their potential marketing reach by introducing a host of biotech products.


- 39 -

Biotechnology is expected to impact different sectors at varying times. Initially pesticides, fine chemicals and plastic additives would be impacted followed by surfactants, coatings and dyes. Areas such as petrochemicals and inorganic chemicals are expected to be among the last to be affected. To pursue opportunities in biotech, a change in the mindset is required in terms of greater risk appetite, higher funding for long term projects and devoting greater resources to generating and developing new ideas. 6. Medicinal plants/Ayurvedic & Unanai Medicines India has very rich and ancient heritage of traditional systems of medicines. Ayurveda, Siddha and Unani, which have been in use in the country over the past several centuries. Ayurveda the ‘Science of Life” lays emphasis on the prevention of disease rather than its cure. At present, unlike allopathic products, Ayurvedic products have not been assigned individual HS codes and therefore, authentic reliable data of export is not available. The market for alternative medicine in India is estimated at US$ 730 Million. Medicinal Plants since times immemorial have been used in virtually all cultures as a source of medicines. Herbal medicines are regarded as a totally different system of medicine and low cost is very rarely the reason for demonstrating a preference for herbal medicines. Several people in the Western countries are turning to alternative medicine because of the side effects induces by synthetic/allopathic drugs. Organisations like UNICEF and WHO have also demonstrated herbal remedies to be used for treatment of diseases such as diarrhea, cholera, bronchitis, high cholesterol level and malaria. The technology used by traditional medicine is relatively simple and non-polluting. Medicinal and aromatic plant material is obtained both from plants growing the wild and from cultivated farms. 7. Herbal medicine market The largest market for herbal medicines are found in Germany, China, Japan, The USA, France, Italy, the UK and Spain. However, the major importing markets are EU and USA. These markets are highly regulated and are very difficult to penetrate particularly for developing countries and LDCs whose products are not undergone the stringent tests applied by developed country pharmaceutical manufacturers before mass production. Lack of proper scientific nomenclature and authentic identification key of many of the medicinal plant of India; Lack of proper facilities and methods for scientific screening of these plants for their medicinal properties. The Government, recognizing the contribution of these systems (alternative medicines), has established a separate Department to encourage standardization in manufacturing and packing methods and quality improvement.


- 40 -

VI. EXPORTS

Indian pharmaceutical exports are to the tune of about US$ 2.4 billion, of which nearly 50% are bulk drugs. Erstwhile USSR was a major market for Indian formulations, but its disintegration affected exports in 1991 – 92. However, overall pharma exports, especially bulk drugs had been growing at the rate of over 20% per annum. There is some deceleration in the recent months though and this is because low domestic margins on account of competitive pressures and DPCO have led players to focus on the export markets. In exports, domestic companies have a 3 – pronged advantage over MNCs:

• Process Patents give freedom to make MNCs patented products, thus enabling wide therapeutic reach;

• Strong process R&D and low manufacturing cost;

• No restrictions on export markets by patents’ overseas ventures. According to Chemicals and Pharmaceuticals Export Promotion Council (Chemexil), exports of drugs and pharmaceuticals were valued at Rs. 119,250 million in 2002-03 against Rs 15,415 million in 1992-93. Overall, from a meager Rs. 460 million worth of pharmaceuticals exports in 1980-81, the exports have risen to over Rs. 119 billion during 2002-03. The growth rate in exports in 2002-03 was 24 % as against the growth rate of 13 % in the preceding year. Table 7. Exports of drugs and pharmaceuticals from India Year Exports ( Rs. Million) 1992-93 15,415 1993-94 19,917 1994-95 24,653 1995-96 34,432 1996-97 43,400 1997-98 53,530 1998-99 61,530 1999-2000 70,476 2000-01 88,740 2001-02 99,430 2002-03 119,250


- 41 -

0

20,000

40,000

60,000

80,000

100,000

120,000

Rs. Million

1992-93

1994-95

1996-97

1998-99

2000-01

2002-03

Exports of Drugs and Pharmaceuticals from India

The details of the exports of formulations & bulk drugs are as follows: (in Rs crores):

Year Finished formulations

Bulk drugs Total

1994-95

1505.50 760.10 2265.60

1995-96

2044.80 1132.90 3177.70

1996-97

2509.20 1581.10 4090.30

1997-98

3343.20 1737.90 5081.10

1998-99

3038.50 2327.70 5366.20

(Source : OPPI) Exports are mainly to developing countries in case of under patent drugs and to the developed nations in case of generics. With the expansion of generics in developed markets like EU and USA and the need to outsource research support service, India has the potential to emerge as global hub. Indian exports are destined to more than 200 countries around the globe including highly regulated markets of Europe, Japan, Australia and the US. Major markets for India’s drugs and pharmaceuticals are given below:


- 42 -

Table 8. Top 15 countries of exports of drugs and pharmaceuticals from India ( Rs. Million )

Country 1998-99 1999-2000 2000-01 2001-02 2002-03 USA 7,098 7,188 9,852 16,412 20,234Germany 3,675 3,477 4,297 5,034 7,277Russia 1,859 5,319 4,969 4,811 4,972UK 1,877 2,132 2,438 2,822 4,099China PR 1,346 1,991 2,671 3,820 3,975Nigeria 2,054 2,874 3,461 3,790 3,548Brazil 1,054 1,854 3,673 3,505 3,441Hong Kong 3,830 4,343 4,428 3,425 3,186Vietnam 1,470 1,553 1,870 2,143 2,624Mexico 623 1,051 1,629 1,496 2,483Canada 56 1,111 1,677 1,492 2,387Japan 580 1,232 1,397 1,513 2,291Netherlands 2,097 2,155 1,912 1,936 2,272Sri Lanka 1,448 1,347 1,734 1,527 2,173Singapore 1,790 2,393 2,147 2,012 2,007Total Above 30,857 40,020 48,155 55,738 66,969

(Source : CHEMEXCIL ANNUAL REPORT)

Major Destinations

others44%

Brazil3%

Mexico2%

Vietnam2%

Canada2%

China PR3%

Hong Kong3%

Nigeria3%

UK3%

Russia4%

Germany6%

Japan2%

Netherlands2%

Sri Lanka2%

Singapore2%

USA17%

An Export Promotion Cell in the Pharmaceuticals Division has been created with the objective of boosting pharmaceuticals exports and to act as a nodal centre for all queries/issues regarding pharma exports. The Cell also undertakes promotional activities for acceleration of pharma exports and considers suggestions for modifications in EXIM policy from the Industry.


- 43 -

In order to give adequate attention to day-to-day problems faced by the exporters, the cell interacts with various Ministers/Departments and Indian Missions abroad. The cell collects statistical data on export and import of pharmaceuticals in the country and provides commercially useful information for developing and increasing drugs and pharmaceuticals exports. The cell has also been entrusted with the organisation of seminars and workshops on standards, quality control requirements etc. of important countries so as to prepare the domestic companies for exporting their products.


- 44 -

VII. IMPORTS

As already indicated, the country is almost self-sufficient in case of formulations required by the consumers. Table 9. Imports of bulk drugs and formulations for the last few years ( Rs. Crore) Year Bulk drugs Finished

Formulations Total

1994-95 811.43 173.02 985.45 1995-96 1,630.00 270.00 1,900.00 1996-97 1,705.00 345.00 2,050.00 1997-98 1,827.00 430.00 2,257.00 1998-99 1,918.00 540.00 2,458.00

1999-2000 2,025.00 680.00 2,705.00 2000-01 2,265.00 715.00 2,980.00 2001-02 3,300.00 2002-03 3,640.00

Note : Rs. 1 crore = Rs. 10 Million Major source of imports of Drugs and Pharmaceuticals are Switzerland, Germany, France, USA, UK, Italy, Indonesia, Ireland, Denmark, and China, etc.

Major sources of Imports

IRELAND 3%

NEPAL 3%

DENMARK 3%

U K 4%

CHINA P RP 3%

Netherland3%

Others19%

Indonesia 4%

ITALY 5%

U S A 9%

FRANCE 10%

GERMANY 14%

Switzerland 20%

There have been no reports of shortage in recent years. The country is almost self-sufficient in case of formulations required by the consumers. It may also be mentioned that Industrial licensing has been done away with. The manufacturers are free to produce any drug duly approved by the Drug Control Authority except for a few items reserved for Public Sector Units. Additionally almost all drugs are allowed to be imported under Open General Licence except items in the Negative List.


- 45 -

The New Export-Import Policy announced in March 2003, allows free imports of some drugs items by deleting them from the negative list of erstwhile policy. However, the free import is subject to the stipulation that items to be imported have to be registered with the Ministry of Health treating these items as “Drugs”. The requirements of raw materials and intermediates for manufacture of APIs (Active Pharmaceutical Ingredients including antibiotics are met through imports. It has been reported that the requirement of registration would cast a heavy burden on the units and will also result in huge delays adversely affecting the production plans and may result in shortage of drugs within the country. The Government has taken a pragmatic decision by de-licensing and de- reserving five bulk drugs, particularly essential Vitamins like B1 & B2 in which serious shortages were experienced. While this is a step in the right direction and should generally lead to expansion of domestic manufacturing base, this may not immediately happen due to consideartions of economies of scale. The Indian Consumer is not able to enjoy the benefits of easy availability and low prices since these drugs continue to appear in the "Restricted" List of EXIM Policy and are allowed to be imported against Special Import Licence (SIL). Additionally, it requires the importer to surrender equivalent value of SIL that makes such imports very expensive. Import duty for life-saving drugs 88 Drugs which were subjected to around 22% duty, will now be levied only 5% basic customs duty as announced in the budget 2003-04. The countervailing duty has been abolished. 13 new drugs have been added to this list. However, a number of drugs required for critical disease like T.B, HIV and AIDS are not included.


- 46 -

VIII. DRUGS POLICIES AND LAWS

The Drug Policy decides the criteria to be used for selecting a bulk drug to be kept under price control. 1. Drug policy of 1986 "Measures for Rationalisation, Quality Control and Growth of Drugs & Pharmaceuticals industry in India" had the following main objectives:

• Ensuring abundant availability, at reasonable prices of essential and life saving and prophylactic medicines of good quality;

• Strengthening the system of quality control over drug production and promoting the rational use of drugs in the country;

• Creating an environment conducive to channelising new investment into the pharmaceutical industry to encouraging cost-effective production with economic sizes and to introducing new technologies and new drugs; and,

• Strengthening the indigenous capability for production of drugs. 2. New drug policy (Sept. 94) The modified criteria in the New Drug Policy (Sept. 94) were:

• Annual turnover calculation basis as on March 31, 1990;:

• Inclusion of a bulk drug if turnover exceeds Rs. 40 million;

• Inclusion of a bulk drug if turnover is over Rs. 10 million, with anz single formulator having a 90% plus market share;

• Exclusion, if at least 5 bulk drug manufacturers and 10 formulation manufacturers exist, none having more than 40% market share;

• Exclusion from price control for 5 years, for drugs developed indigenously for the first time.

Industrial Licensing has been abolished for all Bulk drugs. Till recent past (1998), 5 bulk drugs reserved for PSU viz Vitamin B1, Vitamin B2, Folic Acid, Tetracycline and Oxytetracycline. Now there will be no hinderance to capacity expansions. Supply is expected to rise to meet or exceed demand resulting in the rise in competitive pressures. Recently, the Union Chemicals and Fertilizers Ministry considered allowing Foreign Investment into the pharmaceutical sector to give a boost to R&D in the country. Accordingly, research centres would be set up in partnership with the chemical laboratories, and if domestic companies entered into agreements with foreign companies to finance R&D, joint patents could be held and the returns split. The government was also willing to give multinational companies the same concessions as those offered to domestic firms for R&D as long as they were willing to invest in R&D facilities in the country.


- 47 -

In February 1999, the domestic pharmaceuticals industry made a demand to the government to include amendments in the patent law that allow for provisions enabling companies to undertake research on a new drug while it is patent protected. The provisions referred to as Waxman Hatch (Bolar) type provisions, and are included in the Canadian Patent Law. Under this law, companies are allowed to undertake research in, develop and stockpile a pharmaceutical product during the patent period. The only bar is marketing of the product. This law has been challenged at WTO by the European Commission, alleging that the Canadian law does not provide full protection to the pharmaceutical patents for the entire period of 20 years. It seems unlikely that this demand by the domestic industry will be accepted. Despite its steady growth, the feeling is that growth could have been much higher were it not for the Patent Act of 1970 and the Drugs Price Control Order (DPCO). 3. Patent law The patent law implemented in 1972, which allowed patented products to be manufactured in India through a different process, prevented new products from being marketed in the country, claim multinationals. On the flip side, it is the Patent Act that allowed the Indian pharma industry to flourish and make new drugs available cheaply to the Indian public. But instead of encouraging any real R&D, it has made the Indian industry complacent and unprepared (except for the big players) for the post-WTO regime. 4. Drugs Price Control Order (DPCO) The main purpose of the Drugs Price Control Order (DPCO) was to make available essential drugs at an affordable rate for the common man, and prevent monopoly, is now being cited by Indian pharma companies as responsible for low profitability. 5. National Pharmaceuticals Pricing Authority (NPPA) Since last August, National Pharmaceuticals Pricing Authority (NPPA) is responsible for monitoring the price of bulk drugs and formulations. The NPPA can now ask pharma companies to submit quarterly production-cum-price return data. The DPEA or Drug Price Equalisation Account was set up to encourage domestic production of bulk drugs through retention pricing. Any pharma company making undue profits on bulk drugs would have to deposit this to the DPEA. What happened is that the government slapped claims against the manufacturers for the alleged profits that they had to credit to the DPEA account. The amounts collected in this account, are they being used to promote research in the pharmaceutical sciences, as was originally intended? DPCO controls the domestic prices of major bulk drugs and their formulations with an aim to provide patients with medicines at affordable prices. DPCO ascertains, as per Drug Policy guidelines, the bulk drugs (and their formulations) to be kept under price control. Under DPCO, a bulk drug and formulation are as follows:

• Bulk drug means any pharmaceutical-chemical, biological or plant product including its salts, derivatives etc used as such or as an ingredient in any formulation.


- 48 -

• Formulation means any medicine processed out of or containing one or more bulk drug or drugs for internal or external use or for diagnosis, treatment, mitigation or prevention of disease in human beings or animals, but shall not include any medicine included in any bonafide Ayurvedic, Homeopathic or Unani system of medicine.

Thus, DPCO is applicable only to allopathic drugs. Ceiling prices for the DPCO bulk drugs and formulations are notified by the Government authorities and periodically revised. DPCO came into existence in 1970 thereafter revised in 1979, 1987 and 1995. 6. DPCO 1970 DPCO came into being for the first time in 1970. At that time the Indian pharmaceutical industry predominantly comprised of MNC affiliates and subsidiaries. In its introductory form, DPCO was more of a control on the profitability of a pharmaceutical business, and thereby it indirectly sought to control the prices of pharmaceuticals. The Government stipulated that a company’s pre-tax profit from its pharma business would not exceed 15% of its pharma sales (net of excise duty and sales tax). In case profits exceeded this sum, then the surplus had to be deposited with the Government. So, a pharma company had the freedom to decide its products’ prices. Product-wise margins could be flexible, so long as the overall margin did not exceed the stipulated norm. Also, with individual product prices not requiring approval from the government, bureaucratic hurdles were relatively low. Also, the Indian Patents Act 1970, gave an impetus to local players to reverse engineer drugs and foray into various therapeutic segments. MNCs were not affected too severely by the relatively mild form of DPCO and continued operating in the domestic market. However, FERA that came in mid 70’s did curb MNCs' operations. Overall, the Indian pharma industry prospered from 1970 to the next DPCO in 1979. 7. DPCO 1979 In its 1979 revised version, the DPCO stipulated ceiling prices for controlled categories of bulk drugs and their formulation. In fixing the price, the Government continued to advocate profitability ceiling. In case of bulk drugs, this was through a limit on the company’s return on networth or capital employed. DPCO ’79 put 370 drugs under price control. Further these drugs were segregated into 3 categories, having different MAPE (Max. Allowable Post Manufacturing Expenses). The most important drugs, including life saving drugs were put into Category I, which had the least MAPE of just 40%. Later, the Government introduced a Category IV with 60% MAPE. Some drugs from Category III, such as Vitamins etc were then transferred to Category IV, reducing the margins of these products.


- 49 -

Around 80% of the Indian pharma industry (in value terms) was thus brought under strict price control. The MNCs were the worst hit. Profitability fell steeply, new investments in the sector dwindled and MNCs discontinued many products, especially the life saving products falling under Category I. The MNCs, with industrial licensing requirements restricting new product introduction, reeled under the onslaught of severe dip in profitability. The local players were granted licenses relatively easier compared to MNCs with their ability to speedily introduce new drugs, they were able to keep DPCO coverage lower. Hence, they managed to flourish and effectively fight the might of the established MNCs. But, profitability wise, the Indian pharma sector passed through its worst phase from 1979 till the DPCO was revised in 1987. In 1987, the Government felt a need to liberalise the strict profitability curbs that were a hurdle to the growth of the pharma sector in India. So, in DPCO ’87, the number of drugs under price control, was reduced significantly from 370 to 143. Also, the controlled categories were reduced to 2 and higher MAPE was provided. • Category I: 75% MAPE • Category II: 100% MAPE Industrial licensing norms were made less strict, improving the situation for MNCs desirous of amending their product mix. Around 75% of the pharma industry remained under price control. However, profitability improved due to higher MAPE. 8. DPCO 1995 This latest DPCO revised order was passed in Jan ’95. Its basic structure remains same as the prior two orders of ’79 and ’87. But, it did liberalize the span of control considerably from 143 drugs to just 76. (a) DPCO pricing: formulations DPCO automatically covers all formulations containing the bulk drugs specified in the First Schedule. Prices of formulations under price control are fixed as per the following formula. DPCO ’95 gives a uniform Maximum Allowable Post-manufacturing Expenses (MAPE) of 100% as against earlier MAPE of 75% for some of the drugs. MAPE is the markup on ex-factory costs provided to cover all selling and distribution costs, including the retail and wholesale trade margin. (b) Key issues in DPCO’95 Based on outdated data

The criteria of selection for drugs to be put under price control were decided so as to prevent a cartel of manufacturers from exploiting the customers (patients). But, the basis of selection was the 1990 turnover values. As a result some drugs where there was high level of competition as players had mushroomed after 1990, were unnecessarily included under DPCO.


- 50 -

High span of control

As per the 1990 turnover records, only 50% of the pharma industry is under DPCO ’95. But, as sales of some of the controlled drugs, earlier outside price control, have grown at a higher rate than the overall industry, the actual span of control encompasses 60-65% of the domestic pharma industry. Lack of stability

The number of drugs under DPCO can be modified either increased or decreased any time. There is no stability about the inclusion or exclusion of any drug or formulation under DPCO. So, prices of drugs and formulations in the domestic market can undergo drastic changes, irrespective of the competitive market forces. Prices of input materials are not controlled

Even key intermediates used in the pharma sector are outside DPCO purview. These intermediates often find application in various other chemical industries. As a result their price trends, both in India as well as internationally follow a very different cycle compared to the bulk drugs wherein they are used. Prices of some intermediates get indirectly regulated, if they are largely used in a bulk drugs under DPCO. Penicillin G and Amoxycillin are both bulk drugs under DPCO. Amoxycillin can be developed from basic Pen G stage or from 6-APA, a derivative of Pen G. As 6-APA is classified as an intermediate (it has no medicinal properties), it remains free from any direct price controls. But naturally, its price varies due to presence of alternate process of manufacturing Amoxycillin from Pen-G stage. Artificial disallowances

Prices of DPCO drugs and formulations have to be fixed after taking into the cognisance the cost of inputs used in their manufacture. But, in many cases the actual input costs are not recognised by the Government. For eg in case of sugar, a common ingredient in most formulations, the Government considers price of levy sugar as a benchmark while actually the pharma companies procure their requirement from the open market at a price that’s 20-25% higher. In case of wages, power etc the norms are as prevalent 3-5 years earlier and inflationary impact is not considered. Delays in announcing prices

Price fixation exercise for DPCO drugs (and their formulations) is undertaken only once every 4 years by the Government. Interim price changes are made only on specific price revision applications made by any manufacturer. In such a case, the Government has to collate data of other manufacturers and then come to a conclusive judgment whether the price revision is justified. The Government is expected to give the revised price within 4 months of submitting the application in case of bulk drugs and within 2 months in case of formulations or reject the application with reasons thereof recorded in writing. But, in reality the revisions are much delayed, even taking upto a year after an application for price revision has been filed.


- 51 -

Market forces

For the drugs and formulations under DPCO, only the maximum price is specified. As a result of competition from various players and price undercutting in some products where supply exceeds demand, the actual price may fall below that specified under DPCO. In such cases, artificial price regulation becomes unnecessary. New product launch delayed

A product made by an indigenous process for the first time in India gets a 5 year exemption under DPCO. If any other company launches the same product through another new process, it too has to apply for a separate DPCO exemption pre-launch. Else, if the application has not been filed, the product may be included under DPCO for the second manufacturer. However, once the drug/ formulation developer has filed his application for his new process, he can launch the product without waiting for DPCO clearance. So product launches are not unduly delayed. Trade margins

For formulations derived from DPCO drugs, Government decides the trade margins as well. For DPCO formulations, the minimum retail margin is 16% (otherwise 20% as per industry norms) and minimum wholesale margin is 8% (otherwise 10%) as fixed by the Government. Formulators are free to give higher margins. Some also try to push their products by giving free packs to retailers for eg against 6 injection vials, 1 vial comes free. This is as good as giving the retailer a higher margin. (c) Drug price equalisation account (DPEA) As directed by the Government since DPCO 1979, any pharma company that makes undue profits by selling a DPCO controlled bulk drug or formulation at a price higher than the ceiling price notified by the Government, must deposit the same into the DPEA. The amounts collected in this manner will be used to:

• Paying a manufacturer, importer or distributor, as the case may be, the shortfall between his retention price and the common selling price.

• Meeting the expenses of the Government in discharging the functions under enforcing compliance to DPEA regulations.

• Promoting higher education and research in Pharmaceutical Sciences. 9. New pharmaceutical policy 2002 Main objective:

• To improve on incentives for research and development so as to achieve sustainable growth particularly in view of the anticipated changes in the Patent Law;

• Reduce further price control in view of ongoing process of liberalisation;

• Make available good quality essential medicines at reasonable prices;


- 52 -

• Build indigenous capabilities so that production is cost effective;

• Put emphasis on quality production;

• Create incentive network which would attract new investments and flow of new

technologies;

• Develop and market products that have recently gone out of patent (drugs worth US$ 80 billion are expected to go out of patent in the next 10 years.) The global industry presents several opportunities for the pharmaceutical industry;

• Focus on high potential generic market in US and other developed countries; and

leveraging on cost advantage and skilled manpower base to undertake contract manufacturing and contract research.

The New Pharmaceutical Policy announced by the Govt. Of India was challenged in the Karnataka High Court through Public Interest Litigation (PIL). The court stayed the operation of this policy on the grounds that it has failed to bring various Essentials Drugs into the ambit of Price Control. Subsequently, the Govt. of India filed a Special Leave Petition (SLP) to challenge the Karnataka High Court judgment. It is understood that the SLP is based on the constitutional point that policy formulated by the Govt. of India cannot be challenged by the court of law. The court directed the Govt. to review Drugs which are essentials and life saving in nature and formulate appropriate criteria for ensuring Essential and Life Saving Drugs not to fall out of the Price control. (a) National pharmaceuticals pricing authority (NPPA) It has been set as a regulatory authority for governing the pharma sector for pricing and price control. With a view to enforcing the provisions of the Drugs (prices control) Order (DPCO) and to perform the functions assigned, some of the actions/ steps have been taken by NPPA since its inception are:

(i) Revised/fixed the prices of 12 bulk drugs and 635 formulation packs; (ii) NPPA has asked the manufacturers of all the scheduled formulation pack sizes to

work out the prices of different pack sizes of tablets and capsules of the same strength or composition packed in different strips or blisters on pro-rata basis of the latest ceiling price fixed. This was done to ensure that (a) the manufacturers do not change their pack sizes in a bid to remain out of price control and (b) manufacturers are not forced to approach the government/ NPPA frequently for price approvals for different pack sizes;

(iii) Compiled the data on production and imports of bulk drugs for the year 1997-98

and 1998-99; (iv) Analysed price movement between 1994 and April 1998;


- 53 -

(v) Fixed the prices of three commonly used IV Fluids by exercising the powers available under para 10 (b) of DPCO 1995. These prices are lower by about 40% than the prices charged earlier by the companies from the consumers;

(vi) Kept a check on the prices of drugs, besides advising the state government to

enforce the prices of scheduled formulations; (vii) Set up an expert committee to review the norms of conversion cost (CC0, packing

charges (PC) and process loss (PL). (b) National drug authority It is envisaged that a National Drug Authority may be set up by a separate Act of Parliament to perform the following functions:

• Develop and define basic appropriate standards relating to the manufacture, import, supply, promotion and use of drugs;

• Approve and register pharmaceutical products for use in the country only if

- it meets real medical need, - it is therapeutically effective, and - it is acceptable safe;

• Enforce effectively appropriate quality standards of medicines and Good Manufacturing Practices, throughout the country, having full regard to the needs of public health and standardize dosage strengths and pack sizes of formulations with a view to check proliferation;

• Monitor standard practices in drug promotion and use and to clearly identify those which are acceptable and prohibit those which are unethical and against the consumers' interest;

• Monitor the prescribing practices and to evaluate their appropriateness for the purpose of guiding the medical profession and for achieving the aim of rational prescribing;

• Ensure that appropriate information about registered pharmaceuticals is made available for the guidance of consumers having regard to:

- the adverse consequences of non-compliance by patients particularly in the case of antibiotics, steriods etc.,

- dangers of self-medication, and - the need to involve consumers as full partners in the health care system

• Prepare and publish a national formulary and formularies relevant to various levels (like district hospital, community centre, primary health centre) for the guidance of consumers as well as doctors.

The functions mentioned above involve new responsibilities which will include:

- Special focus on examining the technology of bulk drugs; - Capacity validation of machinery; - Assessing suitability of manpower for bulk drug production; - Undertaking scientific scrutiny of master formulae for manufacture of formulations; - Developing testing labs for cosmetics, diagnostics and devices; - Laying down standards for veterinary drugs;


- 54 -

- Examination of labels and promotional claims and prescribing procedures for public hearing under the Drugs and Cosmetics Act;

- Monitoring of clinical trials for the protection of human rights; - Quality control of herbal medicines; - Updating new drug approval process; - Weeding out of irrational combination formulations; and - Formation of expert committees for examination of new drugs.

In addition, screening promotional literature, monitoring ongoing clinical trials through an Institutional Review Board, unearthing sub-standard and spurious drugs with the help of Legal cum Intelligence Cells, centralising all manufacturing licensees for inter-State commerce and updating Good Manufacturing Practices. (c) Quality control and rational use of drugs Quality Control and Rational use of drugs are important aspects of pharmaceutical industry. Steps have been taken for strengthening Drug Control Organisation by sanctioning additional posts at various levels and by establishing sub-zonal offices at Hyderabad, Ahmedabad and Patna. The Bio-Laboratory at Chennai has been upgraded to the level of national laboratory. The Central Drugs Laboratory at Bombay, functioning from 1992 is in the process of being upgraded while Regional Laboratories at Guwahati, Chandigarh and Hyderabad are in the process of being set up. To improve the existing State Drugs Testing Laboratories and to set up new ones, wherever not established, funds have been sanctioned under a Centrally Sponsored Scheme, besides providing funds under this scheme for augmenting Drug Inspectorate Staff. For certain categories of drugs, which had caused adverse effects due to the lack of drug control in one or the other State, the Central Government has taken upon itself the responsibility of granting license. These drugs are; (i) Large Volume Parenterals, (ii) Sera and Vaccines and (iii) whole Human Blood and Blood Products. Moreover, the Good Manufacturing Practices (GMP) have been made mandatory. Screening of irrational or harmful drugs is an ongoing exercise and 44 categories of formulations have been banned so far and the definition of new drugs has been widened and guidelines issued on clinical trials. With a view to ensuring proper dispensing and rational use of drugs, packaging have been standardised. Five leading hospitals at Pondicherry, Chandigarh, New Delhi, Bombay and Lucknow have been identified as Adverse Drug Reaction Monitoring Centres. 10. Other relevant policies (a) Rifampicin policy Rifampicin is an important anti-TB drug. India is a major consumer of this drug. Its manufacturing technology is difficult and guarded. Till 19991-92, this drug was manufactured in India exclusively from imported 3-FRSV and later from imported Rifamycin-S (Rifa-S) a stage previous to 3-FRSV. From 1991-92, M/s. Gujarat Themis Biosyn Ltd (GTBL), Vapi commenced production of Rifa-S from the basic stage of fermentation. M/s. Lupin Chemicals Ltd followed suit in 1992-93 at their plant in Tarapur, Maharashtra. Towards the end of 1996-97 M/s. Ciba_CKD has commenced production of Rifampicin from basic stage. At present GTBL is


- 55 -

converting Rifa-S into 3 FRSV and thereafter produces Rifampicin whereas Lupin is converting Rifa-S into Rifampicin directly. Since the indigenously produced Rifampicin and Rifampicin intermediates were not sufficient to meet the requirements, it becomes necessary to frame Rifampicin Policy every year to regulate the import and to protect indigenous manufacturers after taking into account the demand and supply in the previous year, the estimated production as well as the country’s demand for the current year. After taking into account the demand and supply of Rifampicin intermediates, a policy was taken on 13-8-96 intimating that no import will be allowed for Rifa-S against indigenous lifting. All the consumers are permitted to lift their requirement from the indigenous producers. This policy continues presently. (b) Pencillin G policy Pencillins are Betalactum antibiotics, produced by the growth of various Pencillin species of moulds. Potassium Pencillin G First Crystals (Pen.G) are indigenously produced by fermentation process and then converted to injectable grade Pencillins, namely, Sodium Pencillin G IP, Procine Pencillin G IP and Benzathine Pencillin G IP. Since the indigenously produced Pencillin G (Pen.G) was not sufficient to meet the country’s requirement it became necessary to frame a Pen.G policy every year to regulate the import and also for allocation of indigenous material, after taking into account the demand and supply in the previous year, the estimated production as well as the country’s demand for the current year. Till November, 1986, manufacture of Pencillin was reserved for public sector in accordance with the provisions of the Drug Policy, 1979, alongwith two private sector units at that time were also engaged in its production in the country. However, in 1988 it was decided to d-reserve the item considering the fact that fresh investments on a large scale would be required to meet future demands of Pen-G for the manufacture of semi-synthetic Pencillins. Presently the following units are engaged in the manufacture of Pen. G: - M/s. Indian Drugs and Pharmaceuticals Ltd (A Public Sector Undertaking) - M/s. Hindustan Max – GB Ltd - M/s. Alembic Chemicals Works Company Ltd - M/s. J K Pharmachem Ltd - M/s. SPIC Pharmaceuticals Ltd - M/s. Torrent Gujarat Biotech Ltd All pencillins are included in the Negative list of imports under the existing Export -Import Policy. In order to support the indigenous basic stage manufacturers of Pencillin G and to keep the imports to the barest minimum, a policy for regulating imports has been in operation for quite some time and this is referred to as the Pen G Policy that is framed for every financial year. Keeping in view the demand and supply of Pen. G a policy decision was taken on 13.8.96 that the allocation of Pen G ahs totally been done away with. The convertors can lift Pen.G as per their requirment from any of the indigenous manufacturers. This policy continues to operate presently.


- 56 -

IX. MARKET PROSPECT

Indian Pharmaceutical industry ranks among the most developed in the third world countries in terms of quality, technology and range of products. It ranks 4th in volume and 13th in value in terms of Global Ranking. 1. Strengths Net exporter of bulk drugs and formulations Lower average cost of production High skill in process development Third largest scientific pool in the world Cost of R&D lower than developed countries India is the 4th largest producer of pharmaceuticals in terms of volume Sustainable supply of raw materials

Only 28% of the almost 1 billion population in India are exposed to the products of the Indian pharmaceutical sector. As the purchasing power of the common person will go up because of the ongoing economic reform process, a yet untapped market of 72% of the Indian population would heavily boost domestic demand for pharmaceuticals. The factors that contribute to advantage India are mainly strong intellectual capital base of technical manpower having entrepreneurial skills, large patient base to conduct international clinical trials, US FDA/WHO compliant manufacturing facilities, strong base in bulk drugs manufacture, fall back situation w.r.t. R&D as 10% of researchers and 15% of USA Scientist in the filed of biotechnology and pharmaceuticals are of Indian origin. The global industry presents several opportunities for the pharmaceutical industry as drugs worth US$ 80 billion are expected to go out of patent in the next 10 years. Focusing on high potential generic market in US and other developed countries; and leveraging on cost advantage and skilled manpower base to undertake contract manufacturing and contract research will be added advantage to India. Health will be a very high priority and one can expect to see strong investment in the sector, especially as it applies to responding to the needs of the less well off. According to World Health Report 2000, Indian families on an average spend 11% on healthcare. India’s health expenditure is 5.2% of GDP while public and private health expenditure is 13% and 87% respectively. India has a large population, bulk of which resides in the rural areas. High level of illiteracy, poor infrastructure and low levels of hygiene make for a poor defence against illness, especially communicable diseases and malnutrition. Majority of Indian are still not covered by any insurance, social security, etc. More than 80 % of the people have to shell out money from their own pocket to meet health costs due to lack of cover.


- 57 -

Although there has been an improvement in the overall scenario over the years, India is way behind the rest of the world on various health parameters. Changing demographic and disease profiles and rising treatment costs will result in healthcare spending more than doubling over the next 10 years. Govt. has to be proactive on primary health issues like clean drinking water, sewerage systems, poverty, literacy levels, infrastructure etc. In fact, a higher govt. spending can result in lower incidence of disease especially communicable ailments. More public-private partnerships are needed in tertiary and secondary sectors. India’s healthcare and pharmaceutical industry would do well if it focuses on providing ‘‘world-class care’’ at an ‘‘affordable cost’’ - and being ‘‘creative and innovative’’ in ‘‘constantly striving to meet the needs and expectations of patients and customers’’. South Korea, China and Mexico, in terms of positive outcomes, benefited by experiencing a boom in the pharmaceutical industry from accepting international patent laws. Most likely India will undergo similar changes after 2005. Table 10. Annual drug expenditure per capita in US$ in various countries Country Per Capita Drug Expenditure in US $ Japan 412 Germany 222 United States 191 Canada 124 United Kingdom 97 Norway 89 Costa Rica 37 Chile 30 Mexico 28 Turkey 21 Morocco 17 Brazil 16 Philippines 11 Ghana 10 China 7 Pakistan 7 Indonesia 5 Kenya 4 India 3 Bangladesh 2 Mozambique 2

(Source: Pharmaceutical Technology, January 2003)


- 58 -

Indian pharmaceutical sector is in the midst of making the transition from being imitation-oriented to becoming innovation oriented. Indian players have, over the years, built up very strong chemistry, production process improvement, and formulations expertise - the opportunity and challenge now is for Indian players to translate their ingenuity and knowhow from imitation to innovation. The change process has already started, and the Indian pharmaceutical sector will become more vibrant and profitable (over the longer term) as a consequence. One can anticipate a very bright future for the Indian industry. Most of the companies have shown more interest in exporting their products while the domestic sales have remained more or less steady. The Indian market is relatively small in value terms with very low margins because of the intense competition in the market (especially with so many copycat and “me-too” products finding the way into the market within a short time after any novel product is launched), while export markets are characteristically much larger and bring substantially higher margins. Hence, one is likely to get much better return on investment of time and effort in export markets than in the Indian domestic market. India, with nearly 20% of the world’s population, typically constitutes just one per cent of the global market for products in most categories. By contrast, the US, with less than five per cent of the world’s population, constitutes 40 per cent or higher of the market (Europe is typically about 30%). Three key areas are Quality, Innovation, Market and business development capabilities. India has many strong points that bode well for the future, and that are already making the country and its healthcare and pharmaceutical industry player a major force. Emphasis on the three key areas above would enable India to effective arbitrage off the tremendous difference in cost of production and clinical testing in India versus the more developed markets - managed right and with vision, India has an excellent chance to become the out-source manufacturing and clinical testing centre of the world, and a major net exporter of high value products, technologies and services - both developed indigenously and in alliance with leading international partners. Many Indian companies maintain highest standards in purity, stability and conform to international SHE norms (safety, health and environmental protection) in production. Citing an example, Global DSM group closed some of its plants abroad and is now sourcing semi-synthetic penicillin from their JV in India. Further an Indian company which specializes in the manufacture of Ibuprofen, has tied up with the original innovator Cos, namely Boots, UK and Glaxo SmithKline, UK, to supply Ibuprofen and Rantidine to these MNCs. Chirotech, UK, Nagase & Co., Japan, Eli Lilly, US are some of the other international companies having manufacturing contracts with Indian companies for S-Naproxen, S-Ibuprofen and Nizatidine, respectively. Anti TB-drug segment is another area where India is a world leader. These tie-ups have been possible due to the highest quality standards maintained by large number of Indian companies as these bulk drugs are used by the buyer companies in the active dosage forms which are subject o stringent assessment by various regulatory authorities in the importing countries. Considering that pharmaceutical industry is an industry involving sophisticated technology and stringent GMP requirements, 40% of the share of Indian pharma exports going to highly developed Western countries speak not only of excellent quality of Indian pharmaceutical products but also the reasonableness of the prices. Many Indian companies, in addition to having WHO GMP certification, have also been getting plant approvals from international regulatory agencies like USFDA, MCA UK, TGA, Australia, HPB Canada, MCC Africa and ISO 9000 certification.


- 59 -

Strategic marketing alliances with European Companies, filing of Abbreviated New Drug Approvals with US FDA, either directly or through US Companies, for such products whose patents in US are about to expire are one of the new areas being explored by Indian companies. With US$ 80 billion worth of drugs reported to be coming off patent between next ten years, India is going to be a leading generic drug supplier on the strengths of its developing cost efficient technological processes for the Generic Versions. With the increasing number of off-patent bulk drugs and capabilities of Indian scientists in process technology, the share of Indian products in world market is expected to rise further. With the expansion of generics in developed markets like EU and USA and the need to outsource research support service, India has the potential to emerge as global hub. Further, it has been observed that globally, healthcare costs are under strong pressure in many of the countries and these countries can look forward to India. India’s strengths also lies in the production of low-cost dosage forms from all therapeutic groups without compromising on quality to suit the cost containment exercises attempted by Health Authorities in various countries. Another critical area of interaction could be technical cooperation with internationally known National Laboratories like Indian Institute of Chemical Technology (IICT), Hyderabad, Centre for Cellular Molecular Biology (CCMB), Hyderabad, National Chemical Laboratory, Pune, Central Drug Research Institute, Lucknow which are also centres of excellence in the field of pharmaceuticals and Biological sciences. Global Companies like DuPont, Merck, Pfizer, USA, Glaxo SmithKline, UK, Yamanouchi, Japan have tied up with institutes like IICT. CCMB is doing fundamental research work on biomedical and societal areas and also on Antimicrobial Peptides to combat infection, high research relating to Ageing and cataract. Thus, for global companies who have their vision focused on cost effective and quality research activity in the area of Drug Development and manufacturing, India is a must-not-miss destination. India has been able to develop cost effective processes for some of the latest potential medicines like Glitazones, Rofecoxib, Colecoxib, Sildenafil Citrale, Statins like Lovastalin, Atorvastatin, Oncology drugs, antiretroviral, Nevirapine, Sibutramine, several Oncology drugs, Antiretroviral drugs like Zidovudine, Lamivudine. These bulk actives are supplied to countries where these are not patented and to USA for R&D work. Western companies, are increasingly finding India a particularly attractive destination for custom manufacture of potential drug molecules and intermediates selected for preclinical and clinical development in view of the excellent human resource skills in organic synthesis, medicinal chemistry, molecular modeling and natural product chemistry. Further, R &D can be carried out in India at as much as 15-20% of the cost in Europe or USA. On a Dollar basis, the cost advantage is estimated to be 10-15 times. Indian leading companies are also setting up Satellite Research laboratories in USA manned by US personnel. Moreover, leading Indian companies by themselves are also conducting clinical trials in India by creating infrastructural facilities independently for their work. Thus, India is becoming a center for clinical trials is reflected from the fact that multi-national companies like Pfizer, Johnson & Johnson, Glaxo Smith Kline, Merck & Co. have filed investigative New Drug Approval through partnership with Indian companies.


- 60 -

Many things will clearly change, including:

• No more low cost generic version rip-offs of patented products;

• Increased emphasis and focus by Indian players on R&D and product innovation for novel products that they can bring to market as proprietary products that would clearly bring better margins in India and internationally;

• Increased interest among Indian players for strategic alliances and partnerships with leading pharma players around the world - both for in-licensing and out-licensing of products;

• Greater confidence among international players in bringing new products into the Indian market (characteristically, major players have avoided bringing their latest products into the Indian market - preferring to bring in off-patent products wherever possible).

Indian Pharmaceuticals and Drugs Companies have also been taking rapid strides in the field of Biotechnology. Use of Recombinant DNA technology for the production of Hepatitis B Vaccine is one such area where even Pfizer USA is sourcing this vaccine from an Indian Company. Companies are also working on newer vaccines and Diagnostic kits. Some companies have already started making a mark in the international biotech market with their vaccines. Biotechnology is expected to impact different sectors at varying times. Increasing interest exists in revisiting the ancient drug systems. The Department of Indian Systems of Medicines and Homeopathy was established in 1995 as a separate department in the Ministry of Health and Family Welfare. One of the organisation’s goals is to prepare standards for ayurvedic, unani, sidhha, and homeopathy drugs. Good manufacturing practices for ayurvedic drugs is at the final stage. The department is actively pursuing a proposal to establish a medicinal-plant board to enhance the availability of quality raw materials, prepare a database of medicinal plants, and collect information from ancient texts. Alternate Medicines (Herbal/Ayurvedic, etc) are gaining popularity and the major importing markets are EU and USA. These markets are however highly regulated and are very difficult to penetrate particularly for developing countries and LDCs whose products are not undergone the stringent tests. Following steps are required to boost the exports of alternate medicines:

• Serious consideration to save this natural heritage of India;

• Evolve a sound system of conservation and rational exploitation of medicinal herbs;

• Propagation of rare and valuable medicinal plants through issue culture technique;

• Application of molecular taxonomy for classifying the plants and for their authentic identification;

• Development of proper facilities and methods for rapid screening of medicinal plants. The Government has already announced Ayurveda as the thrust area in their mid-term policy. They can help Ayurvedic Manufacturers Exporters by formulating the policy by which the expenses can be compensated for the manufacturers, assist the manufacturers to form the Data Bank, carry clinical trials themselves at the Government. Hospitals- most manufacturers will gladly give samples for such trials etc.


- 61 -

2. India’s preparation for 2005 Major issues have surfaced on account of globalization and implementation of India’s obligations under TRIPS that would have had impact on long-term competitiveness of Indian industry. One of the major concerns for India is the TRIPS regime that demands a product patent system as opposed to processed patent in the Pharmaceutical sector. Now –a- days anyone remotely connected to this sector has only one question in mind. What after 2005? The Indian Pharmaceutical Industry is expected to undergo phenomenal change after 1st January 2005, when international patent laws will be implemented. After signing of the General Agreement on Tariffs and Trade (GATT) Uruguay Round Table Agreement in Marrakech, Morocco, in April 1994, WTO was created. WTO is an institution rather than an agreement such as GATT. It sets rules governing trade between its 132 member countries. It has allowed member countries until 1 January 2005 to make necessary adjustments before they are required to abide by WTO rules. Three major conventions exist to protect patents and intellectual property rights: the Paris Convention, which includes the United States and 100 other countries; the Inter-American Convention, which includes the United States and Latin American nations’ and the Madrid Arrangement, which includes 26 European nations (8). The World Intellectual Property Organisation (WIPO), a part of the United Nations, is responsible for promoting the protection of intellectual property as well as administering various multilateral treaties. Despite all the treaties and rules, policing patent infringement and piracy has become a monumental task. Each country is required to take measures to address these problems. The secondary outcome of these efforts could be to develop technology and promote patenting in every country, which will automatically help protect international patents. Likewise India is making efforts to develop modern technology in the pharmaceutical industry. The key task is to promote R & D that is on par with the technology in other advanced countries. After 2005, the globally harmonized patent system would prohibit the production and marketing of patent protected new drugs. Indian officials want to ensure that Indian people do not suffer in terms of high costs of medicines after 2005. The goal is to prevent the American, European, and Japanese pharmaceutical monopolies from exploiting the Indian population. Basic needs for the development of the pharmaceutical sector are funds, infrastructure, R & D management, and human resources. The Indian government and the IPI have been focusing their efforts so that these necessities are ready for 1 January 2005. 3. Efforts by the Indian Government The Indian government is encouraging private and public sectors as well as foreign investors to increase investments in pharmaceutical R&D. Some positive steps taken by the Indian government in recent years include • Recognition of the pharmaceutical industry as a knowledge based industry;

• Reduction in interest rates for export financing;

• Additional tax deductions for R&D expenses;

• Reduction in the price control of pharmaceuticals.


- 62 -

As an example, the import duty surcharge of 3.5% on vaccines and life-savings drugs has been removed. A 10% surcharge on custom duty has also been scuttled (9). Small scale industry exemptions have led to the proliferation of small formulation manufacturers and low cost drug manufactures. 4. Efforts by the Indian pharmaceutical industry The IPI seeking to take full advantage of benefits offered by the government, has been allocating money to R & D. Its focal points are drug discovery, development of drug delivery systems, biotechnology, and bioinformatics. Companies are reevaluating their strengths and emphasizing product segments that are profitable to the company. Many companies are trimming their portfolios to focus on particular therapeutic segments. Pharmaceutical marketing is also changing rapidly, and pharmaceutical companies are making elaborate marketing efforts. Companies such as Sun Pharma, Nicholas Piramal, and Dr. Reddy’s Laboratories have opted for brand/company acquisition to increase therapeutic reach and market penetration. Such specialization would make the entry of MNCs difficult. Some theorize that companies with a strong marketing force would be attractive for possible take over. Many pharmaceutical companies are entering into marketing arrangements such as Hoechst Marion’s agreement with Nicholas Piramal and Ranbaaxy’s pack with Cipla., Glaxo, and Hoechst Marion. Table 11. Leading pharma markets COUNTRY Sales in 2000 (US$ Billion) 1. USA 148.7 2. Japan 57.8 3. Germany 17.2 4. France 16.7 5. UK 11.0 6. Italy 10.9 7. China 6.8 8. Brazil 6.6 9. Canada 6.2 10. Spain 6.1 11. Mexico 5.0 12. Argentina 4.0 13. India 3.8 14. Australia/New Zealand 2.9

Source: OPPI Pharmaceutical Compendium 2001 Top 10 Pharma companies in the world contribute 50% of the global pharma sales.


- 63 -

Table 12. Top 10 pharma companies in the world (US $ Billion) 1. Glaxosmithkline 23.4 2. Pfizer 22.6 3. Merck 18.6 4. Bristol-Myers Squibb 15.9 5. Astrazeneca 15.7 6. Aventis 14.9 7 Pharmacia 12.7 8. Johnson & Johnson 12.0 9. American Home Products 10.8 10. Hoffmann-La-Roche 10.5

Source: OPPI Pharmaceutical Compendium 2001 5. The changing global scenario The health-care costs are rising world-wide. Leading companies are merging. Strategic alliances and collaborations are taking place in order to meet the increasing R&D budgetary requirement that exceeds a billion dollars each for many leading global pharma players. The WTO has imposed upon the Indian pharma industry the challenge of coping with product patents by the end of the year 2004 and exclusive marketing rights (EMRs) in the interim period. Recent advances in molecular biology and genetic engineering have enhanced the basic understanding of human physiology and the biological action of drugs on cell receptors and proteins. New tools of drug discovery such as combinatorial chemistry. Structure based molecular design and high throughput screening have revolutionized the drug discovery process. This increasing scientification of drug research has encouraged a division of labour amongst agents specialized in different segments of the innovation chain i.e. basic medical research, chemical synthesis, process development, clinical testing etc. At present out of ten thousand chemical compounds screened, only one becomes an approved drug in the developed countries. Further about 12-15 years are required for drug development. In order to attempt to reduce the time for drug development to half and improve the success rate of drug discovery, intelligent screening of sources of chemical compounds is required. For this, one and creation and analysis of new tools and data base of compound sources would be necessary, and on the other hand, new tools such as combinatorial chemistry, structure based molecule design and high throughput screening would have to be adopted to great chance the levels of productivity of drug discovery. Further more, some of the new sources of NCEs could be plants, microbes, fungi, insects and various venoms. The extracts from these material sources must continue to form a major source of entirely novel structure. The Human Development Report of 1999 has highlighted that there is a tremendous concern about the control of knowledge as lighter intellectual property rights raise price of technology transfer and increase the technological gap and block the developing countries out of dynamic knowledge sector. On the other hand, the major pharmaceutical companies argue that compliance of the provisions of TRIPS would stimulate transfer of technology, encourage foreign direct investment, strengthen R&D investment and so ensure early introduction of new products in developing countries.


- 64 -

These arguments are invariably backed by data on increased DI in some countries where stringent IPRs were introduced. Whereas these claims and counter claims could be debated, the Indian model has to be based on providing medicines at affordable prices to the needy Indian populace on one hand and also leveraging the Indian intellectual prowess on the other, through which India could create its own intellectual property. An internal networking and co-ordination amongst different constituents of innovation chain has not only become necessary but imperative in order to bring down the time and costs of new drug discovery and its introduction in the market place. This affords a great opportunity to Indian R&D. On reviewing the past and present trends and level of pharmaceutical research, it becomes clear that the future of pharmaceutical research would be mainly about biotech products and gene-therapy. Those products will dominate the marketplace and expected to be effective, cost effective and safe therapeutic agents for treatment and prevention of diseases. Nowadays it is observed that micro-organisms are developing resistance to antibiotics or anti-bacterial and there is continuous shift in disease pattern with newer diseases emerging. Hence, pharmaceutical research has to be oriented towards developing better and effective newer novel drug delivery systems to combat the diseases. In this respect it is certain that various novel drug delivery system of different types i.e. occular, buccal, vaginal, transdermal, nasal, implants, osmotic pumps, oral having targeted (site specific) and controlled release, will replace existing dosage forms of different molecules. It is also certain that biotech process will be utilised for manufacture of various bulk drugs since it is very much easy and less cumbersome than the present day chemical synthesis process. Hence, pharmaceutical research is the most essential part of the growth of pharmaceutical industry as well as for the treatment and prevention of diseases. A strong R & D is the base for growth and prosperity of nation. Therefore, the government, pharmaceutical manufacturers and faculty members should stress on an increased attention upon research particularly for their survival in this competitive global environment. Recent globalization and the development of the information superhighway have brought the countries of the world closer. From a business perspective, the world is one marketplace. The World Bank estimated that five countries – Brazil, China, India, Indonesia, and Russia – whose share of the world pharmaceuticals market is barely one-third of that of the EU will have a fifty per cent higher market share than the EU by 0230. Thus, tremendous economic growth is expected in these five countries in the coming decades. Multinational drug companies spending billions in research and development every year, are introducing newer and newer drugs with less toxicity, with less side effects and better therapeutic efficacy at a regular frequency. But in the long run, it may be mentioned that any MNC who does not respect the Indian sentiment will not succeed in India. It has been observed that the only MNC’s who have succeeded in India was those with an Indian face. Those who tried to dominate as MNC’s have already packed off. This speaks volumes for future strategy.


- 65 -

The major challenge being faced by the country at present is to enable it to cultivate an innovative culture that can only meet the problems of post-GATT period. There is no doubt that the growth of the bulk drug industry in India and the emergence of several Indian companies especially from Hyderabad, with international operations, has been the result of the Indian Patent Act 1970 which recognised the process patents only. However, it has now exhausted its utility as with the recent patent amendment, India would have to accept the product patent system. Piracy of internationally known patented drugs and technologies became a norm and even a respectable practice, leading to proliferation and unhealthy competition. With the amendment to the Indian Patent Act passed in parliament, Indian companies have to stop the production of patented drugs having valid patent period after 2005 and the Indian companies would also not be able to pirate the newer molecules patented by multinationals. It is true that many bulk drugs currently under production would still be prescribed after 2005 for some time. In the new scenario, joint ventures, strategic alliances would be a must for the survival. Otherwise the industry can still continue to produce the drugs which have already gone off-patent but such drugs may be soon obsolete. Or the Indian industry will be left to produce a drug after a gap of 20 years of their global introduction. Indians in numbers must become ‘MNC’ pharma players. Five teams of five each in the next five to ten years, is what may happen in the short term. Ranbaxy, Cipla, Reddy, Nicholas and Dabur make the first five. Wockhardt, Sun, Cadila Health, Lupin, Orchid form a close additional five to make the first Ten future Billion Dollar India ‘MNC’ companies.


- 66 -


- 67 -

ANNEX I

PRODUCTION OF BULK DRUGS (SPECIFIC ITEMS) OF SELECTED COMPANIES IN THE ORGANISED SECTOR

(QUANTITY IN MT) Name of the Bulk Drugs 1999-00 2000-01 2001-02 ANAESTHETICS 35.67 51.63 56.00

Lignocaine/Xylocaine 35.67 51.63 56.00 ANALGESICS & ANTIPYRETIC 3,044.28 3,790.00 2,998.63

Analgin/Metamizole(s) - 151.27 - Aspirin(s) 1,383.02 1,339.60 916.48

Ibuprofen(s) 1,611.54 2,295.13 2,074.39 Oxyphenylbutazone 1.91 0.77 0.21

Pethidine 0.21 0.15 0.34 Phenly Butazone 47.60 3.08 7.21

ANTI ASTHAMATICS 445.74 565.19 467.53 Aminophylline(s) 2.95 3.58 5.57

Ephedrine(s) 263.04 345.45 247.77 Salbutamol 19.99 21.05 18.22 Terbutaline 2.09 2.39 2.47

Theophyline(s) 157.67 192.72 193.50 ANTIBIOTICS 2,269.47 2,351.82 2,222.75

Amoxycillin 1,006.20 962.91 882.70 Ampicillin 154.53 149.22 166.86 Cephalexin 707.32 831.89 769.91

Chloramphenicol Palmitate - - 25.85 Chloramphenicol Powder 7.70 8.74 24.91

Cloxacillin(s) 151.33 134.89 79.23 Doxycycline(s) 6.16 8.27 6.01

Erythromycin(s) 132.70 116.09 173.41 Griseofulvin(s) 19.81 13.31 9.41

Oxytetracycline 83.72 126.50 84.46 PENCILLINS 7,583.34 7,583.43 8,242.96

Penicillin G 1st Crystal 6,913.31 7,056.94 7,695.57 Penicillin G Procaine 131.57 119.91 139.16 Penicillin G Sodium 66.64 65.62 89.46

Penicillin G Benzathine 49.17 24.05 27.95 Rifampicin(s) 335.53 279.00 282.62

Streptomycin(s) 27.74 0.01 0.12 Tetracycline 59.38 37.90 8.08

ANTI DIABETICS 138.59 124.04 128.22 Chlorpropamine 116.51 84.53 67.69

Glibenclamide 10.08 6.22 12.46 Tolbutamide 12.00 33.29 48.07


- 68 -

ANTI DYSENTRY DRUGS 1,496.67 1,435.88 1,756.69

Diloxamide Furoate 19.05 9.80 7.48 Lodocholrohydroxy-quinolline(s) 170.58 129.59 219.75

Metronidazole(s) 864.52 910.52 957.06 Tinidazole 442.52 385.97 572.35

ANTI HILMENTICS - - 63.11 Piperazine and Salts - - 63.11

ANTI HISTAMINS 55.74 45.30 43.50 Pheneramine Maleate(s) 55.74 45.30 43.50

ANTI LEPROTICS 0.72 - - Clofuzamine 0.72 - -

ANTI T B DRUGS 1,136.05 884.86 827.36 Ethambutol 1,016.93 837.02 782.73

INH 109.04 25.93 36.27 Pyrazinamide 0.01 - - Thiacetazone 10.07 21.91 8.36

CARDIOVASCULAR DRUGS 11.35 19.73 14.78 Propranolo 5.88 7.74 10.08

Xanthinol Nicotinate 5.47 11.99 4.70 CNS STIMULANTS 37.12 81.42 30.87

Caffeine 37.12 81.42 30.87 CORTICOSTERIOIDS 6.17 7.33 6.95

Betamethasone(s) 3.71 3.77 3.09 Hydrocortisone 0.57 0.72 0.71 Prednisolone(s) 1.89 2.84 3.15

DIURETICS 16.16 69.85 59.93 Acetazolamide 1.15 - -

Frusemide(s) - 56.13 41.60 Hydrochlorothiazide 15.01 13.72 18.33

GASTRO INTESTINAL 391.06 739.50 797.79 Ranitidine(s) 391.06 739.50 797.79

OTHER ANTI BACTERIALS 443.89 374.65 512.54 Nalidixic Acid(s) 2.05 - - Trimethoprim(s) 441.84 374.65 512.54

SULPHA DRUGS 777.53 274.24 17.67 Sulphacetamide 6.49 5.87 6.44

Sulphamethoxazole 745.94 232.96 - Sulphamoxole(s) 25.10 8.41 11.23

TRANQUILIZERS & SEDATIVES 37.94 35.19 15.94 Imipramine 0.05 0.06 - Nitrazepam 1.28 0.94 0.84

Phenobarbitone 36.61 34.19 15.10


- 69 -

VITAMINS 1,18234 1,490.67 1,374.95

Nicotinamide 325.19 310.55 322.91 Nicotinic Acid 283.57 313.05 329.06

Vitamin A(s) 52.57 59.77 27.83 Vitamin B1/Thiamine(s) 6.42 4.51 4.89

Vitamin B2 45.83 35.23 23.19 Vitamin C 237.25 546.22 439.33

Vitamin D3 0.69 0.63 0.46 Vitamin E 230.86 220.71 227.30

Source: IDMA 42nd Annual Publication 2004


- 70 -


- 71 -

ANNEX II COMPANY/PRODUCT PROFILE FORMS


- 72 -

COMPANY / PRODUCT PROFILE FORM “AsiaHealthCare 2004” Buyers/Sellers Meeting on Pharmaceuticals and Natural Products

SINGAPORE 14-16 JULY 2004

Name and Title: SM Raina, Sr. Vice President-Exports, Subramaniam.K,Officer

Company name ALKEM LABORATORIES LTD.

Street - POB 462,Phoenix House, 3rd Floor, Senapati Bapat Marg

City - Country Mumbai,India-400 013. Email: [email protected] [email protected] Tel: 0091-2224938443 Fax: 009122 24941036

Year established: 1973 Number of employees: 2500 approx Bank Ref:State Bank of INdia A/c No.01650070922

Website address of company: Under construction

Activities

Exporter Wholesaler/Retailer Manufacturer/Producer Importer Trader Other: _______________

Countries previously exported to:Sri Lanka, the UK, The Netherlands, Denmark,Kenya,Nigeria,Ghana,Tanzania, Phillippines, Myanmar,Cambodia,Russia

Description (please give generic names and specify if the product is indigenous) I* E*

1. Anaesthetics: General ansesthetics and oxygen Local anaesthetics Preoperative medication and sedation

2. Analgesics, antipyretics, non-steroidal anti-inflammatory medicines (NSAIMs), medicines used to threat gout and disease modifying agents in rheumatoid disorders (DMARDs) NSAIMs Opioid analgesics Used to treat gout * DMARDs

3. Antiallergics and medicines used in anaphylaxis 4. Antidotes and other substances used in poisoning: Non-specific Specific

5. Anticonvulstants/antiepileptics: 6. Anti-infective medicines: Anthelminthics Antibacterials Antifungal Antiviral Antiprotozoal Insect repellents

7. Antimigraine medicines: For treatment of acute attack For prophylaxis

8. Antineoplastic, immunosuppressives and medicines used in palliative care: Immunosuppressive Cytotoxic medicines Hormones and antihormones Medicines used in palliative care

9. Antiparkinsonism medicines 10. Medicines affecting the blood: Antianaemia medicines Medicines affecting coagulation

11. Blood products and plasma substitutes: Plasma substitutes Plasma fractions fro specific use

12. Cardiovascular medicines: Antianginal Antiarrhythmic Antihypertensive Used in heart failure Antithrombotic Lipid-lowering

13. Dermatological medicines (topical) Antifungal Anti-infective Anti-inflammatory/antipruritic Astringent Skin differentiation/proliferation Scabicides/pediculicides Ultraviolet

14. Diagnostic agents: Ophthalmic Radio contrast media

15. Disinfectants and antiseptics: Antiseptics Disinfectants

16. Diuretics 17. Gastrointestinal medicines: Antacids Antiemetic Antihaemorrhoidal Anti-inflammatory Antispasmodic Laxatives Used in diarrhea Antidiarrhoeal (symptomatic)

18. Hormones, other endocrine medicines and contraceptives: Adrenal/synthetic substitutes Androgens Contraceptives Estrogens Insulin/other antidiabetic agents Ovulation inducers Progestogens Thyroid hormones/antithyroid medicines

19. Immunologicals: Diagnostic agents Sera and immunoglobulins Vaccines

20. Muscle relaxants (peripherally acting) and cholinesterase inhibitors


- 73 -

21. Ophthalmological preparations: Anti-infective Anti-inflammatory Local anesthetics Miotics and antiglaucoma Mydriatics

22. Oxytocics and antioxytocics: Oxytocics Antioxytocics

23. Peritoneal dialysis solution 24. Psychotherapeutic medicines: Psychotic disorders Mood disorders Generalized anxiety and sleep disorders Obsessive compulsive disorders

25. Medicines acting on the respiratory tract

26. Solutions correcting water, electrolyte and acid-base disturbances: Oral Parenteral Miscellaneous

27. Vitamins and minerals 28. Natural ingredients for pharmaceuticals Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal Medicines containing whole plant material or as raw material for the isolation of active substances or extracts Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Fatty oils, fats, waxes and their derivatives Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin 34. Essential oils and oleoresins 35. Biotech

I* = Import, E* = Export


- 74 -

Questionnaire on Demand/Supply Survey of Active Ingredients & Starting Materials, Formulations, Biotech & Natural Products under the South-South

Trade Promotion Programme Name of Company:

• Postal address(office)

• Telephone

• Fax

• E-mail

• Contact Executive(s)

ALKEM LABORATOIRIES LTD. Phoenix House, 462, Senapati Bapat Marg, Mumbai-400 013 0091-22-24938443 0091-22-24941036 [email protected] : [email protected] S.M.Raina, Subramaniam.K

Year of Establishment 1973 Year of Commencement of Exports 1991 Products Manufactured Please refer attached product list

No. of Employees :

• Office • Production • Quality Control • Others

2500 500 900 100 1000

Foreign Collaborations ( if any) Name of Foreign company Type of collaboration

-NA-

(Rs. Million) Sales turnover( Last 5 Year) Value of Exports ( Last 5 year) (Rs. in Million)

1999-00 00-01 01-02 02-03 03-04 3960 4500 5020 01-02 02-03 03-04 183.2 323.3 450

Principal Markets Europe, South East Asia, Russia, Latin America & Africa

Type of business Manufacture & Export of pharmaceutical formulation Legal Status Public Limited Company Banker State Bank of India, Mumbai Capital Ownership Product specifications As per product list attached.. For Exports, we strictly follow

USP or BP

License capacity - Installed capacity(2 shifts/day) Tab-200 million, Caps 600,000,Inj-1.8 million Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04


- 75 -

Capacity utilized /under-utilization

For all above-Capacity utilization -75%

Measures needed for fuller utilization of capacity:

-

If Capacity is constant prospects for expansion of capacity through

• By modernization • By expanding existing units • Creation of new capacity

By modernization Currently going on for certain portions of our factory

Indication for expanding the capacity in internal and foreign exchange resources

-

Availability of indigenous and imported raw material

• Sources • Quality • Quantity • Time availability • Prices

Indigenous Imported Raw Materials are imported either from Local (domestic) Companies or from foreign companies

Impact of prices of raw material on the ex-factory value of the product

Directly proportional effect

Import duty on raw-material In certain Raw materials, listed by the government, import duty is waived.

Govt. incentive for supply of raw-materials

• Allocation for export production

• Supply at world price • Tax/duty exemption

-same as above- (For certain raw materials)

Quality standards Certification approval:

• Quality control facility, if any • Pre-shipment inspection • And quality control

specification • Brand name

Our factory at Amaliya, Dabhel, Daman is approved for cephalosporius (oral and injetible) By the UK MHRA. We shall soon go for the SA. MCC also.

Research & Development:

- R& D facilities available • Technology • product design • Raw material • Quality of standard & testing • Packaging

We have wholly owned clinical Research Organization for conduction of Bio Equivalence studies and clinical trials.


- 76 -

Domestic Demand:

• DD Products in %age • Export demand

90% 10%

Govt. policy on export supplies viz-a-viz domestic requirement

Various incentives for exports available

Trend of exports to Far East countries

Slow growth but will rise exponentially once we open new markets.

Nature of existing export development plans concerning markets and promotional measures

We are shifting from exporting our products to marketing them

Exports incentives provided by the government

Type of co. Manufacturer/Merchant exporter/ trading company/ SSI unit*

Shipping :

• Availability • Suitability • Cost of cargo space • Road/Rail/Air and water

Shipment regularly done by all modes.

Packaging :

• Method of packaging • Packaging material • Their availability • Quality • Cost

Packaging material sourced from high quality vendors

Export credit and finance facilities We take packing credit from our banker Trade promotion activities by Govt and EPCs:

• Publicity abroad • Buyer Seller Meeting* • Trade fair within the

country/abroad* • Seminars • Training events

Online measures needed to improve export performance:

• Product mix for export development

• Expansion of capacity • Supply inputs • Quality improvement &

control • Export marketing methods * • Streamlining export incentives

and procedures

Export Marketing procedures and methods. Information preferably country specific.


- 77 -

Requirement for technical assistance in (Yes/No)

• Product modification / • Adaptation, technology & • Technical know how • Packaging • Market survey • Market promotion • Export management trend • Selling missions

• Strengthening institutional

framework • Other (specify)

All marketing related activities that include market survey, market promotion, target market distribution channels and knowledge related to the medical fraternity is essential in planning any strategy for the markets.

Other production inputs:

• Brief review of availability of indigenous and imported technology and processes, packaging materials, power and labour skilled

We face no problems in any of these areas

• If raw materials and other production inputs are a major constraint for expo development,

substantiate with typical illustrative example -NA- Category of Importer: Actual User/Wholesaler/Agent

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 We import a few raw materials and machinery. Most purchases are from domestic companies. Imports Projection (Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports:

Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify)


- 78 -

Import Channel: Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods: Imports packing & packaging requirements: Structure of distribution: Cost of distribution (%):

PLEASE ENCLOSE YOUR CATALOGUE OF THE PRODUCT


- 79 -



Name and Title:

Company name APEX LABORATORIES LIMITED

Street - POB 38,C.P.Ramasamy Road, Alwarpet,

City - Country Chennai-600018,Tamil Nadu, India

Email: [email protected] Tel: 91-44-2499 8297 Fax: 91-44-2499 7254

Year established: Number of employees: 670 Bank Ref:Bank of India

Website address of company: www.apexlab.com

Activities


Countries previously imported/exported to:



2. Analgesics, antipyretics, non-steroidal anti-inflammatory medicines (NSAIMs), medicines used to threat gout and disease modifying agents in rheumatoid disorders (DMARDs) NSAIMs Opioid analgesics Used to treat gout DMARDs





9. Antiparkinsonism medicines 10. Medicines affecting the blood: Antianaemia medicines * Medicines affecting coagulation









20. Muscle relaxants (peripherally acting) and cholinesterase inhibitors 21. Ophthalmological preparations: Anti-infective Anti-inflammatory Local anesthetics Miotics and antiglaucoma Mydriatics


- 80 -

22. Oxytocics and antioxytocics: Oxytocics Antioxytocics 23. Peritoneal dialysis solution 24. Psychotherapeutic medicines: Psychotic disorders Mood disorders Generalized anxiety and sleep disorders Obsessive compulsive disorders 25. Medicines acting on the respiratory tract 26. Solutions correcting water, electrolyte and acid-base disturbances: Oral Parenteral Miscellaneous 27.* Vitamins and minerals ⌧ 28. Natural ingredients for pharmaceuticals Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal Medicines containing whole plant material or as raw material for the isolation of active substances or extracts Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Fatty oils, fats, waxes and their derivatives Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin 34. Essential oils and oleoresins 35. Biotech 36.Dietary Supplements ⌧ 37.Herbal Products ⌧



- 81 -

Name and Title Mr. S.C. Kachhara - Director

Company Name BDH Industries Limited

Street POB Akurli Road, Kandivli (East) 400101

City - Country Mumbai, INDIA

Email [email protected]

Tel/Fax Nos. Tel : 91-22-28870834,28871370 Fax : 91-22-28868349

Year established 1935

Number of employees : 225

Bank Ref Central Bank of IndiaAndheri (East), MumbaiA/c. No. C/C 200177

Website address of company www.bdhind.com

Activities Manufacturer Producer

Countries previously imported China, Hongkong, Germany, Poland, Netherlands, Finland,Czech Republic

Countries previously exported Canada, Germany, Belgium, USA, Chile, Dominicana, West Indies, China, Hongkong, Singapore, Malaysia, Mynmar, Papua New Guinea,Ethipia, South Africa, Sudan

Description (please give generic names and specify if the product is indigenous)No. Therapeutical category Sub-category Indigenous

1 Anaeshetics Local anaesthic Y2 Analgesics, antipyretics,non-steriodal anti-inflammatory NSAIMs Y

Opiod analgesics YTreat gout YDMARDs Y

3 Antiallergics and anaphylaxis Y4 Antidotes and other substances used in poisoning Non-specific Y5 Anticonvulsants, antiepileptics Y6 Anti-infective medicines Anthelminthics Y

Antibacterials YAntifungals YAntiviral YAntiprotozoal Y

7 Antimigraine medicine Prophylaxis YAcute attack Y

8 Antineoplastic, immunosuppressives Immunosuppressives YCytotoxic Y

9 Medicine affecting the blood Antianaemia YCoagulation Y

10 Dermatological medicines Antifungals YAnti-infectives YAnti-inflammatory Y

11 Diuretics Y12 Gastroinstestinal medicines Antacids Y

Antiemetics YAnti-inflammotory YAntispasmodic YLaxatives Y

13 Muscle relaxants Y14 Ophthalmological preparations Anti-infectives Y

Anti-inflammatory Y15 Psychotherapeutic medicines Psychotic disorders Y16 Medicines acting on the respiratory tract Y17 Vitamins and minerals Y

COMPANY / PRODUCT PROFILE FORMASIAHEALTHCARE 2004 BUYERS/SELLERS MEETING ON PHARMACEUTICALS & NATURAL PRODUCTS

Singapore 14-16 July 2004

BDH Industries LimitedAkurli Road, Kandivli (East), Mumbai - 400101


- 82 -

Name of Company BDH INDUSTRIES LIMITEDPostal address (office) Akurli Road, Kandivli (East)

Mumbai 400101, IndiaTelephone 91-22-28870834, 28871370Fax 91-22-28868349E-mail [email protected] Executive Mr. S.C. Kachhara - Director

Year of Establishment 1935Year of Commencement of Exports 1980Products Manufactured Pharmaceutical Formulations

Bulk Drugs (Active Pharmaceutical Ingredients)Drugs Intermediates

No of EmployeesOffice 50Production 75Quality Control 30Others 70

Foreign Collaborations (if any) Not ApplicableSales turnover (Rs. Million) 1999-00 2000-01 2001-02 2002-03 2003-04

181.85 302.28 234.78 209.00 151.40Value of Exports (Last 5 year) 1999-00 2000-01 2001-02 2002-03 2003-04

90.17 236.2 179.76 172.71 106.75Principal Markets African countries, Latin American countries, Asian countires Type of business Manufacturer & Exporter of Pharmaceutical Formulations,

Bulk Drugs (Active Pharmaceutical Ingredients)Legal Status Public limited companyBanker Central Bank of IndiaCapital (Rs. Millions) 59.3Ownership Public limited company Product specifications Pharmaceutical Formulations with B.P. & U.S.P. standardsLicense capacity Department License capacity

Tablets 3600 millionsCapsules 135 millionsOitments 650000 KgsLiquid & Injectables 400000 Lts

Actual production (last 4 years) Department 1999-2000 2000-01 2001-02 2002-03Tablets (millions) 230 474 539 761Capsules (millions) 12 13 35 41Oitments ('000 Kgs) 40 70 97 16Liquid ('000 Lts) 180 69 635 390

Capacity utilized/under-utilization Under-utilizationMeasures needed for fuller utilization Generate Export Business from existing and new marketsof capacityIf capacity is constraint, prospects for Not Applicableexpansion of capacity throughIndication for expanding the capacity Not Applicablein internal and foreign exchangeresourcesAvailability of indigenous and imported raw material

Sources Directly from manafactuersQuality Quality as per standards of B.P./ U.S.P.Time availability Available within specified time but undue delay in custom clearancePrices Competitive

Impact of prices of raw material on No change in ex-factory value if marginal increases/decrease in price of the ex-facory value of the product Raw Materials. Higher increase/decreas in prices of raw materials

proprtionately effects onex-facory value Import duty on raw-material Import duty is 20%Govt. incentive for supply of raw-materials

Allocation for export production Duty free Capital goods importSupply at world priceTax/duty exemption Import Duty exemption for Raw Materials

Quality standards WHO-GMP Certified ProductsQuality control facility (if any) In-house Quality control facility Pre-shipment inspection Pre-shipment inspection by SGS,Bureau Veritas & Intertek etc.And quality control specification B.P., U.S.P. as well in-house standardsBrand Name Many products exported under our own brand names

Biotech & Natural Products under the South-South Trade Promotion Programme.Questionnaire on Demand/Supply Survey of Active Ingredients & Starting Materials, Formulations


- 83 -

Research & DevelopmentR & D facilities available In-house R & D facility with latest equipmentsTechnology Keeping pace with Modern & Latest technology machineriesProduct design International standard Product designRaw material Uses International standard Raw MaterialsQuality of standard & Testing WHO-GMP, B.P. & U.S.P. Quality standardsPackaging Export seaworthy packaging

Domestic DemandDD Products %age Around 15%Export demand More than 85%

Govt. policy on export supplies viz-a-viz Not encouraging domestic requirementTrend of exports to Far East countries Increasing export business with Far East countries like Singapore,

Malaysia, Mynmar, Philipines, Papue New Guinea etc.Nature of existing export development Participatation in International Exhibitions, Trade fairs, Productplans concerning markets and Show-Case etc. Visiting customers and inviting customer for businesspromotional measures meeting and factory inspection.Export incentives provided by the Hardly any facility is available from governmentgovernmentType of company Manufacturer & SSI unitShipping

Availability Good Number of Airlines & Sea Liners are availableSuitability Sea as Air Transportation is suitableCost of cargo space Air Transportation cost very high compare to Sea TransportationRoad/Rail/Air/Water Sea (water) Transportation & Air Transportation

PackagingMethod of packaging Semi-Automatic packaging systemPackaging material Indigenuos packing materialTheir availability Available in reasonable timeQuality Export Sea Worthy qualityCost Effective

Export credit and finance facilities Export Credit & finance available by bank and ECG Corp. as per govt. export promotional schemes.

Trade promotion activities by Govt.& EPCs:

Publicity aboard Catelogue Publishing, Product Show-case, Directory listing Buyer Seller Meeting Ogranised various buyer seller meeting by FIEO & CHEMEXCILTrade fair within the country/abroad Catelogue Publishing / Product Show-case at Intl. Exhibition/Trade fairsSeminars Seminars by FIEO & CHEMEXCIL with International Delegation Training events

Online measures needed to improveexport performance

Product mix for export development Developing latest generation pharmaceutical formulations.Expansion of capacity Not applicableSupply inputs Planning for timely availability of Raw materialsQuality improvement & control Continuous improvement in quality of productsExport marketing methods Visiting buyers country, Inviting them for factory visitsStreamlining export incentives and Requires more attractive incentives from govt and simple proceduresprocedures

Requirement for technical assistance in (yes/no)

Product modification/Adaptation, technology & technical know-how NoPackaging NoMarket survey YesExport management trend YesSelling missions YesStrengthening institutional framework YesOther specify

Other production inputsBrief review of availability of indigenous and imported technology and processes, packaging materials, power and labour skilled

We have adopted to latest and standard technology which is as per WHO-GMP norms. Packaging materials, Power and skilled labour is available easily.

If raw materials and other production inputs are a major constraint for expo development, substantiate with illustrative example

Raw materials are not major constraint for export development


- 84 -

Category of Importer Active UserImports (Rs. Million)Products Country of imports 1999-00 2000-01 2001-02 2002-03 2003-04Carbamazepine China 0.86 0.94 0.90Chlorpromazine Hcl. China 1.40 2.86 0.69 1.18Erythromycin Thiocynate China 21.40 2.48 2.34 3.95Erythromycin Thiocynate Poland 6.31 8.78 7.27 2.35 10.32Erythromycin Thiocynate USA 8.30 10.49Gentamycin Sulphate China 0.59Griseofulvin China 2.15 2.20Hydrocortisone Acetate China 1.90 1.74 0.41 0.95Hyoscine Butyl Bromide Netherlands 2.17 1.86 0.56 3.38 1.58Metronidazole China 0.75 0.58Nystatin Romania 2.42 1.27 1.33 0.64Paracetamol China 1.34Praziquantel China 0.10 1.78 1.51Prednisolone China 0.65 1.59 0.39Quinine Sulphate Indonesia 1.90 1.15Thioridazine Hcl. China 1.20 1.63 1.58

Imports Projection (Rs. Million)Products Years 2004-05 2005-06 2006-07 2007-08 2008-09

Erythromycin Thiocynate 20.00 22.00 24.20 26.62 29.28Chlorpromazine Hcl. 1.50 1.65 1.82 2.00 2.20Hyoscine Butyl Bromide 2.00 2.20 2.42 2.66 2.93Hydrocortisone Acetate 1.25 1.38 1.51 1.66 1.83

Apparent consumptions KgsProducts Years 2004-05 2005-06 2006-07 2007-08 2008-09

Erythromycin Thiocynate 1500 1650 1815 1997 2196Chlorpromazine Hcl. 750 825 908 998 1098Hyoscine Butyl Bromide 25 28 30 33 37Hydrocortisone Acetate 50 55 61 67 73

Factor affecting Imports : Exchange Rate fluctuationsBackward integrationAnti-dumping duties

Documentary requirements for imports : Certificate of Origin Commercial InvoicePre-shipment Inspection CertificateInsurance CertificateCertificate of AnalysisRegistration of Bulk Drugs & the manufacturer with Govt.of India

Import Channel Manufacturer-Distributors-Agents-End UsersUsual buying methods Asking for Quotations, Samples & COA

Price & Quality AnalysisFinal NegotiationPlacement of Order with Letter of Credit from Bank

Imports packing & packaging Export Seaworthy packaging fibre/plastic or metal drumsrequirements Quantity in drum would be 25/50 kgs

Detailed marking on each drumStructure of distribution Container shipment to destination country

Local distribution by the ordering party or the by local government (Tender)Cost of distribution (%) 5 to 7 %


- 85 -

COMPANY / PRODUCT PROFILE FORM

“AsiaHealthCare 2004” Buyers/Sellers Meeting on Pharmaceuticals and Natural Products SINGAPORE 14-16 JULY 2004

Name and Title: Pankaj Shukla – GM Sales & Marketing

Company name Bharat Serums & Vaccines Ltd

Street - POB 16th Floor Hoechst House Nariman Point

City - Country Mumbai - India Email: [email protected] Tel: 91 22 56560900 Fax: 91 22 56560901

Year established: 1972 Number of employees: > 700 Bank Ref:HDFCBank, ICICI Bank, Corporation Bank

Website address of company: www.bharatserums.com

Activities

Exporter Wholesaler/Retailer Manufacturer/Producer Importer Trader Other: ______



1. Anaesthetics:

* General ansesthetics and oxygen Local anaesthetics Preoperative medication and sedation

*
















- 86 -




25. Medicines acting on the respiratory tract 26. Solutions correcting water, electrolyte and acid-base disturbances: Oral Parenteral Miscellaneous




- 87 -




• Telephone

• Fax

• E-mail


BHARAT SERUMS & VACCINES LTD 16th Floor HOECHST House, Nariman Point Mumbai 400 021 +91 22 56560900 +91 2 56560901 [email protected] Pankaj Shukla

Year of Establishment 1972 Year of Commencement of Exports 2001 - 2002 Products Manufactured As per annexure ‘A’

No. of Employees :


75 200 30 500


Selling and distribution arrangements with some leading global pharmaceutical companies.

(Rs. Million) Sales turnover( Last 5 Year) Value of Exports ( Last 5 year) Mil $s

1999-00 00-01 01-02 02-03 03-04 176 454 564 724 880 0.8 1.6 0.6 31 35

Principal Markets India, Far East, Central & Western Africa, Russia & CIS, Central America

Type of business Pharmaceutical Legal Status Limited Company Banker HDFC Bank, Corporation Bank, IDBI Bank Capital Rs 29.7 mil. Ownership Privately held Product specifications USP/ BP / IP & IHS


- 88 -

License capacity Not Applicable Installed capacity Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

As per sales figures

Capacity utilized / under-utilization

Healthy capacity utilization with adequate provision for meeting sustained growth requirements for domestic and export markets.

Measures needed for fuller utilization of capacity :

Refer note above



Explained under capacity utilization.


From Internal resources and exports

Indigenous

Imported

From Govt. approved suppliers conforming to pharmacopeal norms

EU, US, Far East

Confidential As per BP/USP Adequate Adequate Confidential Confidential




Variable impact

Import duty on raw-material Different duty structure for different categories




Incentives available for exports

Quality standards Certification approval :



In house QC, conforming to the laws, at the site of manufacture As per buyer’s instructions As per pharmacopeal specifications Quality of branded products as per relevant pharmacopeia


- 89 -

Research & Development :


We are a strong R&D driven company. No reverse engineering practiced. We have 3 R&D labs with another 2 in the pipe line. All R&D products are tested and certified by Govt. testing facilities. Our R&D facility has been recognized by the Govt. for PG doctoral studies

Domestic Demand :


As of now, in excess of 90%


Non - restrictive policy. Govt encourages exports


Commenced exports in 04-04. Projected exponential increases in excess of 100% per year.


Identified 8 key markets in far east. Allocated financial and human resources for product promotion and market development.


Credit guarantees, import of capital goods, concessional duty tender.

Type of co. Manufacturer / Exporter

Shipping :


All shipments made by arr as products require cold chain.

Packaging :


Automatic filling with semi automatic packaging. Packed in customized thermocole boxes for temperature stability. All packs legibly marked as per specifications. All quality adheres to GMP specifications.

Export credit and finance facilities Trade promotion activities by Govt and EPCs :

• Publicity abroad • Buyer Seller Meeting • Trade fair within the

country/abroad • Seminars • Training events

Govt of India thoughts export promotion council provides subsidy to participate in trade fairs, B-S-Ms, seminars and conducting market researches.


- 90 -

Online measures needed to improve export performance :


• Expansion of capacity • Supply inputs • Quality improvement & control • Export marketing methods • Streamlining export incentives

and procedures

Putting enablers in identified markets to expand reach and distribution, product awareness and usage amongst medical fraternity.





NO NO NO NO YES YES YES YES YES YES Identification of suitable business partners.

Other production inputs :


• If raw materials and other production inputs are a major constraint for expo development, substantiate with typical illustrative example

No such constraints faced. Category of Importer : Actual User of imported RM for production purposes.

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 CONFIDENTIAL


- 91 -

Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 CONFIDENTIAL Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 Refer sales turnover figures Factor affecting Imports : Plasma availability for blood products Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others All imports directly from manufacturers of international repute with international SOPs for production Usual buying methods : Direct negotiations Imports packing & packaging requirements : As per standard GMP and pharmacopeal requirements Structure of distribution :

1) Through local distributor 2) JV with local manufacturer 3) Self owned distribution networks

Cost of distribution (%): Approx 10% of CIF values



- 92 -



Name and Title: V.KUMAR

Company name BIOMEDICARE (INDIA) PVT. LTD.

Street - POB H-2/102 SUNEJA CHAMBER, ALAKNANDA COMMERCIAL COMPLEX

City - Country INDIA, NEW DELHI

Email: [email protected] Tel: 0091-11-26466169/26284441 Fax: 0091-11-26467830

Year established: 1994 Number of employees: 17 Bank Ref: Canara Bank Overseas branch New Delhi

Website address of company: www.biomedicareindia.com

Activities


Countries previously imported/exported to: Exported to Russia/Ukraine/Latvia/Uzbekistan/ Kazakhstan/Kyrgystan/Moldova/Georgia. We have not imported any medicines till date.

















- 93 -









- 94 -




• Telephone

• Fax

• E-mail


BIOMEDICARE (INDIA) PVT. LTD. H-2/102 SUNEJA CHAMBER ALAKNANDA COMMERCIAL COMPLEX NEW DELHI – 110 019 (INDIA) 0091-11-26466169/26284441 0091-11-26467830 [email protected] MR.V.KUMAR – MANAGING DIRECTOR MR.GEORGE P.K

Year of Establishment 1994 Year of Commencement of Exports 1994 Products Manufactured Merchant Exporter of Pharmaceuticals. And also manufactured our

products under Loan licences

No. of Employees :


17 10 1 1 5


NIL

(Rs. Million) Sales turnover( Last 5 Year) Value of Exports ( Last 5 year)

1999-00 00-01 01-02 02-03 03-04 19.00 30.07 48.19 35.50 53.00 1999-00 00-01 01-02 02-03 03-04 17.45 26.25 41.06 34.00 42.29

Principal Markets CIS Countries

Type of business Mfg. and Exporter Legal Status Pvt. Ltd. Banker Canara Bank ,Overseas Branch

Connaught Place,New Delhi-110 001 Capital Rs.250,300.00 Ownership Directorship Product specifications Pharmaceutical Products as per BP/USP

License capacity N.A Installed capacity N.A Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

N.A


- 95 -


N.A


N.A



N.A


N.A Indigenous

Imported

Purchased from the market




N.A

Import duty on raw-material N.A




N.A




Pre-shipment inspection Quality control specification



N.A


- 96 -

Domestic Demand:





We are participating trade fare in overseas countries and give advertisement in T.V., Metro, etc.


DEPB

Type of co. Manufacturer/Merchant exporter/ trading company/ SSI unit Merchant Exporter

Shipping :


Lot options Sea/air Economical

Packaging :


Export worthy 7 ply cartons Corrugated boxes Sufficient We are maintaining very good quality packings Costly

Export credit and finance facilities Not availing Trade promotion activities by Govt and EPCs:



Trade fair within the country/abroad and attending the buyer seller meeting




and procedures

Quality improvement and control and Product mix for export development


- 97 -







• If raw materials and other production inputs are a major constraint for expo development, substantiate

with typical illustrative example Category of Importer : Actual User/Wholesaler/Agent : Agent

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Nil Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 NIL Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 N.A Factor affecting Imports : N.A Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify)


- 98 -

Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods :

Imports packing & packaging requirements : Structure of distribution : Cost of distribution (%):



- 99 -

PROFILE 1. Name of the company : Concept Pharmaceuticals Ltd. Telephone No. : 91-22 26528888 (10 lines)/ Exports (direct) : Tel : + 91 22 26524590 Fax+9122 26541950 Fax No. : 91-22 –2 6525800/26525801 E-Mail : [email protected]

[email protected] Website : www.conceptpharma.net 2. Activity : Manufacturer of (a)Bulk Drugs/Intermediates

(b)Formulations (Human & Animal Health Including Herbals)

3. Major Products : (A) Bulk Drugs : a) Sterile - Ampicillin sodium, Amoxycillin sodium, Cefotaxime Sodium, Cefuroxime Sodium & Cloxacillin Sodium b) Non-sterile : Nitrendipine Roxithromycin, Pyrazinamide Fluconazole, , Vitamin B2-5 Phosphate Sodium, Olanzapine,Sildenafil Citrate.

(B) Formulations : Leader in Anti T.B. Drugs, (Paediatric), Antibiotics, Gastric

Anti Inflammator, Cardiovascular 4. Performance

Annual sales turnover (Group) : Rs.1.2 billions (Last Year) : U.S. $ 25 millions

Exports : Recognised export house exporting to 20 Countries.

5. Marketing Infrastructure : 16 branch offices and 450 full time marketing staff with a network of about 1000 stockists.

6. Specific Achievement : 1) Manufacturing plant approved for WHO GMP standards with all sections. 2) R&D Centre approved by Government of India. 3) Well diversified, multi locational organization with excellent infrastructure. 4) One of the fast growing companies in the industry.


- 100 -


SINGAPORE 14-16 JULY 2004 Name and Title: ANUP BANERJEE, GENERAL MANAGER – INTERNATIONAL MARKETING

Company name Concept Pharmaceuticals Ltd./Concept International

Street - POB 167 CST ROAD, KALINA

City - Country SANTACRUZ (EAST) , MUMBAI – 400 098 (INDIA)

Email: [email protected] Tel: + 91 22 26524590/26528888 Fax: +91 22 26541954/26525800

Year established: 1984 Number of employees: 217 Bank Ref: Dena Bank, IFB, Cuffe Parade,Mumbai 400 005 (INDIA)

Website address of company: www.conceptpharma.net

Activities

�Exporter �Wholesaler/Retailer �Manufacturer/Producer �Importer �Trader �Other: _______________

Countries previously imported/exported to: Exports : Far East, Middle East, Russia, CIS, CAR, South & Central Africa, South America & European countries. .Imports : China, Hongkong


1. Anaesthetics: General ansesthetics and oxygen Local anaesthetics Preoperative medication and sedation N/A

� �

2. Analgesics, antipyretics, non-steroidal anti-inflammatory medicines (NSAIMs), medicines used to threat gout and disease modifying agents in rheumatoid disorders (DMARDs) NSAIMs Opioid analgesics Used to treat gout

DMARDs

� �

3. Antiallergics and medicines used in anaphylaxis � � 4. Antidotes and other substances used in poisoning: Non-specific Specific

� �

5. Anticonvulstants/antiepileptics: � � 6. Anti-infective medicines: Anthelminthics Antibacterials Antifungal Antiviral Antiprotozoal Insect repellents

� �


� �


� �

9. Antiparkinsonism medicines � � 10. Medicines affecting the blood: Antianaemia medicines Medicines affecting coagulation

E


� �

12. Cardiovascular medicines: Antianginal Antiarrhythmic Antihypertensive Used in heart failure Antithrombotic

Lipid-lowering

� E


� E


� E


� �

16. Diuretics � � 17. Gastrointestinal medicines: Antacids Antiemetic Antihaemorrhoidal Anti-inflammatory Antispasmodic Laxatives Used in diarrhea Antidiarrhoeal (symptomatic)

� E


- 101 -


� �


� �

20. Muscle relaxants (peripherally acting) and cholinesterase inhibitors � E 21. Ophthalmological preparations: Anti-infective Anti-inflammatory Local anesthetics Miotics and antiglaucoma Mydriatics

� E





27. Vitamins and minerals

28. Natural ingredients for pharmaceuticals

Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal

Medicines containing whole plant material or as raw material for the isolation of active substances or extracts Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Fatty oils, fats, waxes and their derivatives Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils E Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin 34. Essential oils and oleoresins 35. Biotech



- 102 -

Questionnaire on Demand/Supply Survey of Active Ingredients & Starting Materials, Formulations, Biotech

& Natural Products under the South-South Trade Promotion Programme

Name of Company:


• Telephone

• Fax

• E-mail


Concept Pharmaceuticals Ltd./Concept International/ Concept Laboratories Pvt.Ltd./Globe Trotters Pvt.Ltd.

1 67 CST ROAD, KALINA, SANTACRUZ (EAST) MUMBAI 400 098 (INDIA

00-91-22-26524590/26528888 00-91-22-26541954/26525800 [email protected] 1) Mr. A . B. GUPTA CHAIRMAN & MANAGING DIRECTOR 2) Mr. YUGIN GUPTA, EXECUTIVE DIRECTOR 3) Mr. ANUP BANERJEE GENERAL MANGER – INTERNATIONAL MARKETING 4) Mr. HEMANT PATHAK - GENERAL MANAGER - EXPORTS

Year of Establishment 1984 Year of Commencement of Exports 1985 Products Manufactured Pharmaceutical formulations (Human & Veterinary), Bulk

APIs, Herbals

No. of Employees :


217 06 127 21 63


Yes MIR-BIOPHARMA JOINT VENTURE COMPANY

(Rs. In Lakhs) Sales turnover( Last 4 Years) *2003-04 : will be available in Sept. 2004 Value of Exports ( Last 5 years)

1999-00 00-01 01-02 02-03 03-04 13730.32 11055.63 10080.04 11621.21 * (Value in USD) 1399100 1440271 816386 438019 1054658

Principal Markets Germany, Singapore, Ghana, Kenya, West Indies, Nigeria, Ukraine, Russia, CIS, CAR countries, Sri-lanka, Sudan, Netherland Antillis, Thailand, Korea etc.


- 103 -

Type of business Manufacturer/Exporter Legal Status Public Limited Bankers a) Bank of Baroda, Kalina Branch, Santacruz (E), Mumbai

400 098 (India) b) Dena Bank, Maker Tower ‘E’ Cuffe Parade, Colaba,

Mumbai 400 005 (India c) Canara Bank, Kalina Branch,Santacruz (E), Mumbai

400 098 (India) d) Central Bank of India , Worli Branch, Mumbai 400 018

(India)

Capital Rs. 25 million Ownership CONCEPT GROUP Product specifications a) Tablets coated as well as uncoated

b) Liquid orals c) Powder and liquid inj. d) Capsules

e) Ointments (External preparations MANUFACTURED AS PER OFFICIAL MONOGRAPH OF INDIAN,BRITISH,US PHARNMACOPOEIA AND /OR INHOUSE SPECIFICATION.

License capacity Installed capacity

a) Tablets coated as well as uncoated 750 million b) Liquid orals 9.5 million c) Powder and liquid inj. 14 Mio Ampoules/vials d) Capsules 90 million e) Ointments (External preparations) 3.5 mio tubes

Actual production (last 5 years) 1999-00 00-01 01-02 02-03 03-04 (P. refer annexure attached)



STRENGTHENING MARKETING



YES YES YES


Indigenous

Imported




- 104 -


Import duty on raw-material







WHO-GMP AND ISO CERTIFIED COMPANY. OWN LAB FOR QC/QA /R&D

Research & Development : R& D facilities available

• Technology • product design • Raw material • Quality of standard & testing • Packaging

YES

OWN OWN PARTLY OWN, REST OUT SOURCING CHECKED AT OWN LAB DESIGNED BY OWN.

Domestic Demand :


75% 25%


NEED TO BE MORE LIBERAL , INCENTIVES HAVE BEEN REDUCED, THEREFORE, A DETERRENT


GOOD GROWTH


BRAND MARKETING, CONTRACT MANUFACTURING, JOINT VENTURES IN LOCAL PACKAGING, AGGRESSIVE LAUNCH OF HERBAL/OTC PRODUCTS


ADVANCE LICENCE/DEPB/MDA

Type of co. Manufacturer/Merchant exporter/ trading company/ SSI unit

Shipping :


AIR/SEA SHIPMENTS AS PER CUSTOMERS NEEDS


- 105 -

Packaging:


OWN

OUTSIDE RESOURCING DOMESTIC AS PER SPECIFICATION & INTERNATIONAL STANDARDS COMPETITIVE

Export credit and finance facilities ECGC/PACKING CREDIT Trade promotion activities by Govt and EPCs:



PARTCIPATION IN INTERNATIONAL EXHIBITIONS YES YES YES YES




control • Export marketing methods • Streamlining export

incentives and procedures

YES YES YES YES YES YES





NO NO NO YES YES YES YES YES -


- 106 -



Products/process developed by In house R&D .Well qualified /experienced staff is engaged in all departments .


substantiate with typical illustrative example

No constraints in procuring any input. Category of Importer : Actual User

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Imports Projection (Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Apparent consumptions: Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports: Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods : APPROVED QUOTES Imports packing & packaging requirements : RM/PM Structure of distribution: Cost of distribution (%):



- 107 -



Name and Title: MR. PARAG SHAH, CHIEF EXECUTIVE OFFICER

Company name DHANVANTARI BOTANICALS PVT. LTD.

Street - POB # 430/A, 10TH CROSS, 21ST MAIN, PHASE II, J P NAGAR

City - Country BANGALORE 560 078, INDIA Email: [email protected] Tel: 080-26591520 Fax: 080-26596062

Year established: Number of employees: Bank Ref:

Website address of company: www.renaissanceherbs.com

Activities

Exporter Wholesaler/Retailer √ Manufacturer/Producer Importer Trader Other: _______________

Countries previously imported/exported to: USA, JAPAN, AUSTRALIA, CHINA, MALAYSIA, THIALAND ETC.



















- 108 -




27. Vitamins and minerals 28. Natural ingredients for pharmaceuticals Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal

Medicines containing whole plant material or as raw material for the isolation of active substances or extracts

Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Fatty oils, fats, waxes and their derivatives Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin

34. Essential oils and oleoresins 35. Biotech



- 109 -




• Telephone

• Fax

• E-mail


DHANVANTARI BOTANICALS PVT. LTD. # 430/A, 10th Cross, 21st Main, Phase II, J P Nagar, Bangalore 560 078 080-26591520 080-26596062 [email protected] MR. PARAG SHAH, CEO

Year of Establishment 1985 Year of Commencement of Exports Products Manufactured BOTANICAL EXTRACTS AND PHYTOCHEMICALS. No. of Employees :


Foreign Collaborations (if any) Name of Foreign company Type of collaboration

RENAISSANCE HERBS INC. CALIFORNIA, USA. WHOLLY OWNED SUBSIDIARY

(Rs. Lakhs) Sales turnover( Last 5 Year) Value of Exports ( Last 5 year)

1999-00 00-01 01-02 02-03 03-04 410.40 353.67 607.42 375.66 862.92 As above

Principal Markets Japan, USA, Australia, China, Indonesia, Malaysia, Thailand etc.

Type of business Legal Status Banker State Bank of India, Bangalore Commercial Branch Capital Ownership Product specifications

License capacity 400 MT/year Installed capacity 300 MT/year Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

Capacity utilized /under-utilization 70% Measures needed for fuller utilization of capacity:

-


- 110 -



Capacity expansion is being planned by modernization and expansion.


Both Indigenous

Imported

All over India South East Asia Good Good OK Good Seasonal Seasonal



Variable Variable Impact of prices of raw material on the ex-factory value of the product

45%

Import duty on raw-material None since we are 100% EOU




Benefits available to 100% EOU unit




Customer driven Yes Yes Yes Yes



Yes Yes Yes Yes Yes -


- 111 -

Domestic Demand:


100% Exports


-

Trend of exports to Far East countries Very well established Nature of existing export development plans concerning markets and promotional measures

Expanding existing market s by enhancing product range.


Those provided to 100% EOU

Type of co. Manufacturer/Merchant exporter/ trading company/ SSI unit Manufacturer

Shipping :


OK

Packaging :


All our products are packaged in HDPE Drums.

Export credit and finance facilities Good Trade promotion activities by Govt and EPCs :



OK




and procedures

Yes - - Yes Yes -


- 112 -





Yes No Yes No No No Yes Yes No

Other production inputs : • Brief review of availability of indigenous and imported technology and processes, packaging materials,

power and labor skilled


Category of Importer : √ Actual User/Wholesaler/Agent

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports :

Documentary requirements for imports: √-Certificate of Origin √ - Pre-shipment Inspection Certificate √- Commercial Invoice √ - Insurance Certificate -Others (Please specify) – Phytosanitary certificate Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods : Direct imports

Imports packing & packaging requirements : Varies with product

Structure of distribution : Cost of distribution (%):



- 113 -



Name and Title: Mr. Ajit Gajwani – Vice President (Exports)

Company name Elder Pharmaceuticals Limited

Street - POB Elder House, C-9, Dalia Industrial Estate, Off New Link Road,

City - Country Andheri (W), Mumbai 400 053 Email: [email protected] Tel: + 91 22 26730058 - 67 Fax: + 91 22 26730051

Year established: 1983 Number of employees: 2000 Bank Ref: Union Bank of India – Lead Bank

Website address of company: www.elder-group.com

Activities Exporter Wholesaler/Retailer Manufacturer/Producer Importer Trader Other: ______________

Countries previously imported/exported to: Mexico, Brazil, Bahamas, Congo, Colombia, Argentina, Madagascar. Belgium, Spain



















- 114 -




27. Vitamins and minerals 28. Natural ingredients for pharmaceuticals Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal Witch Hazel Medicines containing whole plant material or as raw material for the isolation of active substances or extracts Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Evening Primrose Oil Fatty oils, fats, waxes and their derivatives Omega Fish Oil Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin 34. Essential oils and oleoresins 35. Biotech Instruments (spectrophotometer, polarimeter, HPCL System etc.) Devices (pacemalcers, catheters, oxygen concentrations, CPAP, pulse oxymeter)



- 115 -

Annexure II The Company has entered into licensing agreements with the following companies. The manufacture, sale and distribution of products under license agreements with foreign partners accounted for approximately 10% of the Company’s 2003 sales (9% of sales in 2002). The following is a list of current collaborations.

No. Name Details of type of arrangement 1. Advance Biofractures Corporation,

(USA) Manufacture and marketing of

• Collagenese – a wound healing enzyme under the brand name ‘Salutyl’

• Deacylated glycerophospholipids for cosmetic and pharmaceutical use

2. Angelini ACRAF SpA, (Italy) Manufacture and distribution of Tantum range of NSAID products - crème, gel, vaginal douches, oral rinse

3. Nonin Medical (USA) Distribution of Pulse Oximeters 4. Blistex Inc (USA) Manufacture and marketing of Blistex lip care products 5. Covex (Spain) Manufacture and marketing of ‘Excita’ 6. Crinos (Italy) Manufacture and marketing of ‘Foltene’ to prevent hair loss 7. Devon Medical Handel (Germany) Marketing and sale of stents used in angioplasty 8. Ferrer Internacional (Spain) Manufacture and marketing of CDP Choline under the brand name

‘Somazina’ drops and injections for treatment in CNS 9. Fujisawa Pharmaceuticals Co. Ltd.

(Japan) Manufacture and marketing of Cefixime, abroad spectrum third generation cepholosphorin antibiotic under the brand name ‘Suprax’ and ‘Ceftizoxime’.

10. Gea (Denmark) Manufacture and marketing of Tolfenamic acid for NSAID 11. Haw Par Elder India Private Ltd.

(India) Distribution of ‘Tiger’ brand of products

12. Invacare (USA) Distribution of oxygen concentrators 13. J Uriach & CIA (Spain) Manufacture and marketing of ‘Triflusal’ for treatment of cardio

vascular disease. 14. Meeta Corporation (USA) Distribution of ECT units 15. Oxo Chemie (Germany) Manufacture and marketing of Oxoferin Solution from TCDO

concentrate for wound healing 16. Medichem International Ltd. (UK) Distributions of Meddis, Medizyne and Trigene products 17. Paul Hartmann (Germany) Distribution of wound care bandages and incontinence diapers. 18. Polichem SA (Switzerland) Import, manufacture, promote, market and sell Pigitil, Macmirror

and Orange products. 19. Medcare Automation (Holland) Distribution of digital video EEG units and Polysomnigraph

machines 20. SciClone (USA) Manufacture and marketing of Zadaxin for the treatment of

Hepatitis B & C 21. Sigma Tau (Italy) Manufacture and marketing of L-carnitine for treatment of cardio

vascular diseases under the brand name ‘Carnitor’ 22. Stiefel India Private Limited (India) Manufacture and distribution of Fongitar, Acne-Aid, Oilatum 23. Tanabe (Japan) Manufacture and marketing of Tanatril 24. TRB Chemedica (Switzerland) Manufacture and marketing of Artrodar 25. Zambon Group SpA (Italy) Manufacture and distribution of

• N-acetylcysteine for treatment of respiratory diseases • Fosfomycin, Trometeamol for treatment of urinary tract

infection • Ibuprofen Arginine for NSAID

26. Cardionetics Ltd. (UK) Distribution of complete system – C.Net Plus heart monitors


- 116 -

E L D E R P H A R M A C E U T I C A L S L T D.

S K I N C A R E

SR. NO.

PRODUCT COMPOSITION

1 ESLITE - 15 Ointment Hydroquinone Cinnamate 2 % Octyl Methoxy Cinnamate 5 % Oxybenzone 3% 2 LOCOID

LIPOCREAM Hydrocortisone 17-Butyrate 0.1% in Lipocream base 3 LOCOID LOTION Hydrocortisone 17-Butyrate 0.1% in alc/water base with Gly

4 TRECLIN Cream Clindamycin 1.0% Tretinoin 0.025% in a gel base

5 VITILO Lotion Bavachi (Psoralia carylifolia) 4.0%

Karanja (Pongamia glabra) 1.0%

Neem (Azadirachta indica) 2.0%

Manjistha (Rubia cordifolia) 2.0%

Haldi (Curcuma longa) 1.0%

Amba Haldi (Curcuma amada) 1.0%

Raktachandan

(Pterocarpus santalinum) 2.0%

Vacha (Acorus calamus) 1.0%

Processed Jasad Bhasma (ZnO)

6 ANTHICAL LOTION Zinc oxide 15% w/v Mepyramine maleate 2% w/v Glycerin 5% w/v

7 ESLITE CREAM Hydroquinone USP 2% w/w

8

ALPHOSYL CREAM

Each tube of 20 gm contains : Allantoin 2% & Coaltar 5%


- 117 -




• Telephone

• Fax

• E-mail


ELDER PHARMACEUTICALS LTD.

Elder House, C-9, Dalia Industrial Estate, Off New Link Road, Andheri (W), Mumbai – 400 053, INDIA. 91-22-26730058-67 91-22-26730051 [email protected] Mr. Ajit Gajwani -Vice President (Exports) [email protected]

Year of Establishment 1983

Year of Commencement of Exports 1989-90

Products Manufactured Refer Annexure-I

No. of Employees :


2000 316 22 21 1193


Refer Annexure-II

Sales turnover( Last 5 Years) (Rs. Million)

1999-00 00-01 01-02 02-03 03-04 1732.92 1887.82 2030.5 2347.4 under audit

Value of Exports ( Last 5 Years) (Rs. Million)

1999-00 00-01 01-02 02-03 03-04 47.2 60.3 215.7 149.9 under audit

Principal Markets Nigeria, Sri Lanka, Vietnam

Type of business Importer- Manufacturer-Exporter

Legal Status Public Limited company

Banker Union Bank of India – Lead Bank

Capital 200 (Rs. Million)

Ownership Public Limited Company

Product specifications IP / BP / USP / INH

License capacity --


- 118 -

Installed capacity (Year ended 31.03.03)

Class of Goods Unit Capacity Tablets Millions 600 Capsules Millions 390 Injectables Millions - Ointments Tonnes 96.0 Syrups/Liquids Kilo litres 816.0 API & Drug Tonnes 158.40 Intermediates

Actual production (last 5 years) Tablets Capsules Injectables Ointments Syrups/Liquids API & Drug intermediates

Unit Million Million Million Tonnes Kilolitres Tonnes

1999-00 00-01 01-02 02-03 03-04 465.2 430.2 408.0 437.6 under 122.2 114.1 175.0 142.3 audit 0.58 0.48 1.04 0.7 17.67 25.64 25.0 19.7 387.81 494.99 440.44 332.27 - - 45.12 36.71

Capacity utilized /under-utilization Under-utilised


1. Introduction of new products in domestic / export market. 2. Expansion in export markets.




Issued GDR. Indigenous

Imported

Manufacturers/ Traders

Manufacturers/ Traders

IP / BP / USP/ INH EP /BP / USP / JP / INH Minimum order quantity Minimum order quantity

Within one week


• Sources • Quality • Quantity • Time availability • Prices Negotiable Negotiable


Ex-factory value of the product varies directly with the price of the raw material.

Import duty on raw-material 20% Basic + 16% Contravailing duty, 5% basic in case of life specified by Government in Custom Tariff

Govt. incentive for supply of raw-materials • Allocation for export production • Supply at world price • Tax/duty exemption

(Only for Export)


- 119 -


• Quality control facility, if any • Pre-shipment inspection • And quality control specification • Brand name

In house testing lab SGS / QCS for exports Pharmacopoeial / INH



Yes ×

×

Domestic Demand:


90% 10%


NA


Not Available


In the process of identifying distributors and products for Myanmar, Vietnam, Philippines and Sri Lanka. Dossiers for registration under preparation.

Exports incentives provided by the government DEPB, DEEC, DUTY DRAWBACK

Type of co. Manufacturer

Shipping: • Availability • Suitability • Cost of cargo space • Road/Rail/Air and water

Easily available Suitable Competitive

Packaging: • Method of packaging • Packaging material • Their availability • Quality • Cost

Cartons, Shippers, Fibre Drums Easily available Good Reasonable

Export credit and finance facilities Finance available from Bank

Trade promotion activities by Govt and EPCs : • Publicity abroad • Buyer Seller Meeting • Trade fair within the country/abroad • Seminars • Training events


- 120 -


• Product mix for export development • Expansion of capacity • Supply inputs • Quality improvement & control • Export marketing methods • Streamlining export incentives and

procedures


• Product modification / • Adaptation, technology & Technical know how • Packaging • Market survey • Market promotion • Export management trend • Selling missions • Strengthening institutional framework • Other (specify)

Yes

Yes

Yes Yes

Yes No Yes Yes



Available in plenty.

• If raw materials and other production inputs are a major constraint for expo development, substantiate with

typical illustrative example

NA Category of Importer: Actual User

Imports: (Rs. Million) Products 1999-00 00-01 01-02 02-03 03-04 Raw Material 99.40 110.32 134.0 69.76 under audit

Finished Goods 103.14 99.83 97.37 97.57 under

audit Imports Projection (Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Raw Material 150.00 170.00 200.00 250.00 300.00

Finished Goods 100.00 115.00 130.00 150.00 170.00


- 121 -

Apparent consumptions:

Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports :

a) Price b) Registration of product by the overseas manufacturer with FDA India

Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) AWB, COA for raw material Import Channel : Importers/ Agents/Distributors

Usual buying methods : Through Letter of Credit / Direct

Imports packing & packaging requirements : Sea / Air worthy

Structure of distribution : Company C&F Agent Stockiest Retailer Consumer Cost of distribution (%): 4%


Refer Annexure-I for Product Catalogue

LIST OF ANNEXURES

Annexure No.

Contents

I

Product List

II

List of Foreign Collaborations


- 122 -



Name and Title: Vishal Jajodia (C.E.O & Managing Partner)

Company name EURESIAN

Street - POB 101, Marine Chambers, 11 New Marine Lines,

City - Country Mumbai 400 020 , INDIA

Email: [email protected] Tel: +91 22 56332427 Fax: +91 22 22071955

Year established: 1970 Number of employees: 60 Bank Ref: Canara Bank, Mumbai

Website address of company: www.euresian.com

Activities





















- 123 -





27. Vitamins and minerals 28. Natural ingredients for pharmaceuticals Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal Medicines containing whole plant material or as raw material for the isolation of active substances or extracts Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Fatty oils, fats, waxes and their derivatives Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants N/A Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams N/A Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes N/A Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin N/A 34. Essential oils and oleoresins 35. Biotech



- 124 -




• Telephone

• Fax

• E-mail


EURESIAN 101, Marine Chambers, 11, New Marine Lines, Mumbai 400 020 +91 22 5633 2427 +91 22 22071955 [email protected] Vishal Jajodia(CEO & Managing Partner)

Year of Establishment 1970 Year of Commencement of Exports 1980 Products Manufactured As per list enclosed.

No. of Employees :


60 30 10 4 16


In process(cannot inform until agreement is signed) Canadian Company Joint Venture for Manufacturing of APIs & Finished Dosage.


1999-00 00-01 01-02 02-03 03-04 125.91 156.32 211.41 247.07 297.09 Same as sales turnover.

Principal Markets Europe, Americas (North & South), Far East, Russia, Japan.

Type of business Manufacturing Legal Status Proprietorship / Private Limited Banker Canara Bank, Mumbai, India Capital Ownership 100% Private Product specifications As per product list enclosed

(Pharmacopoeia : USP, BP, EP, JP & IP)

License capacity Depends upon installed capacity Installed capacity 30 Tones annually. Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

50 75 100 150 300

Capacity utilized /under-utilization 75%


- 125 -


Partnership in sales & registration in EU



o By Modernization o Creation of New capacity


Target 100% capital utilization

Indigenous

Imported

75% 25% Good Good Sufficient Sufficient Slow Loss of transit time



Negotiable Negotiable Impact of prices of raw material on the ex-factory value of the product

Moderate

Import duty on raw-material 20%

Govt. incentive for supply of raw-materials • Allocation for export production • Supply at world price • Tax/duty exemption

N/A



• Q.C Infrastructure list enclosed. • In house SOP • Pharmacopoeia • EURESIAN (35yr old name)



• All types of glassware to handle reactions, fume hood for corrosive reactions, pressure reactor for hydrogenation & other pressure reactions, oven, Ph meter, K-F apparatus, TLC Kit.

• As per list enclosed • Depends on product. • Pharmacopoeia (As per customer’s requirements) • As per customer’s requirements

Domestic Demand :


Huge

• Demand is several times more than production capacity.


NONE


Huge growth potential


Trade shows: Vitafoods (Geneva), CPhI Japan, Chemspec, CPhI(Brussels)


- 126 -


NONE

Type of co. Manufacturer/Merchant exporter/ trading company/ SSI unit Manufacturing SSI Unit

Shipping :


• Moderate • Moderate • High • Air and water, road

Packaging:


• HDPE Drums / Fibre • Double packed Polyethene • Locally • Good • Moderate

Export credit and finance facilities Good Trade promotion activities by Govt and EPCs:



Huge promotional activities of all kinds (as listed in your column) by CHEMEXCIL.



• Expansion of capacity • Supply inputs • Quality improvement & control • Export marketing methods • Streamlining export incentives and

procedures

Decrease in bureaucracy & complicated government policies

• Can be improved to niche products • Easily possible • Ample availability for our production. • Needs to improve consistently. • Trade shows • Deduction of options and focus on QBAL


• Product modification / • Adaptation, technology & • Technical know how • Packaging • Market survey • Market promotion • Export management trend • Selling missions • Strengthening institutional


YES Lot of Improvements needed in all areas.


- 127 -



Except packaging improvements drastically needed. Rest is quite comparable with developed world. • Processes & indigenous and imported technology: GOOD • Power: EXPENSIVE • Labour skilled: CHEAP

• If raw materials and other production inputs are a major constraint for expo development, substantiate with

typical illustrative example N/A

Category of Importer: Actual User/Wholesaler/Agent: Wholesales / Agent

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 As per list As per list 405.72 441 475.49 552.9 650.48 enclosed Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 As per list 300 400 500 600 700 enclosed Apparent consumptions: Products 2004-05 05-06 06-07 07-08 08-09 N/A Factor affecting Imports :

• Internal demands • Patents(IPR)

Documentary requirements for imports: Moderate (Not SO Complicated) -Certificate of Origin YES - Pre-shipment Inspection Certificate YES - Commercial Invoice YES - Insurance Certificate YES -Others (Please specify)

• Packaging list • Bill of Lading • Shipment Schedule.

Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others: IMPORTERS/AGENTS

Usual buying methods : Direct from Actual Manufacturer

Imports packing & packaging requirements : Fantastic Structure of distribution: In-house domestic stock and sales. Cost of distribution (%): 3%



- 128 -



Name and Title: D.P.Shrivastava – Vice President, International Business

Company name Macleods Pharmaceuticals Limited

Street - POB Atlanta Arcade, 2nd Floor, Marol Church Road, Andheri(East),

City - Country Mumbai – INDIA Email: [email protected] Tel: 009122-56762800 Extn:816 Fax: 009122-28312319 or 28266229

Year established: 1986 Number of employees: 1200 Bank Ref:

Website address of company: macleodspharma.com

Activities

√Exporter Wholesaler/Retailer √Manufacturer/Producer Importer Trader Other: _______________


Description (please give generic names and specify if the product is indigenous) E* I*













16. √Diuretics 17. Gastrointestinal medicines: Antacids Antiemetic Antihaemorrhoidal Anti-inflammatory Antispasmodic Laxatives Used in diarrhea Antidiarrhoeal (symptomatic)





- 129 -







- 130 -



Name and Title: ABHIT SUD , DIRECTOR

Company name MAYAR INDIA LIMITED

Street - POB 12, YAMUNA MARG, CIVIL LINES

City - Country DELHI 110054, INDIA Email: [email protected] Tel: 91-11-23944991-8 Fax: 91-11-23944985 / 23944989

Year established: Number of employees: 100+ Bank Ref: PUNJAB NATIONAL BANK

Website address of company: www.mayargroup.com

Activities


Countries previously imported/exported to: We are in the exports, and our products are successfully exported to Canada, South Africa, Croatia, Holland, Swtizerland, USA, Germany



















- 131 -






* Applicable categories are with Black Box.


- 132 -



• Postal address (office)

• Telephone

• Fax

• E-mail


MAYAR INDIA LIMITED 12, YAMUNA MARG CIVIL LINES, DELHI 110054, INDIA 0091-11-23944991-8 0091-11-23944985 /23944989 [email protected] MR. ABHHITT SUD , DIRECTOR MR. S.M.KHANNA, DIRECTOR

Year of Establishment 1978 Year of Commencement of Exports 2000 Products Manufactured AYURVEDIC, HERBAL HEALTHCARE & PERSONAL

CARE PRODUCTS. No. of Employees :


45 30 12 40

Foreign Collaborations Name of Foreign company Type of collaboration

YES M/s. OMEGA PHARM, UKRAINE M/s. INTERMEDIKO, RUSSIA EXCLUSIVE DISTRIBUTORS IN UKRAINE & RUSSIA RESPECTIVELY

(Rs. Million) Sales turnover( Last 5 Year) Value of Exports ( Last 5 years) (Rs. Million)

1999-00 00-01 01-02 02-03 03-04 2120 2321 2459 2413 3000 1 11 2 2 3

Principal Markets UKRAINE, USA, GERMANY, SWITZERLAND & JAPAN Type of business MANUFACTURER & EXPORTER Legal Status LIMITED COMPANY Banker PUNJAB NATIONAL BANK, CIVIL LINES DELHI,INDIA Capital (Rs. Million) 700 Ownership Closely held Public Limited Company Product specifications Food supplement, cough syrup, single ingredient capsules,

OTC healthcare products & personal care & beauty care product

License capacity 1.5 tons Per Day Installed capacity 1 ton Per Day Capacity utilized /under-utilization under-utilized


More product development, New market development.

Biotech DivisionMAYAR GROUP


- 133 -

If Capacity is constant prospects for expansion of capacity through • By modernization • By expanding existing units • Creation of new capacity

• By modernization • By expanding existing units • If required then creating new capacity


Yes Required

Indigenous

Imported

Yes NOT APPLICABLE Yes NOT APPLICABLE Yes NOT APPLICABLE Yes NOT APPLICABLE



Yes NOT APPLICABLE Impact of prices of raw material on the ex-factory value of the product

No impact

Import duty on raw-material NOT APPLICABLE Govt. incentive for supply of raw-materials

• Allocation for export production • Supply at world price • Tax/duty exemption

Raw Material procured for further production of export goods are Tax / Duty exempted.

Quality standards Certification approval:


• Quality control laboratories is equipped with modern machineries

• Yes! If required

• Products are under companies Brand name as per the Drug License.



Yes Available Yes Yes Yes Yes Yes

Domestic Demand: • DD Products in %age • Export demand

95 % 5%


As per the Govt. Policy, Export goods are Tax / Duty exempted.


JAPAN


Participation in Exhibition, Fairs, Buyers-seller Meet, Seminar, Trade shows.


As per the Govt. Policy, Export goods are Tax / Duty exempted. Marketing development assistance (MDA) in new market development

Type of co. Manufacturer/ trading company Shipping:

• Availability • Suitability • Cost of cargo space

Road/Rail/Air and water

As of Now Products are exported on the FOB basis, But Shipping facilities are available, If Required


- 134 -

Packaging: • Method of packaging • Packaging material • Their availability • Quality • Cost

• Automatic Machines for the Packaging as per the international Standards

• Pet Bottle, Pet Jars, Collapsible Plastic Tube, Glass Bottles, Blister with aluminium foils

• As per the International standard • Cost is 5 % of the cost of the Product

Export credit and finance facilities It is available with our Bank Trade promotion activities by Govt and EPCs :

• Publicity abroad • Buyer Seller Meeting • Trade fair within the country/abroad • Seminars • Training events

Yes Yes Yes Yes Yes


• Product mix for export development • Expansion of capacity • Supply inputs • Quality improvement & control • Export marketing methods • Streamlining export incentives and

procedures

Yes Yes Yes Yes Yes Yes


• Product modification / • Adaptation, technology & • Technical know how? • Packaging • Market survey • Market promotion • Export management trend • Selling missions • Strengthening institutional


Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes



* All the Raw Material & Packaging Material procured as per the govt specified norms, duly tested by the Quality control department, Separate Report of analysis is carried out to meet international standard.


*No! raw materials and other production inputs are a major constraint for expo development Category of Importer : Actual User/Wholesaler/Agent NOT applicable, All The Raw material is sourced indigenously.


- 135 -

Imports: (Rs. Million) NOT APPLICABLE Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 NOT APPLICABLE Imports Projection (Rs. Million): NOT APPLICABLE Products 2004-05 05-06 06-07 07-08 08-09 NOT APPLICABLE Apparent consumptions: NOT APPLICABLE Products 2004-05 05-06 06-07 07-08 08-09 NOT APPLICABLE Factor affecting Imports: NOT APPLICABLE

Documentary requirements for imports: NOT APPLICABLE -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others NOT APPLICABLE Usual buying meth+ods : NOT APPLICABLE Imports packing & packaging requirements : NOT APPLICABLE Structure of distribution: COMPANY---- C&F---DISTRIBUTORS---SUB STOCKIST----RETAILER----CONSUMER Cost of distribution (%): 25 % OF Product cost



- 136 -




• Telephone

• Fax

• E-mail


MIR Holistics Pvt Ltd Thangam Building , Mathew Pailiey Road , Ernakulam North , Kochi 18.

91 484 3093999, 098470 54177 91 484 2355858 [email protected] Arun Kumar . K , Managing Director

Year of Establishment 2001 Year of Commencement of Exports 2004 Products Manufactured Anticig – Antismoking Herbal Tablets

No. of Employees :


8 6 2 4


We have our own office in Moscow . No other collaboration


1999-00 00-01 01-02 02-03 03-04 6

Principal Markets India , Russia , middle east , Europe

Type of business Manufacturing of herbal products Legal Status Private limited company Banker ICICI Bank , kochi Capital 50 lakhs Ownership Closely held shareholders Product specifications

Anticing is a nicotine free antitobacco herbal tablet used for stop smoking and other tobacco Related habits

License capacity 30 million tablet per annum Installed capacity 30 million tablet per annum Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

10 m


40 %


- 137 -


Need to develop further market



NA


NA Indigenous

Imported

Own herbal garden nil Excellent Excellent Do our own cultivation



Cost of cultivation only Impact of prices of raw material on the ex-factory value of the product

Cost is low due to own arrangement of herbal cultivation

Import duty on raw-material nil




nil




Iso 9001 approved company Anticig



Constant reseach is being done on product Improvement , quality and shelf life

Domestic Demand :




This product will have a very good impact for Far east


- 138 -


Export development potential is very high



Shipping :


Packaging :


Export credit and finance facilities Trade promotion activities by Govt and EPCs :






and procedures





- 139 -



• If raw materials and other production inputs are a major constraint for expo development, substantiate

with typical illustrative example Category of Importer : Actual User/Wholesaler/Agent

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports : Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods : Imports packing & packaging requirements : Structure of distribution : Cost of distribution (%):



- 140 -



Name and Title:

Company name N.C.P.Works

Street - POB 97, G.T.Road, PO: Bhadrakali District;Hoogly

City - Country West Bengal

Email: [email protected] Tel: 91-33-26631598/3444 Fax: : 91-33-26633440

Year established: 1994 Number of employees: 15 Bank Ref:

Website address of company:

Activities

Exporter Wholesaler/Retailer ⌧Manufacturer/Producer Importer Trader Other: _______________


Description (please give generic names and specify if the product is indigenous) I* E*1. Anaesthetics: General ansesthetics and oxygen Local anaesthetics Preoperative medication and sedation


3. Antiallergics and medicines used in anaphylaxis

4. Antidotes and other substances used in poisoning: Non-specific Specific

5. Anticonvulstants/antiepileptics:

6. Anti-infective medicines: Anthelminthics Antibacterials Antifungal Antiviral Antiprotozoal Insect repellents



9. Antiparkinsonism medicines

10. Medicines affecting the blood: Antianaemia medicines Medicines affecting coagulation



13. Dermatological medicines (topical) *Antifungal Anti-infective *Anti-inflammatory/antipruritic Astringent Skin differentiation/proliferation Scabicides/pediculicides Ultraviolet

⌧



16. Diuretics

17. Gastrointestinal medicines: Antacids Antiemetic Antihaemorrhoidal Anti-inflammatory Antispasmodic Laxatives Used in diarrhea Antidiarrhoeal (symptomatic)






- 141 -


23. Peritoneal dialysis solution

24. Psychotherapeutic medicines: Psychotic disorders Mood disorders Generalized anxiety and sleep disorders Obsessive compulsive disorders



27. Vitamins and minerals


Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal

Medicines containing whole plant material or as raw material for the isolation of active substances or extracts

Saps and extracts, tinctures, balsams, lacs, gums, resins and starches

Essential oils

Fatty oils, fats, waxes and their derivatives

Colouring agents

29. Natural ingredients for cosmetics

Plant Extracts Vitamins Proteins Waxes Oils

Thickening Agents Other additives Perfumery oils Preservatives

30. Raw plant material

Medicinal and aromatic plants

Seaweed and algae

31. Vegetable saps and extracts

Lacs, natural gums, resins, gum-resins and balsams

Other vegetable saps and extracts

Ephedrine and quinine

32. Vegetables (and animal) derived oils, fats and waxes

Peanut oil & its fractions

Coconut, palm kernel or babassu oil

Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil

Animal or vegetable fats and oils and their fractions

Waxes

Cocoa butter, fat and oil

33. Colouring matter of vegetable or animal origin

34. Essential oils and oleoresins

35. Biotech

36.Herbal ⌧



- 142 -




• Telephone

• Fax

• E-mail


M/s Ophtechnics Unlimited 2209 Phase IV DLF City Gurgaon-122002. Haryana. India. ++ 91 124 5053491 to 5053494 ++ 91 124 5053495 [email protected] Ashish Dange, CEO

Year of Establishment 2002 Year of Commencement of Exports 2002 Products Manufactured Intraocular Lenses, Surgical Blades, Surgical Insruments.

Ophthalmic Solutions: Miotics, Trypan Blue, Viscoelastic

No. of Employees :


2 10 3 3


Ophtechnics Inc., USA Sister Establishment and dedicated buyer.


1999-00 00-01 01-02 02-03 03-04 --- --- ---- 10.00 10.00 --- --- --- 8.00 7.50

Principal Markets USA, UAE, Turkey, El Salvador, Syria, Jordan, Iraq, Nigeria, Bangladesh

Type of business Manufacturing-Exporrting Legal Status SSI registered Banker CITIBANK, NA Capital 2.5 million Rs. Ownership Proprietor Product specifications Miotic – Carbachol 0.01% Ophthalmic Solution

Trypan Blue 0.8% Ophthalmic Solution

License capacity Not applicable Installed capacity scalable Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

--- --- --- 15000 25000 units units


- 143 -


Not Applicable


Contract manufacturing, private labeling



Not Applicable


Have the capability of investing up to $100000 more, as and when required.

Indigenous

Imported

Available Acceptable Internationally -- 3-4 weeks



various Impact of prices of raw material on the ex-factory value of the product

Raw Material Cost is more than 60% of the product cost. So yes, there is an impact of prices of raw material on the ex-factory value

Import duty on raw-material All raw material purchase is domestic



Not availed yet.



For Ophthalmic products we have secured: ISO 9001:2000 CE Marking For Ophthalmic pharmaceuticals CE Marking is being pursued.



We have in-house quality control department. A class 10,000 clean room environment with a Class 100 Work area. We do not have any in-house R&D facility, as yet.

Domestic Demand : • DD Products in %age • Export demand

25% 75%


Not Applicable


Not exported in those markets yet


- 144 -


Aggressive plans of boosting exports for pharmaceutical products through participation in International and Regional Ophthalmic Congresses/Conferences/Exhibitions


Not availed


Shipping :


Products are being shipped using Airport to Airport Air Freight Services at the most competitive prices.

Packaging :


Products are packed individually in unit packs. Unit packs are packed in corrugated boxes for shipment. All packing material is procured locally. Quality is at par with international packing and costs are competitive.

Export credit and finance facilities Never availed. Usually we work on Advance TT/ LC payment basis.

Trade promotion activities by Govt and EPCs :



Not participated in any, so far




and procedures




No No Yes No Yes Yes Yes Yes Yes


- 145 -




Category of Importer : Actual User/Wholesaler/Agent

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports: Not Applicable

Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) Import Channel : Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods:

Imports packing & packaging requirements:

Structure of distribution : Cost of distribution (%):



- 146 -



Name and Title: Mr. Inder Setia, Director

Company name Surya Herbal Limited

Street - POB C-33, Sector-59

City - Country Noida-201301, India

Email: [email protected] Tel: +91-120-2586476 Fax: +91-120-2586478

Year established: 1999 Number of employees: 82 Bank Ref: State Bank of India

Website address of company: www.suryaherbal.com

Activities





















- 147 -







- 148 -


Trade Promotion Programme

Name of Company:


• Telephone

• Fax

• E-mail


Surya Herbal Limited C-33, Sector- 59, Noida – 201301 0120-2586476 0120-2586478 [email protected] Inder Setia (Director)

Year of Establishment 1999 Year of Commencement of Exports 2001 Products Manufactured Herbal/Ayurvedic Medicines,

Food Supplements, Personal Care

No. of Employees :


17 41 5 19


N A

(Rs. Million) Sales turnover (Last 5 Year) (Including Export) approx Value of Exports (Last 5 year)

1999-00 00-01 01-02 N A (1,27,00,000) (3,94,00,000) 02-03 03-04 (5,91,00,000) (4,73,00,000) 1999-00 00-01 01-02 N A (NIL) (77,000) 02-03 03-04 (69,80,000) (72,00,000)

Principal Markets CIS, Russia, UAE, USA, South Africa, Poland

Type of business Manufacturer & Exporter Legal Status Incorporated Limited Company Banker State Bank of India Capital 3 Crore Ownership Public Limited Company Product specifications

As per Indian Pharmacopoeia License capacity N A


- 149 -

Installed capacity Attached Actual production(last 5 years) 1999-00 00-01 01-02 02-03 03-04

No Bifurcation Available


40%


N A



N A


Internal Resources Indigenous

Imported

Farmers/Suppliers N A As per Ayurvedic Pharmacopoeia or Indian Pharmacopoeia

N A

As per requirement N A With in 10 days N A



As per Market Trends N A Impact of prices of raw material on the ex-factory value of the product

We review our prices quarterly.

Import duty on raw-material N A



N A



We follow In House as well as Pharmacopoeia and also follow specific country specification where material to be Exported. In House Q. C. Lab As per contract In House Surya Herbal


- R& D facilities available • Technology • Product design • Raw material • Quality of standard & testing • Packaging

Yes Validated Techniques are used and collaborated/outsources as per requirement In House We use standardized R.M. As per Indian Pharmacopoeia / US Pharmacopoeia We develop finalise packaging


- 150 -

Domestic Demand:



N A


Still exploring the markets


Planning visits for initial break through


N A

Type of co. Manufacturer/ SSI unit

Shipping :


Road/Rail/Air and water

Packaging :


Out Sourcing

Export credit and finance facilities Advance 100% Trade promotion activities by Govt and EPCs :






and procedures


• Product modification / • Adaptation, technology & • Technical know how • Packaging


- 151 -

• Market survey • Market promotion • Export management trend • Selling missions





Attached


We outsource specific testing facilities for our export requirement Category of Importer : Actual User/Wholesaler/Agent N A

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 N A Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 N A Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 N A Factor affecting Imports: N A

Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) N A Import Channel: Importers/ Agents/Distributors/End-users/NGO/Others N A

Usual buying methods: N A

Imports packing & packaging requirements: N A

Structure of distribution: N A Cost of distribution (%):



- 152 -

SURYA HERBAL LTD. C-33, SEC-59, NOIDA, U.P (INDIA)

TEL NO: 0120-2586476,2586477. FAX NO. 0120-2586478 E-Mail- [email protected], [email protected]

PRODUCT LIST

Sr. No

Name of Products Unit Shipper size

Dose Form

Useful in (Aggravated Condition

1 X-Diaba CAPSULE 2x 10Caps

20x10x12 Diabetics, Control Increased Blood Sugar level and generally Debility

Capsule

Kapha

2. CHAWANPRASH

500 gm 1000gm.

24x 500g.m. 12x1000gm

Health Tonic, improve immune body power and give energy to all body part ( A thousand Years old Ayurvedic system)

Paste Vata Kapha

3 RILEEF PAIN BALM

10 g.m. 240x10 g.m. Headache, body ache, muscular pain, and other aches and pains.

Ointment Vata Pita

4 GERIFIT SYRUP 100 Ml 200 Ml

50x100 Ml 30x200 Ml

A physical and mental restorative acts as an antioxidant: improves muscular tone: promotes cellular regeneration and growth: also arrests degenerative changes and helps adjust to and cope with stressful situations.

Syrup Vata Kapha

5

GERIFIT TABLETS

60 Tabs

100x60 Tab

A physical and mental restorative acts as an antioxidant: improves muscular tone: promotes cellular regeneration and growth: also arrests degenerative changes and helps adjust to and cope with stressful situations

Tablets Vata Kapha

6 REGULOVAC TABLETS

60 Tabs

100x60 Tab

Treats constipation and maintains bowel regulations: softens stool, restores normal faecal consistency and facilitates easy defecations without cramps.

Tablets Kapha Pitta

7 SEPNIL TABLET 60 Tabs

100x60 Tab

The safe no-antibotic, anti-infective of choice in a host of infections for tip to toe protection.

Tablets Kapha

8

KOF – S 100Ml 200Ml

50x100Ml 30x200Ml

The cough and cold remedy against allegeric cough, with expectoration and bronchial asthma.

Syrup Kapha

9

SURYACID TABLETS

60 Tabs

100x60 Tab

Checks hyperacidity, reflux oesophagitis, peptic ulcer dyspepsia and flatulenc.

Tablets Pitta Vata

10.

MENSTRURYL CAPSULES

2 Caps

20x12x2 Caps

Regulation and maintenance of menstrual flow and treats dysmenorrhoea: helpful and effective in delayed puberty, oligomenorrhoea, dysfunctional uterine bleeding, annovulation, functional female infertility and menopausal disturbances. Also tones up the endometrial vasculature

Capsule Vata Kapha


- 153 -

11. MENSTRURYL SYRUP

100 Ml 200Ml

50x100 Ml 30x200Ml

Regulation and maintenance of menstrual flow and treats dysmenorrhoea: helpful and effective in delayed puberty, oligomenorrhoea, dysfunctional uterine bleeding, annovulation, functional female infertility and menopausal disturbances. Also tones up the endometrial vasculature

Syrup Vata Pitta

12. X-Piles TABLETS

60 Tabs

100x60 Tab

Relieve painful, Inflamed bleeding piles and also provides relief in varicose veins from symptoms like pain, congestion and night cramps

Tablets Vata Kapha

13.

URALKA SYRUP

100 Ml 200 Ml

50x100 Ml 30x200 ml

Solves the problem of urinary tract infections, disintegrates and expels renal/urinary stones, treats non specific urethirites and cystitis, burning micturition, renal colic and prostrate enlargement

Syrup Vata Pitta

14.

LUCORYL Tablets

60 Tabs

100x60 Tab

Treats all aspects of Leucorrhoea, Normalizes vaginal epithelium, thus toning up the entire uterine musculature.

Tablets Vata Kapha

15. VOMINIL TABLETS

100Tab

100x100Tab

An efficient anti-emetic for vomiting in first trimester of pregnancy, vomiting associated with gastroenteritis, worm infestation and jaundice, motion sickness, pre-medication for preventing drug induced nausea and vomiting

Tablets Vata Kapha

16.

VOMINIL SYRUP

60 Ml

72x60 Ml

An efficient anti-emetic for vomiting in first trimester of pregnancy, vomiting associated with gastroenteritis, worm infestation and jaundice, motion sickness, pre-medication for preventing drug induced nausea and vomiting

Syrup Vata Kapha

17. REGULIV SYRUP 100Ml

50x100 Ml

Protects liver against various hepatototoxins, infections, alcohol, drugs, etc. corrects liver dysfunction and damage: promotes appetite and growth in liver malfunction.

Syrup Pitta Kapha

18. REGULIV TABLETS

100 Tabs

100x100 Tab

Protects liver against various hepatototoxins, infections, alcohol, drugs, etc. corrects liver dysfunction and damage:promotes appetite and growth in liver malfunction

Tablets Pitta Kapha

19 MEMOFIT CAPSULE & SYRUP

60 Cap 100 Ml

60 Capx100 100Ml x 50

Helps overcome Memory Fatigue and stress improved concentration & Grasping ability activates the mind and corrects mental aberrations

Capsule & Syrup

Vata Pitta

20 SLIM-N-TRIMCAPSULE

60 Cap

60Capx100

In control weight and accumulation weight

Capsule Kapha

21 NEEM CAPSULES (Azadirachta indica)

60 Cap

60 Capx100

Immuno modulator and skin disorder

Capsule

Kapha Pitta


- 154 -

22 ASHWGANDHA CAPSULE (Withania somnifera)

60 Cap

60 Capx100

A Physical and mental restorative promotes and helps adjust to and cope with stressful situations.

Capsule Vata

23 GARLIC CAPSULE (Allium sativum )

60 Cap

60 Capx100

Hyper Cholesterol oilemic

Capsule Kapha

24 ARJUNA (Terminalia Arjuna)

60 Cap

60 Capx100

Useful in High B.H.P. and regular blood circulation

Capsule Kapha

25 TERMARIC (Curcuma Longa )

60 Cap

60 Capx100

Useful in allergic conditions, bronchitis, acute infections

Capsule Kapha Vata

26 AMLA CAPSULE (Emblica Officinalis)

60 Cap

60 Capx100

Anti Aging Capsule Capsule Pitta

27 KARELA CAPSULE (Momordica Charantia)

60 Cap

60 Capx100

Useful in NIDDM cases and reduces sugar in blood and urine.

Capsule Kapha

28 BRAHMI CAPSULE (Bacopa Monniera)

60 Cap

60 Capx100

Useful in weakness of memory Capsule Vata

29 BEAL FRUIT CAPSULE (Aegle marmelos )

60 Cap

60 Capx100

Useful in diarrhea Capsule Vata Kapha

30 PUNARNAVA CAPSULE (Boehaavia Diffusa)

60 Cap

60 Capx100

Useful in Dysuria, burning micheration body inflammation

Capsule Vata

31 SALAI GUGGUL CAPSULE (Boswellia Serrata)

60 Cap

60 Capx100

Useful in arthritis, joint pains. Capsule Kapha Vata

32 GOKSHURA CAPSULE (Tributus terrestris)

60 Cap

60 Capx100

Useful in Dysuria, burning micturation Capsule Kapha Vata

33 GUDUCHI CAPSULE (TinosporaCordifolia)

60 Cap

60 Capx100

Useful in liver problem, low immunity Capsule Kapha Vata

34 GUGGUL CAPSULE (Commipora Mukul)

60 Cap

60 Capx100

Useful in joint pain, inflammation Capsule Kapha Vata

35 GUDMAR CAPSULE (Gymnema Sylvestre)

60 Cap

60 Capx100

Useful in Diabetes.

Capsule Kapha

36 HARITAKI CAPSULE (Terminalia chebula)

60 Cap

60 Capx100

Useful in constipation.

Capsule Vata

37 HOLI BASIL CAPSULE (Ocimum sanctum)

60 Cap

60 Capx100

Useful in flu, bronchitis

Capsule Kapha

38 LICORICE CAPSULE (Glycyrrhiza Glabra)

60 Cap

60 Capx100

Useful in Hyperacidity, bronchitis, sore throat.

Capsule Kapha Vata


- 155 -

39 MALABAR NUT CAPSULE (Adhatoda vasica)

60 Cap

60 Capx100

Useful in bronchitis Capsule Kapha

40 SHATAVARI CAPSULE (ASPARAGUS RECEMOSUS)

60 Cap

60 Capx100

(Useful in hyperacidity, menorrhagia ) Capsule

Pitta Vata

41 VIAMEN 60 Cap

60 Capx100

Improves health vigour and sexual power of man.

Capsule Vata Pitta

42 VIAFEM 60 Cap

60 Capx100

Improves health vigour and sexual power of Woman.

Capsule Vata Pitta


- 156 -

SURYA HERBAL LTD. C-33, SEC-59, NOIDA, U.P (INDIA)

TEL NO: 0120-2586476,2586477. FAX NO. 0120-2586478 E-Mail- [email protected], [email protected]

Cosmetics List

SI.

NO. Product Name Quantity

Shipper Size

1 Amla Hair Oil 100 ml 100 x 100 ml 2 Anti Pigmentation Cream 40 gram 100 x 40 gram 3 Anti Pimple/Anti Acne Cream 40 gram 100 x 40 gram 4 Anti Wrinkle Cream 40 gram 100 x 40 gram 5 Antidandruff Hair Cleanser 100 ml 100 x 100 ml 6 Astringent Lotion 100 ml 100 x 100 ml 7 Body Butter 40 gram 100 x 40 gram 8 Borobeauty Cream 25 gram 250 x 25 gram 9 Boromed Anti Acne 25 gram 250 x 25 gram 10 Boromed Anti Pimple 25 gram 250 x 25 gram 11 Boromed Tulsi Calendula 25 gram 250 x 25 gram 12 Boromed Tulsi Rose 25 gram 250 x 25 gram 13 Cleansing Milk 100 ml 100 x 100 ml 14 Cool - Cool Oil 100 ml 100 x 100 ml 15 Face Glow Mask 50 gram 100 x 50 gram 16 Face Scrub 40 gram 100 x 40 gram 17 Fairness Cream 40 gram 100 x 40 gram 18 Fitocare Antidandruff Shampoo 100 ml 100 x 100 ml 19 Fitocare Hair Cleanser 100 ml 100 x 100 ml 20 Hair Cleanser 100 ml 100 x 100 ml 21 Henna 200 gram 100 x 200 gram 22 Massage Oil 100 ml 100 x 100 ml 23 Maxicharm Cream 25 gram 250 x 25 gram 24 Moisturising Lotion 100 ml 100 x 100 ml 25 Neem Oil 100 ml 100 x 100 ml 26 Neem Scalp Tonic 100 ml 100 x 100 ml 27 Nourishing Cream 40 gram 100 x 40 gram 28 Shampoo Gel 40 gram 100 x 40 gram 29 Skin Toner 100 ml 100 x 100 ml 30 Soft Heel 40 gram 100 x 40 gram 31 Sun Block Cream (SPF - 15) 40 gram 100 x 40 gram 32 Surya Antiseptic Cream 25 gram 250 x 25 gram 33 Surya Talc 100 gram 100 x 40 gram 34 Under Eye Gel 40 gram 250 x 25 gram


- 157 -



Name and Title:

Company name Techno Economic Services P.Ltd.,

Street - POB Rd no. 21, Plot No. 323A, MIDC Wagle Est,

City - Country Thane. India 400604 Email: [email protected] Tel: 25821788 Fax: 25824473

Year established: 1978 Number of employees: 100 Bank Ref: Union Bank of India,Mumbai-400077

Website address of company:

Activities

⌧Exporter ⌧Wholesaler ⌧Manufacturer ⌧Importer Trader Other




2.* Analgesics, antipyretics, non-steroidal anti-inflammatory medicines (NSAIMs), medicines used to threat gout and disease modifying agents in rheumatoid disorders (DMARDs) NSAIMs Opioid analgesics Used to treat gout DMARDs

3.* Antiallergics and medicines used in anaphylaxis 4. Antidotes and other substances used in poisoning: Non-specific Specific

5. Anticonvulstants/antiepileptics: 6. Anti-infective medicines: * Anthelminthics * Antibacterials * Antifungal Antiviral * Antiprotozoal Insect repellents






13. Dermatological medicines (topical) * Antifungal Anti-infective Anti-inflammatory/antipruritic Astringent Skin differentiation/proliferation * Scabicides/pediculicides Ultraviolet



16. Diuretics 17. Gastrointestinal medicines: * Antacids Antiemetic Antihaemorrhoidal * Anti-inflammatory * Antispasmodic * Laxatives * Used in diarrhea * Antidiarrhoeal (symptomatic)





- 158 -



25. Medicines acting on the respiratory tract 26. Solutions correcting water, electrolyte and acid-base disturbances: * Oral Parenteral Miscellaneous

27.* Vitamins and minerals 28. Natural ingredients for pharmaceuticals Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal Medicines containing whole plant material or as raw material for the isolation of active substances or extracts Saps and extracts, tinctures, balsams, lacs, gums, resins and starches Essential oils Fatty oils, fats, waxes and their derivatives Colouring agents 29. Natural ingredients for cosmetics Plant Extracts Vitamins Proteins Waxes Oils Thickening Agents Other additives Perfumery oils Preservatives 30. Raw plant material Medicinal and aromatic plants Seaweed and algae 31. Vegetable saps and extracts Lacs, natural gums, resins, gum-resins and balsams Other vegetable saps and extracts Ephedrine and quinine 32. Vegetables (and animal) derived oils, fats and waxes Peanut oil & its fractions Coconut, palm kernel or babassu oil Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil Animal or vegetable fats and oils and their fractions Waxes Cocoa butter, fat and oil 33. Colouring matter of vegetable or animal origin 34. Essential oils and oleoresins 35. Biotech



- 159 -




• Telephone

• Fax

• E-mail


Techno Economic Services Pvt.Ltd., 323 A Wagle Ind. Est. Rd. No.21, M.D.I.C.Thane 400604 25821788 25824473 [email protected] Sunil Desai K S Desai

Year of Establishment 1978 Year of Commencement of Exports 1995 Products Manufactured Tablets,Capsules-General as well as B-Lactum

No. of Employees :


10 70 10 10


Not at present but are negotiating Hanthroposs.Richiegold Austex Grp. Marketing tie up in Europe & putting plant in Nigeria

(Rs. Million) Sales turnover (Last 5 Year) Value of Exports (Last 5 year)

1999-00 00-01 01-02 02-03 03-04 100.00 110.00 120.00 125.00 150.00 Entire sales is export only. 100% exporters

Principal Markets Nigeria, Sierra Leone, Guinea, Liberia & other W African Area

Type of business Manufacturer exporter-pharma Legal Status Private Limited Co. Banker Union Bank of India Capital Rs.150 million Ownership Family concern Product specifications Tablets & Capsules License capacity Not specified Installed capacity Can produce 100million tab:10 million cap P.M. Actual production (last 5 years) 1999-00 00-01 01-02 02-03 03-04

250 mil tables 370 500 500 500P.A 13 mil 15.0 20.0 60.- 60 capsules


- 160 -


Under utilized to the extent of 50 to 60%


Obtaining contract work from some big companies or to expand market area.



There is scope to increase capacity by adding more equipments in tables & capsules


If we can manage to get more orders, we are in position to manage resources.



Prices are effected on ups & downs as R.M.prices. Prices not fixed.


-

Import duty on raw-material 2.5%




Custom duty exempted for exports competition to low price of china is much excise duty exempted for exports.




In house Q.C in Thane Yes, it is being done b SGS ITI & all products are as per B.P. USP or I.P. Some; some are generics



Yes adequate to cope up our requirement under each head


- 161 -

Domestic Demand:



Govt. policy is not much encouraging for exports as Red Tapism in Hindrance


We have not explored there areas


We are suffering heavily due to costly registration formalities, exorbitant visa formalities & Non availability of Govt. help


It is measurably low


Shipping:


OK OK Cost is Escalating-by 30% P.A. by water-sea route

Packaging:


Goods are packed in carton, boxes available easily. PVC Glass “ Good Moderate –no much problem

Export credit and finance facilities Int. rate by bank is higher and poor Trade promotion activities by Govt and EPCs:



Not helpful Not much utility Never properly arranged Never properly arranged Never properly arranged




control • Export marketing methods • Streamlining export

incentives and procedures

Foreign Trade to be Arranged by our Embassies This is not done at all. Needs to be developed Essential-presently not adequate


- 162 -





It is necessary It is necessary It is necessary It is necessary It is necessary Govt. must pay registration fees to S.S.I. exporters & work to be given to association & no power should be beurocaats.




Cheoremphericol & Tetracycline were sold at half the price by China. So all plants in India were closed. As soon as there plants turned obsolete china doubled the price. So India is out of market in R.M. & finished goods. Category of Importer : Actual User

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 20 22 25 30 25


- 163 -

Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 It all depends on demand which may crop up. Not possible to predict Factor affecting Imports: Documentary requirements for imports: -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Q.C. reports & form No.10 Import Channel: Importers/ Agents/Distributors/End-users/NGO/Others Agents/Indentors Usual buying methods: Thro Indentros Imports packing & packaging requirements : Plastic Drums of 25 kg. 50 kg. Structure of distribution: We import for our own consumption Cost of distribution (%):



- 164 -



Name and Title: Umedica Laboratories Private Limited

Company name Umedica Laboratories private Limited

Street - POB 105/108 Rewa Chambers, New Marine Lines

City - Country Mumbai-400 020, India Email: [email protected] Tel: 22085041 /43 / 48 Fax: 22066518

Year established: 1982 Number of employees: 269 Bank Ref: SBI Commercial & International Bank Ltd.

Website address of company: www.amoliindia.com

Activities

�Exporter �Wholesaler/Retailer �Manufacturer/Producer �Importer �Trader �Other: _______________


Description (please give generic names and specify if the product is indigenous) I* E* 1. Anaesthetics: General ansesthetics and oxygen Local anaesthetics Preoperative medication and sedation

� �


� �

3. Antiallergics and medicines used in anaphylaxis � �

4. Antidotes and other substances used in poisoning: Non-specific Specific

� �

5. Anticonvulstants/antiepileptics: � �

6. Anti-infective medicines: Anthelminthics Antibacterials Antifungal Antiviral Antiprotozoal Insect repellents

�


� �


� �

9. Antiparkinsonism medicines � �

10. Medicines affecting the blood: Antianaemia medicines Medicines affecting coagulation

� �


� �


�


� �


� �


� �

16. Diuretics � �

17. Gastrointestinal medicines: Antacids Antiemetic Antihaemorrhoidal Anti-inflammatory Antispasmodic Laxatives Used in diarrhea * Antidiarrhoeal (symptomatic)

�


� �


- 165 -


� �

20. Muscle relaxants (peripherally acting) and cholinesterase inhibitors � �


� �


� �

23. Peritoneal dialysis solution � �

24. Psychotherapeutic medicines: Psychotic disorders Mood disorders Generalized anxiety and sleep disorders Obsessive compulsive disorders

�

25. Medicines acting on the respiratory tract � �


� �

27. Vitamins and minerals � �


Crude raw materials such as roots, rhizomes, leaves, fruits, seeds and (root) barks to be used in herbal � �

Medicines containing whole plant material or as raw material for the isolation of active substances or extracts � �

Saps and extracts, tinctures, balsams, lacs, gums, resins and starches � �

Essential oils � �

Fatty oils, fats, waxes and their derivatives � �

Colouring agents � �

29. Natural ingredients for cosmetics

Plant Extracts Vitamins Proteins Waxes Oils � �

Thickening Agents Other additives Perfumery oils Preservatives � �

30. Raw plant material

Medicinal and aromatic plants � �

Seaweed and algae � �

31. Vegetable saps and extracts

Lacs, natural gums, resins, gum-resins and balsams � �

Other vegetable saps and extracts � �

Ephedrine and quinine � �

32. Vegetables (and animal) derived oils, fats and waxes

Peanut oil & its fractions � �

Coconut, palm kernel or babassu oil � �

Fixed vegetable fats and oils and their fractions, such as jojoba oil, castor oil, tung oil and sesame oil � �

Animal or vegetable fats and oils and their fractions � �

Waxes � �

Cocoa butter, fat and oil � �

33. Colouring matter of vegetable or animal origin � �

34. Essential oils and oleoresins � �

35. Biotech � �

� �

� �

� �

� �

� �



- 166 -




• Telephone

• Fax

• E-mail


Unimax Laboratories Plot No. 7 Sector 24 Faridabad-121005, India 2232441, 5023349, 5021290 2233349 [email protected] Vishal Jain

Year of Establishment 1972 Year of Commencement of Exports 1990 Products Manufactured Pharmaceutical Formulation (tablets/Capsules)

No. of Employees :


(appx) Ten Seventy Five Six Ten


…………….X………….


1999-00 00-01 01-02 02-03 03-04

Principal Markets CIS, Western Africa, Vietnam, Germany

Type of business Legal Status Partnership Banker State Bank of Patiala Capital Ownership Product specifications

License capacity Installed capacity Actual production (last 5 years) 1999-00 00-01 01-02 02-03 03-04




- 167 -


• By modernization • By expanding existing units* • Creation of new capacity


Indigenous

Imported

Organised Sector China, Germany, Korea As per Bl/USP/I>P




Import duty on raw-material Basic 15% to 20%







G.M.P


- R& D facilities available • Technology • product design* • Raw material* • Quality of standard & testing* • Packaging*

Domestic Demand :




- 168 -




Type of co. *Manufacturer/Merchant exporter/ trading company/ SSI unit

Shipping:


Packaging:


Strip, PVC/Blister, Alu/Alu Blister, HDPE Loose

Export credit and finance facilities Trade promotion activities by Govt and EPCs:




• Product mix for export development*


control • Export marketing methods* • Streamlining export incentives

and procedures


- 169 -


• Product modification / * • Adaptation, technology* & • Technical know how* • Packaging • Market survey • Market promotion* • Export management trend • Selling missions






Category of Importer: Actual User/Wholesaler/Agent *

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 Imports Projection (Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 Apparent consumptions : Products 2004-05 05-06 06-07 07-08 08-09 Factor affecting Imports : Availability in local market Prices Quality Documentary requirements for imports: -Certificate of Origin * - Pre-shipment Inspection Certificate * - Commercial Invoice * - Insurance Certificate * -Others (Please specify)


- 170 -

Import Channel: *Importers/* Agents/Distributors/End-users/NGO/Others

Usual buying methods: L/C, O/P Imports packing & packaging requirements: Structure of distribution: Cost of distribution (%):



- 171 -




• Telephone

• Fax

• E-mail


XL Laboratories Private Limited 1-14, Shivlok House 1, Karam Pura Commercial Complex,Shivaji Marg, New Delhi-110 015 +91+11+25920680/ 25920681/ 25920682 +91+11+25920683 / 25167022 xlremendb.vsnl.net.in Mr. A.K. Bhargava

Year of Establishment 2000 Year of Commencement of Exports 2001 Products Manufactured Pharmaceutical formulations like tablets, capsules, liquid orals

WHO-GM certified

No. of Employees :


150 nos.


NIL

(Rs. Million) Sales turnover( Last 5 Year) Value of Exports ( Last 5 year) Million Rs.

1999-00 00-01 01-02 02-03 03-04 2.30 16.00 65.40 51.50 2000.01 2001-02 2002-03 2003-04 2.30 16.00 65.40 51.50

Principal Markets Africa, Asia, CIS, Latin America

Type of business Manufacturer-exporter Legal Status Pvt. Ltd. Co. Banker State Bank of India, Najafgarh Road, N.D. Capital Rs. 26.30 million Ownership Pvt. Ltd. Co. Product specifications Pharmacopoeia

License capacity (Nos.) Tablets:90 Cr,Capsules 40 Cr.Syrup 1.20 bottles Installed capacity Tablets:45 Cr,Capsules 20 Cr.Syrup 0.60 bottles


- 172 -

Actual production(last 5 years) a) Tablets

1999-00 00-01 01-02 02-03 03-04 -


Under-utilization


Need more orders



Yes Yes


Working out Indigenous*

Imported

Olloxacin 546kg Ciprohoxacin 1800kg Gelative 1100 kg Alu.foil 15000 kg



Duplex Bonel 120 tone Impact of prices of raw material on the ex-factory value of the product

Prices are much on higher side

Import duty on raw-material -




Yes Yes




Inhouse As and when needed bycustomer - XL

Research & Development: - R& D facilities available • Technology • product design • Raw material • Quality of standard & testing • Packaging

Inhouse * * *


- 173 -

Domestic Demand:


80%


Should be simplified


Good export potential


*Participation in Healthcare Fairs *Market surveys *BSM’s etc.


Very meagre to complete slobal market

Type of co. *Manufacturer/Merchant exporter/ trading company/ SSI unit

Shipping:


Regular Suitable Available Available

Packaging:


Blister: Alu/Alu Alu/PVC Alum.foils Available locally Good Costly

Export credit and finance facilities Available Trade promotion activities by Govt and EPCs:



Yes Yes Yes Yes -




control • Export marketing methods • Streamlining export incentives

and procedures

Yes Yes Yes Yes


- 174 -





Yes Yes Yes Yes Yes Yes



All are available idigenously


substantiate with typical illustrative example Transaction cost to be reduced inputs to be made available at reduced cost Category of Importer : Actual User/Wholesaler/Agent N/A

Imports: (Rs. Million) Products Country of Imports 1999-00 00-01 01-02 02-03 03-04 - Imports Projection(Rs. Million): Products 2004-05 05-06 06-07 07-08 08-09 - Apparent consumptions : - Products 2004-05 05-06 06-07 07-08 08-09 - Factor affecting Imports: - Documentary requirements for imports: - -Certificate of Origin - Pre-shipment Inspection Certificate - Commercial Invoice - Insurance Certificate -Others (Please specify) -


- 175 -

Import Channel: Importers/ Agents/Distributors/End-users/NGO/Others

Usual buying methods: - Imports packing & packaging requirements: - Structure of distribution: - Cost of distribution (%):



- 176 -


- 177 -

ANNEX III

STATISTICS FROM THE DEPARTMENT OF COMMERCE


- 178 -

Department of Commerce Export Import Data Bank Import: Commodity-wise

Dated: 15/6/2004 Values in US $ Million

Sorted on HSCode

* ITC HS Code of the Commodity is either dropped or re-allocated from April 2003

S.No. HSCode Commodity 2001-2002 %Share 2002-

2003 %Share %Growth

1. 290110 SATURATED ACYCLIC HYDROCARBONS 0.90 0.0018 2.08 0.0034 130.04

2. 290121 UNSATURATED ETHYLENE 24.85 0.0483 8.81 0.0143 -64.55

3. 290122 UNSATURATED PROPENE (PROPYLENE) 9.81 0.0191 0.04 0.0001 -99.58

4. 290123 UNSTRD BUTENE (BUTYLENE)& ISOMERS THEREOF 16.98 0.0330 11.09 0.0181 -34.72

5. 290124 UNSTRD BUTS-1 3-DIENE AND ISOPRENE 0.01 0.0000 0.16 0.0003 1,251.72

6. 290129 OTHER ACYCLIC HYDROCARBONS 5.36 0.0104 5.25 0.0086 -2.05

7. 290211 CYCLOHEXANE 3.76 0.0073 4.36 0.0071 16.17

8. 290219 OTHER CYCLANES,CYCLENES & CYCLOTERPENES 13.08 0.0254 9.91 0.0161 -24.21

9. 290220 BENZENE 10.82 0.0210 2.58 0.0042 -76.15

10. 290230 TOLUENE 8.44 0.0164 8.37 0.0136 -0.78

11. 290241 O-XYLENE 3.93 0.0076 2.43 0.0040 -38.26

12. 290242 M-XYLENE 2.96 0.0057 1.35 0.0022 -54.21

13. 290243 P-XYLENE 106.44 0.2070 118.66 0.1932 11.48

14. 290244 MIXED XYLENE ISOMERS 2.98 0.0058 0.37 0.0006 -87.61

15. 290250 STYRENE 120.34 0.2341 130.13 0.2119 8.13

16. 290260 ETHYLBENZENE 0.08 0.0001 0.16 0.0003 101.88

17. 290270 CUMENE 11.84 0.0230 15.33 0.0250 29.52

18. 290290 OTHER CYCLIC HYDROCARBONS 7.05 0.0137 10.67 0.0174 51.38

19. 290311 SATURATED CHLOROMTHN(MTHYL CHLRD) & CHLOROETHANE (ETHYL CHLORIDE)

1.33 0.0026 1.44 0.0023 7.88

20. 290312 DICHLOROMETHANE (METHYLENE CHLORIDE) 1.37 0.0027 2.56 0.0042 86.87

21. 290313 CHLOROFORM (TRICHLOROMETHANE) 0.47 0.0009 0.85 0.0014 81.34

22. 290314 CARBON TETRACHLORIDE 0.72 0.0014 0.27 0.0004 -61.99

23. 290315 1,2 DICHLOROMETHANE (CETHYLNE DICHLORIDE) 47.14 0.0917 56.61 0.0922 20.09

24. 290316 *1,2-DICHLOROPROPANE (PROPYLENE DICHLORIDE)AND DICHLOROBUTANES,SATURATED

0.13 0.0002 0.03 0.0000 -76.16

25. 290319 OTHER CHLOROMETHANE & CHLOROETHANE 7.24 0.0141 4.99 0.0081 -31.07

26. 290321 VINYL CHLORIDE (CHLOROETHYLENE),UNSTRTD 19.27 0.0375 43.22 0.0704 124.24

27. 290322 TRICHLOROETHYLENE,UNSATURATED 0.53 0.0010 0.46 0.0007 -13.53


- 179 -

28. 290323 TETRACHLOROETHANE (PERCHLOROETHYLENE ) , UNSATRTD 1.64 0.0032 2.10 0.0034 28.06


0.99 0.0019 1.17 0.0019 17.49

30. 290330 FLUORNTD,BRMNTD/IODINATED DERIVATIVES OF ACYCLIC HYDROCARBONS

4.67 0.0091 5.28 0.0086 12.97

31. 290341 TRICHLORO FLUORO METHANE 0.01 0.0000 0.01 0.0000 -4.81

32. 290342 DICHLORO DIFLUORO ETHANE 0.01 0.0000 0.27 0.0004 2,603.45

33. 290343 TRICHLORO TRIFLUORO ETHANE 0.02 0.0000 0.01 0.0000 -39.04


0.10 0.0002 0.07 0.0001 -30.50


0.33 0.0006 0.01 0.0000 -95.74


0.22 0.0004 0.31 0.0005 40.69

37. 290347 OTHER PERHALOGENATED DERIVATIVES 0.09 0.0002 0.11 0.0002 26.20

38. 290349 OTHERDICHLOROTETRAFLUOROETHANE ETC 3.54 0.0069 3.08 0.0050 -13.09

39. 290351 1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE 0.17 0.0003

40. 290359 OTHR HALOGNTD DRVTVS OF CYCLANIC,CYCLENIC 8.58 0.0167 7.82 0.0127 -8.85

41. 290361 CHLOROBENZENE O-DICHLOROBENZENE AND P-DICHLOROBENZENE 2.31 0.0045 2.07 0.0034 -10.33


0.02 0.0000

43. 290369 OTHR HALGNTD DRVTVS OF ARMTC HYDROCARBON 7.42 0.0144 8.98 0.0146 20.96


3.50 0.0068 3.55 0.0058 1.36

45. 290420 DRVTVS CNTNG ONLY NITRO/NITROSO GRPS 5.87 0.0114 7.00 0.0114 19.35

46. 290490 OTHR SULPHONTD NITRTD/NITRSTD DRVTVS 5.24 0.0102 4.99 0.0081 -4.80

47. 290511 SATURATED METHANOL (METHYL ALCOHOL) 53.84 0.1047 58.07 0.0946 7.85

48. 290512 SATURATED PROPAN-1OL(PROPYL ALCOHOL) AND PROPAN-2-OL (ISOPROPYL ALCOHOL)

10.72 0.0209 22.25 0.0362 107.48

49. 290513 SATURATED BUTAN-1-OL(N-BUTYL ALCOHOL) 7.43 0.0144 5.01 0.0082 -32.49

50. 290514 OTHER SATURATED BUTANOLS 12.79 0.0249 10.93 0.0178 -14.58

51. 290515 SATURTD PENTANOL(AMYL ALCHL) & SMRS THEROF 1.10 0.0021 1.66 0.0027 50.24

52. 290516 SATRTD OCTNL(OCTYL ALCHL)& ISMRS THEREOF 4.25 0.0083 2.97 0.0048 -30.07

53. 290517 SATRTD DDCAN-1-OL(LRYL-ALCHL)HXADECAN-1-OL(CETYL ALCHL)&OCTDECN-1-OL(STRYL ALCHL)

0.25 0.0005 0.32 0.0005 28.05

54. 290519 OTHR SATURTED MONOHYDYDRIC ALCHOL 11.78 0.0229 13.59 0.0221 15.34

55. 290522 UNSATURATD ACYCLIC TERPENE ALCOHOLS 4.78 0.0093 5.70 0.0093 19.19

56. 290529 OTHER UNSATURATED MONOHYDRIC ALCOHOLS 1.51 0.0029 1.40 0.0023 -7.14

57. 290531 ETHYLENE GLYCOL (ETHANEDIOL) 0.83 0.0016 13.10 0.0213 1,484.41

58. 290532 PRPPYLENE GLYCOL (PROPANE-1,2-DIOL) 4.84 0.0094 7.18 0.0117 48.15

59. 290539 OTHER DIOLS 5.10 0.0099 5.12 0.0083 0.38

60. 290541 2-ETHYL-2-(HYDROXYMETHYL)PROPANE-1, 3-DIOL (TRIMETHYLOLPROPANE)

0.96 0.0019 1.58 0.0026 64.11

61. 290542 PENTAERYTHRITOL 2.01 0.0039 1.93 0.0031 -4.27


- 180 -

62. 290543 MANNITOL 1.33 0.0026 2.10 0.0034 58.51

63. 290544 D-GLUCITOL (SORBITOL) 0.92 0.0018 0.52 0.0009 -43.25

64. 290545 GLYCEROL 0.69 0.0013 0.88 0.0014 27.95

65. 290549 OTHER POLYHYDRIC ALCOHOLS 4.47 0.0087 4.49 0.0073 0.52

66. 290550 *HALGNTD,SLPHNTD NITRTD/NITRSTD DERIVATIVES OF ACYCLIC ALCOHOLS

0.35 0.0007 0.56 0.0009 58.68

67. 290611 MENTHOL 0.25 0.0005 0.47 0.0008 87.28

68. 290612 CYCLHXNL MTHYLCYCLHXNLS&DIMTHYL CYCLHXNLS 0.49 0.0010 0.41 0.0007 -16.65

69. 290613 STEROLS AND INOSITOLS 0.47 0.0009 0.40 0.0007 -14.02

70. 290614 TERPINEOLS 0.10 0.0002 0.13 0.0002 31.97

71. 290619 OTHR CYCLNIC,CYCLENIC/CYCLOTRPNC ALCHLS 2.83 0.0055 3.18 0.0052 12.66

72. 290621 BENZYL ALCOHOL 0.04 0.0001 0.07 0.0001 71.44

73. 290629 OTHER AROMATIC ALCOHOL 5.81 0.0113 7.45 0.0121 28.30

74. 290711 PHENOL (HYDROXYBENZENE) AND ITS SALTS 17.81 0.0346 13.15 0.0214 -26.18

75. 290712 CRESOLS AND THEIR SALTS 5.24 0.0102 6.79 0.0111 29.50

76. 290713 OCTYLPHNL NONYLPHNL & THR ISOMERS,SALTS 1.28 0.0025 1.04 0.0017 -18.73

77. 290714 XYLENOLS AND THEIR SALTS 2.02 0.0039 2.40 0.0039 18.84

78. 290715 NAPHTHOLS AND THEIR SALTS 10.13 0.0197 17.46 0.0284 72.36

79. 290719 OTHER MONOPHENOLS 9.20 0.0179 10.43 0.0170 13.33

80. 290721 RESORCINOL AND ITS SALTS 1.91 0.0037 2.44 0.0040 27.73

81. 290722 HYDROQUINONE (QUINOL) AND ITS SALTS 3.96 0.0077 5.13 0.0084 29.75


4.47 0.0087 5.64 0.0092 26.00

83. 290729 OTHER POLYPHENOLS 2.49 0.0048 5.87 0.0096 136.10

84. 290730 *PHENOL-ALCOHOLS 0.74 0.0014 0.80 0.0013 8.99

85. 290810 DRIVS CNTNG ONLYHALOGEN SUBSTITUENTS AND THEIR SALTS 2.60 0.0051 0.80 0.0013 -69.44

86. 290820 DRVOVS CNTNG OLLYSULPHO GROUPS,THEIR SALTS & ESTERS 0.21 0.0004 0.25 0.0004 17.16


0.65 0.0013 0.68 0.0011 3.79

88. 290911 DIETHYL ETHER 0.09 0.0002 0.33 0.0005 285.53

89. 290919 OTHR ACYCLIC ETHRS & THR HALGNTD,SLPHNTD NITRATED OR NITROSATED DERIVATIVES

2.60 0.0051 1.54 0.0025 -40.97

90. 290920 CYCLANIC,CYCLENIC/CYCLTRPENC ETHRS & THIR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTS

0.16 0.0003 0.26 0.0004 61.55


1.18 0.0023 1.51 0.0025 28.64

92. 290941 2,2-OXYDIETHANOL (DIETHYLENE GLYCOL,DIGOL) 0.04 0.0001 0.10 0.0002 185.82


0.23 0.0005 4.03 0.0066 1,628.33


0.94 0.0018 1.29 0.0021 38.02


0.32 0.0006 0.35 0.0006 9.07


3.56 0.0069 4.89 0.0080 37.21


- 181 -

97. 290950 ETHR-PHNLS,ETHR-ALCHL-PHNLS & THR HALGNTD SLPHNTD

NITRTD/NITRSTD DRVTVS 0.73 0.0014 1.01 0.0016 37.70

98. 290960 ALCHL PEROXIDES,ETHR PEROXIDES,KETONE PEROXIDES & THR HALGNTD SLPHNTD NITRATED OR NITROSATED DERIVATIVES

0.54 0.0010 1.25 0.0020 134.17

99. 291010 OXIRANE (ETHYLENE OXIDE) 0.18 0.0004 0.06 0.0001 -67.82

100. 291020 METHYLOXIRANE (PROPYLENE OXIDE) 0.89 0.0017 0.98 0.0016 10.48

101. 291030 1-CHLORO-2,3-EPOXYPRPNE(EPICHLOROPHYDRIN) 5.19 0.0101 3.77 0.0061 -27.29

102. 291090 OTHER EPOXIDES,EPOXY ALCHLS ETC 0.35 0.0007 1.26 0.0021 263.63


0.49 0.0010 0.24 0.0004 -51.80

104. 291211 METHANAL (FORMALDEHYDE) 0.20 0.0004 0.17 0.0003 -17.88

105. 291212 ETHANAL (ACETALDEHYDE) 0.23 0.0004 0.57 0.0009 150.78

106. 291213 BUTANOL (BUTYRALDEHYDE,NORMAL ISOMER) 0.62 0.0012 0.48 0.0008 -22.46

107. 291219 OTHR ACYCLIC ALDHYDS WTHOUT OXYGEN FNCTN 4.54 0.0088 6.40 0.0104 40.98

108. 291221 BENZALDEHYDE 3.86 0.0075 4.22 0.0069 9.38

109. 291229 OTHR CYCLC ALDHYDS WTHOUT OTHR OXYGN FNCTN 6.37 0.0124 4.34 0.0071 -31.82

110. 291230 ALDEHYDE-ALCOHOLS 1.17 0.0023 0.93 0.0015 -20.74

111. 291241 VANILLIN(4-HYDROXY-3METHOXY BENZALDEHYDE) 3.94 0.0077 3.01 0.0049 -23.73

112. 291242 ETHYLVANILIN (3-ETHOXY-4-HYDROXYBNZLDHYD) 1.67 0.0032 1.70 0.0028 1.82

113. 291249 OTHR ALDHYD-ETHR,ALDHYD-PHNL& OTHR ALDHYD 2.05 0.0040 2.98 0.0049 45.77

114. 291250 CYCLIC POLYMERSOF ALDEHYDES 0.44 0.0009 0.54 0.0009 22.43

115. 291260 PARA FORMALDEHYDE 2.28 0.0044 2.58 0.0042 13.55


1.92 0.0037 2.01 0.0033 4.20

117. 291411 ACETONE 8.73 0.0170 11.48 0.0187 31.52

118. 291412 BUTANONE (METHYL ETHYL KETONE) 1.78 0.0035 2.16 0.0035 21.47

119. 291413 4-MTHYLPENTAN-2-ONE(MTHYL ISOBTYL KETONE) 4.39 0.0085 7.22 0.0118 64.35

120. 291419 OTHR ACYLC KETONES WTHOUT OTHR OXYGN FNCTN 2.71 0.0053 2.35 0.0038 -13.58

121. 291421 CAMPHOR 1.33 0.0026 1.03 0.0017 -22.76

122. 291422 CYCLOHEXANONE AND METHYL CYCLOHEXANONES 4.11 0.0080 4.11 0.0067 0.22

123. 291423 IONONES AND METHYLIONONES 1.32 0.0026 1.01 0.0016 -23.88


5.21 0.0101 4.94 0.0080 -5.15

125. 291431 PHENYLACETONE 0.21 0.0004 0.16 0.0003 -24.50

126. 291439 OTHR ARMTC KETONES WTHOUT OTHR OXYGEN FUNCTION 10.69 0.0208 5.99 0.0098 -43.93

127. 291440 KETONE-ALCOHOLS & KETONE ALDEHYDES 0.39 0.0008 0.73 0.0012 85.53

128. 291450 KETONE-PHNLS & KETONS WTHOTHR OXYGN FNCTN 1.73 0.0034 1.72 0.0028 -0.30

129. 291461 ANTHRAQUINONE 2.74 0.0053 3.89 0.0063 42.28

130. 291469 OTHER QUINONES 0.70 0.0014 0.90 0.0015 28.04


5.77 0.0112 4.94 0.0080 -14.35

132. 291511 FORMIC ACID 2.05 0.0040 2.09 0.0034 2.03

133. 291512 SALTS OF FORMIC ACID 1.91 0.0037 2.20 0.0036 15.08


- 182 -

134. 291513 ESTERS OF FORMIC ACID 0.65 0.0013 1.58 0.0026 142.68

135. 291521 ACETIC ACID 12.30 0.0239 16.34 0.0266 32.82

136. 291522 SODIUM ACETATE 0.07 0.0001 0.03 0.0001 -55.53

137. 291523 COBALT ACETATES 1.18 0.0023 0.91 0.0015 -22.90

138. 291524 ACETIC ANHYDRIDE 0.11 0.0002

139. 291529 OTHR ACETIC ACID & ITS SLTS 2.70 0.0053 3.51 0.0057 29.94

140. 291531 ETHYL ACETATE 0.19 0.0004 0.46 0.0008 140.87

141. 291532 VINYL ACETATE 9.52 0.0185 10.35 0.0169 8.66

142. 291533 N-BUTYL ACETATE 4.52 0.0088 5.83 0.0095 28.97

143. 291534 ISOBUTYL ACETATE 0.17 0.0003 0.01 0.0000 -91.59

144. 291535 2-ETHOXYETHYL ACETATE 0.06 0.0001

145. 291539 OTHER ESTERS OF ACETIC ACID 5.91 0.0115 10.68 0.0174 80.75

146. 291540 MONO-DI/TRCHLRACTC ACD,THR SLTS & ESTRS 0.69 0.0013 0.76 0.0012 10.75

147. 291550 PROPIONIC ACID ITS SALTS AND ESTERS 2.55 0.0050 3.09 0.0050 21.09

148. 291560 BUTYRIC ACDS,VALERIC ACDS THR SLTS & ESTRS 1.33 0.0026 1.38 0.0023 3.99

149. 291570 PALMTC ACID,STEARIC ACID THR SLTS & ESTRS 2.54 0.0049 2.82 0.0046 11.06

150. 291590 OTHR SATRTD ACYLC,MNOCRBOXYLC ACDS & THR ANHYDRDS,HALDS,PEROXDS,PEROXY ACIDS & THR HALGNTD SLPHNTD NITRTD & NITRSTD DRVTVS

19.82 0.0386 23.11 0.0376 16.58

151. 291611 ACRYLIC ACID AND ITS SALTS 4.92 0.0096 4.83 0.0079 -1.82

152. 291612 ESTERS OF ACRYLIC ACID 22.21 0.0432 25.98 0.0423 16.93

153. 291613 METHACRYLIC ACID AND ITS SALTS 4.41 0.0086 5.29 0.0086 19.88

154. 291614 ESTERS OF METHACRYLIC ACID 4.75 0.0092 4.57 0.0074 -3.76

155. 291615 OLEIC LINOLC/LINOLNC ACDS,THR SLTS & ESTRS 0.55 0.0011 0.61 0.0010 11.86

156. 291619 OTHR UNSATRTD ACYCLC,MONOCRBOXYLC ACDS, THR ANHYDRDS, HALIDES ETC THR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS

2.80 0.0054 3.78 0.0062 35.17

157. 291620 CYCLANIC,CYCLENIC/CYCLOTRPNC MONOCRBOXYLC ACIDS,THEIR ANHYDRDS,HALIDES PEROXIDES PEROXYACIDS AND THEIR DERIVATATIVES

0.19 0.0004 0.73 0.0012 286.29

158. 291631 BENZOIC ACID ITS SALTS AND ESTERS 4.35 0.0085 5.03 0.0082 15.72

159. 291632 BENZYL PEROXYD & BENZOYL CHLRD 0.09 0.0002 0.23 0.0004 168.21

160. 291634 PHENYLACETIC ACID & ITS SALTS 0.01 0.0000 0.15 0.0003 966.21

161. 291635 ESTERS OF PHENYL ACETIC ACID 0.44 0.0009 0.13 0.0002 -71.48


2.55 0.0050 3.03 0.0049 18.89

163. 291711 OXALIC ACID ITS SALTS AND ESTERS 0.08 0.0001 0.24 0.0004 211.97

164. 291712 ADIPIC ACID ITS SALTS AND ESTERS 3.74 0.0073 3.96 0.0065 5.94

165. 291713 AZELAIC ACID,SEBACIC ACID THR SLTS & ESTRS 0.25 0.0005 0.25 0.0004 0.38

166. 291714 MALEIC ANHYDRIDE 0.38 0.0007 0.28 0.0005 -26.98

167. 291719 OTHR ACYLC PLYCRBOXYLC ACDS THR ANHYDRDS HALIDES,PEROXIDES,PEROXYACDS & THR DRVTVS

4.96 0.0096 5.45 0.0089 10.04

168. 291720 CYCLANIC,CYCLENIC/CYCLOTRPNC PLYCRBOXYLC ACIDS THR ANHYDRDS HALIDES PEROXIDES PEROXYACIDS AND THEIR DERIVATIVES

0.55 0.0011 0.48 0.0008 -12.58

169. 291731 DIBUTYL ORTHOPHTHALATES 0.11 0.0002 0.03 0.0000 -77.25

170. 291732 DIOCTYL ORTHOPHTHALATES 2.18 0.0042 2.88 0.0047 32.23

171. 291733 DINONYL OR DIDECYL ORTHOPHTHALATES 0.06 0.0001 0.09 0.0001 53.43

172. 291734 OTHER ESTERS OF ORTHOPHTHALIC ACID 0.07 0.0001 0.10 0.0002 35.46


- 183 -

173. 291735 PHTHALIC ANHYDRIDE 4.38 0.0085 5.94 0.0097 35.61

174. 291736 TEREPHTHALIC ACID AND ITS SALTS 0.45 0.0009 0.56 0.0009 26.06

175. 291737 DIMETHYL TEREPHTHALATE 1.63 0.0026


14.28 0.0278 17.47 0.0284 22.37

177. 291811 LACTIC ACID ITS SALTS AND ESTERS 0.56 0.0011 1.30 0.0021 133.85

178. 291812 TARTARIC ACID 2.34 0.0046 1.76 0.0029 -24.76

179. 291813 SALTS AND ESTERS OF TARTARIC ACID 0.07 0.0001 0.47 0.0008 548.42

180. 291814 CITRIC ACID 5.47 0.0106 3.01 0.0049 -45.02

181. 291815 SALTS AND ESTERS OF CITRIC ACID 0.49 0.0010 0.97 0.0016 98.11

182. 291816 GLUCONIC ACID ITS SALTS AND ESTERS 1.74 0.0034 2.27 0.0037 30.36

183. 291817 *PHENYLGLYCOLIC ACID(MANDELIC ACID) ITS SALTS AND ESTERS 0.47 0.0009 0.17 0.0003 -65.04


1.32 0.0026 3.94 0.0064 198.75

185. 291821 SALICYLIC ACID AND ITS SALTS 0.28 0.0005 0.45 0.0007 62.63

186. 291822 0-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS 0.06 0.0001 0.03 0.0000 -46.94

187. 291823 OTHR ESTERS OF SALICYLIC ACID & THR SALTS 0.40 0.0008 0.52 0.0009 29.71


2.75 0.0053 2.98 0.0049 8.61

189. 291830 CRBXYLC ACIDS WTH ALDHYD/KETONE FNCTN BUT WTHOUT OTHR OXYGN FNCTN THR ANHYDRDS HALDS PEROXIDES PEROXYACIDS & THR DRVTVS

6.19 0.0120 7.87 0.0128 27.12


9.38 0.0182 9.82 0.0160 4.69


1.98 0.0039 2.17 0.0035 9.42


5.71 0.0111 4.42 0.0072 -22.63

193. 292090 OTR ESTERS OF OTR INORGNC ACDS;THRSLTS ETC 4.81 0.0094 6.81 0.0111 41.60

194. 292111 MTHYLAMINE DI-OR TRIMTHYL AMINE & THR SLTS 7.38 0.0143 8.36 0.0136 13.40

195. 292112 DIETHYLAMINE AND ITS SALTS 0.75 0.0015 1.03 0.0017 36.69

196. 292119 OTHR ACYCLIC MONOAMINES & THEIR DEVIVATIVES SALTS THEREOF 6.09 0.0119 7.70 0.0125 26.46

197. 292121 ETHYLENEDIAMINE AND ITS SALTS 5.08 0.0099 6.43 0.0105 26.55

198. 292122 HEXAMETHYLENEDIAMINE AND ITS SALTS 1.43 0.0028 1.19 0.0019 -17.08

199. 292129 OTHR ACYLC PLYAMINS THR DRVTVS SLTS THREOF 7.37 0.0143 7.82 0.0127 6.21


5.83 0.0113 3.83 0.0062 -34.41

201. 292141 ANILINE AND ITS SALTS 1.53 0.0030 2.02 0.0033 32.01

202. 292142 ANILINE DERIVATIVES AND THEIR SALTS 7.98 0.0155 7.21 0.0117 -9.56

203. 292143 TOLUIDINES AND THEIR DRVTVS SLTS THEREOF 1.19 0.0023 2.28 0.0037 92.65

204. 292144 DIPHNYLAMINE & ITS DRVTVS SLTS THEREOF 1.72 0.0034 1.60 0.0026 -7.24

205. 292145 1-NAPHTHYLAMINE 2-NAPHTHYLAMINE AND THEIR DERIVATIVES ; SALTS THEREOF

6.58 0.0128 10.33 0.0168 56.85

206. 292149 OTHR ARMTC MONO AMNS & THR DRVTVS AND SLTS 3.37 0.0066 3.58 0.0058 6.36


3.46 0.0067 4.89 0.0080 41.15

208. 292159 OTHR ARMTC PLYAMNS & THR DRVTVS & SLTS 6.44 0.0125 4.73 0.0077 -26.50

209. 292211 MONOETHANOLAMINE AND ITS SALTS 1.01 0.0020 2.59 0.0042 156.42


- 184 -

210. 292212 DIETHANOLAMINE AND ITS SALTS 2.39 0.0047 2.81 0.0046 17.45

211. 292213 TRIETHANOLAMINE AND ITS SALTS 0.33 0.0006 1.10 0.0018 229.43

212. 292219 OTHER OXYGEN-FUNCTION AMINO-ALCOHOLS 12.98 0.0253 19.77 0.0322 52.31

213. 292221 AMNOHYDRXYNPHTHLENESLPHNC ACDS & THR SLTS 4.75 0.0092 7.90 0.0129 66.50

214. 292222 ANISIDINES DIANISIDINES PHNTDNS & THR SLTS 2.01 0.0039 2.97 0.0048 47.83


8.02 0.0156 10.70 0.0174 33.40

216. 292230 *AMINO-ALDHYDS AMINO-KETONS & AMINO-QUINONSOTHER THAN THOSE CNTNG MORE THAN ONE KND OF OXYGEN FUNCTION;SALTS THEREOF

2.08 0.0040 2.95 0.0048 42.01

217. 292241 LYSINE AND ITS ESTERS SALTS THEREOF 3.48 0.0068 7.14 0.0116 105.34

218. 292242 GLUTAMIC ACID AND ITS SALTS 2.85 0.0055 3.07 0.0050 7.92

219. 292243 ANTHRANILIC ACID AND ITS SALTS 0.02 0.0000 0.03 0.0001 84.61


11.74 0.0228 16.09 0.0262 37.03


5.94 0.0116 6.30 0.0103 6.03

222. 292310 CHOLINE AND ITS SALTS 0.11 0.0002 0.45 0.0007 307.15

223. 292320 LECITHINS AND OTHER PHOSPHOAMINOLIPIDS 0.71 0.0014 1.42 0.0023 99.27


1.22 0.0024 1.22 0.0020 -0.19

225. 292410 *ACYLC AMIDES(INCL ACYLC CARBAMATES) & THER DERIVATIVES SALTS THEREOF

8.35 0.0162 8.14 0.0132 -2.52

226. 292421 UREINES & THEIR DERIVATIVES SALTS THEREOF 0.11 0.0002 0.21 0.0003 101.69

227. 292422 *ACETAMEDOBENZOIC ACID 0.03 0.0001

228. 292429 OTHR CYCLC AMIDES(INCL CYCLC CRBAMATES) & THEIR DERIVATIVES & SALTS THEREOF

11.34 0.0221 13.30 0.0216 17.27

229. 292511 SACCHARIN AND ITS SALTS 2.78 0.0054 3.09 0.0050 10.95

230. 292519 OTHR IMIDES & THR DRVTVS SLTS THEREOF 0.67 0.0013 0.95 0.0015 41.87

231. 292520 IMINES & THR DRVTVS SLTS THEREOF 0.86 0.0017 0.46 0.0007 -46.71

232. 292610 ACRYLONITRILE 69.07 0.1343 58.10 0.0946 -15.89

233. 292620 1-CYANOGUANIDINE(DICYANDIAMIDE) 4.28 0.0083 6.95 0.0113 62.36

234. 292690 OTHR NITRILE-FUNCTION COMPOUNDS 5.31 0.0103 10.32 0.0168 94.19

235. 292700 DIAZO-AZO-OR AZOXY-COMPOUNDS 1.31 0.0025 1.03 0.0017 -21.40

236. 292800 ORGNC DRVTVS OF HYDRAZINE/OF HYDROXYLAMINE 1.20 0.0023 2.51 0.0041 108.49

237. 292910 ISOCYANATES 35.30 0.0687 35.68 0.0581 1.09

238. 292990 OTHR CMPNDS WITH OTHER NITROGEN FUNCTION 2.95 0.0057 3.20 0.0052 8.73

239. 293010 DITHIOCARBONATES(XANTHATES) 0.24 0.0005 0.27 0.0004 8.62

240. 293020 THIOCARBAMATES AND DITHIOCARBAMATES 0.09 0.0002 0.27 0.0004 212.31

241. 293030 THIURAM MONO-,DI-OR TETRASULPHIDES 0.20 0.0004 0.12 0.0002 -41.06

242. 293040 METHIONINE 2.81 0.0055 4.73 0.0077 68.58

243. 293090 OTHER ORGANO-SULPHUR COMPOUNDS 18.66 0.0363 22.91 0.0373 22.75

244. 293100 OTHER ORGANO-INORGANIC COMPOUNDS 24.09 0.0469 29.12 0.0474 20.90

245. 293211 TETRAHYDROFURAN 4.46 0.0087 7.35 0.0120 64.84

246. 293212 2-FURALDEHYDE(FURFURALDEHYDE) 0.26 0.0005 0.27 0.0004 1.76

247. 293213 FURFURYL ALCHL & TETRAHYDROFURFURYL ALCHL 2.12 0.0041 1.66 0.0027 -21.71

248. 293219 OTHR CMPNDS CNTNG AN UNFUSED FURANRING (WHETHER OR NOT HNDRGNTD)IN THE STRUCTURE

2.68 0.0052 2.16 0.0035 -19.73

249. 293221 COUMARIN,MTHYLCOUMRN & EHYLCOUMRN-LACTONES 1.37 0.0027 2.06 0.0034 50.20


- 185 -

250. 293229 OTHR LACTONES 3.54 0.0069 4.85 0.0079 37.16

251. 293291 IS0SAFR0LE 0.00 0.0000 0.23 0.0004 4,909.23

252. 293293 PIPERAN0L 0.44 0.0009 0.23 0.0004 -48.88

253. 293294 SAFR0LE 0.00 0.0000

254. 293299 OTHER HETEROCYCLIC COMPNDS WITH OXYGEN HETERO - ATOM/S) 1.63 0.0032 3.11 0.0051 90.85

255. 293311 PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES 0.07 0.0001 0.32 0.0005 369.60


1.73 0.0034 3.51 0.0057 103.21

257. 293321 HYDANTOIN AND ITS DERIVATIVES 0.28 0.0005 0.43 0.0007 55.90


3.96 0.0077 6.12 0.0100 54.81

259. 293331 PYRIDINE AND ITS SALTS 6.07 0.0118 8.44 0.0137 38.89

260. 293332 PIPERIDINE AND ITS SALTS 0.41 0.0008 0.60 0.0010 45.62


10.04 0.0195 12.35 0.0201 23.06

262. 293340 *HTRCYCLE CMPNDS CNTNG A GUINOLINE OR ISOQUINOLINE RING-SYSTEM(WHETHER OR NOT HYDROGENATED) NOT FURTHER FUSED

3.27 0.0064 3.10 0.0051 -5.08

263. 293351 *MALONYLURES(BARBITURIC ACID) AND ITS DERIVATIVES SALTS THEREOF

1.27 0.0025 0.75 0.0012 -40.92


11.33 0.0220 8.48 0.0138 -25.14

265. 293361 MELAMINE 0.66 0.0013 2.15 0.0035 227.01


8.30 0.0161 21.04 0.0343 153.58

267. 293371 6-HEXANELACTAM (EPSILON-CAPROLACTAM) 5.46 0.0106 3.14 0.0051 -42.48

268. 293379 OTHER LACTAMS 1.22 0.0024 1.73 0.0028 42.33


5.84 0.0114 13.70 0.0223 134.67

270. 293410 CMPNDS CNTNG AN UNFUSED THIAZOLE RING (W/N HYDROGENATED ) IN THE STRUCTURE

2.22 0.0043 0.91 0.0015 -58.91


0.75 0.0015 1.17 0.0019 55.88

272. 293430 CMPNDS CNTNG A PHENOTHIAZINE RING-SYSTEM (W/N HYDRGNTD ) NT FRTHR FUSED

0.25 0.0005 1.06 0.0017 319.72

273. 293490 *OTHER 8.97 0.0175 9.40 0.0153 4.74

274. 293500 SULPHONAMIDES 7.04 0.0137 6.58 0.0107 -6.56

275. 293610 UNMIXED PROVITAMINS 0.23 0.0005 0.44 0.0007 91.18

276. 293621 VITAMINS A AND THEIR DERIVATIVES 1.23 0.0024 0.73 0.0012 -40.87

277. 293622 VITAMIN B1 AND ITS DERIVATIVES 0.95 0.0019 2.20 0.0036 130.58



2.83 0.0055 2.06 0.0034 -27.13

280. 293625 VITAMIN B6 & ITS DRVTS 1.46 0.0028 2.01 0.0033 37.46

281. 293626 VITAMIN B12 AND ITS DERIVATIVES 0.96 0.0019 0.22 0.0004 -77.03

282. 293627 VITAMIN C (ASCORBIC ACID) & ITS DRVTVS 2.86 0.0056 4.65 0.0076 62.28

283. 293628 VITAMIN E AND ITS DERIVATIVES 2.95 0.0057 2.61 0.0043 -11.37

284. 293629 OTHER VITAMINS AND THER DERIVATIVES 3.08 0.0060 3.00 0.0049 -2.55

285. 293690 OTHER VIT & PROVIT INCL NATURAL CONCENTRTS 0.78 0.0015 2.62 0.0043 236.96

286. 293710 *PITUITARY(ANTRR)/SMLR HRMNS & THR DRVTVS 0.50 0.0010 0.92 0.0015 82.88

287. 293721 CORTISONE,HYDROCORTISONE,PREDNISONE (DEHY-DROCORTISONE)AND FREDNISOLONE AND PRDNSLN(DEHYDROHYDROCORTISONE)

4.75 0.0092 4.96 0.0081 4.53

288. 293722 HALGNTD DRVTVS OF CORTI COSTEROIDAL 1.00 0.0019 3.22 0.0052 223.26


- 186 -

289. 293729 OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES 1.44 0.0028 5.10 0.0083 255.16

290. 293791 *INSULIN AND ITS SALTS 12.18 0.0237 21.12 0.0344 73.43

291. 293792 *OESTROGENS AND PROGESTOGENS 6.02 0.0117 6.17 0.0100 2.43

292. 293799 *OTHR HRMNS & THR DRVTVS;OTHR STEROIDS USED PRIMARILY AS HORMONES 21.16 0.0412 16.35 0.0266 -22.75

293. 293810 RUTOSIDE (RUTIN) AND ITS DERIVATIVES 0.22 0.0004 0.18 0.0003 -17.90


1.66 0.0032 1.11 0.0018 -32.96

295. 293910 *ALKLDS OF OPIUM & THR DRVTVS SLTS THEREOF 1.23 0.0024 1.05 0.0017 -14.95

296. 293921 QUININE AND ITS SALTS 1.83 0.0036 3.75 0.0061 105.04

297. 293929 OTHR ALKLDS OF CINCHONA & THR DRVTVS AND SLTS THEREOF 0.55 0.0011 0.16 0.0003 -69.94

298. 293930 CAFFEINE AND ITS SALTS 0.08 0.0002 0.30 0.0005 260.15

299. 293941 EPHIDRINES AND THER SLTS 0.12 0.0002

300. 293942 PSEUDO EPHEDRINE (INN) AND ITS SALTS 0.29 0.0005

301. 293949 OTHER EPHEDRIVES AND THR SALTS 3.21 0.0062 1.69 0.0028 -47.29


0.09 0.0002 0.39 0.0006 334.75

303. 293961 ERGOMETRINE (INN) AND ITS SALTS 0.42 0.0008 0.13 0.0002 -69.48

304. 293962 ERGOTAMINE (INN) AND ITS SALTS 0.07 0.0001 0.10 0.0002 44.12

305. 293969 OTHER ALKALOIDS OF RYE ERGOT & DRVTVS 0.89 0.0017 0.61 0.0010 -31.58

306. 293970 *NICOTINE AND ITS SALTS 0.04 0.0001 0.10 0.0002 131.64

307. 293990 *OTHR VEG ALKLDS THR DRVTVS;SLTS THEROF ETC 1.21 0.0023 1.29 0.0021 7.14


0.62 0.0012 1.32 0.0021 112.50


93.54 0.1819 149.46 0.2434 59.79

310. 294120 STREPTOMYCINS & THR DRVTVS SLTS THEREOF 2.36 0.0046 2.44 0.0040 3.33

311. 294130 TETRACYCLINES & THR DRVTVS SLTS THEREOF 4.87 0.0095 8.23 0.0134 68.86

312. 294140 CHLORAMPHENICOL & ITS DRVTVS SLTS THEREOF 4.01 0.0078 3.39 0.0055 -15.49

313. 294150 ERTHROMYCIN & ITS DRVTVS SLTS THEREOF 21.78 0.0424 36.80 0.0599 68.97

314. 294190 OTHER ANTIBIOTICS 55.20 0.1074 62.07 0.1011 12.46

315. 294200 OTHER ORGANIC COMPOUNDS 209.33 0.4072 300.05 0.4886 43.34

India's Total Import 51,413.29 61,412.13 19.45 Exchange rate: 2001-2002: 1US$ = Rs. 47.6919 2002-2003 : 1US$ = Rs. 48.3953


- 187 -

Department of Commerce Export Import Data Bank

Export: Commodity-wise all countries

Dated: 15/6/2004 Sorted on values of year 2002-2003

Commodity: 29 ORGANIC CHEMICALS Unit: S.No. Country Values in US$ Million Quntity in thousands

2001-2002 2002-2003 %Growth 2001-2002 2002-2003 %Growth

1. U S A 232.74 252.15 8.34

2. GERMAN F REP 115.26 176.32 52.97

3. CHINA P RP 112.92 155.52 37.73

4. U K 64.17 76.39 19.04

5. ITALY 53.26 69.11 29.76

6. JAPAN 41.88 62.46 49.14

7. INDONESIA 27.81 61.94 122.71

8. SPAIN 49.89 61.07 22.42

9. NETHERLAND 41.89 59.40 41.79

10. HONG KONG 51.08 57.00 11.61

11. CHINESE TAIPEI 37.58 56.06 49.18

12. KOREA RP 40.97 54.76 33.67

13. SWITZERLAND 52.76 54.62 3.51

14. CANADA 29.12 51.18 75.79

15. U ARAB EMTS 35.78 51.14 42.94

16. BRAZIL 49.56 50.08 1.03

17. THAILAND 48.64 48.86 0.45

18. SINGAPORE 40.21 47.79 18.85

19. MEXICO 30.01 45.90 52.98

20. PAKISTAN 22.79 45.36 99.02

21. ISRAEL 23.06 33.94 47.19

22. FRANCE 33.00 31.30 -5.13

23. TURKEY 14.71 30.01 104.05

24. BELGIUM 28.22 29.90 5.95

25. BANGLADESH 17.96 26.83 49.44

26. VIETNAM SOC REP 13.17 24.36 84.97

27. IRAN 25.12 22.55 -10.25

28. MALAYSIA 14.37 22.27 54.95

29. SAUDI ARAB 19.51 22.14 13.50

30. ARGENTINA 12.87 19.77 53.62


- 188 -

31. KOREA DP RP 19.09 18.75 -1.81

32. AUSTRALIA 16.55 14.85 -10.30

33. SOUTH AFRICA 9.51 13.36 40.57

34. EGYPT A RP 11.72 12.91 10.11

35. PHILIPPINES 8.96 12.66 41.26

36. RUSSIA 11.34 10.78 -4.95

37. COLOMBIA 7.20 9.29 28.93

38. URUGUAY 9.55 9.24 -3.27

39. JORDAN 5.85 9.10 55.62

40. NIGERIA 9.43 9.06 -3.88

41. PORTUGAL 4.78 8.80 83.86

42. KENYA 5.30 8.74 65.00

43. IRAQ 4.84 8.45 74.65

44. POLAND 5.23 7.75 48.05

45. SRI LANKA 5.09 7.56 48.67

46. DENMARK 6.80 7.12 4.75

47. IRELAND 2.67 6.46 142.06

48. SYRIA 5.42 6.41 18.45

49. HUNGARY 2.89 6.32 118.99

50. GREECE 4.16 5.82 39.86

51. SLOVENIA 2.66 5.25 97.20

52. KAZAKHSTAN 0.21 5.24 2,449.28

53. AUSTRIA 2.70 4.46 65.33

54. GHANA 2.95 4.31 46.14

55. CYPRUS 3.23 3.96 22.47

56. TANZANIA REP 1.69 3.44 103.97

57. OMAN 2.01 3.40 69.35

58. FINLAND 1.23 3.06 148.22

59. TURKS C IS 0.48 3.00 523.37

60. UNSPECIFIED 0.32 2.98 840.11

61. PARAGUAY 2.07 2.78 34.48

62. NEPAL 2.13 2.62 22.99

63. CHILE 3.06 2.61 -14.86

64. ICELAND 0.69 2.57 272.33

65. MOROCCO 1.85 2.41 30.39

66. UGANDA 2.21 2.29 3.58

67. UKRAINE 2.23 2.29 2.61

68. CZECH REPUBLIC 2.44 2.15 -11.77

69. CONGO P REP 0.69 2.13 207.52

70. KUWAIT 1.82 2.02 11.20

71. NORWAY 1.84 1.94 5.33

72. NETHERLANDANTIL 1.10 1.92 74.69

73. BELARUS 0.64 1.84 188.71

74. ALGERIA 0.27 1.81 576.84

75. PERU 1.20 1.61 34.10


- 189 -

76. SUDAN 1.52 1.60 5.57

77. ETHIOPIA 1.25 1.58 25.58

78. PUERTO RICO 3.41 1.45 -57.42

79. ZIMBABWE 0.37 1.43 283.49

80. GUATEMALA 0.93 1.42 52.77

81. ROMANIA 1.33 1.39 4.72

82. NIGER 0.38 1.28 239.67

83. MAYANMAR 0.42 1.24 195.52

84. SWEDEN 0.99 1.22 23.48

85. TUNISIA 0.36 1.21 230.95

86. YEMEN REPUBLC 0.89 1.18 31.68

87. CAMBODIA 0.54 1.16 117.06

88. NEW ZEALAND 0.85 1.15 35.88

89. BULGARIA 1.09 1.12 2.12

90. CROATIA 1.12 0.98 -12.51

91. GAMBIA 0.02 0.98 5,235.51

92. VENEZUELA 1.20 0.97 -18.95

93. LEBANON 0.85 0.95 12.03

94. MOZAMBIQUE 0.15 0.84 442.47

95. MALTA 0.84 0.79 -6.24

96. IVORY COAST 0.83 0.77 -6.90

97. BAHARAIN IS 0.58 0.74 28.66

98. MAURITIOUS 0.56 0.74 30.84

99. COSTA RICA 0.66 0.72 10.54

100. PANAMA REPUBLIC 0.03 0.71 2,494.07

101. QATAR 0.73 0.70 -4.22

102. MALI 0.18 0.66 255.57

103. SLOVAK REP 0.25 0.53 109.35

104. AFGHANISTAN 0.29 0.49 64.78

105. ZAMBIA 0.45 0.42 -5.76

106. YUGOSLAVIA F RP 1.00 0.42 -57.98

107. BHUTAN 0.03 0.41 1,248.57

108. ST HELENA 0.39 0.39 -1.45

109. LATVIA 0.24 0.38 59.08

110. TAJIKISTAN 0.10 0.38 290.03

111. BOLIVIA 0.17 0.36 117.61

112. TRINIDAD 0.13 0.36 170.96

113. CUBA 0.14 0.33 140.57

114. HAITI 0.02 0.31 1,216.44

115. ECUADOR 0.32 0.30 -4.87

116. DOMINIC REP 0.07 0.30 345.30

117. MACEOERNIA 0.01 0.28 5,550.93

118. SWAZILAND 0.11 0.27 136.92

119. NICARAGUA 0.26 0.25 -5.19

120. DJIBOUTI 0.01 0.24 4,096.20


- 190 -

121. NAMIBIA 0.32 0.23 -26.91

122. SENEGAL 0.25 0.23 -7.40

123. LITHUANIA 0.03 0.21 575.09

124. EL SALVADOR 0.21 0.20 -4.84

125. BENIN 0.41 0.20 -52.05

126. ESTONIA 0.08 0.18 135.82

127. ZAIRE REP 0.05 0.18 283.84

128. FR GUIANA 0.06 0.17 171.69

129. ANGOLA 0.03 0.17 438.56

130. CAMEROON 0.30 0.17 -44.31

131. MALAWI 0.21 0.16 -21.59

132. GUADELOUPE 0.13

133. GUINEA 0.03 0.12 345.08

134. BURKINA FASO 0.09 0.12 31.85

135. UZBEKISTAN 0.30 0.12 -61.98

136. MOLDVIA 0.06 0.11 81.26

137. SIERRA LEONE 0.05 0.11 133.83

138. LESOTHO 0.00 0.10 2,380.08

139. TURKMENISTAN 0.11 0.10 -15.44

140. MONGOLIA 0.10

141. BRUNEI 0.05 0.09 80.41

142. HONDURAS 0.09 0.08 -8.08

143. DOMINICA 0.07 0.07 0.36

144. RWANDA 0.05 0.07 29.13

145. BURUNDI 0.01 0.07 444.20

146. GEORGIA 0.04 0.06 53.96

147. PAPUA N GNA 0.02 0.05 225.22

148. LIBYA 0.05 0.05 -4.04

149. ALBANIA 0.06 0.05 -22.71

150. BAHAMAS 0.03 0.05 49.46

151. JAMAICA 0.07 0.05 -31.74

152. BOSNIA-HRZGOVIN 0.05

153. BELIZE 0.02 0.04 127.47

154. MALAGASY RP 0.08 0.04 -49.30

155. MAURITANIA 0.04

156. MACAO 0.17 0.04 -78.30

157. GUYANA 0.01 0.04 174.12

158. MALDIVES 0.11 0.03 -67.31

159. CAYMAN IS 0.03

160. GUINEA BISU 0.03 0.03 -0.96

161. LUXEMBOURG 0.03

162. REUNION 0.12 0.03 -76.48

163. GABON 0.01 0.02 105.77

164. ANDORRA 0.02

165. TOGO 0.01 0.02 241.78


- 191 -

166. VANUATU REP 0.02 0.02 -25.39

167. KYRGHYZSTAN 0.03 0.02 -42.63

168. ANTIGUA 0.00 0.02 895.30

169. AZERBAIJAN 0.01 0.01 64.23

170. LIBERIA 0.00 0.01 399.13

171. TONGA 0.01

172. GUAM 0.11 0.01 -89.59

173. SOMALIA 0.01

174. CHANNEL IS 0.16 0.01 -93.70

175. PITCAIRAN IS 0.01

176. ARMENIA 0.01

177. GREENLAND 0.01

178. SURINAM 0.01

179. COCOS IS 0.00

180. PANAMA C Z 0.02 0.00 -82.05

181. BOTSWANA 0.02 0.00 -76.53

182. FIJI IS 0.10 0.00 -96.40

183. SEYCHELLES 0.00 0.00 662.37

184. ST LUCIA 0.00

185. NEW CALEDONIA 0.00

186. SOLOMON IS 0.06 0.00 -97.94

187. CHAD 0.03 0.00 -96.68

188. LAO PD RP 0.16 0.00 -99.79

189. C AFRI REP 0.02 0.00 -98.09

190. BR VIRGN IS 0.03

191. BARBADOS 0.01

192. ST PIERRE 0.00

193. SAO TOME 0.01

194. EQUTL GUINEA 0.01

195. CRISTMAS IS 0.01

196. COMOROS 0.01

197. VIRGIN IS US 0.04

Total 1,609.07 2,105.56 30.86 Exchange rate: 2001-2002: 1US$ = Rs. 47.6919 2002-2003 : 1US$ = Rs. 48.3953


- 192 -

Department of Commerce Export Import Data Bank Export :: Commodity-wise


Sorted on HSCode


S.No. HSCode Commodity 2001-2002 %Share 2002-2003 %Share %Growth


2. 29012100 UNSATURATED ETHYLENE 0.02 0.0000


4. 29012300 UNSTRD BUTENE (BUTYLENE)& ISOMERS THEREOF 0.01 0.0000 0.01 0.0000 2.36

5. 29012401 *UNSTRD BUTADIENES 0.00 0.0000

6. 29012402 *UNSTRD METHYLBUTADIENES 0.02 0.0000

7. 29012900 *OTHER UNSATURATED ACYCLIC HYDROCARBONS 0.57 0.0013 2.50 0.0047 342.28

8. 29021100 CYCLOHEXANE 0.07 0.0002 0.00 0.0000 -93.56


10. 29022000 BENZENE 14.89 0.0340 32.25 0.0612 116.62

11. 29023000 TOLUENE 0.46 0.0011 1.48 0.0028 220.98

12. 29024100 O-XYLENE 0.66 0.0015 2.58 0.0049 290.74

13. 29024200 M-XYLENE 0.94 0.0021 1.46 0.0028 54.95

14. 29024300 P-XYLENE 0.67 0.0015 47.18 0.0895 6,959.65

15. 29024400 MIXED XYLENE ISOMERS 0.32 0.0007 2.41 0.0046 662.63

16. 29025000 STYRENE 0.63 0.0014 0.63 0.0012 -0.19

17. 29026000 ETHYLBENZENE 0.00 0.0000 0.55 0.0010 12,932.45

18. 29029001 *DIPENTENE PURE 0.02 0.0000 0.38 0.0007 1,860.74

19. 29029002 *DIPHENYL METHANE 0.24 0.0006 0.17 0.0003 -30.37

20. 29029004 *NAPTHALENE CHMCLY/COMRCLLY PURE 0.79 0.0018 0.30 0.0006 -61.99

21. 29029005 *IS0BUTYL BENZENE 0.23 0.0005 0.60 0.0011 158.13

22. 29029009 *OTHERS 0.84 0.0019 0.46 0.0009 -45.13

23. 29031101 *METHYL CHLORIDE 1.28 0.0029 0.38 0.0007 -70.01

24. 29031102 *ETHYL CHLORIDE 0.51 0.0012 0.98 0.0019 90.45


26. 29031301 *1-1-1 TRICHL0R0ETHANE (METHYL CHL0R0F0RM)0Z0NE DEPLETING

2.74 0.0062 1.91 0.0036 -30.13

27. 29031302 *1-1-2 TRICHL0R0ETHANE ( CHL0R0F0RM F0R ANAESTHETTC USE )

0.51 0.0012 0.00 0.0000 -99.81


29. 29031500 1,2 DICHLOROMETHANE (CETHYLNE DICHLORIDE) 0.05 0.0001

30. 29031600 *12-DICHLOROPROPANE(PROPYLENE DICHLORIDE) AND DICHLOROBUTANES,SATURATED

0.03 0.0001 0.15 0.0003 364.13

31. 29031901 *TETRACHLOROETHANE 0.03 0.0001 0.25 0.0005 890.07

32. 29031902 *TRICHLOROETHANE 0.00 0.0000 0.01 0.0000 222.55

33. 29031909 *OTHERS 1.38 0.0031 3.37 0.0064 144.61

34. 29032100 VINYL CHLORIDE (CHLOROETHYLENE),UNSTRTD 0.12 0.0003

35. 29032200 TRICHLOROETHYLENE,UNSATURATED 0.00 0.0000

36. 29032300 TETRACHLOROETHANE (PERCHLOROETHYLENE ) , UNSATRTD

0.01 0.0000


0.65 0.0015 0.59 0.0011 -8.24

38. 29033001 *FLUORINATED HYDROCARBONS OTHER THAN PFIB 1,1,3,3,3-(PENTAFLUORO-2-TRIFLUOROMETHYL) -1-PROPENE

0.81 0.0019 0.26 0.0005 -68.28

39. 29033002 *BROMINATED HYDROCARBONS 0.04 0.0001



- 193 -

41. 29034200 DICHLORO DIFLUORO ETHANE 21.22 0.0484 22.06 0.0418 3.97


43. 29034400 *DICHLORO TETRA FLUORO ETHANE AND CHLORO PENTA FLUORO ETHANE 0.38 0.0009 0.49 0.0009 28.17

44. 29034500 *OTHER DERIVATIVES PERHALOGENATED ONLY WITH FLUORINE & CHLORINE 2.35 0.0054 2.90 0.0055 23.38

45. 29034600 *BROMO CHLORO DIFLUORO METHANE, BROMO TRI FLUORO METHANE & DIBROMOTETRA FLUOROETHANE

0.02 0.0000 0.08 0.0001 284.20


47. 29034901 *HCFCS ( E.G. HCFC-21, HCFC-22/R-22 ) 0.30 0.0007 0.95 0.0018 214.59

48. 29034909 *OTHER CFCS AND HAL0NS ( BCF ) 3.40 0.0078 4.77 0.0090 40.12


50. 29035900 OTHR HALOGNTD DRVTVS OF CYCLANIC,CYCLENIC 0.55 0.0013 0.68 0.0013 23.21

51. 29036101 *CHLOROBENZENE (MONO CHLORO) 0.39 0.0009 0.64 0.0012 63.71

52. 29036102 *ORTHO-DICHLOROBENZENE 0.08 0.0002 0.09 0.0002 5.61

53. 29036103 *PARA-DICHLOROBENZENE 0.91 0.0021 0.81 0.0015 -10.62

54. 29036104 *CHLORO-FLUORO BENZENE 0.00 0.0000 0.15 0.0003 4,004.89

55. 29036201 *BENZENE HEXACHLRD OTHR THN LINDANC 0.33 0.0008 0.16 0.0003 -51.43

56. 29036202 *D.D.T. 0.49 0.0011 1.65 0.0031 239.29

57. 29036901 *BENZAL CHLORIDE (BENZYL DICHLORIDE) 0.50 0.0011 0.86 0.0016 73.32

58. 29036902 *BENZO TRICHLORIDE 0.05 0.0001 0.08 0.0001 64.20

59. 29036903 *BENZYL CHLORIDE 0.19 0.0004 0.70 0.0013 267.37

60. 29036904 *PARA CHLORO TOLUNE (4-CHLORO-MTHYL BENZNE) 0.03 0.0001 0.47 0.0009 1,259.27

61. 29036905 *NAPTHALENE CHLORINATED 0.03 0.0001 0.01 0.0000 -66.69

62. 29036906 *CHLORO FLUORO ANILINE 0.00 0.0000 0.02 0.0000 980.80

63. 29036909 *HALGNTD DRVTVS OF ARMTC HYDROCRBN,NES 1.78 0.0041 2.55 0.0048 42.72

64. 29041001 *BENZENE SULPHONIC ACID 1.62 0.0037 3.67 0.0070 126.58

65. 29041002 *1:5 NAPTHLN DISULPHNC ACID(ARMSSTRNG ACID) 0.37 0.0008 0.23 0.0004 -37.37

66. 29041003 *NAPTHALENE SULPHONIC ACID 0.57 0.0013 0.65 0.0012 13.57

67. 29041004 *VINYL SULPHONE 30.08 0.0686 38.82 0.0736 29.04

68. 29041009 *OTHR DRVTV CNTNG ONLY SULPHO GROUP, THEIR SALTS AND ETHYL ESTERS 2.46 0.0056 4.06 0.0077 64.94

69. 29042001 *2:4 META DINITROBENZENE 0.00 0.0000 0.05 0.0001 10,115.79

70. 29042002 *DINITROTOLUENE 0.06 0.0001

71. 29042003 *NITROBENZENE 0.90 0.0021 0.00 0.0000 -99.88

72. 29042006 *PARA NITROTOLUENE 0.34 0.0008 1.28 0.0024 276.80

73. 29042009 *OTHR DRVTVS CNTNG ONLY NITRO/NITROSO GRPS 0.48 0.0011 0.64 0.0012 33.46

74. 29049001 *2:5 DICHLORONITROBENZENE 0.65 0.0015 0.39 0.0007 -39.98

75. 29049002 *DINITROCHLOROBENZENE 0.68 0.0016 1.69 0.0032 147.44

76. 29049003 *META NITROCHLOROBENZENE 0.07 0.0002 0.03 0.0001 -56.56

77. 29049004 *ORTHO NITROCHLOROBENZENE 1.49 0.0034 3.43 0.0065 130.43

78. 29049005 *PARA NITROCHLOROBENZENE 0.25 0.0006 0.44 0.0008 72.76

79. 29049007 *SODIUM META NITROBENZENE SULPHONATE 1.87 0.0043 3.41 0.0065 82.40

80. 29049008 *TRICHLORO NITRO-METHANE (CHLOROPICRIN) 0.05 0.0001

81. 29049009 *OTHRS 4.41 0.0101 7.89 0.0150 78.85

82. 29051100 SATURATED METHANOL (METHYL ALCOHOL) 0.28 0.0006 0.12 0.0002 -55.38

83. 29051201 *PROPYL AND ISOPROPYL ALCOHOL (PROPANOLS) 0.01 0.0000 0.03 0.0000 103.48

84. 29051202 *PROPANOL(NORMAL PROPYL ALCOHOL),SATURATED 0.02 0.0001 0.00 0.0000 -79.00

85. 29051300 SATURATED BUTAN-1-OL(N-BUTYL ALCOHOL) 0.02 0.0000 0.03 0.0001 71.11

86. 29051401 *ETHAMBUTOL, ETHAMBUTOL HCL 6.70 0.0153 7.34 0.0139 9.48

87. 29051402 *SALBUTAMOL SULPHATE 1.69 0.0039 2.46 0.0047 45.66

88. 29051403 *AMINO BUTANOL 1.65 0.0038 2.30 0.0044 39.42

89. 29051409 *OTHERS 0.94 0.0021 1.59 0.0030 70.15

90. 29051500 SATURTD PENTANOL(AMYL ALCHL) & SMRS THEROF 0.04 0.0001


- 194 -

91. 29051601 *OTHR SATURTED MONOHYDYDRIC ALCHOL 0.03 0.0001

92. 29051609 *OTHERS 0.11 0.0002 0.38 0.0007 255.50


10.22 0.0233 11.81 0.0224 15.52

94. 29051902 *2-ETHYL HEXANOL 0.09 0.0002 0.12 0.0002 28.11

95. 29051909 *OTHER HEXANOL 0.14 0.0003 0.44 0.0008 208.16

96. 29052201 *CITRANELLOL 0.01 0.0000 0.01 0.0000 36.64

97. 29052202 *GERANIOL 0.00 0.0000

98. 29052203 *LINALOOL 0.00 0.0000

99. 29052900 OTHER UNSATURATED MONOHYDRIC ALCOHOLS 0.02 0.0000 0.09 0.0002 350.05

100. 29053100 ETHYLENE GLYCOL (ETHANEDIOL) 6.08 0.0139 2.74 0.0052 -54.92


102. 29053901 *1,4/1,3/2,3 BUTYLENE GLYCOL(BUTANEDIOL) 0.14 0.0003 0.42 0.0008 195.71

103. 29053909 *OTHERS 7.38 0.0168 1.06 0.0020 -85.62

104. 29054100 2-ETHYL-2-(HYDROXYMETHYL)PROPANE-1, 3-DIOL (TRIMETHYLOLPROPANE) 0.09 0.0002 0.07 0.0001 -24.26

105. 29054201 *DIPENTA ERYTHRITOL 1.17 0.0027 0.81 0.0015 -30.81

106. 29054209 *OTHERS 0.36 0.0008 0.30 0.0006 -16.93

107. 29054300 MANNITOL 0.01 0.0000 0.04 0.0001 201.21


109. 29054501 *GLYCERIN REFINED & CHEMICALLY PURE 4.93 0.0112 3.64 0.0069 -26.10

110. 29054509 *GLYCEROL NES 0.18 0.0004 0.43 0.0008 143.42


112. 29055000 *HALGNTD,SLPHNTD NITRTD/NITRSTD DERIVATIVES OF ACYCLIC ALCOHOLS 0.11 0.0002 0.15 0.0003 34.27

113. 29061100 MENTHOL 44.85 0.1023 45.35 0.0860 1.11

114. 29061200 CYCLHXNL MTHYLCYCLHXNLS&DIMTHYL CYCLHXNLS 0.03 0.0001 0.14 0.0003 398.64

115. 29061301 *CHOLESTEROL 0.00 0.0000

116. 29061309 *OTHER STEROLS & INOSITOLS 0.01 0.0000

117. 29061400 TERPINEOLS 0.00 0.0000 0.05 0.0001 5,660.96

118. 29061901 *BERNEOL 0.31 0.0007 0.05 0.0001 -82.75

119. 29061909 *CYCLANIC,CYCLENIC/CYCLOTRPENIC ALCHLS NES 0.00 0.0000 0.02 0.0000 6,904.64

120. 29062100 BENZYL ALCOHOL 0.20 0.0005 0.17 0.0003 -17.94

121. 29062901 *CHINNAMIC ALCOHOL 0.03 0.0001 0.14 0.0003 298.16

122. 29062902 *PHENYLETHYL ALCOHOL 0.00 0.0000 0.02 0.0000 358.07

123. 29062909 *OTHERS 4.07 0.0093 4.37 0.0083 7.46

124. 29071101 *COMMERCIAL CARBOLIC ACID (PHENOL) 0.69 0.0016 0.29 0.0005 -58.35

125. 29071102 *PURE CARBOLIC ACID (PHENOL) 0.05 0.0001 0.20 0.0004 333.44

126. 29071201 *PARA CRESOL 0.14 0.0003 0.12 0.0002 -17.90

127. 29071202 *COMMERCIAL CRESYLIC ACID 0.05 0.0001

128. 29071204 *ALKYL PHENOLS 0.77 0.0018 1.32 0.0025 71.80

129. 29071209 *OTHER CRESOLS AND THEIR SALTS 1.71 0.0039 1.76 0.0033 2.52

130. 29071300 OCTYLPHNL NONYLPHNL & THR ISOMERS,SALTS 0.25 0.0006 0.30 0.0006 16.72


132. 29071501 *ALPHA NAPHTHOL 0.11 0.0002 0.37 0.0007 249.62

133. 29071502 *BETA NAPHTHOL 0.30 0.0007 0.21 0.0004 -27.80

134. 29071901 *PHENYL PHENOLS (ORTHO AND PARA) 0.32 0.0007 0.64 0.0012 101.31

135. 29071902 *THYMOL 0.14 0.0003 0.13 0.0003 -2.23

136. 29071903 *PARA TARTIARY BUTYL PHENOL 0.02 0.0000 0.13 0.0003 658.12

137. 29071909 *OTHERS 0.95 0.0022 2.04 0.0039 114.89


- 195 -

138. 29072100 RESORCINOL AND ITS SALTS 0.17 0.0004 0.01 0.0000 -94.21


140. 29072300 4,4-ISOPROPYLIDENEPHNL (BISPHNL A, DIPHENYLOLPROPANE) AND ITS SALTS 2.63 0.0060 0.74 0.0014 -71.87

141. 29072901 *1:5 DIHYDROXY NAPTHALENE 0.92 0.0021 0.66 0.0012 -28.75

142. 29072909 *OTHERS 8.22 0.0188 7.81 0.0148 -5.02

143. 29073000 *PHENOL-ALCOHOLS 0.22 0.0005 0.06 0.0001 -72.70


145. 29082001 *G ACID (2-NAPHTHOL-6)8-DISULPHONIC ACID 0.33 0.0007 0.13 0.0003 -59.00

146. 29082002 *G.ACID SALTS 0.13 0.0003 0.01 0.0000 -89.29

147. 29082003 *NAPHTHOL SULPHONIC ACIDS N.E.S. 0.36 0.0008 0.31 0.0006 -15.13

148. 29082004 *BETA,NAPHTHOL SULPHONIC ACID 0.13 0.0003 0.07 0.0001 -49.60

149. 29082005 *NEVILE-WNTHR ACID(1-NPHTHL 4 SULPHNC ACID) 0.02 0.0001 0.02 0.0000 -23.98

150. 29082006 *R.ACID (2-NPHTHL 3,6-DISLPHNC) AND ITS DISODIUM SALT (R SALT) 2.16 0.0049 1.49 0.0028 -30.85

151. 29089001 *PARA NITROPHENOL 0.25 0.0006 0.38 0.0007 52.19

152. 29089003 *CHROMOTROPIC ACID 0.02 0.0001 0.00 0.0000 -80.92

153. 29089009 *OTHERS 2.38 0.0054 3.11 0.0059 30.65

154. 29091100 DIETHYL ETHER 0.06 0.0001 0.12 0.0002 86.53


1.07 0.0024 1.62 0.0031 51.94


0.01 0.0000 0.05 0.0001 361.60

157. 29093001 *ANISOLE AND THEIR DERIVATIVES N.E.S. 0.46 0.0010 0.13 0.0002 -72.00

158. 29093002 *4-CHLORO-2-NITRO ANISOLE 0.03 0.0001

159. 29093003 *DIPHENYL OXIDE 1.48 0.0034 1.77 0.0034 19.32

160. 29093004 *ORTHO NITRO ANISOLE 0.09 0.0002 0.03 0.0001 -67.48

161. 29093005 *MUSK AMBRETTE 0.09 0.0002 0.07 0.0001 -24.69


163. 29094200 MONOMTHYL ETHRS OF ETHYLENE GLYCOL OR OF DIETHYLENE GLYCOL 1.14 0.0026 0.06 0.0001 -95.10

164. 29094300 MONOBUTYL ETHERS OF ETHYLENE GLYCOL OR OF DIETHYLENE GLYCOL 0.00 0.0000 0.11 0.0002 2,352.04

165. 29094400 OTHER MONOALKYL ETHERS OF ETHYLENE GLYCOL OR OF DIETHYLENE GLYCOL 0.42 0.0009 1.18 0.0022 182.45

166. 29094901 *GUAIAC0 ETHERS 0.10 0.0002 0.11 0.0002 18.21

167. 29094909 *0THERS 0.88 0.0020 1.08 0.0020 22.68

168. 29095001 *ISOEUGENOL 0.24 0.0005 0.48 0.0009 98.88

169. 29095002 *POTASSIUM GUAIACOL SULPHONATE 0.06 0.0001 0.15 0.0003 171.00


0.43 0.0010 2.01 0.0038 372.07

171. 29101000 OXIRANE (ETHYLENE OXIDE) 0.03 0.0001 0.06 0.0001 93.11

172. 29102000 METHYLOXIRANE (PROPYLENE OXIDE) 0.00 0.0000



175. 29110001 *ACETALS AND HEMIACETALS 1.46 0.0033 2.94 0.0056 101.51

176. 29110002 *DERIVATIVES OF ACETALS AND HEMIACETALS 0.49 0.0011 0.10 0.0002 -78.99

177. 29121100 METHANAL (FORMALDEHYDE) 0.55 0.0013 0.63 0.0012 14.16


179. 29121300 BUTANOL (BUTYRALDEHYDE,NORMAL ISOMER) 0.00 0.0000 0.00 0.0000 216.65

180. 29121901 *CROTONALDEHYDE 0.16 0.0004 0.02 0.0000 -89.85

181. 29121902 *HEPTALDEHYDE (HEPTANAL) 0.12 0.0002

182. 29121909 *OTHERS 0.19 0.0004 0.67 0.0013 256.36

183. 29122100 BENZALDEHYDE 8.71 0.0199 15.86 0.0301 82.08

184. 29122901 *CINNAMIC ALDEHYDE 0.57 0.0013 0.33 0.0006 -42.67

185. 29122902 *PHENYL ACETALDEHYDE 0.01 0.0000


- 196 -

186. 29122909 *OTHERS 2.38 0.0054 1.52 0.0029 -35.98

187. 29123000 ALDEHYDE-ALCOHOLS 0.01 0.0000 0.07 0.0001 506.50



190. 29124901 *ANISIC ALDEHYDE 1.00 0.0023 0.69 0.0013 -31.36

191. 29124902 *HELIOTROPINE (PIPERONYL ALDEHYDE) 0.09 0.0002

192. 29124903 *THIACETAZONE 0.00 0.0000

193. 29124909 *OTHRS 8.39 0.0191 10.46 0.0198 24.71

194. 29125001 *HEPTENE 0.01 0.0000

195. 29125009 *OTHR CYCLIC POLYMERS OF ALDEHYDES 0.20 0.0005 0.03 0.0001 -86.25

196. 29126000 PARA FORMALDEHYDE 0.04 0.0001 0.01 0.0000 -74.42

197. 29130001 *ORTHO-CHLORO-BENZALDEHYDE 0.37 0.0008 0.13 0.0002 -65.52

198. 29130009 *DRVTVS OF ALDHYDS ALDHYD ALCHLS, ALDHYD-ETHRS,ALDHYD-PHNLS&OTHR SINGLE OR COMPLEX OXYGEN-FUNCTION ALDAYDS

0.26 0.0006 0.67 0.0013 155.84

199. 29141100 ACETONE 0.63 0.0014 0.44 0.0008 -30.93



202. 29141901 *IS0PH0R0N 1.91 0.0043 3.52 0.0067 84.51

203. 29141909 *0THERS 1.53 0.0035 4.93 0.0093 222.55

204. 29142101 *NATURAL CAMPHOR 0.03 0.0001 0.17 0.0003 461.09

205. 29142102 *SYNTHETIC CAMPHOR 0.15 0.0003 0.16 0.0003 6.66


207. 29142301 *BETA-IONONE 0.47 0.0011 0.35 0.0007 -25.71

208. 29142309 *OTHERS 0.82 0.0019 0.48 0.0009 -41.82

209. 29142901 *L-CARAVONE 0.08 0.0002 0.05 0.0001 -41.76

210. 29142909 *OTHERS 0.20 0.0004 0.16 0.0003 -19.73

211. 29143100 PHENYLACETONE 0.05 0.0001 0.07 0.0001 40.57

212. 29143901 *ACETONE PHENONE 0.58 0.0013 0.35 0.0007 -39.34

213. 29143902 *BEZANTHRONE 0.07 0.0002 0.21 0.0004 183.16

214. 29143903 *BENZOPHENONE(e.g. MICHLAR'S KETONE ETC) 0.20 0.0005 0.03 0.0001 -83.56

215. 29143904 *DIBENZANTHRONE (VIOLANTHRONE) 0.20 0.0005 0.21 0.0004 4.87



218. 29146100 ANTHRAQUINONE 0.01 0.0000

219. 29146901 *1:4 DIHYDROXY ANTHRAQUINONE (QUINIZARIN) 0.26 0.0006 0.14 0.0003 -47.86

220. 29146902 *METHYL ANTHRAQUINONE 0.03 0.0001 0.01 0.0000 -56.63

221. 29147001 *1-CHLORO ANTHRA QUINONE 0.00 0.0000 0.15 0.0003 18,577.25

222. 29147002 *MUSK KETONE 0.04 0.0001 0.00 0.0000 -91.33

223. 29147009 *OTHR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS 7.84 0.0179 5.12 0.0097 -34.66

224. 29151100 FORMIC ACID 0.06 0.0001 0.42 0.0008 665.98

225. 29151201 *SODIUM FORMATE 0.03 0.0001 0.02 0.0000 -25.13

226. 29151202 *AMMONIUM FORMATE 0.03 0.0001

227. 29151209 *OTHERS 0.09 0.0002 0.05 0.0001 -41.00


229. 29152100 ACETIC ACID 5.17 0.0118 6.40 0.0121 23.73

230. 29152200 SODIUM ACETATE 0.26 0.0006 0.26 0.0005 -2.23

231. 29152300 COBALT ACETATES 0.00 0.0000

232. 29152400 ACETIC ANHYDRIDE 0.03 0.0001 0.02 0.0000 -49.69

233. 29152901 *CALCIUM ACETATE 0.44 0.0010 0.04 0.0001 -91.93

234. 29152902 *MAGNESIUM ACETATE 0.03 0.0001 0.10 0.0002 200.56

235. 29152903 *MANGANESE ACETATE 0.35 0.0008 0.33 0.0006 -5.90


- 197 -

236. 29152909 *OTHER ACETIC ACID & ITS SALTS,NES 0.44 0.0010 0.34 0.0006 -22.16

237. 29153100 ETHYL ACETATE 6.27 0.0143 19.57 0.0371 212.17

238. 29153200 VINYL ACETATE 0.15 0.0003 0.15 0.0003 2.05

239. 29153300 N-BUTYL ACETATE 0.02 0.0000 0.04 0.0001 131.43



242. 29153901 *BENZYL ACETATE 1.03 0.0023 1.29 0.0024 25.36

243. 29153903 *4INALYL ACETATE 0.00 0.0000

244. 29153904 *METHYL ACETATE 0.55 0.0013 0.09 0.0002 -83.78

245. 29153905 *PHENYL PROPYL ACETATE 0.00 0.0000 0.00 0.0000 -27.44

246. 29153906 *TERPINYL ACETATE 0.00 0.0000

247. 29153909 *ESTERS OF ACETIC ACID & DRVTVS N.E.S. 6.34 0.0145 7.71 0.0146 21.58

248. 29154001 *MONOCHLOROACETIC ACID,THR SALTS & ESTERS 1.10 0.0025 1.16 0.0022 5.57

249. 29154002 *TRICHLORO ACETIC ACID,THEIR SALTS & ESTERS 0.47 0.0011 0.20 0.0004 -58.12

250. 29154003 *DICHLOROACETIC ACID,THEIR SALTS & ESTERS 2.08 0.0047 0.11 0.0002 -94.67


252. 29156001 *BUTYRIC ACIDS, ITS SALTS AND ESTERS 0.05 0.0001 0.03 0.0001 -31.12

253. 29156002 *VALERIC ACIDS, ITS SALTS AND ESTERS 0.10 0.0002

254. 29157001 *GLYCEROL MONOSTEARATE 0.02 0.0000 0.18 0.0003 717.02

255. 29157002 *PALMITIC ACID 0.05 0.0001

256. 29157003 *STEARIC ACID 6.37 0.0145 2.74 0.0052 -57.02

257. 29157004 *HCO FATTY ACID(INCL 12-HYDROXY STEARC ACD) 4.99 0.0114 7.94 0.0151 59.11

258. 29157005 *D.C.0. FATTY ACID 0.21 0.0005 0.39 0.0007 86.07

259. 29157006 *DIMER AND DIMER ACID 0.05 0.0001 0.09 0.0002 80.20

260. 29159001 *ACETYL CHL0RIDE 2.70 0.0062 1.32 0.0025 -51.16

261. 29159002 *OCTOIC ACID (CAPRYLIC ACID) 0.02 0.0000 0.01 0.0000 -55.21

262. 29159003 *HEXOIC ACID (CAPROIC ACID) 0.04 0.0001 0.02 0.0000 -58.34

263. 29159009 *0THER CHL0RIDE 4.88 0.0111 3.03 0.0057 -37.97


265. 29161201 *BUTYL ACRYLATE 0.11 0.0002 0.02 0.0000 -84.99

266. 29161209 *OTHERS 0.57 0.0013 0.43 0.0008 -25.09

267. 29161301 *METHACRYLIC ACID MONOMER 0.00 0.0000 0.01 0.0000 646.66

268. 29161302 *SALTS OF METHACRYLIC ACID 0.01 0.0000 0.07 0.0001 418.96

269. 29161400 ESTERS OF METHACRYLIC ACID 0.05 0.0001 0.09 0.0002 66.58

270. 29161501 *OLEIC ACID 0.01 0.0000

271. 29161509 *OTHERS EXCLUDNG OLEIC ACID 0.04 0.0001 0.01 0.0000 -68.52

272. 29161901 *UNDECYLANIC ACID 0.91 0.0021 1.71 0.0032 88.60

273. 29161903 *POTSUM CMPNDS OF UNSATRTDS ACYLC MONDACDS 0.07 0.0002 0.22 0.0004 197.84

274. 29161904 *SODIUM CMPNDS OF UNSATRTD ACYLC MONOACDS 0.07 0.0002 0.09 0.0002 35.88

275. 29161906 *SORBIC ACID 0.04 0.0001 0.00 0.0000 -99.40

276. 29161909 *OTHRS 1.26 0.0029 0.55 0.0010 -56.38


0.34 0.0008 0.41 0.0008 20.18

278. 29163101 *BENZOIC ACID 2.15 0.0049 2.58 0.0049 19.72

279. 29163102 *BENZYL BENZOATE 1.18 0.0027 0.80 0.0015 -32.54

280. 29163103 *METHYL BENZOATE 0.46 0.0010 0.19 0.0004 -58.35


- 198 -

281. 29163104 *SODIUM BENZOATE 1.41 0.0032 1.15 0.0022 -18.17

282. 29163105 *BENZOCAINE (ETHYLPARA-AMINO BENZOATE) 0.01 0.0000 0.01 0.0000 -40.58

283. 29163106 *ORTHOCHLORO BENZOIC ACID 0.00 0.0000 0.08 0.0001 1,863.71

284. 29163109 *OTHER SALTS AND ESTERS OF BENZOIC ACID 1.51 0.0035 2.05 0.0039 35.69

285. 29163200 BENZYL PEROXYD & BENZOYL CHLRD 0.41 0.0009 0.17 0.0003 -58.30

286. 29163400 PHENYLACETIC ACID & ITS SALTS 0.00 0.0000 0.20 0.0004 6,402.36


288. 29163901 *CINNAMIC ACID 0.51 0.0012 0.23 0.0004 -55.62

289. 29163903 *POTASSIUM COMPOUNDS OF AROMATIC MONOACIDS 0.10 0.0002

290. 29163904 *SODIUM COMPOUNDS OF AROMATIC MONOACIDS 0.09 0.0002 0.12 0.0002 44.81

291. 29163905 *ESTERS OF AROMATIC MONOACIDS NES 0.30 0.0006

292. 29163909 *OTHERS 1.70 0.0039 5.32 0.0101 212.29

293. 29171101 *OXALIC ACID 1.44 0.0033 1.12 0.0021 -22.06

294. 29171102 *CALCIUM OXALATE 0.00 0.0000 0.02 0.0000 1,093.92

295. 29171104 *DIETHYL OXALATE 0.68 0.0016 0.72 0.0014 5.43

296. 29171109 *OTHER SALTS AND ESTERS OF OXALIC ACID 0.59 0.0013 1.57 0.0030 167.26

297. 29171200 ADIPIC ACID ITS SALTS AND ESTERS 0.00 0.0000 0.11 0.0002 7,271.49


299. 29171400 MALEIC ANHYDRIDE 0.53 0.0012 0.65 0.0012 22.15

300. 29171901 *MALEIC ACID 0.71 0.0016 1.26 0.0024 76.33

301. 29171903 *SUCCINIC ACID 0.01 0.0000 0.03 0.0001 304.65

302. 29171904 *FERROUS FUMERATE 0.83 0.0019 1.07 0.0020 28.27

303. 29171905 *FUMBRIC ACID 1.24 0.0028 1.55 0.0029 24.65

304. 29171907 *ETH0XY METHYLENE MAL0NATE,DIETHYL MAL0NATE 0.04 0.0001 0.01 0.0000 -84.82

305. 29171909 *OTHR ACYLC PLYCRBOXYLC ACDS & THR DRVTVS 1.74 0.0040 0.70 0.0013 -59.96


3.58 0.0082 0.01 0.0000 -99.86

307. 29173100 DIBUTYL ORTHOPHTHALATES 0.00 0.0000 0.03 0.0001 483.90

308. 29173200 DIOCTYL ORTHOPHTHALATES 0.01 0.0000 0.00 0.0000 -81.03

309. 29173300 DINONYL OR DIDECYL ORTHOPHTHALATES 0.02 0.0000

310. 29173400 OTHER ESTERS OF ORTHOPHTHALIC ACID 0.00 0.0000



313. 29173700 DIMETHYL TEREPHTHALATE 0.97 0.0022 7.55 0.0143 677.63

314. 29173901 *DIBUTYL PHTHALATE 0.54 0.0012 0.13 0.0002 -76.01

315. 29173902 *DIOCTL PHTHALATE 0.04 0.0001 0.19 0.0004 423.41

316. 29173903 *PHTHALIC ACID 3.65 0.0083 2.22 0.0042 -39.37

317. 29173904 *DIMETHYL PHTHALATE 12.47 0.0285 2.32 0.0044 -81.38

318. 29173909 *OTHERS 3.56 0.0081 6.06 0.0115 70.19

319. 29181101 *LACTIC ACID 0.56 0.0013 0.25 0.0005 -55.34

320. 29181102 *CALCIUM LACTATE 0.84 0.0019 0.42 0.0008 -49.68

321. 29181109 *OTHER SALTS AND ESTERS OF LACTIC ACID 0.14 0.0003 0.34 0.0007 149.81

322. 29181200 TARTARIC ACID 0.76 0.0017 0.23 0.0004 -69.69

323. 29181301 *POTASSIUM BITARTRATE 0.02 0.0000 0.06 0.0001 195.11

324. 29181302 *METROPROLOL TARTRATE 0.52 0.0012 1.07 0.0020 107.22

325. 29181309 *OTHER SALTS AND ESTERS OF TARTARIC ACID 0.11 0.0003 0.01 0.0000 -90.83


- 199 -

326. 29181400 CITRIC ACID 0.05 0.0001 0.60 0.0011 1,120.14

327. 29181501 *POTASSIUM CITRATE 0.35 0.0008 0.39 0.0007 11.39

328. 29181502 *SODIUM CITRATE 0.32 0.0007 0.27 0.0005 -17.33

329. 29181504 *DISODIUM HIDROGEN CIRTATE 0.03 0.0001

330. 29181505 *FERRIC AMMONIUM CITRATE 0.10 0.0002 0.29 0.0005 184.63

331. 29181509 *OTHER SALTS AND ESTERS OF CITRIC ACID 0.46 0.0011 0.59 0.0011 28.93

332. 29181601 *CALCIUM GLUCONATE 2.92 0.0067 2.41 0.0046 -17.33

333. 29181602 *FERROUS GLUCONATE 0.02 0.0001 0.06 0.0001 187.87

334. 29181609 *OTHER GLUCONIC ACID ITS SALTS AND ESTERS 0.96 0.0022 0.96 0.0018 -0.23

335. 29181700 *PHENYLGLYCOLIC ACID (MANDELIC ACID) ITS SALTS AND ESTERS 0.22 0.0005 0.19 0.0004 -15.96

336. 29181901 *2,2-DIPHENYL-2-HYDROXY ACETIC ACID 1.04 0.0024 0.75 0.0014 -28.19

337. 29181909 *OTHERS 0.66 0.0015 0.71 0.0013 7.42

338. 29182101 *SALICYLIC ACID 0.71 0.0016 0.45 0.0009 -36.20

339. 29182102 *SODIUM SALICYLATE 0.01 0.0000 0.10 0.0002 691.56

340. 29182200 0-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS 0.20 0.0005 0.67 0.0013 235.89

341. 29182301 *METHYL SALICYLATE 0.02 0.0000 0.23 0.0004 1,112.79

342. 29182302 *AMINO SALICYLATE 0.05 0.0001

343. 29182303 *SALICYLAMIDE 0.02 0.0000 0.02 0.0000 -19.36

344. 29182309 *OTHERS 0.27 0.0006 1.04 0.0020 287.85

345. 29182901 *GALIC ACID 0.39 0.0009 1.05 0.0020 169.05

346. 29182902 *BETA HYDROXY NAPHTHOIC ACID 0.08 0.0002 0.47 0.0009 475.78

347. 29182903 *PROPYL GALLATE 0.04 0.0001 0.09 0.0002 112.76

348. 29182909 *OTHERS 0.64 0.0015 0.67 0.0013 3.34

349. 29183001 *LEVULINIC ACID 0.04 0.0001 0.02 0.0000 -54.04

350. 29183002 *ETHYL ACETO ACETATE(ACETOACETIC ESTER) 0.03 0.0001

351. 29183003 *NALIDIXIC ACID 1.55 0.0035 1.50 0.0028 -3.27

352. 29183004 *METHYL ACET0 ACETATE 0.01 0.0000

353. 29183009 *OTHERS 0.47 0.0011 0.46 0.0009 -2.12


0.69 0.0016 0.87 0.0016 25.26

355. 29190001 *CALCIUM GLYCEROPHOSPHATE 0.49 0.0011 1.09 0.0021 121.49

356. 29190002 *GLYCEROPHOSPHATE ACID 0.04 0.0001 0.20 0.0004 435.78

357. 29190003 *SODIUM GLYCEROPHOSPHATE 0.04 0.0001 0.02 0.0000 -38.10

358. 29190004 *TRICRESYL PHOSPHATE 0.14 0.0003

359. 29190009 *OTHERS 1.12 0.0026 0.97 0.0018 -13.59

360. 29201009 *OTHERS 0.03 0.0001 0.67 0.0013 2,217.73

361. 29209001 *DIETHYL SULPHATE 0.62 0.0014 0.74 0.0014 18.98

362. 29209002 *DIMETHYL SULPHATE 5.40 0.0123 5.32 0.0101 -1.47

363. 29209003 *METHYL PHOSPHONYL DICHLORIDE 0.10 0.0002 0.01 0.0000 -89.82

364. 29209004 *DI-METHYL METHYL PHOSPHONATE 0.04 0.0001

365. 29209006 *TRI-METHYL PHOSPHITE 0.36 0.0008 0.36 0.0007 1.10

366. 29209007 *DI-ETHYL PHOSPHITE 0.05 0.0001 0.01 0.0000 -83.12

367. 29209009 *OTHER INORGNC ESTRS THR SLTS & DRVTVS 1.06 0.0024 2.57 0.0049 141.60

368. 29211101 *DIMETHYL FORMIDE 1.10 0.0025 2.48 0.0047 125.58

369. 29211102 *N-METHYL FORMAMIDE 0.01 0.0000

370. 29211103 *MONO_METHYLAMINE 0.09 0.0002 0.02 0.0000 -79.18


- 200 -

371. 29211109 *FORMAMIDE,N.E.S. 0.87 0.0020 0.74 0.0014 -15.30


373. 29211901 *N,N-DIALKYL(ME,ET,N-PR OR I-PR) AMINO ETHYL-2-CHLORIDES & CORRSPNDNG PROTONATED SALTS THEREOF

0.91 0.0021 1.53 0.0029 68.79

374. 29211902 *MONO-ETHYLAMINE 0.03 0.0001 0.41 0.0008 1,540.86

375. 29211909 *OTHERS 2.45 0.0056 3.41 0.0065 39.31


377. 29212200 HEXAMETHYLENEDIAMINE AND ITS SALTS 0.31 0.0007 0.37 0.0007 18.36

378. 29212901 *HEXAMETHYLENE TETRAMINE (HEXAMINE) NOT PUT UP AS FUEL OR MEDICAMENT

0.20 0.0004 1.19 0.0023 503.90

379. 29212902 *TRIMETHYLENE TRINIFRAMINE 0.01 0.0000

380. 29212909 *OTHERS 2.47 0.0056 0.62 0.0012 -74.87

381. 29213001 *CYCLOHEXYLAMINE 0.11 0.0002 1.60 0.0030 1,398.59

382. 29213009 *OTHERS 0.44 0.0010 0.56 0.0011 28.19

383. 29214101 *ANILINE 0.41 0.0009 1.08 0.0020 161.01

384. 29214102 *ANILINE HYDROCHLORIDE 0.01 0.0000 0.05 0.0001 248.71

385. 29214109 *OTHR ANILINE SALTS 1.21 0.0028 2.19 0.0042 80.54

386. 29214201 *PARA CHLOROANILINE 0.60 0.0014 2.29 0.0043 280.14

387. 29214202 *ORTHO CHLORO PARANITROANILINE 2.67 0.0061 3.12 0.0059 17.08

388. 29214203 *DICHLOROANILINE 0.82 0.0019 2.02 0.0038 147.15

389. 29214204 *2:6-DICHLORO PARANITROANILINE 0.04 0.0001 0.06 0.0001 60.20

390. 29214205 *DIETHYLANILINE 0.56 0.0013 0.50 0.0010 -10.32

391. 29214206 *DIMETHYL ANILINE 0.83 0.0019 1.36 0.0026 65.04

392. 29214207 *ETHYL ANILINE 0.03 0.0001 0.08 0.0002 213.10

393. 29214208 *META NITROANILINE 0.25 0.0006 0.29 0.0006 15.49

394. 29214211 PARA CHLOROANILINE 0.51 0.0012 0.65 0.0012 26.30

395. 29214212 ORTHO CHLORO PARANITROANILINE 0.34 0.0008 0.14 0.0003 -59.00

396. 29214213 DICHLOROANILINE 0.18 0.0004 0.08 0.0002 -52.21

397. 29214214 2:6-DICHLORO PARANITROANILINE 1.42 0.0033 2.28 0.0043 60.32

398. 29214215 2-4-5-TRICHLOROANILINE 2.46 0.0056 2.82 0.0054 14.87

399. 29214216 *ETHYL HYDROXY ETHYLANILINE 0.07 0.0002 0.17 0.0003 143.26

400. 29214217 *METHYL DOPA(L-ALPHA METHYL-3, 4-DIHYDROXYPHENYLALANINE) 0.09 0.0002 0.08 0.0002 -4.81

401. 29214218 *CARBIDOPA 0.07 0.0002

402. 29214221 BENZYL ETHYL ANILINE 0.12 0.0003 0.16 0.0003 35.66

403. 29214229 *OTHERS 11.10 0.0253 14.10 0.0267 27.08

404. 29214301 *DIETHYL TOLUIDINE 0.08 0.0002 0.19 0.0004 134.55

405. 29214302 *DIMETHYL TOLUIDNE 2.05 0.0047 1.12 0.0021 -45.32

406. 29214303 *ORTHO TOLUIDINE 1.39 0.0032 0.55 0.0010 -60.63

407. 29214304 *META TOLUIDINE 0.05 0.0001 0.06 0.0001 5.23

408. 29214305 *PARA TOLUIDNE 0.39 0.0009 1.11 0.0021 183.31

409. 29214306 *2-CHLORO-5-TOLUIDINE-4-SULPHONIC ACID 0.04 0.0001 0.04 0.0001 25.66

410. 29214307 *2-CHLORO-4-TOLUIDN-5-SLPHNC ACID(SOD SLT) 0.33 0.0007 1.03 0.0020 215.42

411. 29214308 *4-TOLUIDINE-3-SULPHONIC ACID 0.03 0.0001 0.04 0.0001 63.05

412. 29214309 *OTHR TOLUIDINES & THR DRVTVS SLTS THEREOF 2.36 0.0054 3.99 0.0076 68.98

413. 29214401 *DIPHENYLAMINE (E.G. 16-DPA) 0.43 0.0010 2.35 0.0045 451.75

414. 29214409 *OTHR DIPHNYLAMINE & ITS DRVTVS;SLTS THROF 2.91 0.0066 2.82 0.0054 -3.09

415. 29214501 *ALPHA NAPHTHYLAMINE 0.25 0.0006 0.97 0.0018 292.92

416. 29214502 *PHENYL ALPHA NAPHTHYLAMINE 0.48 0.0011 1.25 0.0024 162.74

417. 29214503 *PHENYL BETA NAPHTHYLAMINE 0.00 0.0000

418. 29214504 *AMINO F-ACID 0.00 0.0000 0.11 0.0002 2,669.05

419. 29214505 *BRONNER'S ACID (2 NPHTHYLAMN-6-SLPHNC ACD) 0.50 0.0011 0.35 0.0007 -29.43

420. 29214506 *CLEVE'S ACID(1 NAPHTHYLAMN-6-SLPHNC ACID) 0.03 0.0001 0.06 0.0001 96.44


- 201 -

421. 29214507 *EPSLN ACD(1-NAPHTHYLAMN-3,8-DISLPHNC ACD) 0.73 0.0017 0.36 0.0007 -50.53

422. 29214508 *KCH'S ACD(1-NPTHYLAMN-3,6,8-TRISLPHNC ACD) 3.45 0.0079 2.29 0.0043 -33.63

423. 29214511 ALPHA NAPHTHYLAMINE 0.05 0.0001 0.11 0.0002 143.25

424. 29214512 PHENYL ALPHA NAPHTHYLAMINE 0.01 0.0000 0.03 0.0001 488.08

425. 29214513 PHENYL BETA NAPHTHYLAMINE 0.00 0.0000 0.09 0.0002 27,217.52

426. 29214514 AMINO F-ACID 0.16 0.0004 0.10 0.0002 -37.08

427. 29214515 AMINOLINELI-R-ACID 0.08 0.0002 0.00 0.0000 -98.60

428. 29214516 SODIUM NAPHTHIONATE 0.18 0.0004 0.04 0.0001 -78.67

429. 29214517 *TOBIAS ACID(2-NAPHTHYLAMINE-1-SLPHNC ACD) 3.57 0.0081 4.77 0.0090 33.78

430. 29214519 *OTHR 1-NPTHYLAMN 2-NPTHYLAMN AND THEIR DRVTVS AND SLTS THREOF 4.85 0.0111 5.45 0.0103 12.42

431. 29214901 *BENZYL ETHYL ANILINE 0.51 0.0012 0.65 0.0012 27.21

432. 29214902 *BENZYL ETHYL ANILINE SULPHURIC ACID 0.16 0.0004 0.01 0.0000 -95.75

433. 29214903 *2-5-XYLIDINE 0.26 0.0006 0.09 0.0002 -66.15

434. 29214904 *XYLIDINE (MIXED) 0.55 0.0013 0.97 0.0018 75.98

435. 29214909 *COTHERS 3.09 0.0071 3.30 0.0063 6.63

436. 29215101 *M-PHENYLENEDIAMINE (M-DIAMINOBENZENE) 0.52 0.0012 1.43 0.0027 171.74

437. 29215102 *PARA-AMINO ACETANILIDE 0.04 0.0001 0.05 0.0001 46.63

438. 29215103 *META TOLUYLENE DIAMINE 0.00 0.0000

439. 29215109 *OTHR O-M-P-PHNYLENEDIAMINE DIAMINOTOLUENE AND THEIR DRVTVS SALTS THEREOF

2.11 0.0048 2.76 0.0052 30.84

440. 29215901 *BENZIDINE 0.77 0.0018 1.08 0.0020 40.86

441. 29215902 *BENZIDINE DIHDROCHLORIDE 0.24 0.0005 0.90 0.0017 283.99

442. 29215903 *3:3 DICNLOROBEZIDINE DIHYDROCHLORIDE, SULPHATE 8.58 0.0196 10.63 0.0202 23.93

443. 29215909 *OTHERS 10.37 0.0237 8.36 0.0159 -19.43

444. 29221101 *N,N-DIALKL (ME,ET,N-PR) AMNO-ETHN-2/OLS & CORSPNGNG PRTNTD SALTS EXCL N,N-DI MTHL / DIETHL AMNO ETHNL & CORSPNDNG PRTNTD SALT

0.43 0.0010 0.14 0.0003 -67.89

445. 29221109 *OTHERS 0.36 0.0008 1.76 0.0033 382.85


447. 29221301 *TRIETHANOLAMINE 0.05 0.0001 0.52 0.0010 910.45

448. 29221302 *SALTS OF TRIETHANOLAMINE 0.12 0.0003 0.03 0.0001 -73.16

449. 29221901 *METHYL DI-ETHANOLAMINE 2.85 0.0065 2.43 0.0046 -14.76

450. 29221903 *N,N-DIALKYL (ME,ET,N-PR OR IPR) AMINO- ETHANE -2-THIOLS & CORRSPNDNG PROTONATED SALTS

0.05 0.0001

451. 29221909 *OTHERS 1.28 0.0029 1.45 0.0028 13.48

452. 29222101 *AMINO-G-ACID 1.35 0.0031 1.88 0.0036 38.97

453. 29222102 *AMINO-J-ACID 0.15 0.0003 0.19 0.0004 24.41

454. 29222103 *1-AMINO-2-NAPHTHOL-4-SULPHONIC ACID 0.91 0.0021 0.15 0.0003 -84.02

455. 29222104 *GAMMA ACID 2.97 0.0068 3.94 0.0075 32.80

456. 29222105 *J ACID (2-AMINO-5-NAPTHOL-7 SLPHNC ACID) 1.15 0.0026 1.01 0.0019 -12.49

457. 29222106 *H-ACID 12.52 0.0286 14.17 0.0269 13.20

458. 29222107 *ORTHO PHENYL SULPHONYL H-ACID 0.49 0.0011 0.09 0.0002 -81.70

459. 29222111 *CHICAGO ACID 0.33 0.0006

460. 29222119 *OTHERS 8.81 0.0201 11.42 0.0217 29.64

461. 29222201 *ORTHO ANISIDINES 1.78 0.0041 2.48 0.0047 39.70

462. 29222202 *PARA ANISIDINES 0.17 0.0004 0.23 0.0004 29.11

463. 29222209 *OTHR ANISIDNS DIANSDNS PHNTDNS & THR SLTS 1.71 0.0039 1.73 0.0033 1.34

464. 29222901 *2-AMINO 4-NITROPHENOL 1.32 0.0030 1.55 0.0029 17.89

465. 29222902 *META AMINOPHENOL THN ONE KIND OF OXYGEN FUNCTION ;SALTS 1.28 0.0029 1.34 0.0025 4.86

466. 29222903 *PARA AMINOPHENOL 0.08 0.0002 0.26 0.0005 215.79

467. 29222904 *2-AMINO-1-PHENOL-4-SULPHONIC ACID 0.72 0.0017 1.48 0.0028 103.73

468. 29222905 *META DIETHYL AMINO-PHENOL 2.33 0.0053 2.17 0.0041 -6.73

469. 29222906 *6-NITRO-0-AMINOPHENOL-4-SULPHONIC ACID 0.58 0.0013 0.37 0.0007 -37.30


- 202 -

470. 29222907 *N-METHYL-PARA-AMINOPHENOL SULPHATE(MOTOL) 0.65 0.0015 0.39 0.0007 -40.33

471. 29222908 *PHENYL GAMMA ACID(PHENYL 2--AMINO-8- NAPHTHOL-6-SULPHONIC ACID) 0.09 0.0002 0.21 0.0004 134.09

472. 29222911 2-AMINO 4-NITROPHENOL 0.69 0.0016 1.11 0.0021 61.49

473. 29222912 META AMINOPHENOL THN ONE KIND OF OXYGEN FUNCTION ;SALTS 0.62 0.0014 0.45 0.0009 -27.83

474. 29222913 PARA AMINOPHENOL 0.19 0.0004 0.01 0.0000 -95.24

475. 29222914 META DIETHYL AMINO-PHENOL 2.89 0.0066 4.19 0.0080 45.04

476. 29222915 *PARA CRESIDINE 0.70 0.0016 0.52 0.0010 -26.27

477. 29222916 *PICRAMIC ACID (T-GRADE) 0.09 0.0002

478. 29222917 *META-PHENYLENE DIAMENE-4-SULPH0NIC ACID 1.83 0.0042 2.33 0.0044 27.46

479. 29222919 *OTHERS 11.99 0.0273 20.01 0.0380 66.92

480. 29223001 *2-ACETYLAMINO-3-CHLORO-ANTHRAQUINONE 0.10 0.0002 0.24 0.0005 129.35

481. 29223002 *1-AMINO-ANTHRAQUINONE 0.01 0.0000

482. 29223003 *2-AMINO-ANTHRAQUINONE 0.01 0.0000

483. 29223004 *1:4 DIMINO ANTHRAQUINONE 0.00 0.0000 0.01 0.0000 605.74

484. 29223009 *OTHERS 1.22 0.0028 0.89 0.0017 -26.86


486. 29224201 *M0N0S0DIUM GLUTAMATE ( AZINAMAT0 ) 0.09 0.0002 0.04 0.0001 -55.76

487. 29224209 *GLUTAMIC ACID AND 0THER SALTS 0.20 0.0005 0.01 0.0000 -93.39


489. 29224901 *AMINO ACETIC ACID (GLYCINE) 2.26 0.0051 2.76 0.0052 22.15

490. 29224909 *OTHERS 4.30 0.0098 1.97 0.0037 -54.31

491. 29225002 *PARA-AMINO-SALICYLIC ACID 0.10 0.0002 0.51 0.0010 397.85

492. 29225004 *METHYL ANTHRANILATE 0.88 0.0020 0.66 0.0013 -24.73

493. 29225005 *PROCAINE HYDROCHLORIDE 0.01 0.0000

494. 29225006 *AMINO ANISIC ACID ANILIDE 0.03 0.0001 0.22 0.0004 708.70

495. 29225007 *L-TYROSINE(p-HYDROXYPHENYLAMINE) 0.01 0.0000 0.06 0.0001 713.81

496. 29225008 *FRUSEMIDE 3.70 0.0085 3.51 0.0066 -5.37

497. 29225011 PARA-AMINO-SALICYLIC ACID 0.02 0.0000 0.01 0.0000 -47.80

498. 29225012 METHYL ANTHRANILATE 0.01 0.0000 0.06 0.0001 1,013.03

499. 29225013 PROCAINE HYDROCHLORIDE 1.61 0.0037 2.03 0.0039 25.95

500. 29225019 *OTHERS 2.71 0.0062 4.82 0.0091 77.91

501. 29231000 CHOLINE AND ITS SALTS 1.52 0.0035 1.52 0.0029 -0.02

502. 29232001 *LECITHINS (OTHER THAN MEDICAMENTS) 0.90 0.0021 2.31 0.0044 155.59

503. 29232009 *OTHERS (PHOSPHOAMINOLIPIDS) 0.01 0.0000 0.16 0.0003 2,025.91


5.54 0.0126 8.63 0.0164 55.84

505. 29241001 *ACETANILIDE 1.45 0.0033 1.42 0.0027 -2.01

506. 29241002 *ACETO ACETANILIDE 1.16 0.0026 0.61 0.0011 -47.65

507. 29241003 *ACETO ACETIC ORTHO CHLORANILIDE 0.25 0.0006 0.05 0.0001 -78.74

508. 29241004 *ACETO ACETIC PARA CHLORANILIDE 0.05 0.0001 0.09 0.0002 88.42

509. 29241005 *DIETHYL DIPHENYL UREA 0.00 0.0000

510. 29241006 *DIMETHYL DIPHENYL UREA (ZENTRALIN) 0.00 0.0000 0.01 0.0000 179.00


- 203 -

511. 29241007 *TOLBUTAMIDE 0.40 0.0009 0.20 0.0004 -49.72

512. 29241008 *CHLOROPROPAMIDE 0.52 0.0012 0.42 0.0008 -19.59

513. 29241011 *PARACHLORO BENZENE SULPHONYL UREA 0.01 0.0000 0.01 0.0000 4.69

514. 29241019 *OTHERS 4.23 0.0097 5.32 0.0101 25.69

515. 29242100 *UREINES & THEIR DERIVATIVES SALTS THEREOF 0.17 0.0004 0.47 0.0009 174.46

516. 29242901 *PHENYL ACETAMIDE 0.31 0.0007 0.24 0.0005 -21.51

517. 29242902 *PYRAZINAMIDE(PYRAZINE CARBOXAMIDE) 1.16 0.0026 1.47 0.0028 26.78

518. 29242909 *OTHERS 2.19 0.0050 2.77 0.0053 26.48



521. 29252001 *GUANIDINE NITRATE 1.34 0.0031 1.50 0.0028 11.66

522. 29252009 *OTHERS 0.65 0.0015 0.32 0.0006 -50.99

523. 29261000 ACRYLONITRILE 0.60 0.0014 0.07 0.0001 -89.03



526. 29270001 *PARA AMINO-AZO-BENZENE 1.18 0.0027 1.48 0.0028 25.90

527. 29270009 *OTHER DIAZO-AZO-OR AZOXY-COMPOUNDS 1.13 0.0026 1.35 0.0026 19.67

528. 29280001 *ORGANIC DERIVATIVEE OF HYDRAZINE OR OF"HYDRDXYLAMINE-ISONIAZID" 1.43 0.0033 1.94 0.0037 35.54

529. 29280009 *OTHR ORGNC DRVTS OF HYDRAZINE/HYDRXYLMINE 2.74 0.0063 1.70 0.0032 -38.02

530. 29291001 *PHENYL ISOCYANATE 0.45 0.0010 0.72 0.0014 60.49

531. 29291002 *TOLUENE DIISOCYANATE 0.12 0.0003 2.27 0.0043 1,796.88

532. 29291009 *ISOCYANATS & DIISOCYNTS OF HYDRCRBN N.E.S. 0.26 0.0006 0.29 0.0005 12.44

533. 29299000 OTHR CMPNDS WITH OTHER NITROGEN FUNCTION 10.91 0.0249 10.24 0.0194 -6.17

534. 29301000 DITHIOCARBONATES(XANTHATES) 0.09 0.0002 0.02 0.0000 -81.59

535. 29302000 THIOCARBAMATES AND DITHIOCARBAMATES 0.05 0.0001 0.02 0.0000 -57.53

536. 29303000 THIURAM MONO-,DI-OR TETRASULPHIDES 0.00 0.0000 0.01 0.0000 197.31

537. 29304000 METHIONINE 0.02 0.0000 0.52 0.0010 3,101.91

538. 29309001 *THIOUREA(SULPHOUREA) 0.93 0.0021 4.51 0.0086 383.47

539. 29309002 *CALCIUM SALTS OF METHIONINE 0.03 0.0001 0.04 0.0001 55.48

540. 29309003 *SULTONES 0.02 0.0000

541. 29309004 *THIO SULPHONIC ACID 0.00 0.0000 0.06 0.0001 10,916.20

542. 29309005 *L-CYSTINE (ALPHA-AMINO BETA-THIO PROPIONICACID)-SULPHUR CONTAINING AMINO ACID

1.57 0.0036 0.22 0.0004 -86.28

543. 29309006 *SULPHONIC ACID 0.12 0.0003 0.05 0.0001 -63.53

544. 29309007 *SULPHOXIDE 0.01 0.0000 0.07 0.0001 734.37

545. 29309008 *MERCAPTAN 0.13 0.0003 0.21 0.0004 59.49

546. 29309019 *OTHERS 3.98 0.0091 1.74 0.0033 -56.23

547. 29310001 *ORGANO-MERCURY COMPOUNDS 1.62 0.0037 2.17 0.0041 33.99

548. 29310002 *ORGANO-ARSENIC COMPOUNDS 0.62 0.0014 0.40 0.0008 -36.57

549. 29310003 *TETRA-ETHYL LEAD 0.05 0.0001

550. 29310009 *OTHER ORGAN-INORGANIC COMPOUNDS NES 23.12 0.0527 15.52 0.0294 -32.86


552. 29321200 2-FURALDEHYDE(FURFURALDEHYDE) 0.13 0.0003

553. 29321300 FURFURYL ALCHL & TETRAHYDROFURFURYL ALCHL 0.00 0.0000 0.01 0.0000 175.71

554. 29321901 *HYDROXY-3-DIBENZFUREN CARBOXYLIC ACID 0.02 0.0000 0.15 0.0003 828.60

555. 29321909 *OTHERS 2.55 0.0058 4.34 0.0082 70.33


557. 29322901 *PHENOLPHTHALEIN 0.14 0.0003 0.01 0.0000 -90.98

558. 29322909 *OTHERS 0.30 0.0007 1.04 0.0020 252.83

559. 29329100 IS0SAFR0LE 0.00 0.0000 0.00 0.0000 -68.64



- 204 -

561. 29331100 PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES 0.58 0.0013 0.57 0.0011 -1.15

562. 29331901 *3-CARBOXY (PARA SLPHPHNYL)-5 PYRAZOLONE 0.91 0.0021 6.82 0.0129 647.05

563. 29331902 *1(2:5 DCHLR-4-SLPHPHNYL)-3-MTHYL-5-PYRAZLN 0.36 0.0008 0.41 0.0008 12.91

564. 29331903 *3-MTHYL-1(4-SLPHO-0-TOLUYL-5-PYRAZOLDNE) 0.30 0.0007 0.16 0.0003 -45.53

565. 29331904 *PHENYL-METHYL PYRAZOLONE 0.13 0.0003 0.06 0.0001 -49.99

566. 29331905 *1-PHNYL-5-PYRAZLN-3-CRBOXYLC ACD ETHYLESTR 0.11 0.0003 0.05 0.0001 -55.96

567. 29331906 *1-(M-SULPHOPHENYL)-3-PYRAZOLONE 0.05 0.0001 0.08 0.0001 52.15

568. 29331907 *ANALGIN 0.01 0.0000 0.19 0.0004 1,765.92

569. 29331908 *0XYPHENBUTAZONE 0.24 0.0004

570. 29331911 *MEFENAMIC- ACID 0.10 0.0002 0.08 0.0002 -13.92

571. 29331912 *NAPROXEN 6.82 0.0156 9.49 0.0180 39.15

572. 29331913 *NIMESULIDE 0.86 0.0020 0.48 0.0009 -43.94

573. 29331914 *PENTAZOCIN 0.02 0.0000

574. 29331915 *PHENYL BUTAZONE 0.02 0.0000 0.00 0.0000 -85.05

575. 29331916 *ALLOPURINOL 0.01 0.0000 0.08 0.0002 954.13

576. 29331919 *OTHERS 2.63 0.0060 3.12 0.0059 18.49


578. 29332901 *TINIDAZOLE 2.28 0.0052 5.44 0.0103 138.43

579. 29332902 *METRONIDAZOLE AND ITS SALTS 2.81 0.0064 3.01 0.0057 7.25

580. 29332903 *MEBENDAZOLE 1.43 0.0033 1.88 0.0036 31.56

581. 29332904 *DIMETRIDAZOLE 0.28 0.0006 0.10 0.0002 -62.85

582. 29332905 *ALBENDAZ0LE 0.47 0.0011 1.19 0.0023 153.34

583. 29332909 *OTHERS 4.48 0.0102

584. 29332912 *ASTEMIZOLE 0.05 0.0001 0.10 0.0002 115.03

585. 29332913 *FLUCONAZOLE 1.43 0.0033 1.57 0.0030 9.97

586. 29332914 *FENBENDAZOLE 0.05 0.0001

587. 29332915 *KETOCONAZOLE 0.71 0.0016 1.41 0.0027 98.11

588. 29332916 *LANSOPRAZOLE 0.86 0.0020 1.77 0.0034 107.06

589. 29332917 *OMEPRAZOLE 13.62 0.0311 11.80 0.0224 -13.36

590. 29332919 6.31 0.0120



593. 29333901 *AMINO PYRIDINE 1.88 0.0043 2.72 0.0052 44.44

594. 29333902 *ALPHA PICOLINE(2-METHYL PYRIDINE) 0.32 0.0007 0.50 0.0009 55.27

595. 29333903 *GAMMA PICOLINE(4-METHYL PYRIDINE) 0.05 0.0001 0.02 0.0000 -61.50

596. 29333904 *CHLORPHENIRAMINE MALEATE 1.93 0.0044 1.52 0.0029 -21.07

597. 29333905 *DIPHENOXYLATE HYDROCHLORIDE 0.02 0.0000 0.01 0.0000 -44.89

598. 29333906 *BETA PIC0LINE ( 3-METHYL PYRIDINE ) 0.03 0.0001 0.06 0.0001 124.52

599. 29333907 *M0RPH0LINE 0.09 0.0002 0.09 0.0002 3.64

600. 29333908 *LUTIDINE 0.03 0.0001 0.15 0.0003 399.23

601. 29333909 *OTHERS 2.64 0.0060

602. 29333919 OTHER DERIVATIVES OF PYRADINE 3.54 0.0067

603. 29334001 *QUINOLINE 2.54 0.0058 4.16 0.0079 63.97

604. 29334002 *2:4 DIHYDROXY QUINOLINE (2:4 DIOXY-QUINLN) 0.04 0.0001

605. 29334003 *4-HYDROXY-N-METHYL-2-QUINOLINE 0.09 0.0002 0.11 0.0002 22.15

606. 29334004 *8-HYDROXY QUINOLINE AND ITS SALTS 0.01 0.0000 0.01 0.0000 -40.26

607. 29334005 *AMODIAQUINE HYDROCHLORIDE 1.53 0.0035 0.73 0.0014 -52.39

608. 29334006 *IODOHYDROXY & DI-IODOHYDROXY QUINOLINE 0.78 0.0018 0.78 0.0015 -0.12

609. 29334007 *DICHLORO QUINOLINE 1.23 0.0028 0.61 0.0012 -50.84

610. 29334019 *OTHERS 1.59 0.0036 1.86 0.0035 16.93

611. 29335101 *BARBITURIC ACID 0.04 0.0001 0.08 0.0002 91.68


- 205 -

612. 29335102 *PHENOBARBITAL 0.13 0.0003

613. 29335109 *OTHR SLTS & DRVTVS OF BARBITURIC ACID 0.94 0.0022 2.36 0.0045 149.45

614. 29335901 *AMINOPHYLLINE(CORDOPHYLIN) 0.92 0.0021 1.20 0.0023 30.31

615. 29335902 *TRIMETHOPRIM 2.24 0.0051 1.74 0.0033 -22.34

616. 29335903 *DIETHYL CARBANAZINE CITRATE 0.08 0.0002 0.07 0.0001 -10.23

617. 29335904 *CARBAZOLE 0.13 0.0003 0.16 0.0003 26.92

618. 29335909 *OTHERS 1.22 0.0028 0.95 0.0018 -22.29

619. 29336100 MELAMINE 0.34 0.0008 0.02 0.0000 -94.70

620. 29336901 *CYANURIC ACID & ITS SALTS 0.50 0.0011 0.11 0.0002 -78.13

621. 29336909 *OTHERS 2.59 0.0059 2.36 0.0045 -8.90


623. 29337900 OTHER LACTAMS 10.49 0.0239 7.75 0.0147 -26.08

624. 29339001 *CARBAMAZIPINE 3.53 0.0080 4.46 0.0085 26.30

625. 29339009 *OTHERS 4.92 0.0112 4.69 0.0089 -4.58


0.59 0.0013 1.67 0.0032 183.98


0.21 0.0005 0.22 0.0004 4.30


0.04 0.0001

629. 29349001 *ACRIFLAVINE BPC NEUTRAL 0.80 0.0018 1.53 0.0029 91.22

630. 29349003 *INDOLE 0.34 0.0008 1.57 0.0030 365.04

631. 29349005 *NIFURAZOLE 0.00 0.0000 0.00 0.0000 2.83

632. 29349006 *MICONAZOLE 0.60 0.0014 0.72 0.0014 20.23

633. 29349007 *CLORTRIMAZOLE 0.09 0.0002 0.24 0.0005 173.30

634. 29349008 *FURAZ0LIDINE 0.18 0.0004 0.15 0.0003 -17.16

635. 29349011 *3,4, METHYLENE DI0XY PHENYL-2-PR0PAN0NE 0.21 0.0004

636. 29349019 *0THERS 2.10 0.0048 1.72 0.0033 -17.81

637. 29350001 *SULPHAMETHOXAZOLE 26.85 0.0613 25.00 0.0474 -6.88

638. 29350003 *SULPHADIAZINE 0.05 0.0001 0.00 0.0000 -99.26

639. 29350004 *SULPHADIMIDINE 0.00 0.0000 0.05 0.0001 12,303.68

640. 29350005 *SULPHACETAMIDE 0.01 0.0000 0.00 0.0000 -85.34

641. 29350007 *SULPHAMETHIAZOLE 0.26 0.0006 0.24 0.0004 -9.54

642. 29350008 *SULPHAMOXOLE 0.03 0.0001 0.10 0.0002 214.17

643. 29350011 SULPHAMETHOXAZOLE 0.12 0.0002

644. 29350012 SULPHAFURAZOLE 0.00 0.0000 0.09 0.0002 2,618.62

645. 29350019 *OTHER SULPHONAMIDES 1.29 0.0030 2.04 0.0039 57.82


647. 29362100 VITAMINS A AND THEIR DERIVATIVES 0.02 0.0000 0.07 0.0001 233.49

648. 29362200 *VITAMINS B1(THIAMINE/ANEURIN) & ITS DRVTVS 0.14 0.0003 0.06 0.0001 -57.99

649. 29362300 *VITAMINS B2(RIBOFLAVIN)& ITS DRVTVS 0.50 0.0011 0.38 0.0007 -24.92


0.12 0.0003 0.10 0.0002 -10.67

651. 29362500 VITAMIN B6 & ITS DRVTS 0.24 0.0005 0.01 0.0000 -96.15

652. 29362600 *VITAMIN B12(CYANOCOBALANIM) & ITS DRVTVS 4.10 0.0094 7.47 0.0142 82.06


654. 29362800 VITAMIN E AND ITS DERIVATIVES 0.29 0.0007 0.34 0.0007 17.46

655. 29362902 *FOLIC ACID 2.67 0.0061 2.13 0.0040 -20.40

656. 29362903 *NCTNC ACID & NCTNMD(NIACINAMIDE/NIACINE 6.43 0.0147 8.94 0.0170 39.10

657. 29362904 *PARA AMINO BENZOIC ACID (PABA) 0.04 0.0001

658. 29362909 *OTHER VITAMIN B COMPLEX 0.04 0.0001 0.13 0.0003 248.78

659. 29362912 *VITAMIN K (MENAPHTHONUM B.P.) 0.11 0.0002 0.06 0.0001 -41.16

660. 29362914 *VITAMIN H (BI0LIN) 0.06 0.0001


- 206 -

661. 29362915 *ATORVASTATIN 1.96 0.0045 3.29 0.0062 67.21

662. 29362916 *GEMFIBROZIL 0.06 0.0001

663. 29362917 *LOVASTATIN 1.99 0.0045 4.31 0.0082 116.59

664. 29362918 *PRAVASTATIN & OTHER STATIN 1.82 0.0041 1.96 0.0037 8.14

665. 29362919 *OTHERS 0.47 0.0011 3.13 0.0059 572.46


667. 29371001 *OXYTOCIN 0.91 0.0021 1.10 0.0021 20.99

668. 29372101 *CORTISONE 0.00 0.0000

669. 29372102 *HYDROCORTISONE ITS SALTS AND DERIVATIVES 0.05 0.0001 0.20 0.0004 276.72

670. 29372103 *PREDNISONE(DEHYDRO CORTISONE) 0.01 0.0000

671. 29372104 *PREDNISOLONE(DEHYDROHYDRO CORTISONE) 0.09 0.0002 0.09 0.0002 8.18

672. 29372200 HALGNTD DRVTVS OF CORTI COSTEROIDAL 0.05 0.0001 0.02 0.0000 -54.17

673. 29372901 *EPINEPHRINE (ADRENALINE) AND SALTS 0.01 0.0000 0.02 0.0000 108.24

674. 29372909 *OTHERS 0.13 0.0003 0.31 0.0006 139.09

675. 29379102 *INSULIN REFERENCE STANDARD 0.01 0.0000 0.01 0.0000 -42.64

676. 29379203 *ESTROGENS N.E.S. 0.03 0.0001

677. 29379204 *ETHISTERONE & ITS DERIVATIVES (DANAZOL) 0.60 0.0014 0.98 0.0019 63.53

678. 29379901 *METHYL TESTOSTERONE 0.30 0.0007 0.64 0.0012 111.81

679. 29379902 *TESTOSTERONE PROPIONATE 0.01 0.0000

680. 29379903 *DEXAMETHASONE 0.46 0.0010 0.25 0.0005 -44.48

681. 29379904 *BETAMETHASONE 2.63 0.0060 1.29 0.0024 -51.01

682. 29379905 *ANDROGEN 0.00 0.0000 0.01 0.0000 1,302.04

683. 29379907 *NANDROLONE 0.01 0.0000

684. 29379912 *HYDROCORTISONE SODIUM SUCCINATE 0.01 0.0000

685. 29379913 *METHYL PREDNISOLONE ACCTALE 0.01 0.0000

686. 29379915 *BECLOMETHASONE DIPROP./SALTS 0.03 0.0001 0.02 0.0000 -45.35

687. 29379916 *CLOBETASOLE 0.06 0.0001 0.11 0.0002 76.94

688. 29379918 *CLOSTEBOL SALTS 0.02 0.0000

689. 29379923 *FLUCORTOLONE 0.00 0.0000

690. 29379925 *FLUTICOSONE PROP./SALTS 0.01 0.0000

691. 29379927 *LEVONORGESTEROC 0.13 0.0003

692. 29379928 *MEDROXYPROGESTERONE ACETATE. 0.26 0.0006 0.37 0.0007 42.98

693. 29379933 *GLIBENCLAMIDE 0.41 0.0009 0.42 0.0008 2.18

694. 29379934 *GLICLAZIDE 0.12 0.0003 0.03 0.0001 -75.81

695. 29379935 *GLIPIZIDE 0.03 0.0001 0.02 0.0000 -25.47

696. 29379936 *PHENFORMIN 0.00 0.0000 0.00 0.0000 -23.58

697. 29379937 *METFORMIN 5.90 0.0135 9.05 0.0172 53.38

698. 29379942 *CARBIMAZOLE 0.00 0.0000

699. 29379944 *CLOMIPHENE 0.01 0.0000 0.03 0.0001 292.92

700. 29379953 *METHYL PREDISOLONE SODIUM SUCCINATE 0.43 0.0010 0.02 0.0000 -96.43


- 207 -

701. 29379957 *METHENEDIONONE 0.23 0.0005 0.14 0.0003 -39.54

702. 29379958 *METHOXSALEN 0.05 0.0001 0.08 0.0001 54.81

703. 29379969 *OTHERS 1.93 0.0044 1.31 0.0025 -32.18

704. 29381001 *VITAMIN P 0.16 0.0004 0.01 0.0000 -91.89

705. 29381009 *OTHR RUTOSIDE (RUTIN) AND ITS DRVTVS 0.06 0.0001 0.19 0.0004 220.67

706. 29389001 *DIGOXIN 0.17 0.0004 0.36 0.0007 110.58

707. 29389002 *GLYCSDS OF DGTLS NES (DEGITALIN DIGITOXIN) 0.11 0.0002

708. 29389003 *DEXTROMETHORPHAN 6.25 0.0143 2.78 0.0053 -55.55

709. 29389009 *OTHRS 0.06 0.0001 1.27 0.0024 2,052.25

710. 29391001 *PAPAVERINE THEIR SALTS AND DERIVATIVES 0.38 0.0009 4.53 0.0086 1,087.63

711. 29391002 *N0SCAPINE ( NARC0TINE ) & THEIR DERIVATIV 1.74 0.0040 2.03 0.0038 16.54

712. 29391009 *OTHR ALKLDS OF OPIUM AND THR DRVTVS AND SALTS THEREOF 11.63 0.0265 12.41 0.0235 6.78

713. 29392101 *QUININE ALKALOIDS 0.13 0.0003 0.34 0.0007 169.54

714. 29392102 *QUININE HYDROCHLORIDE 0.29 0.0007 0.12 0.0002 -58.25

715. 29392103 *QUININE SULPHATE 0.30 0.0007 0.53 0.0010 77.22

716. 29392104 *CHL0R0QUINE PH0SPHATE 2.82 0.0064 1.13 0.0021 -59.81

717. 29392105 *MEFLOQUINE 0.04 0.0001

718. 29392109 *SALTS AND OTHR DRVTVS OF QUININE NES 0.36 0.0008 0.55 0.0011 52.62

719. 29392900 OTHR ALKLDS OF CINCHONA & THR DRVTVS AND SLTS THEREOF 0.13 0.0003 0.35 0.0007 167.15

720. 29393000 CAFFEINE AND ITS SALTS 1.13 0.0026 0.88 0.0017 -21.87

721. 29394101 *EPHEDRINE ALKALOIDS 2.40 0.0055 3.22 0.0061 33.96

722. 29394102 *EPHEDRINE HYDROCHLORIDE 4.86 0.0111 3.91 0.0074 -19.52

723. 29394109 *OTHER EPHEDRINE & ITS SALTS 0.25 0.0006 0.25 0.0005 0.96

724. 29394200 PSEUDO EPHEDRINE (INN) AND ITS SALTS 11.95 0.0273 14.89 0.0282 24.66

725. 29394901 *NOREPHEDRINE 0.03 0.0001

726. 29394909 *OTHERS 0.17 0.0004 0.08 0.0002 -51.55


0.07 0.0002 0.01 0.0000 -88.68

728. 29396109 *OTHER 0.00 0.0000 0.00 0.0000 -43.93

729. 29396300 LYSERGIC ACID AND ITS SALTS 0.00 0.0000

730. 29396900 OTHER ALKALOIDS OF RYE ERGOT & DRVTVS 0.00 0.0000

731. 29397001 *NICOTINE ALKALOIDS 0.25 0.0006 0.10 0.0002 -60.84

732. 29397002 *NICOTINE SULPHATE 0.79 0.0018 0.26 0.0005 -67.54

733. 29397009 *SALTS AND DERIVATIVES OF NICOTINE 0.15 0.0003 0.32 0.0006 107.42

734. 29399001 *ATROPINE SULPHATE 3.45 0.0079 3.34 0.0063 -3.24

735. 29399002 *BERBERINE HYDROCHLORIDE 0.03 0.0001 0.03 0.0000 -19.90

736. 29399003 *COCOINE HYDROCHLORIDE 0.00 0.0000

737. 29399005 *EMETINE ALKALOIDS 0.03 0.0001

738. 29399007 *ROUWOLFIA ALKALOIDS 0.05 0.0001 0.20 0.0004 319.12

739. 29399008 *STRYCHNINE ALKALOIDS 0.63 0.0014 0.52 0.0010 -16.80

740. 29399011 *SLTS, OTHR DRVTVS OF NX-VMC ALKLDS BRUCINE 0.06 0.0001 0.09 0.0002 53.65

741. 29399012 *THEOPHYLLINE THEOBROMINE ALKALOIDS, THEIR SALTS & OTHR DERIVATVES 0.80 0.0018 1.37 0.0026 70.87

742. 29399013 *COLCHICINE 1.10 0.0025 0.53 0.0010 -51.70

743. 29399014 *VINCA ROSEA ALKALOIDSVINCRITINE, VINBLA SLINE, VINCISTERINE 0.09 0.0002 0.01 0.0000 -87.85

744. 29399015 *BROMOHEXIN & ITS DRVTV (VASAK ALKALOID) 0.44 0.0010 0.81 0.0015 84.61

745. 29399018 *PILOCARPINE 0.09 0.0002 0.00 0.0000 -99.60


- 208 -

746. 29399022 *BISACODYL 0.12 0.0003 0.02 0.0000 -82.95

747. 29399023 *ISOSORBIDE MONO/DI NITRATE 0.09 0.0002 0.11 0.0002 21.13

748. 29399024 *METOCLOPRAMIDE 0.09 0.0002 0.04 0.0001 -50.56

749. 29399029 *OTHERS 1.63 0.0037 2.58 0.0049 57.94

750. 29400001 *DEXTROSE 0.35 0.0008 0.81 0.0015 132.34

751. 29400009 *OTHERS 0.64 0.0015 1.40 0.0027 119.56

752. 29411002 *AMPICILLINE & ITS SALTS 36.21 0.0826 54.25 0.1029 49.82

753. 29411003 *AMOXYCILLINE & ITS SALTS 39.35 0.0898 66.83 0.1268 69.84

754. 29411004 *CLOXACILLINE & ITS SALTS 4.19 0.0096 8.92 0.0169 113.15

755. 29411005 *PENICILLINE 2.55 0.0058 2.55 0.0048 0.12

756. 29411006 *PENICILLIN PROCAINE !G! 0.03 0.0001 0.06 0.0001 144.47

757. 29411007 *PENICILLIN !G! POTASSIUM 0.16 0.0004 0.49 0.0009 212.12

758. 29411008 *PENICILLIN !G!SODIUM 0.25 0.0006 0.20 0.0004 -19.82

759. 29411011 *PENICILLIN V-POTASSIUM 0.47 0.0011 0.38 0.0007 -19.82

760. 29411013 *PIPERACILLIN 0.23 0.0004

761. 29411014 *BENZATHIN PEN G. 0.01 0.0000

762. 29411015 *PHENOXY METHYL PENICILIN 0.03 0.0001

763. 29411016 *FLUCLOXACILLIN 0.60 0.0014 0.78 0.0015 29.52

764. 29411017 *CARBENICILLIN 0.01 0.0000

765. 29411018 *OXACILLIN 0.56 0.0013 0.62 0.0012 9.64

766. 29411021 *GRISEOFULVIN 0.02 0.0000

767. 29411022 *TOLNAFLATE 0.01 0.0000

768. 29411029 *OTHERS 2.86 0.0065 3.32 0.0063 15.84

769. 29412000 *STREPTOMYCINS & THR DRVTVS SLTS THEREOF 1.06 0.0024 1.39 0.0026 30.73

770. 29413001 *DOXYCYLIME & ITS SALTS 0.12 0.0003 0.43 0.0008 257.49

771. 29413002 *TETRACYCLINE &ITS SALTS 0.19 0.0004 0.08 0.0001 -58.01

772. 29413003 *OXYTETRACYCLINE & ITS SALTS 0.06 0.0001

773. 29413004 *MINOCYCLINE & ITS SALTS 0.02 0.0000

774. 29413009 *OTHER DERIVATIVES OF TETRACYCLINE AND SALTS THEREOF 1.03 0.0023 1.03 0.0020 0.17

775. 29414000 CHLORAMPHENICOL & ITS DRVTVS SLTS THEREOF 1.16 0.0027 1.75 0.0033 50.61

776. 29415001 *ERYTHROMYCIN AND ITS SALTS 8.28 0.0189 9.88 0.0187 19.36

777. 29415002 *ROXYTHROMYCIN AND ITS SALTS 1.42 0.0032 1.42 0.0027 0.52

778. 29415003 *AZITHROMYCIN AND ITS SALTS 3.42 0.0078 2.93 0.0056 -14.51

779. 29415004 *CLARITHROMYCIN 6.31 0.0144 8.50 0.0161 34.74

780. 29415009 *OTHERS 0.81 0.0018 0.90 0.0017 11.38

781. 29419001 *RIFAMPICIN & ITS SALTS 11.53 0.0263 17.82 0.0338 54.55

782. 29419002 *CEPHALEXIN & ITS SALTS 37.62 0.0858 26.14 0.0496 -30.51

783. 29419003 *CIPROFLOXACINE & ITS SALTS 4.87 0.0111 8.25 0.0156 69.24

784. 29419004 *GENTAMYCIN & ITS SALTS 0.23 0.0005 0.01 0.0000 -93.97

785. 29419005 *NEOMYCIN 0.05 0.0001 0.01 0.0000 -74.19

786. 29419006 *CEFAZOLIN AND ITS SALTS 2.77 0.0063 4.82 0.0091 74.14

787. 29419007 *CEFUROXIME AND ITS SALTS 2.76 0.0063 6.03 0.0114 118.59

788. 29419008 *CEFACLOR AND ITS SALTS 3.68 0.0084 6.02 0.0114 63.79

789. 29419011 RIFAMPICIN 0.00 0.0000 0.36 0.0007 7,981.89

790. 29419012 3 FORMYL RIFA S V (RIFA INT) 1.25 0.0028 0.54 0.0010 -56.40

791. 29419013 RIFA OR RIFA S SODIUM (RIFAINT) 3.87 0.0088 4.33 0.0082 11.97

792. 29419014 1 - AMINO -4 - METHYL PIPERAZINE (RIFAINT) 1.20 0.0027 2.76 0.0052 129.97

793. 29419015 *CEFIXIME AND ITS SALTS 0.76 0.0017 3.31 0.0063 333.07

794. 29419016 *CEFTIZOXIME AND ITS SALTS 0.32 0.0007 0.04 0.0001 -86.28

795. 29419017 *CEPHRADINE AND ITS SALTS 1.48 0.0034 2.04 0.0039 38.42


- 209 -

796. 29419018 *KANAMYCIN AND ITS SALTS 0.03 0.0001 0.02 0.0000 -23.12

797. 29419022 *SISOMYCIN 0.23 0.0004

798. 29419024 *AMIKACIN AND ITS SALTS 0.00 0.0000

799. 29419026 *POLYMIXIN B AND ITS SALTS 0.04 0.0001

800. 29419031 *FRAMYCETIN AND ITS SALTS 0.00 0.0000

801. 29419033 *DOXORUBICIN 0.12 0.0003 0.46 0.0009 294.22

802. 29419034 *FLUXETINE 0.05 0.0001 0.79 0.0015 1,354.00

803. 29419039 *OTHERS 2.45 0.0056 5.65 0.0107 130.90

804. 29420001 *NORFLOXACIN & ITS SALTS 37.08 0.0846 47.02 0.0892 26.82

805. 29420002 *CEFADROXIL & ITS SALTS 2.58 0.0059 2.06 0.0039 -19.99

806. 29420003 *IBUPROFANE 20.43 0.0466 27.01 0.0512 32.25

807. 29420004 *DIAZEPAM 0.00 0.0000 0.05 0.0001 1,054.69

808. 29420005 *NIFEDIPINE 1.44 0.0033 0.28 0.0005 -80.78

809. 29420006 *RANITIDINE 18.76 0.0428 21.25 0.0403 13.24

810. 29420007 *DANES SALT OF D (-) PHENYL GLYCINE 0.27 0.0006 0.49 0.0009 81.72

811. 29420008 *D(-) PARA HYDROXY DANE'S SALTS 0.36 0.0008 0.48 0.0009 33.43

812. 29420011 CEFADROXIL 0.21 0.0005 0.33 0.0006 54.64

813. 29420012 IBUPROFANE 0.24 0.0006 0.36 0.0007 47.68

814. 29420013 NIFEDIPINE 0.17 0.0004 0.12 0.0002 -28.61

815. 29420014 RANITIDINE 0.02 0.0001 0.08 0.0001 233.35

816. 29420015 DANES SALT OF D (-) PHENYL GLYCINE 0.53 0.0012 0.66 0.0012 24.75

817. 29420016 D(-) PARA HYDROXY DANE'S SALTS 0.65 0.0015 0.81 0.0015 25.29

818. 29420017 *CYSTEANUNE HCL 0.01 0.0000 0.11 0.0002 1,737.54

819. 29420018 *ATENOLOL, PROPRONALOL 3.78 0.0086 3.85 0.0073 1.65

820. 29420021 TIMOLOL MALEATE 5.14 0.0117 2.82 0.0054 -45.12

821. 29420022 TERBUTOLINE SULPHATE 0.03 0.0001 0.01 0.0000 -58.06

822. 29420023 D(-) PHENYL GLYCIN CHLORIDE HCL (DPGCH) 0.48 0.0011 0.50 0.0010 5.70

823. 29420024 IMIPRAMINE HCL 0.87 0.0020 1.43 0.0027 63.66

824. 29420026 CYSTEANUNE HCL 0.15 0.0003 0.11 0.0002 -26.50

825. 29420027 ATENOLOL, PROPRONALOL 0.06 0.0001 0.46 0.0009 728.30

826. 29420028 *ACYCLOVIR 2.57 0.0059 14.09 0.0267 448.96

827. 29420031 DILOXANIDE FUROATE 0.07 0.0002 1.96 0.0037 2,728.47

828. 29420032 CIMETIDINE 0.02 0.0000

829. 29420034 FAMOTIDINE 0.00 0.0000

830. 29420035 *ACETAZOLAMIDE 0.01 0.0000

831. 29420036 *BETAXOLOL 0.00 0.0000 0.02 0.0000 6,653.31

832. 29420041 *AMLODIPIN 0.74 0.0017 0.79 0.0015 6.71

833. 29420042 *AMBROXOL 0.39 0.0009 0.52 0.0010 34.52

834. 29420043 *ACEBUTOLOL 0.01 0.0000 0.08 0.0002 485.44

835. 29420044 *ALPRAZOLAM 0.15 0.0003 0.16 0.0003 5.17

836. 29420045 *BISOPROLOL 0.02 0.0000

837. 29420046 *CAPTOPRIL 0.95 0.0022 0.02 0.0000 -97.52

838. 29420047 *CHLOROROMAZINE 0.06 0.0001 0.28 0.0005 371.27

839. 29420048 *CINNARAZINE 0.78 0.0018 0.53 0.0010 -33.00

840. 29420051 *CYCLOSPORIN 0.28 0.0006 0.87 0.0016 210.45

841. 29420052 *CETRIZINE 1.01 0.0023 2.11 0.0040 110.31

842. 29420053 *CELECOXIB 0.01 0.0000 0.07 0.0001 630.42

843. 29420054 *DICLOFENAC SALTS 0.91 0.0021 0.79 0.0015 -12.78

844. 29420055 *DILTIZEM 1.64 0.0038 1.33 0.0025 -19.33

845. 29420056 *ENALAPRIN MALEATE 0.42 0.0009 0.73 0.0014 74.76


- 210 -

846. 29420057 *5-FLUROURACIL 0.01 0.0000

847. 29420058 *FELODIPINE 0.17 0.0004 0.39 0.0007 121.80

848. 29420061 *FLURBIPROFEN 1.22 0.0028 0.43 0.0008 -65.20

849. 29420062 *HYOSCINE N BUTYL BROMIDE 0.31 0.0007 0.45 0.0009 44.65

850. 29420064 *ISOXSUPRINE 0.13 0.0003 0.01 0.0000 -94.05

851. 29420065 *KETOPROFEN 0.36 0.0008 0.07 0.0001 -81.05

852. 29420066 *LISINOPRIL 0.45 0.0010 2.24 0.0042 399.56

853. 29420067 *LORATIDINE 3.48 0.0079 5.93 0.0112 70.36

854. 29420068 *REFECOXIB 0.05 0.0001 0.13 0.0002 150.26

855. 29420071 *SELEGILINE 0.07 0.0002 0.00 0.0000 -97.73

856. 29420072 *TAMOXIFEN 0.01 0.0000 0.09 0.0002 731.55

857. 29420073 *TRIPROLIDINE 0.19 0.0004 0.19 0.0004 -0.31

858. 29420074 *TERFENADINE 0.41 0.0009 0.13 0.0003 -67.94

859. 29420079 *OTHERS 346.61 0.7909 455.12 0.8633 31.31

India's Total Export 43,826.73 52,719.43 20.29

Exchange rate: 2001-2002: 1US$ = Rs. 47.6919 2002-2003 : 1US$ = Rs. 48.3953

DOC-NIC


- 211 -

Department of Commerce Export Import Data Bank Export: Commodity-wise

Dated: 15/6/2004Values in US $ Million

Sorted on HSCode



2003 %Share %Growth

1. 30011001 *PANCREATIN & DRIED PWDR OF PANCREAS 6.61 0.0151 6.41 0.0122 -3.01

2. 30011009 *OTHR GLNDS/ORGNS DRIED W/N PWDRD 0.03 0.0001 0.07 0.0001 139.00

3. 30012001 *LIQUID EXTRACTS OF LIVER 0.12 0.0003 0.02 0.0000 -79.59

4. 30012002 *LIVER EXTRACTS DRY 0.00 0.0000

5. 30012003 *HEPARIN 0.08 0.0002

6. 30012004 *SNAKE VENOM 0.24 0.0005 0.26 0.0005 8.70


0.03 0.0001 0.02 0.0000 -32.88


0.57 0.0013 1.01 0.0019 75.67

9. 30021001 *BLOOD PLASMA 2.19 0.0050 2.19 0.0041 0.07

10. 30021002 *DIPTHERIA ANTISERA 0.10 0.0002 0.10 0.0002 -8.31

11. 30021003 *TETANUS ANTISERA 0.03 0.0001 0.03 0.0001 13.74

12. 30021005 *SNAKE VENOM ANTISERA 0.38 0.0009 0.78 0.0015 107.31

13. 30021006 *HUMAN GAMMA GLOBULIN 0.00 0.0000


0.00 0.0000

15. 30021009 *ANTI BACTERIAL SERUMS & ANTI SERUM NES 0.17 0.0004 0.20 0.0004 13.83

16. 30022001 *VACCINES FOR CHOLERA 5.63 0.0129 3.09 0.0059 -45.14

17. 30022002 *VACCINES FR DPTHRA(DPTHRA TXD-FT,APT ETC 6.95 0.0158 6.47 0.0123 -6.92

18. 30022003 *VACCINES FOR POLIO 0.27 0.0006 0.02 0.0000 -92.97

19. 30022004 *MIXED VACCINES FR T.A.B. OR T.A.B.C. 0.25 0.0006 0.00 0.0000 -99.03

20. 30022005 *VCCNS FR TTNS(TTNS TXD-FT,APT,PTAH ETC) 5.19 0.0118 8.83 0.0168 70.23

21. 30022006 *VACCINES FOR TUBERCULINS(B.C.G.) 0.01 0.0000 0.12 0.0002 2,149.34

22. 30022008 *MIXED VACCINES FOR DPT-TRIPLE ANTI GEN 5.31 0.0121 5.08 0.0096 -4.31

23. 30022011 VACCINES FOR CHOLERA AND TYPHOID 15.81 0.0361 20.99 0.0398 32.78

24. 30022012 VACCINES FOR HEPATITIS 2.15 0.0049 1.35 0.0026 -37.38

25. 30022013 VCCNS FOR TETANUS 0.01 0.0000 0.02 0.0000 134.66

26. 30022014 VACCINES FOR POLIO 0.00 0.0000 0.01 0.0000 642.59

27. 30022015 VACCINES FOR TUBERCULINS(B.C.G.) 0.23 0.0005 0.03 0.0001 -87.23

28. 30022016 ANTI RABIES VACCINE 0.03 0.0001 0.38 0.0007 1,115.61

29. 30022019 OTHER SINGLE VACCINE 9.51 0.0217 19.66 0.0373 106.71

30. 30023000 VACCINES FOR VETERINARY MADICINE 1.88 0.0043 2.23 0.0042 18.92

31. 30029001 *TOXINS 2.64 0.0060 2.20 0.0042 -16.84

32. 30029002 *MICROBIAL CULTURES 0.05 0.0001 0.01 0.0000 -72.74

33. 30029009 *OTHER BACTERIOLOGICAL PRODUCTS 0.48 0.0011 0.36 0.0007 -24.11

34. 30029019 *OTHR CULTURES OF MICROORGANISMS ETC 0.89 0.0020 1.37 0.0026 53.62


4.71 0.0107 6.31 0.0120 34.11

36. 30032000 MEDICAMENTS CONT. OTHER ANTI-BIOTICS 2.19 0.0050 3.17 0.0060 44.70

37. 30032005 *AMIKACIN 0.06 0.0001 0.01 0.0000 -90.25

38. 30032019 *OTHERS ANTIBIOTICS (OTHER THAN HEADING NO. 300310 ) 4.34 0.0099 15.78 0.0299 263.81

39. 30033100 MEDICAMENTS CONTAINING INSULIN 0.12 0.0003 0.10 0.0002 -9.96


- 212 -


16. 30022001 *VACCINES FOR CHOLERA 5.63 0.0129 3.09 0.0059 -45.14

17. 30022002 *VACCINES FR DPTHRA(DPTHRA TXD-FT,APT ETC 6.95 0.0158 6.47 0.0123 -6.92

18. 30022003 *VACCINES FOR POLIO 0.27 0.0006 0.02 0.0000 -92.97

19. 30022004 *MIXED VACCINES FR T.A.B. OR T.A.B.C. 0.25 0.0006 0.00 0.0000 -99.03


21. 30022006 *VACCINES FOR TUBERCULINS(B.C.G.) 0.01 0.0000 0.12 0.0002 2,149.34

22. 30022008 *MIXED VACCINES FOR DPT-TRIPLE ANTI GEN 5.31 0.0121 5.08 0.0096 -4.31

23. 30022011 VACCINES FOR CHOLERA AND TYPHOID 15.81 0.0361 20.99 0.0398 32.78



26. 30022014 VACCINES FOR POLIO 0.00 0.0000 0.01 0.0000 642.59


28. 30022016 ANTI RABIES VACCINE 0.03 0.0001 0.38 0.0007 1,115.61



31. 30029001 *TOXINS 2.64 0.0060 2.20 0.0042 -16.84





4.71 0.0107 6.31 0.0120 34.11


37. 30032005 *AMIKACIN 0.06 0.0001 0.01 0.0000 -90.25

38. 30032019 *OTHERS ANTIBIOTICS (OTHER THAN HEADING NO. 300310 ) 4.34 0.0099 15.78 0.0299 263.81



42.52 0.0970 24.89 0.0472 -41.45


0.02 0.0000 0.30 0.0006 1,268.55

42. 30039001 *AYURVEDIC & UNANI MEDICINES 19.35 0.0441 108.57 0.2059 461.24

43. 30039002 *HOMOEOPATHIC MEDICINE 0.43 0.0010 0.48 0.0009 11.69

44. 30039014 MEDICANTS OF HOMOEOPATHIC SYSTEM 2.56 0.0059 3.39 0.0064 32.39

45. 30039027 *GRIPE WATER 0.14 0.0003 0.05 0.0001 -68.19

46. 30039033 CALCIUM SENNOSIDE 0.31 0.0007 0.44 0.0008 39.53


0.65 0.0015 0.00 0.0000 -99.52

48. 30039038 *MENTHOL CRYSTAL 33.11 0.0756 34.91 0.0662 5.41

49. 30039043 *MLK OF MAGNESIA 0.00 0.0000

50. 30039074 *BOVINE ALBUMIN AND DRUGS OF ANIMAL ORIGIN 0.24 0.0005 0.06 0.0001 -74.58


- 213 -

51. 30039078 *MEDICINAL CASTOR OIL B.P. 0.01 0.0000 0.00 0.0000 -56.46

52. 30039081 *MERBROMIN N.F.12(MERCUROCHROME) 0.01 0.0000 0.08 0.0002 556.54

53. 30039082 *CALCIUM SENNOSIDE 2.50 0.0057 2.37 0.0045 -5.39

54. 30039084 *ALUMINIUM HYDROXIDE GEL 0.32 0.0007 0.48 0.0009 52.42

55. 30039085 *LIGNOCAINE /LIDICAINE 0.13 0.0003 0.10 0.0002 -26.00

56. 30039087 *OTHER ANAESTHETIC AGENTS LIKE KETAMINE,HALOTHINE,THIOPENTANE

0.09 0.0002 0.14 0.0003 59.18

57. 30039088 *ISAFGUL HUSK AND PHYLLIUN HUSK PREPN. 0.08 0.0002 0.02 0.0000 -71.84

58. 30039091 *CETRIMIDE (SAVLON) 0.10 0.0002 0.20 0.0004 95.33

59. 30039092 *CHLOROXYLENOLS (DETTOL) 0.06 0.0001 0.04 0.0001 -32.93


74.14 0.1692 74.21 0.1408 0.10

61. 30041001 *STRPTMYCN & ITS SLTS IN CPSLS INJCTNS ETC 0.72 0.0017 1.59 0.0030 120.08

62. 30041002 *PENICILLIN IN CAPSULES, INJECTIONS ETC. 3.86 0.0088 4.76 0.0090 23.11

63. 30041003 *AMPICILLINE IN CAPSULES, INJECTIONS ETC. 19.55 0.0446 13.58 0.0258 -30.54

64. 30041004 *AMOXYCYLLIN IN CAPSULES, INJECTIONS ETC. 36.24 0.0827 34.60 0.0656 -4.52

65. 30041005 *CLOXACILLIN IN CAPSULES, INJECTIONS ETC. 5.55 0.0127 4.03 0.0076 -27.43

66. 30041006 *AMCLOS IN CAPSULES INJECTIONS ETC. 3.66 0.0083 5.44 0.0103 48.66

67. 30041007 *AMPICILLIN WITH SULBACTUM FORMULATIONS 0.85 0.0019 0.87 0.0017 3.09

68. 30041008 *AMOXYCILLIN WITH CLAVULANIC ACID & PROBENICID PREPNS. 0.35 0.0008 1.36 0.0026 288.40

69. 30041011 *BECAMPICILLIN 0.06 0.0001

70. 30041013 *PEFLOXACIN 0.01 0.0000 0.06 0.0001 608.31

71. 30041014 *OFLOXACIN 0.14 0.0003 0.16 0.0003 11.68

72. 30041015 *LOMEFLOXACIN 0.06 0.0001 0.34 0.0007 433.53

73. 30041016 *ENROFLOXACIN 2.11 0.0048 1.73 0.0033 -17.79

74. 30041017 *GEMFIBROZIL 0.03 0.0001 0.02 0.0000 -29.60

75. 30041019 *OTHERS 12.74 0.0291 8.61 0.0163 -32.39

76. 30042001 *CHLORMPHENICOL CAPSULES, INJECTIONS ETC. 13.34 0.0304 23.86 0.0453 78.93

77. 30042002 *TETRACYLINE IN CAPSULES, INJECTIONS, OINTMENTS ETC. 3.69 0.0084 2.93 0.0056 -20.46

78. 30042003 *ERYTHROMYCIN IN CAPSULES,INJECTIONS, OINTMENTS ETC. 4.73 0.0108 5.48 0.0104 15.99


0.46 0.0010 1.19 0.0023 161.77

80. 30042007 *RIFMPICINE - FORMULATIONS, IN CSPSULES ETC 4.33 0.0099 6.27 0.0119 44.66

81. 30042008 *CEPHALEXIN - FORMULATIONS THEREOF, IN CAPSULES ETC. 28.42 0.0648 33.73 0.0640 18.69

82. 30042011 CEFAZOLIN 10.78 0.0246 15.04 0.0285 39.48

83. 30042012 CEPHALEXIN - FORMULATIONS THEREOF, IN CAPSULES ETC. 1.73 0.0040 1.33 0.0025 -23.10

84. 30042013 CIPROFLOXACINE- IN CAPSUL,TBLTS FORM ETC 1.40 0.0032 1.96 0.0037 40.36

85. 30042014 CEFOXITIN 0.81 0.0019 1.20 0.0023 47.28

86. 30042017 *KANAMYCIN AND ITS SALTS 0.70 0.0016 0.14 0.0003 -80.16

87. 30042018 *CEFACLOR AND ITS SALTS 0.93 0.0021 3.01 0.0057 224.41

88. 30042021 *CEFUROXIME AND ITS SALTS 1.68 0.0038 19.68 0.0373 1,072.36

89. 30042022 *CEFTAZIDIME AND ITS SALTS 0.07 0.0002 0.23 0.0004 207.59


91. 30042024 *CEFIXIME AND ITS SALTS 0.44 0.0010 0.51 0.0010 15.42

92. 30042026 *AMIKACIN AND ITS SALTS 0.01 0.0000 0.13 0.0002 1,627.07

93. 30042027 *NEOMYCIN AND ITS SALTS 0.06 0.0001 0.03 0.0001 -50.11

94. 30042028 *POLYMIXIN !B! AND ITS SALTS 0.10 0.0002 0.13 0.0003 28.70

95. 30042031 NORFLOXACIN 2.42 0.0055 3.83 0.0073 58.34


- 214 -

96. 30042032 NALIDIXIC ACID 0.99 0.0023 0.15 0.0003 -84.89

97. 30042033 CIPROFLOXACIN (FLUOROQUINOLONES) 2.36 0.0054 2.09 0.0040 -11.34

98. 30042034 OFLOXACIN 1.20 0.0027 2.49 0.0047 107.22

99. 30042039 OTHER FLUOROQUINOLONES 19.74 0.0450 24.97 0.0474 26.52

100. 30043103 *INSULIN (HUMAN) INJECTION 0.11 0.0003 0.29 0.0006 155.33

101. 30043104 *INSULIN (BOVINE/PORK) INJECTION 0.01 0.0000

102. 30043109 *INSULIN IN OTHER FORMS 0.02 0.0000 0.05 0.0001 153.93


0.00 0.0000 0.02 0.0000 2,915.01


0.39 0.0009 0.63 0.0012 63.69

105. 30043902 *PREDNISOLONE TABLETS,INJECTIONS ETC. 1.01 0.0023 1.20 0.0023 19.12

106. 30043903 *DXAMTASNE TBLTS ETC INCL EYE/EAR DROPS ETC 2.82 0.0064 2.43 0.0046 -13.94

107. 30043904 *DANAZOL TABLETS, INJECTIONS ETC. 1.21 0.0028 0.78 0.0015 -35.78


0.18 0.0004 0.38 0.0007 110.07


0.00 0.0000 0.01 0.0000 2,293.86


5.48 0.0125 6.33 0.0120 15.42

111. 30043911 PITUITARY HORMONES 0.09 0.0002 0.69 0.0013 711.05

112. 30043912 PREDNISOLONE 0.00 0.0000 0.04 0.0001 1,822.16

113. 30043913 DEXAMETHASONE 0.06 0.0001

114. 30043915 *STANOZOLOL-FORMULATIONS THEREOF IN TABLETS ETC. 0.01 0.0000

115. 30043917 *ETHINYLOESTRADIOL-FORMULATIONS THEREOF IN TABLETS ETC.

0.06 0.0001

116. 30043918 *LYNESTRENOL - FORMULATIONS THEREOF IN TABLETS , INJECTIONS ETC.

0.07 0.0002

117. 30043922 LUTEINISING HORMONE 0.11 0.0003 0.81 0.0015 608.72

118. 30043924 *CLOBETASOLE-FORMULATIONS THEREOF 0.02 0.0000 0.01 0.0000 -16.53

119. 30043925 *FLUCINOLONE-FORMULATIONS THEREOF IN TABLETS,INJECTIONS ETC.

0.03 0.0001 0.00 0.0000 -92.74

120. 30043926 *TRIAMCINOLONE - FORMULATIONS THEREOF IN TABLETS,INJECTIONS ETC.

0.00 0.0000 0.15 0.0003 10,320.59

121. 30043927 *CLOSTEBOL - FORMULATIONS THEREOF IN TABLETS,CAPSULES ETC.

0.00 0.0000

122. 30043928 *FLUTICASONE - FORMULATIONS THEREOF IN TABLETS, CAPSULES ETC.

0.03 0.0001 0.00 0.0000 -91.36

123. 30043933 *OXYTOCIN-FORMULATIONS THEREOF 0.26 0.0006 0.17 0.0003 -35.21

124. 30043934 *CHLORPROPAMIDE- FORMULATIONS THEREOF 0.12 0.0003 0.14 0.0003 16.64

125. 30043935 *TOLBUTAMIDE - FORMULATIONS THEREOF 0.08 0.0002 0.06 0.0001 -29.84

126. 30043936 *PHENFORMIN ; METFORMIN -FORMULATIONS THEREOF 3.50 0.0080 5.93 0.0113 69.57

127. 30043939 *OTHER HORMONES FORMULASTIONS 2.64 0.0060 1.73 0.0033 -34.47


0.65 0.0015 0.50 0.0009 -23.33

129. 30044002 *FORMULATIONS OF CAFFEIN & ITS SALTS 0.94 0.0022 0.06 0.0001 -93.47

130. 30044005 *FORMULATIONS OF EPHEDRINE & PSEUDOEPHEDRINE IN TABLETS, EXPECTORANT PREPN.

1.19 0.0027 1.71 0.0033 43.72

131. 30044007 *FORMULATIONS OF ERGOTPREPARATA, ERGOTAMINE & METHYL ERGOMETRINE IN TABLETS,INJECTIONS ETC.(E.G.METHYL ERGOMET

0.32 0.0007 0.18 0.0003 -44.18

132. 30044013 *FORMULATIONS OF PAPAVERINE HYDROCHLORIDE 0.09 0.0002 0.15 0.0003 62.55


- 215 -

133. 30044015 *FORMULATIONS OF RESERPINE & OTHER RAUWOL FIA ALKALOIDS IN TABLETS ETC.

3.69 0.0084 0.49 0.0009 -86.84

134. 30044017 *FORMULATIONS OF BROMOHEXIN WITH DEXTROMETHORPHAN, PHENYL PROPANALOMINE, DYPHENHYDRAMINE IN EXPECTORANT PREPN.

0.70 0.0016 1.37 0.0026 96.16

135. 30044018 *THEOPHYLLINE, AMINO PHYLLINE & ETOPHYLLINEFORMULATIONS LIKE TABLETS,SYRUP ETC.

0.37 0.0008 0.36 0.0007 -2.22

136. 30044019 *FRMLTNS OF OTHR VGTBL ALKLDS & ITS DRVTVS 1.01 0.0023 0.89 0.0017 -11.78

137. 30044021 *ISOPRENALINE-FORMULATIONS THEREOF IN TABLETS, INJECTION ETC.

0.03 0.0001 0.00 0.0000 -93.89

138. 30044022 *TRIPOLINE-FORMULATIONS THEREOF 0.03 0.0001

139. 30044023 *PHENIRAMINE MALEATE (AVIL) - FORMULATIONS THEREOF IN TABLETS, OINTMENTS ETC.

0.05 0.0001 0.01 0.0000 -81.68

140. 30044024 *TERBUTALINE - FORMULATIONS THEREOF IN INJECTIONS ETC. 0.01 0.0000 0.00 0.0000 -55.42

141. 30044025 *LORATADINE -FORMULATIONS THEREOF 1.01 0.0023 1.10 0.0021 8.28

142. 30044026 *CETIRAZINE-FORMULATIONS THEREOF 0.61 0.0014 0.50 0.0010 -17.40

143. 30044027 *TERFENADINE-FORMULATIONS THEREOF 0.11 0.0003 0.00 0.0000 -97.14

144. 30044028 *ASTEMIZOLE-FORMULATIONS THEREOF 0.01 0.0000 0.01 0.0000 -12.52

145. 30044031 *TIMOLOL MALEATE-FORMULATIONS THEREOF 0.03 0.0001 0.06 0.0001 62.19

146. 30044033 *ACETAZOLAMIDE -FORMULASTIONS THEREOF 0.02 0.0000 0.00 0.0000 -95.70

147. 30044039 *OTHERS 1.52 0.0035 2.50 0.0047 65.01

148. 30045001 *APPETITE STIMULANTS BASED ON CIPROHEPTADINE,AMINO ACIDS ETC.

2.50 0.0057 2.34 0.0044 -6.04


1.32 0.0030 1.69 0.0032 28.09

150. 30045003 *MINERAL & PARENTERAL NUTRITIONAL SPPLMNTS/CONTNG CALSIUM SLTS WTH VTMN IN TABLTS ETC

0.46 0.0010 0.33 0.0006 -28.09

151. 30045004 *TABLETS,CAPSULES,SYRUP ETC OF VITAMIN A INCLD) EXCEPT SALVES OINIMNTS & VACCINES

1.02 0.0023 0.65 0.0012 -36.29

152. 30045005 *TABLETS,CAPSULES ETC OF VITAMIN "B" GROUP 2.47 0.0056 3.44 0.0065 39.46


0.50 0.0011 0.46 0.0009 -8.07

154. 30045007 *VITAMIN 'D' IN TABLETS, CAPSULES, SYRUP ET 0.16 0.0004 0.41 0.0008 150.32

155. 30045008 *MULTIVITAMINS CONTAINING VITAMIN A, B-GR. C,D OR NY TWO OF THESE IN TABS, CAPS, INJECTIBLES, ETC

5.59 0.0127 3.12 0.0059 -44.12

156. 30045012 *VITAMIN E IN CAPS.TABS,SYRUP ETC 1.09 0.0025 3.43 0.0065 213.10

157. 30045013 *OTHER AMINO ACID/ PROTEIN PREPN. WITH / WITHOUT VITAMINS,SPIRULINA & THE LIKE.

1.70 0.0039 2.17 0.0041 27.55

158. 30045014 *TONICS , BASED ON VITAMINS GLYCEROPHOS PHATES, GINSENG PREPN.

0.69 0.0016 0.86 0.0016 24.45

159. 30045016 *FOLIC ACID AND NIACINAMIDE (VITAMIN"B9") IN TABLETS AND OTHER FORMULATIONS WITH /WITHOUT OTHER ADDITIVES.

0.97 0.0022 0.70 0.0013 -28.15

160. 30045017 *HEPATO BILARY PREPARATIONS LIKE - L ASPERTATE. 0.01 0.0000

161. 30045019 *OTHERS PUT UP FOR RETAIL SALE 33.96 0.0775 44.73 0.0848 31.72

162. 30049001 *AYURVEDIC & UNANI MEDCNS 30.93 0.0706 45.13 0.0856 45.91

163. 30049002 *HOMEOPATHIC MEDICINE 0.78 0.0018 1.22 0.0023 55.21


3.75 0.0086 5.35 0.0101 42.65


0.92 0.0021 2.15 0.0041 134.37

166. 30049005 *PARACETAMOL PANDOL ETC IN TBLTS SYRUP ETC 21.16 0.0483 23.55 0.0447 11.26


5.46 0.0125 8.21 0.0156 50.37

168. 30049007 *IBUPROFEN WTH/WTHOUT OTHR CMPND IN TABS ETC 8.74 0.0199 13.34 0.0253 52.63


- 216 -

169. 30049008 *OXYPHN/PHENYL BUTAZON IN TBS, CPSLS ETC 0.45 0.0010 0.36 0.0007 -19.38

170. 30049011 MEDICAMENTS OF AYURVEDIC SYSTEM 8.22 0.0188 9.75 0.0185 18.58

171. 30049012 MEDICAMENTS OF UNANI SYSTEM 0.38 0.0009 0.52 0.0010 36.30

172. 30049013 MEDICAMENTS OF SIDDHA SYSTEM 0.80 0.0018 0.28 0.0005 -65.40

173. 30049014 HOMEOPATHIC MEDICINE 2.25 0.0051 2.23 0.0042 -0.88

174. 30049015 MEDICAMENTS OF BIO-CHEMIC SYSTEM 0.26 0.0006 0.46 0.0009 80.84

175. 30049016 *TRIMETHOPRIM - FRMLTNS THROF IN TBLTS ETC 0.63 0.0014 0.57 0.0011 -9.31


5.74 0.0131 7.13 0.0135 24.24

177. 30049018 *CEFADR0XYL IN CAPSULES,INJECTI0NS ETC. 1.57 0.0036 1.65 0.0031 5.35

178. 30049021 ANTHELMINTICS AND PREPARATIONS THEREOF 0.41 0.0009 1.66 0.0032 308.21


10.88 0.0248 9.88 0.0187 -9.22


2.05 0.0047 1.61 0.0031 -21.53

181. 30049024 SECNIDAZOLE 3.07 0.0070 1.89 0.0036 -38.43

182. 30049025 DILUXAMIDE FUROATE 0.10 0.0002 0.40 0.0008 290.92

183. 30049026 SODIUM STIBOGLUCONATE 1.41 0.0032 1.74 0.0033 22.82

184. 30049027 PENTAMIDINE 4.02 0.0092 3.58 0.0068 -10.94

185. 30049028 *OTHER ANTI-TUBERCULOUS FORMULATIONS- IN TABLETS ETC. OF PYRAZINAMIDE,THIACETAZONE, ISONIAZIDE,ETC.(EXCLUDING REFAMPICIN)

4.15 0.0095 3.89 0.0074 -6.34

186. 30049031 PROMETHAZINE, CHLORPHENIRAMINE, ASTEMIZOLE AND CETEIRIZINE

4.74 0.0108 3.38 0.0064 -28.59

187. 30049032 SODIUM BICARBONAT, MAGNSM HYDROXID, MAGNSMCARBONAT,MAGNSIUM TRISILICAT, ALUMINIUM HYDROXIDE GEL,MAGALDARATE & COMB. THEREOF

1.06 0.0024 1.28 0.0024 21.21

188. 30049034 OMEPRAZOLE AND LANSOPRAZOLE 3.41 0.0078 4.55 0.0086 33.69

189. 30049035 DICYCLOMINE, METOCLOPRAMIDE AND DEXAME THASONE AND ONDANSETRON

1.81 0.0041 3.33 0.0063 84.11

190. 30049036 CHENODIOL AND URSODIOL 0.80 0.0018 1.83 0.0035 127.62

191. 30049037 *ALUMINIUM HYDROXIDE GEL IN TBLTS, LQD ETC WTH MAG HYDRX & MG TRISILICTE ETC IN TABLTS LIQUID ETC

0.73 0.0017 0.97 0.0018 31.90

192. 30049038 *OTHER ANTACID ETC. 2.69 0.0061 0.92 0.0017 -65.86

193. 30049041 CYCLOPHOSPHAMIDE 0.96 0.0022 0.93 0.0018 -3.40

194. 30049042 METHOTREXATE, 5-FLUOROURACIL(5-FU) AND FTORAFUR 18.35 0.0419 21.45 0.0407 16.89

195. 30049043 BINCRISTINE AND VINBLASTINE 1.27 0.0029 0.88 0.0017 -31.27

196. 30049044 PACLITAXEL AND DOCETAXEL 0.06 0.0001 0.11 0.0002 92.76

197. 30049045 ETOPOSIDE 6.14 0.0140 3.91 0.0074 -36.39

198. 30049046 ACTINOMYCIN D DACTINOMYCIN AND DOXORUBICIN 0.32 0.0007 0.39 0.0007 21.56

199. 30049047 L-ASPARAGINASE, CISPLATIN AND CARBOPLATIN 0.11 0.0003 0.12 0.0002 8.27

200. 30049048 TAMOXIFEN 0.24 0.0005 0.07 0.0001 -70.94

201. 30049051 ISONIAZID 0.21 0.0005 0.24 0.0005 13.94

202. 30049052 RIFAMPICIN 0.10 0.0002 0.13 0.0003 29.03

203. 30049053 PYRAZINAMIDE AND ETHAMBUTOL 0.20 0.0005 1.14 0.0022 462.70

204. 30049054 STREPTOMYCIN 3.54 0.0081 3.84 0.0073 8.37


0.07 0.0002 0.20 0.0004 186.85


- 217 -

206. 30049056 CHLOROQUINE, AMODIAQUINE, MEFLOQUINE, QUININE, CHLOROGUAMIDE, PYRIMETHAMINE

1.47 0.0033 1.85 0.0035 26.03

207. 30049057 OTHER ANTITUBERCULAR DRUGS 0.13 0.0003 0.09 0.0002 -35.24

208. 30049058 OTHER ANTILEPROTIC DRUGS 0.17 0.0004 0.12 0.0002 -28.97


2.07 0.0047 2.17 0.0041 4.92


3.01 0.0069 3.22 0.0061 7.19


0.10 0.0002 1.35 0.0026 1,226.47


0.03 0.0001 0.05 0.0001 79.53

213. 30049065 INDOMETHACIN 1.37 0.0031 1.43 0.0027 4.08

214. 30049066 MEPHENAMIC ACID, DACTOFENAC SODIUM, PIROXICAM, TENOXICAM AND MELOXICAM

2.40 0.0055 3.51 0.0067 46.00

215. 30049067 KETOROLAC, NIMESULIDE, NABUMETONE AND NEFOPAM 0.13 0.0003 2.47 0.0047 1,783.68

216. 30049072 VERAPAMIL, NIFEDIPINE, AMLODIPINE AND LACIDIPINE 3.26 0.0074 2.91 0.0055 -10.77

217. 30049073 LOSARTAN 0.07 0.0002 0.10 0.0002 44.32

218. 30049074 PROPRANOLOL, METOPROLOL, ATENOLOL AND LABETALOL

0.11 0.0003 0.33 0.0006 193.36

219. 30049075 PRAZOSIN, TERAZOSIN, PHENTOLAMINE AND PHENOXYBENZAMINE

2.90 0.0066 2.00 0.0038 -30.94

220. 30049076 CLONIDINE, METHYLDOPA 0.32 0.0007 0.11 0.0002 -65.36

221. 30049077 HYDRALAZINE, MINOXIDIL AND DIAZOXIDE 0.04 0.0001 0.01 0.0000 -82.51

222. 30049078 *OTHER SALINE WATER 0.27 0.0006 0.29 0.0006 9.47

223. 30049081 PHENOBARBITONE,MEPHOBARBITONE,PRIMIDONE, PHENYTOIN,CARBAMAZPIN,ETHOSUCIMID,VALPORICACID ,DIAZEPA,LAMOTRIGIN,GABAPENTIN ETC

5.05 0.0115 4.77 0.0090 -5.61

224. 30049082 OTHER ANTIEPILEPTIC DRUGS 0.01 0.0000 0.02 0.0000 157.81

225. 30049083 SULPHA DRUGS NOT ELSEWHERE SPECIFIED 0.94 0.0021 1.33 0.0025 41.96

226. 30049084 PREPARATIONS OF ENZYMES 0.01 0.0000 0.34 0.0006 5,511.56

227. 30049085 VETERINARY MEDICINAL PREPARATIONS N.E.S. 0.59 0.0013 0.46 0.0009 -22.20

228. 30049086 ORAL REHYDRATION SALTS 2.71 0.0062 5.97 0.0113 120.55

229. 30049087 ANTIBACTERIAL FORMULATIONS, N.E.S. 0.03 0.0001 0.18 0.0003 416.47


0.86 0.0020 1.40 0.0027 62.06

231. 30049092 PLASMA EXPANDERS 0.43 0.0010 0.13 0.0002 -70.24

232. 30049093 CHLOROPHENIRAMINE MALEATE, WITH OR WITHOUTOTHER COMPOUNDS (EXCL. STERIODS&ALKALOIDS)

0.33 0.0008 0.87 0.0016 159.51

233. 30049094 THEOPHYLLINE, AMINOPHYLLINE AND OTHER BRONCHO DILATORS

0.38 0.0009 0.38 0.0007 -1.57

234. 30049095 CARCINO-CHEMOTHERAPEUTIC DRUGS N.E.S. 0.04 0.0001 0.01 0.0000 -70.10

235. 30049096 *CLOTRIMAZOLE - FORMULATIONS THEREOF 0.59 0.0013 0.79 0.0015 34.09

236. 30049097 *SINVASTATIN; LOVASTATIN, ATORVASTATIN. 1.92 0.0044 4.38 0.0083 128.32

237. 30049099 OTHER MEDCNE PUT UP FOR RETAIL SALE N.E.S 313.96 0.7164 456.98 0.8668 45.56

238. 30051001 *ADHESIVE GAUZE BANDAGE 0.82 0.0019 0.76 0.0014 -6.79

239. 30051002 *ADHESIVE TAPE (MEDICINAL) 0.35 0.0008 0.30 0.0006 -13.72

240. 30051003 *PLASTER OF PARIS (SURGICAL) 1.08 0.0025 1.42 0.0027 31.22

241. 30051009 *OTHER BANDAGES 2.44 0.0056 3.00 0.0057 23.09

242. 30059001 *COTTON WOOL MEDICATED 1.12 0.0026 0.85 0.0016 -23.52

243. 30059002 *POULTICE OF KAOLIN 0.23 0.0005 0.44 0.0008 94.43

244. 30059003 *MEDICATED LINT 2.41 0.0055 1.84 0.0035 -23.36


- 218 -

245. 30059004 *BANDAGES WITHOUT ADHESIVE LAYER 1.24 0.0028 1.52 0.0029 22.59


2.42 0.0055 2.94 0.0056 21.41


0.19 0.0004 0.14 0.0003 -24.23

248. 30062000 BLOOD-GROUPING REAGENTS 0.03 0.0001 0.18 0.0003 451.24

249. 30063000 OPACIFYING PRPNS FR X-RAY EXAMS;DIAGNOSTICREAGNTS DSGND TO BE ADMNSTRD TO PATIENT BE ADMINISTERED TO THE PATIENT

0.04 0.0001 0.15 0.0003 290.53


2.13 0.0049 2.71 0.0051 27.30

251. 30065000 FIRST-AID BOXES AND KITS 0.32 0.0007 0.45 0.0009 42.57


4.40 0.0100 4.37 0.0083 -0.73

India's Total Export 43,826.73 52,719.43 20.29 Exchange rate: 2001-2002: 1US$ = Rs. 47.6919 2002-2003 : 1US$ = Rs. 48.3953


- 219 -



Sorted on HSCode



2003 %Share %Growth

1. 300110 GLNDS & OTHR ORGNS DRIED W/N PWDRDED 6.64 0.0151 6.48 0.0123 -2.42

2. 300120 EXTRCTS OF GLNDS/OTHR ORGNS/OF THR SECRTNS

0.39 0.0009 0.39 0.0007 -0.69

3. 300190 HEPARIN SLTS;OTHR HUMAN/ANML SUBSTNS FR THRUPTC/PROPHYLACTIC USE NES

0.57 0.0013 1.01 0.0019 75.67

4. 300210 ANTSRA & OTHR BLD FRCTN;MDFD IMUNLGCL PRDTS W/N BY BITECHNOLGCL PRCES

2.87 0.0066 3.30 0.0063 14.92

5. 300220 VACCINES FOR HUMAN MEDICINE 51.35 0.1172 66.04 0.1253 28.61


7. 300290 TOXNS,CULTURS OF MICRORGNSM & SMLR PRODTS

4.07 0.0093 3.95 0.0075 -2.92


4.71 0.0107 6.31 0.0120 34.11




42.52 0.0970 24.89 0.0472 -41.45


0.02 0.0000 0.30 0.0006 1,268.55

13. 300390 OTHR MEDICANTS(EXCL HEADNG 3002,3005,3006)FOR THERAPEUTIC PROPHYLACTIC USES NOT PUT UP FOR RETAIL SALE

134.24 0.3063 225.55 0.4278 68.03

14. 300410 MDCMNTS CNTNG PENCLLNS/DRVTVS THROF WTH A PENCLLNC ACID STRCTR/STRPTMYCNS OR THR DERVTVS PUT UP FOR RTL SALE

85.88 0.1960 77.23 0.1465 -10.07

15. 300420 MEDICAMENTS CONTAINING OTHER ANTIBIOTICS AND PUT UP FOR RETAIL SALE

100.98 0.2304 150.56 0.2856 49.09

16. 300431 MEDICAMENTS CONTAINING INSULIN 0.13 0.0003 0.35 0.0007 162.65


0.00 0.0000 0.02 0.0000 2,915.01

18. 300439 OTHR PRPNS CNTNG HORMONES/OTHR PRDCTS OF HDGN. 2937 BUT NOT CONTNG ANTIBIOTICS

18.11 0.0413 21.56 0.0409 19.09

19. 300440 MDCAMNTS CNTNG ALKLDS/DRVTVS THEREOF BUT NOT CONTNG HRMNS OTHR PRDCTS OF HDG 2937

12.40 0.0283 9.90 0.0188 -20.18

20. 300450 OTHER MDCMNTS CNTNG VITAMINS/OTHER PRODUCTS OF HEADING NO 2936 PUT UP FOR RETAIL SALE

52.44 0.1197 64.33 0.1220 22.67

21. 300490 OTHER MEDCNE PUT UP FOR RETAIL SALE 510.66 1.1652 696.23 1.3206 36.34

22. 300510 ADHESIVE DRSSNGS & OTHR ARTCLS HAVING AN ADHESIVE LAYER

4.69 0.0107 5.48 0.0104 17.05

23. 300590 OTHER DRESSING ARTICLES 4.99 0.0114 4.66 0.0088 -6.64

24. 300610 STERILE SURGCL ETC FR SURGCL WOUND CLOSURESTERILE LAMINARIA ETC STERILE ABSRBLE SURGICAL OR DENTAL HAEMOSTATICS

2.61 0.0060 3.09 0.0059 18.10



- 220 -


0.04 0.0001 0.15 0.0003 290.53


2.13 0.0049 2.71 0.0051 27.30

28. 300650 FIRST-AID BOXES AND KITS 0.32 0.0007 0.45 0.0009 42.57

29. 300660 CHMCL CONTRACEPTIVE PRPNS BASED ON HORMONES/SPERMISIDES

4.40 0.0100 4.37 0.0083 -0.73



- 221 -



Sorted on HSCode



2003 %Share %Growth


2. 290121 UNSATURATED ETHYLENE 0.02 0.0000


4. 290123 UNSTRD BUTENE (BUTYLENE)& ISOMERS THEREOF 0.01 0.0000 0.01 0.0000 2.36

5. 290124 UNSTRD BUTS-1 3-DIENE AND ISOPRENE 0.00 0.0000 0.02 0.0000 4,817.49

6. 290129 OTHER ACYCLIC HYDROCARBONS 0.57 0.0013 2.50 0.0047 342.28

7. 290211 CYCLOHEXANE 0.07 0.0002 0.00 0.0000 -93.56


9. 290220 BENZENE 14.89 0.0340 32.25 0.0612 116.62

10. 290230 TOLUENE 0.46 0.0011 1.48 0.0028 220.98

11. 290241 O-XYLENE 0.66 0.0015 2.58 0.0049 290.74

12. 290242 M-XYLENE 0.94 0.0021 1.46 0.0028 54.95

13. 290243 P-XYLENE 0.67 0.0015 47.18 0.0895 6,959.65

14. 290244 MIXED XYLENE ISOMERS 0.32 0.0007 2.41 0.0046 662.63

15. 290250 STYRENE 0.63 0.0014 0.63 0.0012 -0.19

16. 290260 ETHYLBENZENE 0.00 0.0000 0.55 0.0010 12,932.45

17. 290290 OTHER CYCLIC HYDROCARBONS 2.13 0.0048 1.91 0.0036 -10.14

18. 290311 SATURATED CHLOROMTHN(MTHYL CHLRD) & CHLOROETHANE (ETHYL CHLORIDE)

1.80 0.0041 1.36 0.0026 -24.07


20. 290313 CHLOROFORM (TRICHLOROMETHANE) 3.24 0.0074 1.91 0.0036 -41.01


22. 290315 1,2 DICHLOROMETHANE (CETHYLNE DICHLORIDE) 0.05 0.0001

23. 290316 *1,2-DICHLOROPROPANE (PROPYLENE DICHLORIDE)AND DICHLOROBUTANES,SATURATED

0.03 0.0001 0.15 0.0003 364.13

24. 290319 OTHER CHLOROMETHANE & CHLOROETHANE 1.41 0.0032 3.63 0.0069 158.05

25. 290321 VINYL CHLORIDE (CHLOROETHYLENE),UNSTRTD 0.12 0.0003


- 222 -

26. 290322 TRICHLOROETHYLENE,UNSATURATED 0.00 0.0000

27. 290323 TETRACHLOROETHANE (PERCHLOROETHYLENE ) , UNSATRTD 0.01 0.0000


0.65 0.0015 0.59 0.0011 -8.24

29. 290330 FLUORNTD,BRMNTD/IODINATED DERIVATIVES OF ACYCLIC HYDROCARBONS

0.81 0.0019 0.29 0.0006 -63.71


31. 290342 DICHLORO DIFLUORO ETHANE 21.22 0.0484 22.06 0.0418 3.97



0.38 0.0009 0.49 0.0009 28.17


2.35 0.0054 2.90 0.0055 23.38


0.02 0.0000 0.08 0.0001 284.20


37. 290349 OTHERDICHLOROTETRAFLUOROETHANE ETC 3.70 0.0085 5.72 0.0108 54.32


39. 290359 OTHR HALOGNTD DRVTVS OF CYCLANIC,CYCLENIC 0.55 0.0013 0.68 0.0013 23.21

40. 290361 CHLOROBENZENE O-DICHLOROBENZENE AND P-DICHLOROBENZENE 1.39 0.0032 1.70 0.0032 22.10


0.82 0.0019 1.81 0.0034 121.26

42. 290369 OTHR HALGNTD DRVTVS OF ARMTC HYDROCARBON 2.59 0.0059 4.68 0.0089 80.98


35.11 0.0801 47.44 0.0900 35.10

44. 290420 DRVTVS CNTNG ONLY NITRO/NITROSO GRPS 1.72 0.0039 2.04 0.0039 18.16

45. 290490 OTHR SULPHONTD NITRTD/NITRSTD DRVTVS 9.42 0.0215 17.32 0.0329 83.84

46. 290511 SATURATED METHANOL (METHYL ALCOHOL) 0.28 0.0006 0.12 0.0002 -55.38

47. 290512 SATURATED PROPAN-1OL(PROPYL ALCOHOL) AND PROPAN-2-OL (ISOPROPYL ALCOHOL)

0.04 0.0001 0.03 0.0001 -14.03

48. 290513 SATURATED BUTAN-1-OL(N-BUTYL ALCOHOL) 0.02 0.0000 0.03 0.0001 71.11

49. 290514 OTHER SATURATED BUTANOLS 10.98 0.0250 13.69 0.0260 24.73

50. 290515 SATURTD PENTANOL(AMYL ALCHL) & SMRS THEROF 0.04 0.0001

51. 290516 SATRTD OCTNL(OCTYL ALCHL)& ISMRS THEREOF 0.11 0.0002 0.42 0.0008 287.36


10.22 0.0233 11.81 0.0224 15.52

53. 290519 OTHR SATURTED MONOHYDYDRIC ALCHOL 0.24 0.0005 0.56 0.0011 137.41

54. 290522 UNSATURATD ACYCLIC TERPENE ALCOHOLS 0.01 0.0000 0.02 0.0000 34.85

55. 290529 OTHER UNSATURATED MONOHYDRIC ALCOHOLS 0.02 0.0000 0.09 0.0002 350.05

56. 290531 ETHYLENE GLYCOL (ETHANEDIOL) 6.08 0.0139 2.74 0.0052 -54.92


58. 290539 OTHER DIOLS 7.52 0.0172 1.48 0.0028 -80.32


0.09 0.0002 0.07 0.0001 -24.26

60. 290542 PENTAERYTHRITOL 1.53 0.0035 1.11 0.0021 -27.57

61. 290543 MANNITOL 0.01 0.0000 0.04 0.0001 201.21


63. 290545 GLYCEROL 5.10 0.0116 4.07 0.0077 -20.27



0.11 0.0002 0.15 0.0003 34.27


- 223 -

66. 290611 MENTHOL 44.85 0.1023 45.35 0.0860 1.11

67. 290612 CYCLHXNL MTHYLCYCLHXNLS&DIMTHYL CYCLHXNLS 0.03 0.0001 0.14 0.0003 398.64

68. 290613 STEROLS AND INOSITOLS 0.01 0.0000

69. 290614 TERPINEOLS 0.00 0.0000 0.05 0.0001 5,660.96

70. 290619 OTHR CYCLNIC,CYCLENIC/CYCLOTRPNC ALCHLS 0.31 0.0007 0.07 0.0001 -77.21

71. 290621 BENZYL ALCOHOL 0.20 0.0005 0.17 0.0003 -17.94

72. 290629 OTHER AROMATIC ALCOHOL 4.11 0.0094 4.54 0.0086 10.34

73. 290711 PHENOL (HYDROXYBENZENE) AND ITS SALTS 0.73 0.0017 0.49 0.0009 -33.46

74. 290712 CRESOLS AND THEIR SALTS 2.68 0.0061 3.19 0.0061 19.25

75. 290713 OCTYLPHNL NONYLPHNL & THR ISOMERS,SALTS 0.25 0.0006 0.30 0.0006 16.72


77. 290715 NAPHTHOLS AND THEIR SALTS 0.40 0.0009 0.58 0.0011 45.03

78. 290719 OTHER MONOPHENOLS 1.43 0.0033 2.96 0.0056 107.39

79. 290721 RESORCINOL AND ITS SALTS 0.17 0.0004 0.01 0.0000 -94.21



2.63 0.0060 0.74 0.0014 -71.87

82. 290729 OTHER POLYPHENOLS 9.14 0.0209 8.47 0.0161 -7.42

83. 290730 *PHENOL-ALCOHOLS 0.22 0.0005 0.06 0.0001 -72.70


85. 290820 DRVOVS CNTNG OLLYSULPHO GROUPS,THEIR SALTS & ESTERS 3.13 0.0071 2.03 0.0039 -35.06


2.65 0.0061 3.49 0.0066 31.68

87. 290911 DIETHYL ETHER 0.06 0.0001 0.12 0.0002 86.53


1.07 0.0024 1.62 0.0031 51.94


0.01 0.0000 0.05 0.0001 361.60


2.15 0.0049 2.00 0.0038 -7.32



1.14 0.0026 0.06 0.0001 -95.10


0.00 0.0000 0.11 0.0002 2,352.04


0.42 0.0009 1.18 0.0022 182.45


0.98 0.0022 1.19 0.0023 22.24

96. 290950 ETHR-PHNLS,ETHR-ALCHL-PHNLS & THR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS

0.30 0.0007 0.63 0.0012 112.36


0.43 0.0010 2.01 0.0038 372.07

98. 291010 OXIRANE (ETHYLENE OXIDE) 0.03 0.0001 0.06 0.0001 93.11

99. 291020 METHYLOXIRANE (PROPYLENE OXIDE) 0.00 0.0000




1.95 0.0044 3.04 0.0058 56.16

103. 291211 METHANAL (FORMALDEHYDE) 0.55 0.0013 0.63 0.0012 14.16


105. 291213 BUTANOL (BUTYRALDEHYDE,NORMAL ISOMER) 0.00 0.0000 0.00 0.0000 216.65


- 224 -

106. 291219 OTHR ACYCLIC ALDHYDS WTHOUT OXYGEN FNCTN 0.35 0.0008 0.80 0.0015 132.04

107. 291221 BENZALDEHYDE 8.71 0.0199 15.86 0.0301 82.08

108. 291229 OTHR CYCLC ALDHYDS WTHOUT OTHR OXYGN FNCTN 2.95 0.0067 1.86 0.0035 -37.09

109. 291230 ALDEHYDE-ALCOHOLS 0.01 0.0000 0.07 0.0001 506.50



112. 291249 OTHR ALDHYD-ETHR,ALDHYD-PHNL& OTHR ALDHYD 9.39 0.0214 11.24 0.0213 19.76

113. 291250 CYCLIC POLYMERSOF ALDEHYDES 0.20 0.0005 0.04 0.0001 -82.06

114. 291260 PARA FORMALDEHYDE 0.04 0.0001 0.01 0.0000 -74.42


0.63 0.0014 0.80 0.0015 26.49

116. 291411 ACETONE 0.63 0.0014 0.44 0.0008 -30.93



119. 291419 OTHR ACYLC KETONES WTHOUT OTHR OXYGN FNCTN 3.43 0.0078 8.44 0.0160 145.93

120. 291421 CAMPHOR 0.18 0.0004 0.33 0.0006 83.03


122. 291423 IONONES AND METHYLIONONES 1.29 0.0029 0.83 0.0016 -35.94


0.28 0.0006 0.21 0.0004 -26.17

124. 291431 PHENYLACETONE 0.05 0.0001 0.07 0.0001 40.57

125. 291439 OTHR ARMTC KETONES WTHOUT OTHR OXYGEN FUNCTION 1.05 0.0024 0.80 0.0015 -23.53



128. 291461 ANTHRAQUINONE 0.01 0.0000

129. 291469 OTHER QUINONES 0.29 0.0007 0.15 0.0003 -48.84


7.89 0.0180 5.28 0.0100 -33.05

131. 291511 FORMIC ACID 0.06 0.0001 0.42 0.0008 665.98

132. 291512 SALTS OF FORMIC ACID 0.11 0.0003 0.10 0.0002 -7.36


134. 291521 ACETIC ACID 5.17 0.0118 6.40 0.0121 23.73

135. 291522 SODIUM ACETATE 0.26 0.0006 0.26 0.0005 -2.23

136. 291523 COBALT ACETATES 0.00 0.0000

137. 291524 ACETIC ANHYDRIDE 0.03 0.0001 0.02 0.0000 -49.69

138. 291529 OTHR ACETIC ACID & ITS SLTS 1.26 0.0029 0.81 0.0015 -35.66

139. 291531 ETHYL ACETATE 6.27 0.0143 19.57 0.0371 212.17

140. 291532 VINYL ACETATE 0.15 0.0003 0.15 0.0003 2.05

141. 291533 N-BUTYL ACETATE 0.02 0.0000 0.04 0.0001 131.43



144. 291539 OTHER ESTERS OF ACETIC ACID 7.92 0.0181 9.09 0.0172 14.84

145. 291540 MONO-DI/TRCHLRACTC ACD,THR SLTS & ESTRS 3.64 0.0083 1.47 0.0028 -59.74


147. 291560 BUTYRIC ACDS,VALERIC ACDS THR SLTS & ESTRS 0.05 0.0001 0.13 0.0003 169.54

148. 291570 PALMTC ACID,STEARIC ACID THR SLTS & ESTRS 11.63 0.0265 11.37 0.0216 -2.26

149. 291590 OTHR SATRTD ACYLC,MNOCRBOXYLC ACDS & THR ANHYDRDS,HALDS,PEROXDS,PEROXY ACIDS & THR HALGNTD SLPHNTD NITRTD & NITRSTD DRVTVS

7.64 0.0174 4.37 0.0083 -42.78


- 225 -


151. 291612 ESTERS OF ACRYLIC ACID 0.68 0.0015 0.44 0.0008 -34.64

152. 291613 METHACRYLIC ACID AND ITS SALTS 0.02 0.0000 0.08 0.0002 445.15

153. 291614 ESTERS OF METHACRYLIC ACID 0.05 0.0001 0.09 0.0002 66.58

154. 291615 OLEIC LINOLC/LINOLNC ACDS,THR SLTS & ESTRS 0.05 0.0001 0.01 0.0000 -76.14

155. 291619 OTHR UNSATRTD ACYCLC,MONOCRBOXYLC ACDS, THR ANHYDRDS, HALIDES ETC THR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS

2.34 0.0053 2.57 0.0049 9.73


0.34 0.0008 0.41 0.0008 20.18

157. 291631 BENZOIC ACID ITS SALTS AND ESTERS 6.73 0.0153 6.85 0.0130 1.88

158. 291632 BENZYL PEROXYD & BENZOYL CHLRD 0.41 0.0009 0.17 0.0003 -58.30

159. 291634 PHENYLACETIC ACID & ITS SALTS 0.00 0.0000 0.20 0.0004 6,402.36



2.30 0.0052 6.08 0.0115 164.16

162. 291711 OXALIC ACID ITS SALTS AND ESTERS 2.71 0.0062 3.42 0.0065 26.50

163. 291712 ADIPIC ACID ITS SALTS AND ESTERS 0.00 0.0000 0.11 0.0002 7,271.49


165. 291714 MALEIC ANHYDRIDE 0.53 0.0012 0.65 0.0012 22.15

166. 291719 OTHR ACYLC PLYCRBOXYLC ACDS THR ANHYDRDS HALIDES,PEROXIDES,PEROXYACDS & THR DRVTVS

4.57 0.0104 4.61 0.0087 0.81


3.58 0.0082 0.01 0.0000 -99.86

168. 291731 DIBUTYL ORTHOPHTHALATES 0.00 0.0000 0.03 0.0001 483.90

169. 291732 DIOCTYL ORTHOPHTHALATES 0.01 0.0000 0.00 0.0000 -81.03

170. 291733 DINONYL OR DIDECYL ORTHOPHTHALATES 0.02 0.0000

171. 291734 OTHER ESTERS OF ORTHOPHTHALIC ACID 0.00 0.0000



174. 291737 DIMETHYL TEREPHTHALATE 0.97 0.0022 7.55 0.0143 677.63


20.26 0.0462 10.92 0.0207 -46.10

176. 291811 LACTIC ACID ITS SALTS AND ESTERS 1.54 0.0035 1.02 0.0019 -33.82

177. 291812 TARTARIC ACID 0.76 0.0017 0.23 0.0004 -69.69

178. 291813 SALTS AND ESTERS OF TARTARIC ACID 0.65 0.0015 1.15 0.0022 76.29

179. 291814 CITRIC ACID 0.05 0.0001 0.60 0.0011 1,120.14

180. 291815 SALTS AND ESTERS OF CITRIC ACID 1.24 0.0028 1.57 0.0030 27.32

181. 291816 GLUCONIC ACID ITS SALTS AND ESTERS 3.90 0.0089 3.43 0.0065 -11.95

182. 291817 *PHENYLGLYCOLIC ACID(MANDELIC ACID) ITS SALTS AND ESTERS 0.22 0.0005 0.19 0.0004 -15.96


1.70 0.0039 1.46 0.0028 -14.41

184. 291821 SALICYLIC ACID AND ITS SALTS 0.72 0.0017 0.55 0.0010 -24.01

185. 291822 0-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS 0.20 0.0005 0.67 0.0013 235.89

186. 291823 OTHR ESTERS OF SALICYLIC ACID & THR SALTS 0.31 0.0007 1.33 0.0025 333.10


1.16 0.0026 2.28 0.0043 96.59

188. 291830 CRBXYLC ACIDS WTH ALDHYD/KETONE FNCTN BUT WTHOUT OTHR OXYGN FNCTN THR ANHYDRDS HALDS PEROXIDES PEROXYACIDS

2.07 0.0047 2.01 0.0038 -3.08


- 226 -


0.69 0.0016 0.87 0.0016 25.26


1.69 0.0039 2.43 0.0046 43.57


0.03 0.0001 0.67 0.0013 2,217.73

192. 292090 OTR ESTERS OF OTR INORGNC ACDS;THRSLTS ETC 7.63 0.0174 9.01 0.0171 18.03

193. 292111 MTHYLAMINE DI-OR TRIMTHYL AMINE & THR SLTS 2.06 0.0047 3.24 0.0061 57.41


195. 292119 OTHR ACYCLIC MONOAMINES & THEIR DEVIVATIVES SALTS THEREOF

3.38 0.0077 5.36 0.0102 58.40


197. 292122 HEXAMETHYLENEDIAMINE AND ITS SALTS 0.31 0.0007 0.37 0.0007 18.36

198. 292129 OTHR ACYLC PLYAMINS THR DRVTVS SLTS THREOF 2.69 0.0061 1.81 0.0034 -32.56


0.54 0.0012 2.16 0.0041 297.92

200. 292141 ANILINE AND ITS SALTS 1.64 0.0037 3.32 0.0063 102.19

201. 292142 ANILINE DERIVATIVES AND THEIR SALTS 22.14 0.0505 30.22 0.0573 36.51

202. 292143 TOLUIDINES AND THEIR DRVTVS SLTS THEREOF 6.71 0.0153 8.13 0.0154 21.09

203. 292144 DIPHNYLAMINE & ITS DRVTVS SLTS THEREOF 3.34 0.0076 5.17 0.0098 54.86

204. 292145 1-NAPHTHYLAMINE 2-NAPHTHYLAMINE AND THEIR DERIVATIVES ; SALTS THEREOF

14.33 0.0327 15.98 0.0303 11.56

205. 292149 OTHR ARMTC MONO AMNS & THR DRVTVS AND SLTS 4.57 0.0104 5.01 0.0095 9.61


2.67 0.0061 4.24 0.0080 58.90

207. 292159 OTHR ARMTC PLYAMNS & THR DRVTVS & SLTS 19.95 0.0455 20.97 0.0398 5.11

208. 292211 MONOETHANOLAMINE AND ITS SALTS 0.79 0.0018 1.90 0.0036 138.88


210. 292213 TRIETHANOLAMINE AND ITS SALTS 0.18 0.0004 0.56 0.0011 216.46

211. 292219 OTHER OXYGEN-FUNCTION AMINO-ALCOHOLS 4.18 0.0095 3.88 0.0074 -7.20

212. 292221 AMNOHYDRXYNPHTHLENESLPHNC ACDS & THR SLTS 28.35 0.0647 33.17 0.0629 17.02

213. 292222 ANISIDINES DIANISIDINES PHNTDNS & THR SLTS 3.66 0.0084 4.44 0.0084 21.27


25.95 0.0592 36.46 0.0692 40.54

215. 292230 *AMINO-ALDHYDS AMINO-KETONS & AMINO-QUINONSOTHER THAN THOSE CNTNG MORE THAN ONE KND OF OXYGEN FUNCTION;SALTS THEREOF

1.32 0.0030 1.16 0.0022 -12.68


217. 292242 GLUTAMIC ACID AND ITS SALTS 0.29 0.0007 0.05 0.0001 -82.34



6.56 0.0150 4.72 0.0090 -28.02


9.07 0.0207 11.90 0.0226 31.20

221. 292310 CHOLINE AND ITS SALTS 1.52 0.0035 1.52 0.0029 -0.02

222. 292320 LECITHINS AND OTHER PHOSPHOAMINOLIPIDS 0.91 0.0021 2.47 0.0047 171.23


5.54 0.0126 8.63 0.0164 55.84

224. 292410 *ACYLC AMIDES(INCL ACYLC CARBAMATES) & THER DERIVATIVES SALTS THEREOF

8.07 0.0184 8.13 0.0154 0.74

225. 292421 UREINES & THEIR DERIVATIVES SALTS THEREOF 0.17 0.0004 0.47 0.0009 174.46


- 227 -

226. 292429 OTHR CYCLC AMIDES(INCL CYCLC CRBAMATES) & THEIR DERIVATIVES & SALTS THEREOF

3.65 0.0083 4.48 0.0085 22.55



229. 292520 IMINES & THR DRVTVS SLTS THEREOF 1.99 0.0045 1.81 0.0034 -8.87

230. 292610 ACRYLONITRILE 0.60 0.0014 0.07 0.0001 -89.03



233. 292700 DIAZO-AZO-OR AZOXY-COMPOUNDS 2.30 0.0053 2.83 0.0054 22.84

234. 292800 ORGNC DRVTVS OF HYDRAZINE/OF HYDROXYLAMINE 4.17 0.0095 3.64 0.0069 -12.78

235. 292910 ISOCYANATES 0.82 0.0019 3.27 0.0062 298.28

236. 292990 OTHR CMPNDS WITH OTHER NITROGEN FUNCTION 10.91 0.0249 10.24 0.0194 -6.17

237. 293010 DITHIOCARBONATES(XANTHATES) 0.09 0.0002 0.02 0.0000 -81.59

238. 293020 THIOCARBAMATES AND DITHIOCARBAMATES 0.05 0.0001 0.02 0.0000 -57.53

239. 293030 THIURAM MONO-,DI-OR TETRASULPHIDES 0.00 0.0000 0.01 0.0000 197.31

240. 293040 METHIONINE 0.02 0.0000 0.52 0.0010 3,101.91

241. 293090 OTHER ORGANO-SULPHUR COMPOUNDS 6.79 0.0155 6.89 0.0131 1.54

242. 293100 OTHER ORGANO-INORGANIC COMPOUNDS 25.36 0.0579 18.13 0.0344 -28.50


244. 293212 2-FURALDEHYDE(FURFURALDEHYDE) 0.13 0.0003

245. 293213 FURFURYL ALCHL & TETRAHYDROFURFURYL ALCHL 0.00 0.0000 0.01 0.0000 175.71

246. 293219 OTHR CMPNDS CNTNG AN UNFUSED FURANRING (WHETHER OR NOT HNDRGNTD)IN THE STRUCTURE

2.56 0.0058 4.49 0.0085 75.09


248. 293229 OTHR LACTONES 0.43 0.0010 1.05 0.0020 144.54

249. 293291 IS0SAFR0LE 0.00 0.0000 0.00 0.0000 -68.64


251. 293311 PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES 0.58 0.0013 0.57 0.0011 -1.15


12.31 0.0281 21.29 0.0404 73.02



28.47 0.0650 34.60 0.0656 21.54




6.99 0.0159 8.61 0.0163 23.24

258. 293340 *HTRCYCLE CMPNDS CNTNG A GUINOLINE OR ISOQUINOLINE RING-SYSTEM(WHETHER OR NOT HYDROGENATED) NOT FURTHER FUSED

7.82 0.0178 8.25 0.0157 5.50

259. 293351 *MALONYLURES(BARBITURIC ACID) AND ITS DERIVATIVES SALTS THEREOF

1.12 0.0026 2.44 0.0046 117.70


4.59 0.0105 4.12 0.0078 -10.20

261. 293361 MELAMINE 0.34 0.0008 0.02 0.0000 -94.70


3.10 0.0071 2.47 0.0047 -20.15


264. 293379 OTHER LACTAMS 10.49 0.0239 7.75 0.0147 -26.08


8.44 0.0193 9.15 0.0173 8.32

266. 293410 CMPNDS CNTNG AN UNFUSED THIAZOLE RING (W/N 0.59 0.0013 1.67 0.0032 183.98


- 228 -


0.21 0.0005 0.22 0.0004 4.30


0.04 0.0001

269. 293490 *OTHER 4.10 0.0094 6.13 0.0116 49.56

270. 293500 SULPHONAMIDES 28.49 0.0650 27.64 0.0524 -3.00


272. 293621 VITAMINS A AND THEIR DERIVATIVES 0.02 0.0000 0.07 0.0001 233.49




0.12 0.0003 0.10 0.0002 -10.67

276. 293625 VITAMIN B6 & ITS DRVTS 0.24 0.0005 0.01 0.0000 -96.15



279. 293628 VITAMIN E AND ITS DERIVATIVES 0.29 0.0007 0.34 0.0007 17.46

280. 293629 OTHER VITAMINS AND THER DERIVATIVES 15.54 0.0355 24.05 0.0456 54.73


282. 293710 *PITUITARY(ANTRR)/SMLR HRMNS & THR DRVTVS 0.91 0.0021 1.10 0.0021 20.99

283. 293721 CORTISONE,HYDROCORTISONE,PREDNISONE (DEHY-DROCORTISONE)AND FREDNISOLONE AND PRDNSLN(DEHYDROHYDROCORTISONE)

0.14 0.0003 0.30 0.0006 112.37

284. 293722 HALGNTD DRVTVS OF CORTI COSTEROIDAL 0.05 0.0001 0.02 0.0000 -54.17

285. 293729 OTHR STEROIDAL HORMONS THR DRVTVS AND STRCTL ANLGES

0.14 0.0003 0.34 0.0006 136.53

286. 293791 *INSULIN AND ITS SALTS 0.01 0.0000 0.01 0.0000 -42.64

287. 293792 *OESTROGENS AND PROGESTOGENS 0.63 0.0014 0.98 0.0019 56.47

288. 293799 *OTHR HRMNS & THR DRVTVS;OTHR STEROIDS USED PRIMARILY AS HORMONES

12.88 0.0294 13.95 0.0265 8.32

289. 293810 RUTOSIDE (RUTIN) AND ITS DERIVATIVES 0.22 0.0005 0.21 0.0004 -5.63


6.48 0.0148 4.52 0.0086 -30.21

291. 293910 *ALKLDS OF OPIUM & THR DRVTVS SLTS THEREOF 13.75 0.0314 18.97 0.0360 38.02

292. 293921 QUININE AND ITS SALTS 3.93 0.0090 2.68 0.0051 -31.79

293. 293929 OTHR ALKLDS OF CINCHONA & THR DRVTVS AND SLTS THEREOF

0.13 0.0003 0.35 0.0007 167.15

294. 293930 CAFFEINE AND ITS SALTS 1.13 0.0026 0.88 0.0017 -21.87

295. 293941 EPHIDRINES AND THER SLTS 7.52 0.0172 7.39 0.0140 -1.73

296. 293942 PSEUDO EPHEDRINE (INN) AND ITS SALTS 11.95 0.0273 14.89 0.0282 24.66

297. 293949 OTHER EPHEDRIVES AND THR SALTS 0.17 0.0004 0.11 0.0002 -34.95


0.07 0.0002 0.01 0.0000 -88.68

299. 293961 ERGOMETRINE (INN) AND ITS SALTS 0.00 0.0000 0.00 0.0000 -43.93

300. 293963 LYSERGIC ACID AND ITS SALTS 0.00 0.0000

301. 293969 OTHER ALKALOIDS OF RYE ERGOT & DRVTVS 0.00 0.0000

302. 293970 *NICOTINE AND ITS SALTS 1.19 0.0027 0.67 0.0013 -43.78

303. 293990 *OTHR VEG ALKLDS THR DRVTVS;SLTS THEROF ETC 8.67 0.0198 9.68 0.0184 11.66


0.99 0.0023 2.21 0.0042 124.07


87.27 0.1991 138.65 0.2630 58.88


- 229 -

306. 294120 STREPTOMYCINS & THR DRVTVS SLTS THEREOF 1.06 0.0024 1.39 0.0026 30.73

307. 294130 TETRACYCLINES & THR DRVTVS SLTS THEREOF 1.33 0.0030 1.61 0.0031 20.84

308. 294140 CHLORAMPHENICOL & ITS DRVTVS SLTS THEREOF 1.16 0.0027 1.75 0.0033 50.61

309. 294150 ERTHROMYCIN & ITS DRVTVS SLTS THEREOF 20.23 0.0462 23.63 0.0448 16.79

310. 294190 OTHER ANTIBIOTICS 75.08 0.1713 89.65 0.1700 19.40

311. 294200 OTHER ORGANIC COMPOUNDS 456.70 1.0421 599.86 1.1378 31.35



- 230 -


Import: Commodity-wise all countries

Dated: 15/6/2004

Commodity: 29 ORGANIC CHEMICALS Unit: S.No. Country Values in US$ Million Quntity in thousands

2001-2002 2002-2003 %Growth 2001-2002 2002-2003 %Growth

1. ARGENTINA 0.44 0.61 37.71

2. AUSTRALIA 4.91 4.11 -16.33

3. AUSTRIA 8.98 20.83 131.88

4. AZERBAIJAN 1.40

5. BAHARAIN IS 0.00 0.01 275.72

6. BANGLADESH 0.10

7. BELGIUM 22.90 28.58 24.79

8. BRAZIL 24.54 14.99 -38.91

9. BULGARIA 0.14 2.54 1,686.02

10. BELARUS 0.02

11. CAMBODIA 0.01

12. CAMEROON 0.02

13. CANADA 2.27 2.65 16.93

14. CHILE 0.24 0.58 145.23

15. CHINESE TAIPEI 37.30 37.19 -0.28

16. CHINA P RP 343.20 468.43 36.49

17. COCOS IS 0.05

18. COLOMBIA 0.08 0.34 356.03

19. CONGO P REP 0.03 0.96 3,074.92

20. CROATIA 0.21 0.33 54.71

21. CUBA 0.07

22. CYPRUS 0.27 0.14 -48.43

23. CZECH REPUBLIC 3.95 6.23 57.66

24. DENMARK 15.25 17.15 12.50

25. ECUADOR 0.08 0.01 -82.05

26. EGYPT A RP 0.14 0.31 114.78

27. ESTONIA 0.00

28. FINLAND 1.48 1.24 -16.45

29. FRANCE 55.97 61.19 9.33

30. GAMBIA 0.20

31. GEORGIA 0.52

32. GERMAN F REP 125.32 138.02 10.14

33. GREECE 0.07 0.06 -16.82

34. HONDURAS 0.04

35. HONG KONG 5.61 17.13 205.36

36. HUNGARY 4.98 3.42 -31.32


- 231 -

37. ICELAND 0.10 0.27 171.69

38. INDONESIA 45.96 50.61 10.12

39. IRAN 33.68 32.86 -2.44

40. IRELAND 0.69 0.94 36.02

41. ISRAEL 10.45 8.85 -15.32

42. ITALY 60.76 71.76 18.10

43. IVORY COAST 0.09 0.06 -37.44

44. JAPAN 124.25 124.18 -0.05

45. JORDAN 1.81 0.03 -98.29

46. KAZAKHSTAN 0.02

47. KENYA 0.08 0.00 -99.97

48. KOREA DP RP 0.27 0.04 -84.96

49. KOREA RP 49.18 58.96 19.88

50. KUWAIT 0.03 8.64 25,319.23

51. LATVIA 0.11 0.16 43.24

52. LIBERIA 5.79

53. LIBYA 0.18

54. LUXEMBOURG 0.04

55. MALAYSIA 63.64 96.67 51.92

56. MALI 0.03

57. MALTA 0.00

58. MAYANMAR 1.32

59. MEXICO 3.19 9.94 211.30

60. MOROCCO 0.07 0.17 124.79

61. NEPAL 1.02 0.15 -85.04

62. NETHERLAND 66.04 57.80 -12.48

63. NEW CALEDONIA 0.02

64. NEW ZEALAND 0.41 0.37 -11.38

65. NIGERIA 0.73 6.51 797.28

66. NORWAY 7.35 2.05 -72.16

67. OMAN 0.52 0.26 -49.34

68. PAKISTAN 0.24 0.16 -29.96

69. PANAMA REPUBLIC 0.00

70. PARAGUAY 0.00 0.00 -0.83

71. PERU 0.02

72. PHILIPPINES 1.61 1.63 1.30

73. POLAND 2.19 2.47 13.12

74. PORTUGAL 0.07 0.34 421.89

75. QATAR 31.81 60.67 90.77

76. REUNION 0.02


- 232 -

77. ROMANIA 8.01 2.14 -73.27

78. RUSSIA 9.90 14.28 44.27

79. SAUDI ARAB 121.77 117.28 -3.69

80. SENEGAL 0.49

81. YUGOSLAVIA F RP 0.00

82. SIERRA LEONE 0.18 0.13 -23.86

83. SLOVAK REP 2.54 2.68 5.43

84. SINGAPORE 131.69 112.59 -14.51

85. SLOVENIA 6.60 9.90 49.90

86. SOMALIA 0.52 0.02 -95.94

87. SOUTH AFRICA 17.03 18.85 10.68

88. SPAIN 30.69 37.80 23.16

89. SRI LANKA 2.28 0.58 -74.51

90. SUDAN 0.63 1.55 144.78

91. SURINAM 0.00 0.02 2,115.91

92. SWAZILAND 0.06

93. SWEDEN 11.15 14.73 32.15

94. SWITZERLAND 56.31 111.55 98.08

95. SYRIA 0.02

96. THAILAND 10.68 12.98 21.57

97. TUNISIA 0.08

98. TURKEY 9.82 6.78 -31.01

99. TURKS C IS 0.01

100. UGANDA 0.02 0.25 1,247.94

101. U ARAB EMTS 9.13 5.05 -44.73

102. U K 49.30 46.43 -5.82

103. UKRAINE 1.21 5.07 318.13

104. U S A 191.64 243.83 27.23

105. URUGUAY 0.23

106. VIETNAM SOC REP 0.18 0.78 332.53

107. VIRGIN IS US 0.01

108. YEMEN REPUBLC 0.01

109. ZIMBABWE 0.50

110. UNSPECIFIED 1.59 16.34 926.44



- 233 -


Import: Commodity-wise all countries


Commodity: 30 PHARMACEUTICAL PRODUCTS Unit: S.No. Country Values in US$ Million Quntity in thousands

2001-2002 2002-2003 %Growth 2001-2002 2002-2003 %Growth

1. SWITZERLAND 17.42 46.90 169.26

2. GERMAN F REP 26.78 32.35 20.77

3. FRANCE 11.73 24.54 109.25

4. U S A 15.73 22.00 39.85

5. ITALY 6.45 11.97 85.73

6. U K 9.78 10.34 5.72

7. INDONESIA 9.20 8.44 -8.21

8. IRELAND 8.62 8.29 -3.80

9. NEPAL 8.75 7.96 -8.94

10. DENMARK 6.04 7.48 23.94

11. CHINA P RP 2.92 6.40 119.33

12. NETHERLAND 4.58 6.30 37.54

13. BELGIUM 6.96 5.29 -24.03

14. JAPAN 1.79 5.27 194.36

15. ISRAEL 1.24 4.95 299.34

16. KOREA RP 3.94 4.36 10.73

17. MALAYSIA 3.23 2.87 -11.08

18. SWEDEN 5.42 2.80 -48.30

19. AUSTRIA 1.46 2.52 72.39

20. AUSTRALIA 2.68 1.95 -27.10

21. HUNGARY 1.79 1.82 2.12

22. MEXICO 1.82 1.73 -4.88

23. CANADA 0.57 1.35 138.21

24. ARGENTINA 0.14 1.16 738.83

25. UNSPECIFIED 0.04 0.93 2,224.80

26. RUSSIA 2.05 0.90 -56.07

27. HONG KONG 0.32 0.86 163.46

28. VIETNAM SOC REP 0.65

29. FINLAND 0.22 0.59 170.77

30. LATVIA 0.18 0.52 193.48

31. SINGAPORE 1.02 0.51 -49.81

32. BELARUS 0.44

33. CUBA 0.49 0.42 -13.19

34. SPAIN 0.25 0.39 53.90

35. IRAN 0.38

36. CHINESE TAIPEI 0.36 0.33 -9.51

37. POLAND 0.24 0.29 20.61

38. THAILAND 0.18 0.23 25.76


- 234 -

39. PHILIPPINES 0.06 0.21 247.88

40. CZECH REPUBLIC 0.26 0.19 -28.41

41. IVORY COAST 0.00 0.16 6,440.98

42. ICELAND 0.15

43. BRAZIL 0.25 0.15 -40.02

44. GREECE 0.02 0.12 388.17

45. NORWAY 0.01 0.09 1,204.33

46. NEW ZEALAND 0.07 0.08 15.60

47. CROATIA 0.07

48. SOUTH AFRICA 0.06 0.06 -4.81

49. COLOMBIA 0.01 0.06 723.80

50. ROMANIA 0.04

51. GEORGIA 0.03

52. NIGERIA 0.00 0.03 813.75

53. SRI LANKA 0.11 0.02 -77.57

54. U ARAB EMTS 0.04 0.02 -52.30

55. SIERRA LEONE 0.01 0.02 63.87

56. TRINIDAD 0.02

57. PUERTO RICO 0.02

58. TANZANIA REP 0.01

59. ZIMBABWE 0.01 0.01 6.78

60. PORTUGAL 0.01 0.00 -78.36

61. PAKISTAN 0.00 0.00 -30.06

62. SLOVENIA 0.00

63. BULGARIA 0.01 0.00 -97.59

64. CYPRUS 0.00

65. KUWAIT 0.00

66. TURKEY 0.00

67. YUGOSLAVIA F RP 0.70

68. SUDAN 0.00

69. MAYANMAR 0.00

70. BENIN 0.02

71. CAMEROON 0.02

72. PERU 0.00

73. QATAR 0.00

74. SAUDI ARAB 0.01

75. MAURITIOUS 0.00

76. KOREA DP RP 0.02

77. SOMALIA 0.00

78. UKRAINE 0.01

79. BAHARAIN IS 0.00

80. ESTONIA 0.45

81. GUATEMALA 0.01

82. BANGLADESH 0.00

Total 166.56 238.06 42.93 Exchange rate: 2001-2002: 1US$ = Rs. 47.6919 2002-2003 : 1US$ = Rs. 48.3953


- 235 -

Department of Commerce Export Import Data Bank Import :: Commodity-wise


Sorted on HSCode



2003 %Share %Growth

1. 30011001 *PANCREATIN & DRIED PWDR OF PANCREAS 0.02 0.0000 0.37 0.0006 1,615.18

2. 30011009 *OTHR GLNDS/ORGNS DRIED W/N PWDRD 0.22 0.0004 0.74 0.0012 244.00

3. 30012003 *HEPARIN 0.67 0.0013 0.12 0.0002 -82.70


0.02 0.0000 0.57 0.0009 3,180.83


3.70 0.0072 0.98 0.0016 -73.45

6. 30021001 *BLOOD PLASMA 1.32 0.0026 1.75 0.0029 32.43

7. 30021002 *DIPTHERIA ANTISERA 0.00 0.0000 0.02 0.0000 414.13

8. 30021003 *TETANUS ANTISERA 0.72 0.0014 1.77 0.0029 144.62

9. 30021004 *RABIES ANTISERA 0.27 0.0005 0.90 0.0015 230.05

10. 30021006 *HUMAN GAMMA GLOBULIN 1.48 0.0029 0.56 0.0009 -62.10


0.54 0.0011 0.46 0.0007 -15.83

12. 30021008 *HAEM0GL0BIN P0WDER 0.59 0.0010


14. 30022001 *VACCINES FOR CHOLERA 0.56 0.0011 0.89 0.0014 57.47

15. 30022002 *VACCINES FR DPTHRA(DPTHRA TXD-FT,APT ETC 0.00 0.0000

16. 30022003 *VACCINES FOR POLIO 3.28 0.0064 6.46 0.0105 96.76


18. 30022006 *VACCINES FOR TUBERCULINS(B.C.G.) 0.00 0.0000

19. 30022007 *VACCINES FOR WHOOPING COUGH (PERTUSIS) 0.00 0.0000

20. 30022008 *MIXED VACCINES FOR DPT-TRIPLE ANTI GEN 1.38 0.0027

21. 30022011 VACCINES FOR CHOLERA AND TYPHOID 0.07 0.0001



24. 30022014 VACCINES FOR POLIO 0.40 0.0008 0.09 0.0001 -77.35


26. 30022016 ANTI RABIES VACCINE 0.05 0.0001 0.42 0.0007 722.20



29. 30029001 *TOXINS 2.14 0.0042 0.89 0.0014 -58.52





0.91 0.0018 1.59 0.0026 75.24


35. 30032005 *AMIKACIN 0.05 0.0001 0.17 0.0003 283.64

36. 30032019 *OTHERS ANTIBIOTICS (OTHER THAN HEADING NO. 300310 )

0.34 0.0007 0.73 0.0012 113.24


- 236 -



11.44 0.0223 4.73 0.0077 -58.65


0.00 0.0000

40. 30039001 *AYURVEDIC & UNANI MEDICINES 11.71 0.0228 9.91 0.0161 -15.39

41. 30039002 *HOMOEOPATHIC MEDICINE 1.28 0.0025 1.57 0.0025 22.18

42. 30039014 MEDICANTS OF HOMOEOPATHIC SYSTEM 0.06 0.0001 0.04 0.0001 -40.87


0.03 0.0000

44. 30039084 *ALUMINIUM HYDROXIDE GEL 0.00 0.0000

45. 30039087 *OTHER ANAESTHETIC AGENTS LIKE KETAMINE,HALOTHINE,THIOPENTANE

0.01 0.0000 0.07 0.0001 480.50

46. 30039092 *CHLOROXYLENOLS (DETTOL) 0.20 0.0003


0.59 0.0011 3.32 0.0054 465.22

48. 30041001 *STRPTMYCN & ITS SLTS IN CPSLS INJCTNS ETC 0.28 0.0006 0.03 0.0000 -89.83

49. 30041002 *PENICILLIN IN CAPSULES, INJECTIONS ETC. 0.02 0.0000

50. 30041004 *AMOXYCYLLIN IN CAPSULES, INJECTIONS ETC. 1.09 0.0021

51. 30041014 *OFLOXACIN 0.06 0.0001

52. 30041019 *OTHERS 0.43 0.0008 1.10 0.0018 153.78

53. 30042001 *CHLORMPHENICOL CAPSULES, INJECTIONS ETC. 1.38 0.0027 1.08 0.0018 -21.24

54. 30042002 *TETRACYLINE IN CAPSULES, INJECTIONS, OINTMENTS ETC. 0.00 0.0000 0.02 0.0000 471.15

55. 30042003 *ERYTHROMYCIN IN CAPSULES,INJECTIONS, OINTMENTS ETC. 0.29 0.0006


0.14 0.0003 0.10 0.0002 -28.39

57. 30042007 *RIFMPICINE - FORMULATIONS, IN CSPSULES ETC 0.05 0.0001

58. 30042011 CEFAZOLIN 0.07 0.0001 0.01 0.0000 -86.19

59. 30042012 CEPHALEXIN - FORMULATIONS THEREOF, IN CAPSULES ETC. 0.01 0.0000 0.02 0.0000 29.92

60. 30042013 CIPROFLOXACINE- IN CAPSUL,TBLTS FORM ETC 0.00 0.0000

61. 30042028 *POLYMIXIN !B! AND ITS SALTS 0.03 0.0001

62. 30042031 NORFLOXACIN 0.11 0.0002

63. 30042039 OTHER FLUOROQUINOLONES 0.88 0.0017 1.21 0.0020 37.74

64. 30043103 *INSULIN (HUMAN) INJECTION 3.19 0.0062 1.60 0.0026 -49.86

65. 30043104 *INSULIN (BOVINE/PORK) INJECTION 0.22 0.0004 0.12 0.0002 -44.70

66. 30043109 *INSULIN IN OTHER FORMS 2.18 0.0042 3.75 0.0061 72.24


1.93 0.0038 1.98 0.0032 2.47

68. 30043902 *PREDNISOLONE TABLETS,INJECTIONS ETC. 0.86 0.0017

69. 30043904 *DANAZOL TABLETS, INJECTIONS ETC. 0.07 0.0001


0.21 0.0004 0.09 0.0002 -55.59


1.01 0.0020 1.18 0.0019 17.02


0.00 0.0000 0.00 0.0000 2,162.69

73. 30043911 PITUITARY HORMONES 0.12 0.0002

74. 30043918 *LYNESTRENOL - FORMULATIONS THEREOF IN TABLETS , INJECTIONS ETC.

0.02 0.0000

75. 30043921 GONADOTROPHINS 0.12 0.0002


- 237 -

76. 30043939 *OTHER HORMONES FORMULASTIONS 3.30 0.0064 5.55 0.0090 68.09


0.02 0.0000 0.02 0.0000 16.20

78. 30044019 *FRMLTNS OF OTHR VGTBL ALKLDS & ITS DRVTVS 0.00 0.0000

79. 30044039 *OTHERS 0.00 0.0000 0.27 0.0004 5,656.79

80. 30045001 *APPETITE STIMULANTS BASED ON CIPROHEPTADINE,AMINO ACIDS ETC.

0.39 0.0008 0.25 0.0004 -36.12


0.02 0.0000 0.02 0.0000 -0.73

82. 30045005 *TABLETS,CAPSULES ETC OF VITAMIN "B" GROUP 0.05 0.0001 0.00 0.0000 -91.65


0.09 0.0002

84. 30045007 *VITAMIN 'D' IN TABLETS, CAPSULES, SYRUP ET 0.01 0.0000 0.01 0.0000 -0.56

85. 30045012 *VITAMIN E IN CAPS.TABS,SYRUP ETC 0.00 0.0000

86. 30045014 *TONICS , BASED ON VITAMINS GLYCEROPHOS PHATES, GINSENG PREPN.

0.01 0.0000

87. 30045019 *OTHERS PUT UP FOR RETAIL SALE 0.20 0.0004 1.05 0.0017 435.50

88. 30049001 *AYURVEDIC & UNANI MEDCNS 17.30 0.0336 30.54 0.0497 76.57

89. 30049002 *HOMEOPATHIC MEDICINE 0.06 0.0001 0.05 0.0001 -7.41


0.09 0.0002 0.04 0.0001 -53.60


0.01 0.0000 0.01 0.0000 27.43

92. 30049005 *PARACETAMOL PANDOL ETC IN TBLTS SYRUP ETC 0.07 0.0001 0.06 0.0001 -8.39


0.16 0.0003 0.02 0.0000 -84.86

94. 30049008 *OXYPHN/PHENYL BUTAZON IN TBS, CPSLS ETC 0.01 0.0000 0.02 0.0000 55.24

95. 30049011 MEDICAMENTS OF AYURVEDIC SYSTEM 0.98 0.0019 3.70 0.0060 279.56

96. 30049012 MEDICAMENTS OF UNANI SYSTEM 0.00 0.0000

97. 30049013 MEDICAMENTS OF SIDDHA SYSTEM 0.03 0.0001

98. 30049014 HOMEOPATHIC MEDICINE 0.00 0.0000

99. 30049015 MEDICAMENTS OF BIO-CHEMIC SYSTEM 0.01 0.0000


0.00 0.0000

101. 30049018 *CEFADR0XYL IN CAPSULES,INJECTI0NS ETC. 0.03 0.0001 0.01 0.0000 -77.04

102. 30049021 ANTHELMINTICS AND PREPARATIONS THEREOF 0.05 0.0001


0.02 0.0000


0.52 0.0010 0.43 0.0007 -18.02

105. 30049026 SODIUM STIBOGLUCONATE 0.12 0.0002

106. 30049028 *OTHER ANTI-TUBERCULOUS FORMULATIONS- IN TABLETS ETC. OF PYRAZINAMIDE,THIACETAZONE, ISONIAZIDE,ETC.(EXCLUDING REFAMPICIN)

0.34 0.0006

107. 30049032 SODIUM BICARBONAT, MAGNSM HYDROXID, MAGNSMCARBONAT,MAGNSIUM TRISILICAT, ALUMINIUM HYDROXIDE GEL,MAGALDARATE & COMB. THEREOF

0.00 0.0000

108. 30049036 CHENODIOL AND URSODIOL 0.01 0.0000 0.44 0.0007 4,001.43

109. 30049038 *OTHER ANTACID ETC. 0.00 0.0000

110. 30049042 METHOTREXATE, 5-FLUOROURACIL(5-FU) AND FTORAFUR 0.00 0.0000


- 238 -


111. 30049044 PACLITAXEL AND DOCETAXEL 0.02 0.0000

112. 30049045 ETOPOSIDE 0.01 0.0000

113. 30049047 L-ASPARAGINASE, CISPLATIN AND CARBOPLATIN 0.01 0.0000

114. 30049048 TAMOXIFEN 0.02 0.0000

115. 30049051 ISONIAZID 0.04 0.0001

116. 30049052 RIFAMPICIN 0.01 0.0000


0.02 0.0000

118. 30049058 OTHER ANTILEPROTIC DRUGS 0.04 0.0001


0.13 0.0002


0.00 0.0000


0.05 0.0001


0.07 0.0001

123. 30049065 INDOMETHACIN 0.30 0.0006 0.67 0.0011 125.11

124. 30049072 VERAPAMIL, NIFEDIPINE, AMLODIPINE AND LACIDIPINE 0.00 0.0000 0.02 0.0000 1,327.94

125. 30049073 LOSARTAN 0.13 0.0002

126. 30049078 *OTHER SALINE WATER 0.01 0.0000

127. 30049081 PHENOBARBITONE,MEPHOBARBITONE,PRIMIDONE, PHENYTOIN,CARBAMAZPIN,ETHOSUCIMID,VALPORICACID ,DIAZEPA,LAMOTRIGIN,GABAPENTIN ETC

0.46 0.0009 0.18 0.0003 -60.80

128. 30049085 VETERINARY MEDICINAL PREPARATIONS N.E.S. 0.03 0.0000


0.03 0.0001 0.00 0.0000 -95.75

130. 30049092 PLASMA EXPANDERS 0.04 0.0001

131. 30049093 CHLOROPHENIRAMINE MALEATE, WITH OR WITHOUTOTHER COMPOUNDS (EXCL. STERIODS&ALKALOIDS)

0.17 0.0003

132. 30049099 OTHER MEDCNE PUT UP FOR RETAIL SALE N.E.S 34.27 0.0667 76.44 0.1245 123.01

133. 30051001 *ADHESIVE GAUZE BANDAGE 0.33 0.0006 1.14 0.0018 245.88

134. 30051002 *ADHESIVE TAPE (MEDICINAL) 0.44 0.0009 0.48 0.0008 8.33

135. 30051003 *PLASTER OF PARIS (SURGICAL) 0.11 0.0002 0.00 0.0000 -99.95

136. 30051009 *OTHER BANDAGES 0.58 0.0011 0.51 0.0008 -12.70

137. 30059001 *COTTON WOOL MEDICATED 1.96 0.0038 2.37 0.0039 20.58

138. 30059002 *POULTICE OF KAOLIN 0.17 0.0003 0.14 0.0002 -17.28

139. 30059003 *MEDICATED LINT 0.12 0.0002 0.05 0.0001 -63.00

140. 30059004 *BANDAGES WITHOUT ADHESIVE LAYER 1.05 0.0020 0.37 0.0006 -64.61


1.35 0.0026 2.40 0.0039 77.04


0.01 0.0000 0.10 0.0002 1,605.66



5.39 0.0105 8.44 0.0137 56.69


3.05 0.0059 3.62 0.0059 18.60

146. 30065000 FIRST-AID BOXES AND KITS 0.53 0.0010 0.06 0.0001 -88.70


0.54 0.0010 1.51 0.0025 180.65


- 239 -

Department of Commerce Export Import Data Bank Import: Commodity-wise


Sorted on HSCode



2003 %Share %Growth


2. 29012100 UNSATURATED ETHYLENE 24.85 0.0483 8.81 0.0143 -64.55


4. 29012300 UNSTRD BUTENE (BUTYLENE)& ISOMERS THEREOF

16.98 0.0330 11.09 0.0181 -34.72

5. 29012401 *UNSTRD BUTADIENES 0.01 0.0000 0.15 0.0002 1,209.26

6. 29012402 *UNSTRD METHYLBUTADIENES 0.00 0.0000

7. 29012900 *OTHER UNSATURATED ACYCLIC HYDROCARBONS

5.36 0.0104 5.25 0.0086 -2.05

8. 29021100 CYCLOHEXANE 3.76 0.0073 4.36 0.0071 16.17


10. 29022000 BENZENE 10.82 0.0210 2.58 0.0042 -76.15

11. 29023000 TOLUENE 8.44 0.0164 8.37 0.0136 -0.78

12. 29024100 O-XYLENE 3.93 0.0076 2.43 0.0040 -38.26

13. 29024200 M-XYLENE 2.96 0.0057 1.35 0.0022 -54.21

14. 29024300 P-XYLENE 106.44 0.2070 118.66 0.1932 11.48

15. 29024400 MIXED XYLENE ISOMERS 2.98 0.0058 0.37 0.0006 -87.61

16. 29025000 STYRENE 120.34 0.2341 130.13 0.2119 8.13

17. 29026000 ETHYLBENZENE 0.08 0.0001 0.16 0.0003 101.88

18. 29027000 CUMENE 11.84 0.0230 15.33 0.0250 29.52

19. 29029001 *DIPENTENE PURE 1.24 0.0024 2.68 0.0044 116.57

20. 29029002 *DIPHENYL METHANE 0.05 0.0001 0.03 0.0001 -32.61

21. 29029003 *DODECYCL BENZENES (EXCL MXD ALKYLARENES)

0.03 0.0001 0.09 0.0001 203.53

22. 29029004 *NAPTHALENE CHMCLY/COMRCLLY PURE 2.89 0.0056 3.56 0.0058 23.15

23. 29029005 *IS0BUTYL BENZENE 0.15 0.0003 0.40 0.0006 166.56

24. 29029006 *ALLYBENZENE 0.00 0.0000

25. 29029009 *OTHERS 2.69 0.0052 3.91 0.0064 45.29

26. 29031101 *METHYL CHLORIDE 1.26 0.0024 1.14 0.0019 -9.37

27. 29031102 *ETHYL CHLORIDE 0.07 0.0001 0.30 0.0005 299.93


29. 29031301 *1-1-1 TRICHL0R0ETHANE (METHYL CHL0R0F0RM)0Z0NE DEPLETING

0.38 0.0007 0.68 0.0011 80.04

30. 29031302 *1-1-2 TRICHL0R0ETHANE ( CHL0R0F0RM F0R ANAESTHETTC USE )

0.09 0.0002 0.17 0.0003 86.79


32. 29031500 1,2 DICHLOROMETHANE (CETHYLNE DICHLORIDE) 47.14 0.0917 56.61 0.0922 20.09

33. 29031600 *12-DICHLOROPROPANE(PROPYLENE DICHLORIDE) AND DICHLOROBUTANES,SATURATED

0.13 0.0002 0.03 0.0000 -76.16

34. 29031901 *TETRACHLOROETHANE 2.05 0.0040 1.44 0.0023 -29.98

35. 29031909 *OTHERS 5.19 0.0101 3.55 0.0058 -31.50

36. 29032100 VINYL CHLORIDE (CHLOROETHYLENE),UNSTRTD 19.27 0.0375 43.22 0.0704 124.24


- 240 -

37. 29032200 TRICHLOROETHYLENE,UNSATURATED 0.53 0.0010 0.46 0.0007 -13.53

38. 29032300 TETRACHLOROETHANE (PERCHLOROETHYLENE ) , UNSATRTD 1.64 0.0032 2.10 0.0034 28.06


0.99 0.0019 1.17 0.0019 17.49

40. 29033001 *FLUORINATED HYDROCARBONS OTHER THAN PFIB 1,1,3,3,3-(PENTAFLUORO-2-TRIFLUOROMETHYL) -1-PROPENE

2.35 0.0046 4.17 0.0068 77.29

41. 29033002 *BROMINATED HYDROCARBONS 2.06 0.0040 0.74 0.0012 -64.09

42. 29033003 *IODINATED HYDROCARBONS 0.23 0.0004 0.09 0.0001 -59.53

43. 29033004 *PFIB:1,1,3,3,3-PENTA FLUORO-2(TRIFLUORO- METHYL)-1-PROPENE 0.03 0.0001 0.27 0.0004 698.85


45. 29034200 DICHLORO DIFLUORO ETHANE 0.01 0.0000 0.27 0.0004 2,603.45


47. 29034400 *DICHLORO TETRA FLUORO ETHANE AND CHLORO PENTA FLUORO ETHANE

0.10 0.0002 0.07 0.0001 -30.50

48. 29034500 *OTHER DERIVATIVES PERHALOGENATED ONLY WITH FLUORINE & CHLORINE

0.33 0.0006 0.01 0.0000 -95.74

49. 29034600 *BROMO CHLORO DIFLUORO METHANE, BROMO TRI FLUORO METHANE & DIBROMOTETRA FLUOROETHANE

0.22 0.0004 0.31 0.0005 40.69


51. 29034901 *HCFCS ( E.G. HCFC-21, HCFC-22/R-22 ) 1.40 0.0027 1.14 0.0018 -18.89

52. 29034909 *OTHER CFCS AND HAL0NS ( BCF ) 2.14 0.0042 1.94 0.0032 -9.31


54. 29035900 OTHR HALOGNTD DRVTVS OF CYCLANIC,CYCLENIC 8.58 0.0167 7.82 0.0127 -8.85

55. 29036101 *CHLOROBENZENE (MONO CHLORO) 0.24 0.0005 0.38 0.0006 56.17

56. 29036102 *ORTHO-DICHLOROBENZENE 0.35 0.0007 0.36 0.0006 3.08

57. 29036103 *PARA-DICHLOROBENZENE 0.02 0.0000

58. 29036104 *CHLORO-FLUORO BENZENE 1.71 0.0033 1.31 0.0021 -23.68

59. 29036201 *BENZENE HEXACHLRD OTHR THN LINDANC 0.01 0.0000

60. 29036202 *D.D.T. 0.01 0.0000

61. 29036901 *BENZAL CHLORIDE (BENZYL DICHLORIDE) 0.93 0.0018 1.89 0.0031 103.05

62. 29036902 *BENZO TRICHLORIDE 0.13 0.0002 0.01 0.0000 -90.17

63. 29036903 *BENZYL CHLORIDE 0.10 0.0002 0.05 0.0001 -44.77

64. 29036904 *PARA CHLORO TOLUNE (4-CHLORO-MTHYL BENZNE) 0.75 0.0015 1.02 0.0017 36.23

65. 29036905 *NAPTHALENE CHLORINATED 0.08 0.0001

66. 29036906 *CHLORO FLUORO ANILINE 0.27 0.0005 0.10 0.0002 -62.54

67. 29036909 *HALGNTD DRVTVS OF ARMTC HYDROCRBN,NES 5.25 0.0102 5.83 0.0095 11.05

68. 29041001 *BENZENE SULPHONIC ACID 1.63 0.0032 1.61 0.0026 -1.42

69. 29041002 *1:5 NAPTHLN DISULPHNC ACID(ARMSSTRNG ACID) 0.03 0.0000

70. 29041004 *VINYL SULPHONE 0.02 0.0000 0.09 0.0001 415.12

71. 29041009 *OTHR DRVTV CNTNG ONLY SULPHO GROUP, THEIR SALTS AND ETHYL ESTERS

1.85 0.0036 1.82 0.0030 -1.74

72. 29042001 *2:4 META DINITROBENZENE 0.59 0.0011 0.71 0.0012 20.92

73. 29042002 *DINITROTOLUENE 0.01 0.0000

74. 29042003 *NITROBENZENE 0.12 0.0002 0.00 0.0000 -99.64

75. 29042004 *META NITROTOLUENE 0.09 0.0002 0.09 0.0001 -5.21


- 241 -

76. 29042005 *ORTHO NITROTOLUENE 0.42 0.0008 0.30 0.0005 -28.64

77. 29042006 *PARA NITROTOLUENE 3.03 0.0059 2.69 0.0044 -10.93

78. 29042007 *NITROETHANE 0.25 0.0005 0.05 0.0001 -78.81

79. 29042009 *OTHR DRVTVS CNTNG ONLY NITRO/NITROSO GRPS 1.37 0.0027 3.14 0.0051 130.03

80. 29049001 *2:5 DICHLORONITROBENZENE 0.83 0.0016 1.24 0.0020 49.26

81. 29049002 *DINITROCHLOROBENZENE 0.02 0.0000 0.02 0.0000 1.25

82. 29049003 *META NITROCHLOROBENZENE 0.01 0.0000

83. 29049004 *ORTHO NITROCHLOROBENZENE 0.39 0.0008 0.39 0.0006 -0.96

84. 29049005 *PARA NITROCHLOROBENZENE 1.52 0.0029 1.33 0.0022 -11.91

85. 29049008 *TRICHLORO NITRO-METHANE (CHLOROPICRIN) 0.37 0.0007 0.02 0.0000 -94.82

86. 29049009 *OTHRS 2.12 0.0041 1.97 0.0032 -6.74

87. 29051100 SATURATED METHANOL (METHYL ALCOHOL) 53.84 0.1047 58.07 0.0946 7.85

88. 29051201 *PROPYL AND ISOPROPYL ALCOHOL (PROPANOLS) 9.40 0.0183 21.06 0.0343 124.00

89. 29051202 *PROPANOL(NORMAL PROPYL ALCOHOL),SATURATED 1.32 0.0026 1.19 0.0019 -9.85

90. 29051300 SATURATED BUTAN-1-OL(N-BUTYL ALCOHOL) 7.43 0.0144 5.01 0.0082 -32.49

91. 29051401 *ETHAMBUTOL, ETHAMBUTOL HCL 1.00 0.0019 0.85 0.0014 -15.24

92. 29051402 *SALBUTAMOL SULPHATE 0.06 0.0001 2.30 0.0038 3,553.17

93. 29051403 *AMINO BUTANOL 3.47 0.0067 2.23 0.0036 -35.77

94. 29051404 *PINACOLYL ALCOHOL 3,3-DIMETHYL BUTAN-2-OL 0.00 0.0000

95. 29051409 *OTHERS 8.26 0.0161 5.55 0.0090 -32.85

96. 29051500 SATURTD PENTANOL(AMYL ALCHL) & SMRS THEROF 1.10 0.0021 1.66 0.0027 50.24

97. 29051601 *OTHR SATURTED MONOHYDYDRIC ALCHOL 0.20 0.0004 0.28 0.0005 42.46

98. 29051609 *OTHERS 4.05 0.0079 2.69 0.0044 -33.56


0.25 0.0005 0.32 0.0005 28.05

100. 29051902 *2-ETHYL HEXANOL 6.60 0.0128 6.34 0.0103 -3.95

101. 29051909 *OTHER HEXANOL 5.19 0.0101 7.25 0.0118 39.88

102. 29052201 *CITRANELLOL 2.85 0.0055 3.98 0.0065 40.04

103. 29052202 *GERANIOL 0.99 0.0019 0.66 0.0011 -33.37

104. 29052203 *LINALOOL 0.95 0.0018 1.04 0.0017 10.42

105. 29052204 *RHODINOL 0.00 0.0000 0.01 0.0000 2,626.51

106. 29052900 OTHER UNSATURATED MONOHYDRIC ALCOHOLS 1.51 0.0029 1.40 0.0023 -7.14

107. 29053100 ETHYLENE GLYCOL (ETHANEDIOL) 0.83 0.0016 13.10 0.0213 1,484.41


109. 29053901 *1,4/1,3/2,3 BUTYLENE GLYCOL(BUTANEDIOL) 2.94 0.0057 3.20 0.0052 8.96

110. 29053909 *OTHERS 2.17 0.0042 1.92 0.0031 -11.24


0.96 0.0019 1.58 0.0026 64.11

112. 29054201 *DIPENTA ERYTHRITOL 0.88 0.0017 0.99 0.0016 12.03

113. 29054209 *OTHERS 1.13 0.0022 0.94 0.0015 -16.96

114. 29054300 MANNITOL 1.33 0.0026 2.10 0.0034 58.51


116. 29054501 *GLYCERIN REFINED & CHEMICALLY PURE 0.59 0.0011 0.76 0.0012 29.54

117. 29054509 *GLYCEROL NES 0.10 0.0002 0.12 0.0002 18.39


- 242 -



0.35 0.0007 0.56 0.0009 58.68

120. 29061100 MENTHOL 0.25 0.0005 0.47 0.0008 87.28

121. 29061200 CYCLHXNL MTHYLCYCLHXNLS&DIMTHYL CYCLHXNLS 0.49 0.0010 0.41 0.0007 -16.65

122. 29061301 *CHOLESTEROL 0.33 0.0006 0.33 0.0005 -0.15

123. 29061309 *OTHER STEROLS & INOSITOLS 0.14 0.0003 0.07 0.0001 -46.74

124. 29061400 TERPINEOLS 0.10 0.0002 0.13 0.0002 31.97

125. 29061901 *BERNEOL 1.37 0.0027 2.12 0.0035 54.70

126. 29061909 *CYCLANIC,CYCLENIC/CYCLOTRPENIC ALCHLS NES 1.45 0.0028 1.06 0.0017 -27.01

127. 29062100 BENZYL ALCOHOL 0.04 0.0001 0.07 0.0001 71.44

128. 29062901 *CHINNAMIC ALCOHOL 1.65 0.0032 2.14 0.0035 29.81

129. 29062902 *PHENYLETHYL ALCOHOL 0.50 0.0010 0.77 0.0013 53.91

130. 29062909 *OTHERS 3.65 0.0071 4.53 0.0074 24.10

131. 29071101 *COMMERCIAL CARBOLIC ACID (PHENOL) 14.70 0.0286 11.07 0.0180 -24.72

132. 29071102 *PURE CARBOLIC ACID (PHENOL) 3.11 0.0060 2.08 0.0034 -33.07

133. 29071201 *PARA CRESOL 2.98 0.0058 4.33 0.0070 45.35

134. 29071202 *COMMERCIAL CRESYLIC ACID 0.22 0.0004 0.05 0.0001 -78.94

135. 29071203 *PURE CRESYLIC ACID 0.02 0.0000

136. 29071204 *ALKYL PHENOLS 0.24 0.0005 0.25 0.0004 3.21

137. 29071209 *OTHER CRESOLS AND THEIR SALTS 1.81 0.0035 2.15 0.0035 19.05

138. 29071300 OCTYLPHNL NONYLPHNL & THR ISOMERS,SALTS 1.28 0.0025 1.04 0.0017 -18.73


140. 29071501 *ALPHA NAPHTHOL 1.59 0.0031 3.69 0.0060 132.00

141. 29071502 *BETA NAPHTHOL 8.54 0.0166 13.77 0.0224 61.25

142. 29071901 *PHENYL PHENOLS (ORTHO AND PARA) 3.06 0.0059 2.78 0.0045 -9.12

143. 29071902 *THYMOL 0.00 0.0000 0.00 0.0000 -72.42

144. 29071903 *PARA TARTIARY BUTYL PHENOL 3.33 0.0065 3.01 0.0049 -9.61

145. 29071909 *OTHERS 2.81 0.0055 4.64 0.0075 65.06

146. 29072100 RESORCINOL AND ITS SALTS 1.91 0.0037 2.44 0.0040 27.73



4.47 0.0087 5.64 0.0092 26.00

149. 29072901 *1:5 DIHYDROXY NAPTHALENE 0.90 0.0017 1.44 0.0024 61.40

150. 29072909 *OTHERS 1.59 0.0031 4.43 0.0072 178.11

151. 29073000 *PHENOL-ALCOHOLS 0.74 0.0014 0.80 0.0013 8.99


153. 29082001 *G ACID (2-NAPHTHOL-6)8-DISULPHONIC ACID 0.04 0.0001 0.04 0.0001 1.75

154. 29082002 *G.ACID SALTS 0.12 0.0002 0.01 0.0000 -93.85

155. 29082003 *NAPHTHOL SULPHONIC ACIDS N.E.S. 0.02 0.0000 0.03 0.0001 116.75

156. 29082004 *BETA,NAPHTHOL SULPHONIC ACID 0.02 0.0000 0.04 0.0001 101.65

157. 29082005 *NEVILE-WNTHR ACID(1-NPHTHL 4 SULPHNC ACID) 0.02 0.0000 0.13 0.0002 564.61

158. 29082006 *R.ACID (2-NPHTHL 3,6-DISLPHNC) AND ITS DISODIUM SALT (R SALT) 0.00 0.0000

159. 29089001 *PARA NITROPHENOL 0.11 0.0002 0.10 0.0002 -5.39

160. 29089002 *MUSK XYLOL 0.00 0.0000

161. 29089003 *CHROMOTROPIC ACID 0.00 0.0000 0.01 0.0000 206.17

162. 29089009 *OTHERS 0.54 0.0011 0.57 0.0009 5.28

163. 29091100 DIETHYL ETHER 0.09 0.0002 0.33 0.0005 285.53


- 243 -


2.60 0.0051 1.54 0.0025 -40.97


0.16 0.0003 0.26 0.0004 61.55

166. 29093001 *ANISOLE AND THEIR DERIVATIVES N.E.S. 0.80 0.0016 1.23 0.0020 52.96

167. 29093002 *4-CHLORO-2-NITRO ANISOLE 0.06 0.0001 0.01 0.0000 -82.40

168. 29093003 *DIPHENYL OXIDE 0.22 0.0004 0.27 0.0004 25.50

169. 29093004 *ORTHO NITRO ANISOLE 0.05 0.0001 0.00 0.0000 -94.34

170. 29093005 *MUSK AMBRETTE 0.05 0.0001



0.23 0.0005 4.03 0.0066 1,628.33


0.94 0.0018 1.29 0.0021 38.02


0.32 0.0006 0.35 0.0006 9.07

175. 29094901 *GUAIAC0 ETHERS 2.30 0.0045 2.81 0.0046 22.01

176. 29094909 *0THERS 1.26 0.0024 2.08 0.0034 65.00

177. 29095001 *ISOEUGENOL 0.59 0.0011 0.69 0.0011 17.34

178. 29095002 *POTASSIUM GUAIACOL SULPHONATE 0.14 0.0003 0.32 0.0005 120.79


0.54 0.0010 1.25 0.0020 134.17

180. 29101000 OXIRANE (ETHYLENE OXIDE) 0.18 0.0004 0.06 0.0001 -67.82

181. 29102000 METHYLOXIRANE (PROPYLENE OXIDE) 0.89 0.0017 0.98 0.0016 10.48



184. 29110001 *ACETALS AND HEMIACETALS 0.15 0.0003 0.21 0.0003 42.88

185. 29110002 *DERIVATIVES OF ACETALS AND HEMIACETALS 0.34 0.0007 0.03 0.0000 -92.60

186. 29121100 METHANAL (FORMALDEHYDE) 0.20 0.0004 0.17 0.0003 -17.88


188. 29121300 BUTANOL (BUTYRALDEHYDE,NORMAL ISOMER) 0.62 0.0012 0.48 0.0008 -22.46

189. 29121901 *CROTONALDEHYDE 1.31 0.0025 2.06 0.0034 57.73

190. 29121902 *HEPTALDEHYDE (HEPTANAL) 0.00 0.0000

191. 29121903 *GLYOXAL 0.14 0.0003 0.28 0.0005 93.10

192. 29121909 *OTHERS 3.09 0.0060 4.06 0.0066 31.53

193. 29122100 BENZALDEHYDE 3.86 0.0075 4.22 0.0069 9.38

194. 29122901 *CINNAMIC ALDEHYDE 2.74 0.0053 1.76 0.0029 -35.82

195. 29122902 *PHENYL ACETALDEHYDE 0.03 0.0001 0.09 0.0001 203.03

196. 29122909 *OTHERS 3.60 0.0070 2.49 0.0041 -30.74

197. 29123000 ALDEHYDE-ALCOHOLS 1.17 0.0023 0.93 0.0015 -20.74



200. 29124901 *ANISIC ALDEHYDE 0.30 0.0006 0.91 0.0015 206.90

201. 29124902 *HELIOTROPINE (PIPERONYL ALDEHYDE) 0.07 0.0001 0.04 0.0001 -43.19

202. 29124904 *3,4,5-TRIMETHOXY-BENZALDEHYEDE 0.20 0.0004 0.09 0.0002 -53.29

203. 29124909 *OTHRS 1.47 0.0029 1.94 0.0032 31.50

204. 29125001 *HEPTENE 0.16 0.0003 0.09 0.0001 -44.04

205. 29125009 *OTHR CYCLIC POLYMERS OF ALDEHYDES 0.29 0.0006 0.46 0.0007 59.28

206. 29126000 PARA FORMALDEHYDE 2.28 0.0044 2.58 0.0042 13.55


- 244 -

207. 29130001 *ORTHO-CHLORO-BENZALDEHYDE 0.50 0.0010 0.87 0.0014 74.49

208. 29130009 *DRVTVS OF ALDHYDS ALDHYD ALCHLS, ALDHYD-ETHRS,ALDHYD-PHNLS&OTHR SINGLE OR COMPLEX OXYGEN-FUNCTION ALDAYDS

1.43 0.0028 1.14 0.0019 -20.24

209. 29141100 ACETONE 8.73 0.0170 11.48 0.0187 31.52



212. 29141901 *IS0PH0R0N 0.79 0.0015 0.28 0.0005 -64.15

213. 29141909 *0THERS 1.92 0.0037 2.06 0.0034 7.16

214. 29142101 *NATURAL CAMPHOR 0.65 0.0013 0.66 0.0011 2.73

215. 29142102 *SYNTHETIC CAMPHOR 0.69 0.0013 0.37 0.0006 -46.69


217. 29142301 *BETA-IONONE 0.67 0.0013 0.51 0.0008 -23.46

218. 29142302 *PSEUD0 I0N0NE 0.12 0.0002 0.01 0.0000 -89.87

219. 29142309 *OTHERS 0.54 0.0010 0.48 0.0008 -9.57

220. 29142901 *L-CARAVONE 2.07 0.0040 2.28 0.0037 9.87

221. 29142909 *OTHERS 3.14 0.0061 2.67 0.0043 -15.07

222. 29143100 PHENYLACETONE 0.21 0.0004 0.16 0.0003 -24.50

223. 29143901 *ACETONE PHENONE 10.34 0.0201 5.68 0.0092 -45.08

224. 29143902 *BEZANTHRONE 0.01 0.0000 0.01 0.0000 -14.66

225. 29143903 *BENZOPHENONE(e.g. MICHLAR'S KETONE ETC) 0.26 0.0005 0.24 0.0004 -9.24

226. 29143904 *DIBENZANTHRONE (VIOLANTHRONE) 0.08 0.0002 0.07 0.0001 -11.76



229. 29146100 ANTHRAQUINONE 2.74 0.0053 3.89 0.0063 42.28

230. 29146901 *1:4 DIHYDROXY ANTHRAQUINONE (QUINIZARIN) 0.70 0.0014 0.77 0.0013 10.06

231. 29146902 *METHYL ANTHRAQUINONE 0.13 0.0002

232. 29147001 *1-CHLORO ANTHRA QUINONE 0.51 0.0010 0.85 0.0014 68.31

233. 29147002 *MUSK KETONE 0.07 0.0001 0.11 0.0002 58.25

234. 29147009 *OTHR HALGNTD SLPHNTD NITRTD/NITRSTD DRVTVS 5.19 0.0101 3.97 0.0065 -23.42

235. 29151100 FORMIC ACID 2.05 0.0040 2.09 0.0034 2.03

236. 29151201 *SODIUM FORMATE 1.07 0.0021 1.33 0.0022 24.05

237. 29151209 *OTHERS 0.84 0.0016 0.87 0.0014 3.69


239. 29152100 ACETIC ACID 12.30 0.0239 16.34 0.0266 32.82

240. 29152200 SODIUM ACETATE 0.07 0.0001 0.03 0.0001 -55.53

241. 29152300 COBALT ACETATES 1.18 0.0023 0.91 0.0015 -22.90

242. 29152400 ACETIC ANHYDRIDE 0.11 0.0002

243. 29152901 *CALCIUM ACETATE 0.47 0.0009 0.99 0.0016 112.41

244. 29152903 *MANGANESE ACETATE 0.02 0.0000 0.02 0.0000 3.19

245. 29152909 *OTHER ACETIC ACID & ITS SALTS,NES 2.22 0.0043 2.50 0.0041 12.89

246. 29153100 ETHYL ACETATE 0.19 0.0004 0.46 0.0008 140.87

247. 29153200 VINYL ACETATE 9.52 0.0185 10.35 0.0169 8.66

248. 29153300 N-BUTYL ACETATE 4.52 0.0088 5.83 0.0095 28.97



251. 29153901 *BENZYL ACETATE 1.30 0.0025 3.25 0.0053 150.13

252. 29153902 *BOMYL ACETATE 0.00 0.0000 0.00 0.0000 -1.45


- 245 -

253. 29153903 *4INALYL ACETATE 0.45 0.0009 0.30 0.0005 -32.58

254. 29153904 *METHYL ACETATE 0.27 0.0005 0.35 0.0006 30.26

255. 29153905 *PHENYL PROPYL ACETATE 0.00 0.0000 0.01 0.0000 183.64

256. 29153909 *ESTERS OF ACETIC ACID & DRVTVS N.E.S. 3.88 0.0076 6.76 0.0110 74.07

257. 29154001 *MONOCHLOROACETIC ACID,THR SALTS & ESTERS 0.64 0.0012 0.43 0.0007 -31.97

258. 29154002 *TRICHLORO ACETIC ACID,THEIR SALTS & ESTERS 0.00 0.0000 0.03 0.0001 3,220.81

259. 29154003 *DICHLOROACETIC ACID,THEIR SALTS & ESTERS 0.05 0.0001 0.30 0.0005 501.80


261. 29156001 *BUTYRIC ACIDS, ITS SALTS AND ESTERS 0.74 0.0014 1.06 0.0017 43.57

262. 29156002 *VALERIC ACIDS, ITS SALTS AND ESTERS 0.59 0.0012 0.32 0.0005 -45.53

263. 29157001 *GLYCEROL MONOSTEARATE 0.48 0.0009 0.77 0.0013 61.75

264. 29157002 *PALMITIC ACID 0.10 0.0002 0.18 0.0003 70.76

265. 29157003 *STEARIC ACID 0.40 0.0008 0.64 0.0010 62.01

266. 29157004 *HCO FATTY ACID(INCL 12-HYDROXY STEARC ACD) 0.02 0.0000 0.01 0.0000 -22.98

267. 29157005 *D.C.0. FATTY ACID 0.01 0.0000 0.07 0.0001 410.48

268. 29157006 *DIMER AND DIMER ACID 1.53 0.0030 1.14 0.0018 -25.51

269. 29159001 *ACETYL CHL0RIDE 5.41 0.0105 9.51 0.0155 75.76

270. 29159002 *OCTOIC ACID (CAPRYLIC ACID) 1.09 0.0021 0.42 0.0007 -61.56

271. 29159003 *HEXOIC ACID (CAPROIC ACID) 0.20 0.0004 0.26 0.0004 28.30

272. 29159009 *0THER CHL0RIDE 13.12 0.0255 12.92 0.0210 -1.55


274. 29161201 *BUTYL ACRYLATE 16.09 0.0313 20.54 0.0335 27.70

275. 29161209 *OTHERS 6.13 0.0119 5.43 0.0088 -11.35

276. 29161301 *METHACRYLIC ACID MONOMER 3.67 0.0071 4.78 0.0078 30.35

277. 29161302 *SALTS OF METHACRYLIC ACID 0.75 0.0014 0.51 0.0008 -31.63

278. 29161400 ESTERS OF METHACRYLIC ACID 4.75 0.0092 4.57 0.0074 -3.76

279. 29161501 *OLEIC ACID 0.29 0.0006 0.48 0.0008 66.73

280. 29161509 *OTHERS EXCLUDNG OLEIC ACID 0.26 0.0005 0.13 0.0002 -49.22

281. 29161901 *UNDECYLANIC ACID 0.88 0.0017 1.37 0.0022 54.91

282. 29161902 *BISMUTH CMPNDS OF UNSATRTD ACYLC MONOACIDS 0.00 0.0000 0.02 0.0000 621.84

283. 29161903 *POTSUM CMPNDS OF UNSATRTDS ACYLC MONDACDS 0.03 0.0001

284. 29161904 *SODIUM CMPNDS OF UNSATRTD ACYLC MONOACDS 0.00 0.0000 0.03 0.0000 877.97

285. 29161905 *ESTRS OF UNSATRTD ACYLC MONOACDS NES 0.01 0.0000

286. 29161906 *SORBIC ACID 0.15 0.0003 0.07 0.0001 -51.55

287. 29161909 *OTHRS 1.72 0.0034 2.29 0.0037 32.85


0.19 0.0004 0.73 0.0012 286.29

289. 29163101 *BENZOIC ACID 0.77 0.0015 1.46 0.0024 88.88

290. 29163102 *BENZYL BENZOATE 0.00 0.0000

291. 29163103 *METHYL BENZOATE 0.00 0.0000

292. 29163104 *SODIUM BENZOATE 0.06 0.0001 0.01 0.0000 -88.88

293. 29163105 *BENZOCAINE (ETHYLPARA-AMINO BENZOATE) 0.03 0.0000

294. 29163106 *ORTHOCHLORO BENZOIC ACID 0.09 0.0002 0.03 0.0001 -64.58

295. 29163109 *OTHER SALTS AND ESTERS OF BENZOIC ACID 3.43 0.0067 3.51 0.0057 2.35

296. 29163200 BENZYL PEROXYD & BENZOYL CHLRD 0.09 0.0002 0.23 0.0004 168.21


- 246 -

297. 29163400 PHENYLACETIC ACID & ITS SALTS 0.01 0.0000 0.15 0.0003 966.21


299. 29163901 *CINNAMIC ACID 0.96 0.0019 1.25 0.0020 29.73

300. 29163903 *POTASSIUM COMPOUNDS OF AROMATIC MONOACIDS 0.20 0.0003

301. 29163905 *ESTERS OF AROMATIC MONOACIDS NES 0.00 0.0000 0.01 0.0000 2,815.48

302. 29163909 *OTHERS 1.58 0.0031 1.57 0.0026 -0.60

303. 29171101 *OXALIC ACID 0.00 0.0000 0.03 0.0000 424.69

304. 29171109 *OTHER SALTS AND ESTERS OF OXALIC ACID 0.07 0.0001 0.21 0.0003 197.28

305. 29171200 ADIPIC ACID ITS SALTS AND ESTERS 3.74 0.0073 3.96 0.0065 5.94


307. 29171400 MALEIC ANHYDRIDE 0.38 0.0007 0.28 0.0005 -26.98

308. 29171901 *MALEIC ACID 0.83 0.0016 1.31 0.0021 56.94

309. 29171902 *MALONIC ACID 0.23 0.0004 0.22 0.0004 -3.82

310. 29171903 *SUCCINIC ACID 0.05 0.0001 0.01 0.0000 -79.77

311. 29171905 *FUMBRIC ACID 0.05 0.0001 0.27 0.0004 415.91

312. 29171906 *ITAC0NIC ACID 0.08 0.0002 0.03 0.0001 -58.44

313. 29171907 *ETH0XY METHYLENE MAL0NATE,DIETHYL MAL0NATE 2.16 0.0042 2.21 0.0036 2.07

314. 29171909 *OTHR ACYLC PLYCRBOXYLC ACDS & THR DRVTVS 1.55 0.0030 1.41 0.0023 -9.02


0.55 0.0011 0.48 0.0008 -12.58

316. 29173100 DIBUTYL ORTHOPHTHALATES 0.11 0.0002 0.03 0.0000 -77.25

317. 29173200 DIOCTYL ORTHOPHTHALATES 2.18 0.0042 2.88 0.0047 32.23

318. 29173300 DINONYL OR DIDECYL ORTHOPHTHALATES 0.06 0.0001 0.09 0.0001 53.43

319. 29173400 OTHER ESTERS OF ORTHOPHTHALIC ACID 0.07 0.0001 0.10 0.0002 35.46



322. 29173700 DIMETHYL TEREPHTHALATE 1.63 0.0026

323. 29173901 *DIBUTYL PHTHALATE 0.82 0.0016 3.43 0.0056 316.93

324. 29173902 *DIOCTL PHTHALATE 3.76 0.0073 3.87 0.0063 3.11

325. 29173903 *PHTHALIC ACID 1.52 0.0030 1.71 0.0028 12.38

326. 29173904 *DIMETHYL PHTHALATE 0.00 0.0000 0.06 0.0001 6,410.80

327. 29173909 *OTHERS 8.18 0.0159 8.39 0.0137 2.66

328. 29181101 *LACTIC ACID 0.35 0.0007 0.62 0.0010 76.31

329. 29181102 *CALCIUM LACTATE 0.09 0.0002 0.03 0.0000 -68.40

330. 29181109 *OTHER SALTS AND ESTERS OF LACTIC ACID 0.11 0.0002 0.65 0.0011 481.73

331. 29181200 TARTARIC ACID 2.34 0.0046 1.76 0.0029 -24.76

332. 29181301 *POTASSIUM BITARTRATE 0.05 0.0001 0.18 0.0003 260.79

333. 29181302 *METROPROLOL TARTRATE 0.00 0.0000 0.00 0.0000 60.22

334. 29181309 *OTHER SALTS AND ESTERS OF TARTARIC ACID 0.02 0.0000 0.28 0.0005 1,376.96

335. 29181400 CITRIC ACID 5.47 0.0106 3.01 0.0049 -45.02

336. 29181501 *POTASSIUM CITRATE 0.08 0.0002 0.09 0.0001 11.61

337. 29181502 *SODIUM CITRATE 0.29 0.0006 0.26 0.0004 -10.31

338. 29181504 *DISODIUM HIDROGEN CIRTATE 0.03 0.0000

339. 29181509 *OTHER SALTS AND ESTERS OF CITRIC ACID 0.12 0.0002 0.59 0.0010 406.40

340. 29181601 *CALCIUM GLUCONATE 0.40 0.0008 1.16 0.0019 191.10

341. 29181602 *FERROUS GLUCONATE 0.02 0.0000

342. 29181609 *OTHER GLUCONIC ACID ITS SALTS AND ESTERS 1.32 0.0026 1.11 0.0018 -15.69


- 247 -

343. 29181700 *PHENYLGLYCOLIC ACID (MANDELIC ACID) ITS SALTS AND ESTERS 0.47 0.0009 0.17 0.0003 -65.04

344. 29181901 *2,2-DIPHENYL-2-HYDROXY ACETIC ACID 0.52 0.0010 1.37 0.0022 165.48

345. 29181909 *OTHERS 0.80 0.0016 2.57 0.0042 220.19

346. 29182101 *SALICYLIC ACID 0.27 0.0005 0.45 0.0007 63.59

347. 29182102 *SODIUM SALICYLATE 0.00 0.0000

348. 29182200 0-ACETYLSALICYLIC ACID ITS SALTS AND ESTRS 0.06 0.0001 0.03 0.0000 -46.94

349. 29182301 *METHYL SALICYLATE 0.20 0.0004 0.32 0.0005 58.00

350. 29182309 *OTHERS 0.20 0.0004 0.20 0.0003 0.76

351. 29182901 *GALIC ACID 1.01 0.0020 1.06 0.0017 4.73

352. 29182902 *BETA HYDROXY NAPHTHOIC ACID 0.15 0.0003 0.09 0.0001 -37.11

353. 29182903 *PROPYL GALLATE 0.00 0.0000

354. 29182909 *OTHERS 1.59 0.0031 1.83 0.0030 15.27

355. 29183001 *LEVULINIC ACID 1.45 0.0028 2.99 0.0049 106.14

356. 29183002 *ETHYL ACETO ACETATE(ACETOACETIC ESTER) 0.51 0.0010 0.28 0.0005 -45.47

357. 29183004 *METHYL ACET0 ACETATE 1.77 0.0034 1.85 0.0030 4.88

358. 29183009 *OTHERS 2.47 0.0048 2.75 0.0045 11.69


9.38 0.0182 9.82 0.0160 4.69

360. 29190001 *CALCIUM GLYCEROPHOSPHATE 0.47 0.0009 0.58 0.0009 22.64

361. 29190002 *GLYCEROPHOSPHATE ACID 0.09 0.0001

362. 29190004 *TRICRESYL PHOSPHATE 0.01 0.0000 0.00 0.0000 -63.00

363. 29190005 *N,N DIALKYL (ME,ET,N-PR OR I-PR PHOSPHO- RAMIDIC DIHALIDES) 0.00 0.0000

364. 29190009 *OTHERS 1.50 0.0029 1.50 0.0024 -0.24

365. 29201001 *AMITON:0,0-DIETHYL S-2-(DIETHYLAMINO) ETHYL | PHOSPHOROTHIOLATE &CORRSPNDNG ALKYLATED/PROTONATED SALTS

0.51 0.0010 0.17 0.0003 -66.24

366. 29201009 *OTHERS 5.20 0.0101 4.25 0.0069 -18.34

367. 29209001 *DIETHYL SULPHATE 0.72 0.0014 2.06 0.0034 187.03

368. 29209002 *DIMETHYL SULPHATE 0.06 0.0001 0.06 0.0001 9.48

369. 29209004 *DI-METHYL METHYL PHOSPHONATE 0.16 0.0003

370. 29209005 *DI-METHYL PHOSPHITE 0.16 0.0003 0.09 0.0002 -40.07

371. 29209008 *TRI-ETHYL PHOSPHITE 0.05 0.0001 0.00 0.0000 -92.28

372. 29209009 *OTHER INORGNC ESTRS THR SLTS & DRVTVS 3.83 0.0074 4.43 0.0072 15.84

373. 29211101 *DIMETHYL FORMIDE 5.65 0.0110 6.72 0.0109 18.96

374. 29211102 *N-METHYL FORMAMIDE 0.14 0.0003 0.21 0.0003 45.87

375. 29211103 *MONO_METHYLAMINE 0.01 0.0000

376. 29211109 *FORMAMIDE,N.E.S. 1.58 0.0031 1.44 0.0023 -8.85


378. 29211901 *N,N-DIALKYL(ME,ET,N-PR OR I-PR) AMINO ETHYL-2-CHLORIDES & CORRSPNDNG PROTONATED SALTS THEREOF

1.96 0.0038 3.06 0.0050 55.82

379. 29211902 *MONO-ETHYLAMINE 0.00 0.0000 0.04 0.0001 1,393.33

380. 29211909 *OTHERS 4.13 0.0080 4.61 0.0075 11.66


382. 29212200 HEXAMETHYLENEDIAMINE AND ITS SALTS 1.43 0.0028 1.19 0.0019 -17.08

383. 29212901 *HEXAMETHYLENE TETRAMINE (HEXAMINE) NOT PUT UP AS FUEL OR MEDICAMENT

2.04 0.0040 3.16 0.0051 54.67

384. 29212902 *TRIMETHYLENE TRINIFRAMINE 0.01 0.0000 0.07 0.0001 1,138.76

385. 29212909 *OTHERS 5.32 0.0103 4.59 0.0075 -13.61


- 248 -

386. 29213001 *CYCLOHEXYLAMINE 1.46 0.0028 1.72 0.0028 17.86

387. 29213009 *OTHERS 4.37 0.0085 2.11 0.0034 -51.85

388. 29214101 *ANILINE 0.63 0.0012 0.81 0.0013 27.88

389. 29214109 *OTHR ANILINE SALTS 0.90 0.0017 1.21 0.0020 34.93

390. 29214201 *PARA CHLOROANILINE 1.27 0.0025 1.10 0.0018 -13.77

391. 29214202 *ORTHO CHLORO PARANITROANILINE 1.58 0.0031 0.10 0.0002 -93.71

392. 29214203 *DICHLOROANILINE 0.07 0.0001

393. 29214204 *2:6-DICHLORO PARANITROANILINE 0.12 0.0002

394. 29214205 *DIETHYLANILINE 0.69 0.0014 0.51 0.0008 -26.82

395. 29214206 *DIMETHYL ANILINE 0.09 0.0002 0.14 0.0002 66.31

396. 29214207 *ETHYL ANILINE 0.04 0.0001 0.06 0.0001 61.36

397. 29214211 PARA CHLOROANILINE 0.13 0.0002 0.96 0.0016 662.66

398. 29214212 ORTHO CHLORO PARANITROANILINE 0.02 0.0000

399. 29214215 2-4-5-TRICHLOROANILINE 0.02 0.0000 0.14 0.0002 471.14

400. 29214217 *METHYL DOPA(L-ALPHA METHYL-3, 4-DIHYDROXYPHENYLALANINE) 0.17 0.0003 0.06 0.0001 -63.74

401. 29214218 *CARBIDOPA 0.20 0.0004 0.34 0.0006 72.13

402. 29214229 *OTHERS 3.78 0.0073 3.59 0.0059 -4.88

403. 29214301 *DIETHYL TOLUIDINE 0.28 0.0005 0.56 0.0009 99.63

404. 29214303 *ORTHO TOLUIDINE 0.21 0.0004 0.43 0.0007 105.96

405. 29214304 *META TOLUIDINE 0.05 0.0001 0.08 0.0001 44.57

406. 29214305 *PARA TOLUIDNE 0.24 0.0005 0.21 0.0003 -11.20

407. 29214308 *4-TOLUIDINE-3-SULPHONIC ACID 0.02 0.0000 0.01 0.0000 -33.30

408. 29214309 *OTHR TOLUIDINES & THR DRVTVS SLTS THEREOF 0.38 0.0007 0.99 0.0016 158.94

409. 29214401 *DIPHENYLAMINE (E.G. 16-DPA) 0.98 0.0019 1.20 0.0020 22.61

410. 29214409 *OTHR DIPHNYLAMINE & ITS DRVTVS;SLTS THROF 0.75 0.0015 0.40 0.0007 -46.32

411. 29214501 *ALPHA NAPHTHYLAMINE 0.35 0.0007 1.56 0.0025 350.29

412. 29214503 *PHENYL BETA NAPHTHYLAMINE 0.00 0.0000

413. 29214506 *CLEVE'S ACID(1 NAPHTHYLAMN-6-SLPHNC ACID) 0.06 0.0001 0.02 0.0000 -57.42

414. 29214511 ALPHA NAPHTHYLAMINE 0.09 0.0002

415. 29214512 PHENYL ALPHA NAPHTHYLAMINE 0.03 0.0001

416. 29214514 AMINO F-ACID 0.25 0.0004

417. 29214515 AMINOLINELI-R-ACID 0.01 0.0000 0.01 0.0000 86.35

418. 29214516 SODIUM NAPHTHIONATE 0.03 0.0001 0.02 0.0000 -28.41

419. 29214517 *TOBIAS ACID(2-NAPHTHYLAMINE-1-SLPHNC ACD) 5.60 0.0109 6.47 0.0105 15.55

420. 29214519 *OTHR 1-NPTHYLAMN 2-NPTHYLAMN AND THEIR DRVTVS AND SLTS THREOF

0.54 0.0011 1.86 0.0030 240.95

421. 29214901 *BENZYL ETHYL ANILINE 0.89 0.0017 1.20 0.0020 34.44

422. 29214903 *2-5-XYLIDINE 0.03 0.0000 0.20 0.0003 674.73

423. 29214904 *XYLIDINE (MIXED) 0.88 0.0017 0.75 0.0012 -15.01

424. 29214909 *COTHERS 1.57 0.0031 1.44 0.0023 -8.39

425. 29215101 *M-PHENYLENEDIAMINE (M-DIAMINOBENZENE) 2.15 0.0042 3.58 0.0058 66.14

426. 29215102 *PARA-AMINO ACETANILIDE 0.12 0.0002 0.58 0.0009 381.01

427. 29215103 *META TOLUYLENE DIAMINE 0.01 0.0000 0.02 0.0000 97.90

428. 29215109 *OTHR O-M-P-PHNYLENEDIAMINE DIAMINOTOLUENE AND THEIR DRVTVS SALTS THEREOF

1.18 0.0023 0.71 0.0012 -39.65

429. 29215901 *BENZIDINE 1.32 0.0026 1.89 0.0031 43.23

430. 29215909 *OTHERS 5.12 0.0100 2.84 0.0046 -44.46

431. 29221101 *N N-DIALKL (ME ET N-PR) AMNO-ETHN-2/OLS & CORSPNGNG PRTNTD 0.26 0.0005 0.32 0.0005 22.31


- 249 -

432. 29221109 *OTHERS 0.75 0.0015 2.27 0.0037 203.62


434. 29221301 *TRIETHANOLAMINE 0.29 0.0006 0.93 0.0015 225.00

435. 29221302 *SALTS OF TRIETHANOLAMINE 0.05 0.0001 0.17 0.0003 255.96

436. 29221901 *METHYL DI-ETHANOLAMINE 8.11 0.0158 7.47 0.0122 -7.95

437. 29221902 *ETHYL DI-ETHANOLAMINE 0.02 0.0000 0.02 0.0000 0.33

438. 29221903 *N,N-DIALKYL (ME,ET,N-PR OR IPR) AMINO- ETHANE -2-THIOLS & CORRSPNDNG PROTONATED SALTS

0.07 0.0001

439. 29221909 *OTHERS 4.85 0.0094 12.22 0.0199 151.80

440. 29222101 *AMINO-G-ACID 0.18 0.0004 0.99 0.0016 442.93

441. 29222102 *AMINO-J-ACID 0.37 0.0007 0.38 0.0006 2.47

442. 29222103 *1-AMINO-2-NAPHTHOL-4-SULPHONIC ACID 0.01 0.0000

443. 29222104 *GAMMA ACID 0.13 0.0002

444. 29222105 *J ACID (2-AMINO-5-NAPTHOL-7 SLPHNC ACID) 2.74 0.0053 2.26 0.0037 -17.63

445. 29222106 *H-ACID 0.52 0.0010 2.76 0.0045 434.96

446. 29222107 *ORTHO PHENYL SULPHONYL H-ACID 0.01 0.0000 0.13 0.0002 1,252.32

447. 29222111 *CHICAGO ACID 0.05 0.0001

448. 29222119 *OTHERS 0.92 0.0018 1.20 0.0020 29.97

449. 29222201 *ORTHO ANISIDINES 1.43 0.0028 1.68 0.0027 17.38

450. 29222202 *PARA ANISIDINES 0.22 0.0004 0.70 0.0011 215.15

451. 29222203 *ORTHO PHENETIDINE(2-AMINOPHENITOLE) 0.08 0.0002 0.00 0.0000 -94.50

452. 29222209 *OTHR ANISIDNS DIANSDNS PHNTDNS & THR SLTS 0.28 0.0005 0.59 0.0010 112.86

453. 29222901 *2-AMINO 4-NITROPHENOL 0.50 0.0010 1.97 0.0032 297.08

454. 29222902 *META AMINOPHENOL THN ONE KIND OF OXYGEN FUNCTION ;SALTS

0.27 0.0005 0.25 0.0004 -7.44

455. 29222903 *PARA AMINOPHENOL 0.04 0.0001 0.16 0.0003 333.91

456. 29222904 *2-AMINO-1-PHENOL-4-SULPHONIC ACID 0.06 0.0001 0.09 0.0002 55.83

457. 29222905 *META DIETHYL AMINO-PHENOL 0.03 0.0001

458. 29222906 *6-NITRO-0-AMINOPHENOL-4-SULPHONIC ACID 0.09 0.0002

459. 29222908 *PHENYL GAMMA ACID(PHENYL 2--AMINO-8- NAPHTHOL-6-SULPHONIC ACID)

0.13 0.0002

460. 29222911 2-AMINO 4-NITROPHENOL 0.09 0.0002 0.21 0.0003 127.53

461. 29222912 META AMINOPHENOL THN ONE KIND OF OXYGEN FUNCTION ;SALTS 0.08 0.0001

462. 29222913 PARA AMINOPHENOL 0.00 0.0000

463. 29222914 META DIETHYL AMINO-PHENOL 2.64 0.0051 3.68 0.0060 39.31

464. 29222915 *PARA CRESIDINE 0.33 0.0006 0.75 0.0012 127.40

465. 29222916 *PICRAMIC ACID (T-GRADE) 0.05 0.0001 0.05 0.0001 -6.70

466. 29222917 *META-PHENYLENE DIAMENE-4-SULPH0NIC ACID 0.07 0.0001

467. 29222919 *OTHERS 3.87 0.0075 3.29 0.0054 -15.06

468. 29223001 *2-ACETYLAMINO-3-CHLORO-ANTHRAQUINONE 1.67 0.0033 1.01 0.0016 -39.54

469. 29223002 *1-AMINO-ANTHRAQUINONE 0.05 0.0001 0.08 0.0001 51.73

470. 29223009 *OTHERS 0.35 0.0007 1.86 0.0030 426.80


472. 29224201 *M0N0S0DIUM GLUTAMATE ( AZINAMAT0 ) 2.22 0.0043 2.58 0.0042 16.24

473. 29224209 *GLUTAMIC ACID AND 0THER SALTS 0.62 0.0012 0.49 0.0008 -21.79


475. 29224901 *AMINO ACETIC ACID (GLYCINE) 5.04 0.0098 8.08 0.0132 60.35

476. 29224902 *N-METHYL TAURINE 0.00 0.0000 0.00 0.0000 -3.94


- 250 -

477. 29224909 *OTHERS 6.70 0.0130 8.00 0.0130 19.51

478. 29225002 *PARA-AMINO-SALICYLIC ACID 0.88 0.0017 1.32 0.0021 50.40

479. 29225004 *METHYL ANTHRANILATE 0.00 0.0000

480. 29225005 *PROCAINE HYDROCHLORIDE 0.24 0.0005 0.28 0.0005 16.95

481. 29225006 *AMINO ANISIC ACID ANILIDE 0.00 0.0000 0.04 0.0001 1,182.48

482. 29225007 *L-TYROSINE(p-HYDROXYPHENYLAMINE) 0.05 0.0001

483. 29225008 *FRUSEMIDE 0.32 0.0006 0.15 0.0003 -51.51

484. 29225011 PARA-AMINO-SALICYLIC ACID 0.00 0.0000 0.23 0.0004 241,108.25

485. 29225013 PROCAINE HYDROCHLORIDE 0.23 0.0005 0.13 0.0002 -43.11

486. 29225019 *OTHERS 4.22 0.0082 4.13 0.0067 -2.00

487. 29231000 CHOLINE AND ITS SALTS 0.11 0.0002 0.45 0.0007 307.15

488. 29232001 *LECITHINS (OTHER THAN MEDICAMENTS) 0.63 0.0012 0.97 0.0016 54.55

489. 29232009 *OTHERS (PHOSPHOAMINOLIPIDS) 0.09 0.0002 0.45 0.0007 418.33


1.22 0.0024 1.22 0.0020 -0.19

491. 29241001 *ACETANILIDE 2.41 0.0047 2.85 0.0046 18.21

492. 29241002 *ACETO ACETANILIDE 0.12 0.0002 0.02 0.0000 -80.31

493. 29241003 *ACETO ACETIC ORTHO CHLORANILIDE 0.01 0.0000

494. 29241004 *ACETO ACETIC PARA CHLORANILIDE 0.03 0.0001

495. 29241005 *DIETHYL DIPHENYL UREA 0.02 0.0000

496. 29241006 *DIMETHYL DIPHENYL UREA (ZENTRALIN) 0.27 0.0005 0.21 0.0003 -22.05

497. 29241007 *TOLBUTAMIDE 0.13 0.0002

498. 29241011 *PARACHLORO BENZENE SULPHONYL UREA 0.02 0.0000 0.01 0.0000 -43.17

499. 29241019 *OTHERS 5.52 0.0107 4.86 0.0079 -11.88

500. 29242100 *UREINES & THEIR DERIVATIVES SALTS THEREOF 0.11 0.0002 0.21 0.0003 101.69

501. 29242200 *ACETAMEDOBENZOIC ACID 0.03 0.0001

502. 29242901 *PHENYL ACETAMIDE 2.81 0.0055 4.94 0.0080 75.77

503. 29242902 *PYRAZINAMIDE(PYRAZINE CARBOXAMIDE) 0.90 0.0017 0.00 0.0000 -99.98

504. 29242909 *OTHERS 7.63 0.0148 8.35 0.0136 9.51



507. 29252001 *GUANIDINE NITRATE 0.22 0.0004 0.24 0.0004 10.84

508. 29252009 *OTHERS 0.64 0.0012 0.21 0.0003 -66.47

509. 29261000 ACRYLONITRILE 69.07 0.1343 58.10 0.0946 -15.89



512. 29270001 *PARA AMINO-AZO-BENZENE 0.79 0.0015 0.43 0.0007 -45.73

513. 29270009 *OTHER DIAZO-AZO-OR AZOXY-COMPOUNDS 0.51 0.0010 0.60 0.0010 16.13

514. 29280001 *ORGANIC DERIVATIVEE OF HYDRAZINE OR OF"HYDRDXYLAMINE-ISONIAZID"

0.39 0.0007 1.01 0.0016 161.62

515. 29280009 *OTHR ORGNC DRVTS OF HYDRAZINE/HYDRXYLMINE 0.82 0.0016 1.50 0.0024 83.48

516. 29291001 *PHENYL ISOCYANATE 17.94 0.0349 20.22 0.0329 12.69

517. 29291002 *TOLUENE DIISOCYANATE 1.97 0.0038 2.22 0.0036 12.35

518. 29291009 *ISOCYANATS & DIISOCYNTS OF HYDRCRBN N.E.S. 15.38 0.0299 13.25 0.0216 -13.90

519. 29299000 OTHR CMPNDS WITH OTHER NITROGEN FUNCTION 2.95 0.0057 3.20 0.0052 8.73

520. 29301000 DITHIOCARBONATES(XANTHATES) 0.24 0.0005 0.27 0.0004 8.62


- 251 -

521. 29302000 THIOCARBAMATES AND DITHIOCARBAMATES 0.09 0.0002 0.27 0.0004 212.31

522. 29303000 THIURAM MONO-,DI-OR TETRASULPHIDES 0.20 0.0004 0.12 0.0002 -41.06

523. 29304000 METHIONINE 2.81 0.0055 4.73 0.0077 68.58

524. 29309001 *THIOUREA(SULPHOUREA) 6.40 0.0124 8.46 0.0138 32.21

525. 29309002 *CALCIUM SALTS OF METHIONINE 0.67 0.0013 0.08 0.0001 -87.62

526. 29309003 *SULTONES 0.01 0.0000 0.02 0.0000 158.88

527. 29309004 *THIO SULPHONIC ACID 0.31 0.0006 0.01 0.0000 -97.61

528. 29309005 *L-CYSTINE (ALPHA-AMINO BETA-THIO PROPIONICACID)-SULPHUR CONTAINING AMINO ACID

0.11 0.0002 0.05 0.0001 -59.00

529. 29309006 *SULPHONIC ACID 0.01 0.0000 0.11 0.0002 798.44

530. 29309007 *SULPHOXIDE 2.77 0.0054 6.36 0.0104 129.66

531. 29309008 *MERCAPTAN 1.79 0.0035 2.24 0.0036 25.01

532. 29309011 *THIODIGLYCOL:BIS (2-HYDROXYETHYL)SULPHIDE 0.08 0.0002 0.04 0.0001 -49.18

533. 29309019 *OTHERS 6.50 0.0127 5.53 0.0090 -14.91

534. 29310001 *ORGANO-MERCURY COMPOUNDS 4.76 0.0093 7.96 0.0130 67.12

535. 29310002 *ORGANO-ARSENIC COMPOUNDS 0.01 0.0000

536. 29310003 *TETRA-ETHYL LEAD 0.03 0.0001 0.11 0.0002 228.48

537. 29310009 *OTHER ORGAN-INORGANIC COMPOUNDS NES 19.30 0.0375 21.05 0.0343 9.10


539. 29321200 2-FURALDEHYDE(FURFURALDEHYDE) 0.26 0.0005 0.27 0.0004 1.76

540. 29321300 FURFURYL ALCHL & TETRAHYDROFURFURYL ALCHL 2.12 0.0041 1.66 0.0027 -21.71

541. 29321901 *HYDROXY-3-DIBENZFUREN CARBOXYLIC ACID 0.43 0.0008 0.61 0.0010 41.04

542. 29321909 *OTHERS 2.25 0.0044 1.54 0.0025 -31.42


544. 29322901 *PHENOLPHTHALEIN 0.68 0.0013 1.12 0.0018 65.19

545. 29322902 *SPIRANOLACTONE 0.69 0.0013 1.67 0.0027 144.14

546. 29322909 *OTHERS 2.17 0.0042 2.06 0.0034 -5.30

547. 29329100 IS0SAFR0LE 0.00 0.0000 0.23 0.0004 4,909.23

548. 29329300 PIPERAN0L 0.44 0.0009 0.23 0.0004 -48.88

549. 29329400 SAFR0LE 0.00 0.0000

550. 29329900 OTHER HETEROCYCLIC COMPNDS WITH OXYGEN HETERO - ATOM/S)

1.63 0.0032 3.11 0.0051 90.85

551. 29331100 PHENAZONE (ANTIPYRIN) AND ITS DERIVATIVES 0.07 0.0001 0.32 0.0005 369.60

552. 29331901 *3-CARBOXY (PARA SLPHPHNYL)-5 PYRAZOLONE 0.33 0.0006 0.61 0.0010 84.88

553. 29331902 *1(2:5 DCHLR-4-SLPHPHNYL)-3-MTHYL-5-PYRAZLN 0.03 0.0001

554. 29331904 *PHENYL-METHYL PYRAZOLONE 0.02 0.0000 0.06 0.0001 211.62

555. 29331905 *1-PHNYL-5-PYRAZLN-3-CRBOXYLC ACD ETHYLESTR 0.00 0.0000

556. 29331907 *ANALGIN 0.71 0.0014 0.47 0.0008 -33.17

557. 29331911 *MEFENAMIC- ACID 0.02 0.0000

558. 29331912 *NAPROXEN 0.11 0.0002

559. 29331919 *OTHERS 0.54 0.0011 2.32 0.0038 327.82


561. 29332901 *TINIDAZOLE 0.29 0.0006 0.76 0.0012 157.64

562. 29332902 *METRONIDAZOLE AND ITS SALTS 1.93 0.0038 2.46 0.0040 27.54

563. 29332903 *MEBENDAZOLE 0.06 0.0001 0.07 0.0001 15.81

564. 29332905 *ALBENDAZ0LE 0.07 0.0001 0.27 0.0004 273.87

565. 29332909 *OTHERS 1.60 0.0031


- 252 -

566. 29332912 *ASTEMIZOLE 0.00 0.0000

567. 29332913 *FLUCONAZOLE 0.00 0.0000

568. 29332919 2.56 0.0042



571. 29333901 *AMINO PYRIDINE 1.39 0.0027 3.47 0.0057 150.38

572. 29333902 *ALPHA PICOLINE(2-METHYL PYRIDINE) 0.20 0.0004 0.51 0.0008 154.24

573. 29333903 *GAMMA PICOLINE(4-METHYL PYRIDINE) 0.15 0.0003 0.27 0.0004 85.52

574. 29333904 *CHLORPHENIRAMINE MALEATE 0.06 0.0001 0.06 0.0001 7.24

575. 29333905 *DIPHENOXYLATE HYDROCHLORIDE 0.00 0.0000

576. 29333906 *BETA PIC0LINE ( 3-METHYL PYRIDINE ) 0.96 0.0019 1.57 0.0026 62.56

577. 29333907 *M0RPH0LINE 2.11 0.0041 2.89 0.0047 37.01

578. 29333908 *LUTIDINE 0.13 0.0003 0.30 0.0005 132.39

579. 29333909 *OTHERS 5.05 0.0098

580. 29333919 OTHER DERIVATIVES OF PYRADINE 3.28 0.0053

581. 29334001 *QUINOLINE 0.49 0.0009 0.76 0.0012 55.63

582. 29334002 *2:4 DIHYDROXY QUINOLINE (2:4 DIOXY-QUINLN) 0.02 0.0000 0.04 0.0001 139.87

583. 29334003 *4-HYDROXY-N-METHYL-2-QUINOLINE 0.19 0.0004 0.16 0.0003 -17.95

584. 29334004 *8-HYDROXY QUINOLINE AND ITS SALTS 0.23 0.0004 0.62 0.0010 173.19

585. 29334007 *DICHLORO QUINOLINE 0.01 0.0000

586. 29334011 0.06 0.0001

587. 29334019 *OTHERS 2.33 0.0045 1.46 0.0024 -37.42

588. 29335101 *BARBITURIC ACID 0.53 0.0010 0.33 0.0005 -38.25

589. 29335109 *OTHR SLTS & DRVTVS OF BARBITURIC ACID 0.73 0.0014 0.42 0.0007 -42.87

590. 29335901 *AMINOPHYLLINE(CORDOPHYLIN) 1.71 0.0033 1.28 0.0021 -25.31

591. 29335902 *TRIMETHOPRIM 0.09 0.0002 0.49 0.0008 430.99

592. 29335903 *DIETHYL CARBANAZINE CITRATE 0.03 0.0001

593. 29335904 *CARBAZOLE 0.11 0.0002 0.35 0.0006 233.02

594. 29335909 *OTHERS 9.43 0.0183 6.34 0.0103 -32.79

595. 29336100 MELAMINE 0.66 0.0013 2.15 0.0035 227.01

596. 29336901 *CYANURIC ACID & ITS SALTS 6.45 0.0125 19.18 0.0312 197.21

597. 29336909 *OTHERS 1.85 0.0036 1.86 0.0030 1.02


599. 29337900 OTHER LACTAMS 1.22 0.0024 1.73 0.0028 42.33

600. 29339001 *CARBAMAZIPINE 2.51 0.0049 4.17 0.0068 65.88

601. 29339002 *1-PHENYL-2-PR0PAN0ME 0.22 0.0004

602. 29339009 *OTHERS 3.32 0.0065 9.31 0.0152 180.13


2.22 0.0043 0.91 0.0015 -58.91


0.75 0.0015 1.17 0.0019 55.88


0.25 0.0005 1.06 0.0017 319.72


- 253 -

606. 29349001 *ACRIFLAVINE BPC NEUTRAL 2.99 0.0058 3.99 0.0065 33.50

607. 29349003 *INDOLE 0.00 0.0000 0.01 0.0000 383.12

608. 29349004 *DEHYDRO THIO PARA TOLUIDINE SULPHONIC ACID 0.01 0.0000

609. 29349006 *MICONAZOLE 0.00 0.0000

610. 29349007 *CLORTRIMAZOLE 0.02 0.0000 0.08 0.0001 271.00

611. 29349008 *FURAZ0LIDINE 0.81 0.0016 0.83 0.0014 3.37

612. 29349019 *0THERS 5.15 0.0100 4.47 0.0073 -13.24

613. 29350001 *SULPHAMETHOXAZOLE 2.83 0.0055 2.73 0.0044 -3.57

614. 29350002 *SULPHAFURAZOLE 0.03 0.0001 0.04 0.0001 41.40

615. 29350003 *SULPHADIAZINE 0.13 0.0002 0.17 0.0003 33.88

616. 29350004 *SULPHADIMIDINE 0.43 0.0008 0.19 0.0003 -56.14

617. 29350007 *SULPHAMETHIAZOLE 0.08 0.0001 0.16 0.0003 103.14

618. 29350008 *SULPHAMOXOLE 0.02 0.0000

619. 29350011 SULPHAMETHOXAZOLE 0.29 0.0006 0.29 0.0005 -1.02

620. 29350012 SULPHAFURAZOLE 1.85 0.0036 1.41 0.0023 -23.79

621. 29350013 SULPHADIAZINE 0.08 0.0001

622. 29350019 *OTHER SULPHONAMIDES 1.41 0.0027 1.50 0.0024 6.63


624. 29362100 VITAMINS A AND THEIR DERIVATIVES 1.23 0.0024 0.73 0.0012 -40.87

625. 29362200 *VITAMINS B1(THIAMINE/ANEURIN) & ITS DRVTVS 0.95 0.0019 2.20 0.0036 130.58

626. 29362300 *VITAMINS B2(RIBOFLAVIN)& ITS DRVTVS 0.74 0.0014 1.88 0.0031 154.75


2.83 0.0055 2.06 0.0034 -27.13

628. 29362500 VITAMIN B6 & ITS DRVTS 1.46 0.0028 2.01 0.0033 37.46

629. 29362600 *VITAMIN B12(CYANOCOBALANIM) & ITS DRVTVS 0.96 0.0019 0.22 0.0004 -77.03


631. 29362800 VITAMIN E AND ITS DERIVATIVES 2.95 0.0057 2.61 0.0043 -11.37

632. 29362902 *FOLIC ACID 0.23 0.0004 0.31 0.0005 33.97

633. 29362903 *NCTNC ACID & NCTNMD(NIACINAMIDE/NIACINE 0.02 0.0000 0.03 0.0000 37.45

634. 29362909 *OTHER VITAMIN B COMPLEX 0.11 0.0002 0.04 0.0001 -65.79

635. 29362912 *VITAMIN K (MENAPHTHONUM B.P.) 0.01 0.0000 0.00 0.0000 -50.62

636. 29362913 *VITAMIN D 0.11 0.0002 0.20 0.0003 82.40

637. 29362914 *VITAMIN H (BI0LIN) 0.92 0.0018 0.45 0.0007 -50.58

638. 29362916 *GEMFIBROZIL 0.07 0.0001

639. 29362919 *OTHERS 1.62 0.0032 1.97 0.0032 21.42


641. 29371001 *OXYTOCIN 0.33 0.0006 0.41 0.0007 23.15

642. 29371002 *HORMONES OF THE PITUITARY GLAND N.E.S. 0.17 0.0003 0.51 0.0008 199.88

643. 29372101 *CORTISONE 1.45 0.0028 0.66 0.0011 -54.55

644. 29372102 *HYDROCORTISONE ITS SALTS AND DERIVATIVES 1.38 0.0027 2.67 0.0044 93.16

645. 29372103 *PREDNISONE(DEHYDRO CORTISONE) 0.32 0.0006 0.12 0.0002 -64.11

646. 29372104 *PREDNISOLONE(DEHYDROHYDRO CORTISONE) 1.59 0.0031 1.52 0.0025 -4.95

647. 29372200 HALGNTD DRVTVS OF CORTI COSTEROIDAL 1.00 0.0019 3.22 0.0052 223.26

648. 29372901 *EPINEPHRINE (ADRENALINE) AND SALTS 0.66 0.0013 1.44 0.0023 117.67

649. 29372909 *OTHERS 0.78 0.0015 3.67 0.0060 371.74

650. 29379102 *INSULIN REFERENCE STANDARD 3.14 0.0061 5.27 0.0086 67.63


- 254 -

651. 29379103 *INSULIN (HUMAN) 0.35 0.0007 2.77 0.0045 700.10

652. 29379104 *INSULIN (BOVINE OR PORK) 0.46 0.0009 2.62 0.0043 475.31

653. 29379109 *OTHER INSULIN AND ITS SALTS 8.23 0.0160 10.46 0.0170 27.04

654. 29379201 *ESTRADIOL ITS SALTS AND DERIVATIVES ETC 1.21 0.0024 0.58 0.0009 -51.83

655. 29379202 *PROGESTERONE (LUTESTORONE) 2.12 0.0041 2.44 0.0040 15.14

656. 29379203 *ESTROGENS N.E.S. 0.57 0.0011 0.32 0.0005 -43.01

657. 29379204 *ETHISTERONE & ITS DERIVATIVES (DANAZOL) 2.13 0.0041 2.82 0.0046 32.78

658. 29379901 *METHYL TESTOSTERONE 1.64 0.0032 0.55 0.0009 -66.59

659. 29379902 *TESTOSTERONE PROPIONATE 0.08 0.0001

660. 29379903 *DEXAMETHASONE 0.54 0.0010 0.88 0.0014 64.24

661. 29379904 *BETAMETHASONE 2.56 0.0050 2.77 0.0045 8.31

662. 29379906 *OXYMETHOLONE 0.06 0.0001

663. 29379908 *STANOZOLO 0.00 0.0000

664. 29379912 *HYDROCORTISONE SODIUM SUCCINATE 0.03 0.0001

665. 29379913 *METHYL PREDNISOLONE ACCTALE 0.04 0.0001 0.13 0.0002 272.14

666. 29379914 *TRIAMCINOLORE ACCTONIDE 0.03 0.0001

667. 29379915 *BECLOMETHASONE DIPROP./SALTS 0.85 0.0017 0.42 0.0007 -51.23

668. 29379923 *FLUCORTOLONE 0.03 0.0000

669. 29379926 *HYDROXY PROGESTERONE CAPROATE ETC, 0.16 0.0003 0.39 0.0006 141.36

670. 29379927 *LEVONORGESTEROC 0.14 0.0003 0.24 0.0004 68.35

671. 29379928 *MEDROXYPROGESTERONE ACETATE. 0.29 0.0006

672. 29379934 *GLICLAZIDE 0.14 0.0003 0.06 0.0001 -58.74

673. 29379936 *PHENFORMIN 0.04 0.0001

674. 29379941 *ASPARTAME 0.41 0.0008 0.47 0.0008 15.73

675. 29379945 *BROMOCRYPTINE 0.05 0.0001

676. 29379948 *ALLYLESTRENOL 0.05 0.0001

677. 29379951 *ANDROSTERON 0.17 0.0003

678. 29379954 *NORETHISTERONE 0.25 0.0005 0.22 0.0004 -12.08

679. 29379969 *OTHERS 13.81 0.0269 10.02 0.0163 -27.44

680. 29381001 *VITAMIN P 0.02 0.0000 0.03 0.0001 50.87

681. 29381009 *OTHR RUTOSIDE (RUTIN) AND ITS DRVTVS 0.20 0.0004 0.15 0.0002 -25.10

682. 29389001 *DIGOXIN 0.24 0.0005 0.12 0.0002 -51.83

683. 29389002 *GLYCSDS OF DGTLS NES (DEGITALIN DIGITOXIN) 0.00 0.0000

684. 29389009 *OTHRS 1.41 0.0028 1.00 0.0016 -29.52

685. 29391001 *PAPAVERINE THEIR SALTS AND DERIVATIVES 0.03 0.0001 0.05 0.0001 34.61

686. 29391002 *N0SCAPINE ( NARC0TINE ) & THEIR DERIVATIV 0.34 0.0007 0.22 0.0004 -33.15

687. 29391009 *OTHR ALKLDS OF OPIUM AND THR DRVTVS AND SALTS THEREOF 0.86 0.0017 0.78 0.0013 -9.81

688. 29392101 *QUININE ALKALOIDS 0.07 0.0001 0.41 0.0007 512.63

689. 29392102 *QUININE HYDROCHLORIDE 0.08 0.0002 0.21 0.0003 151.76

690. 29392103 *QUININE SULPHATE 0.46 0.0009 0.87 0.0014 88.22

691. 29392104 *CHL0R0QUINE PH0SPHATE 0.85 0.0017 0.90 0.0015 5.06

692. 29392109 *SALTS AND OTHR DRVTVS OF QUININE NES 0.36 0.0007 1.37 0.0022 276.08

693. 29392900 OTHR ALKLDS OF CINCHONA & THR DRVTVS AND SLTS THEREOF 0.55 0.0011 0.16 0.0003 -69.94

694. 29393000 CAFFEINE AND ITS SALTS 0.08 0.0002 0.30 0.0005 260.15

695. 29394101 *EPHEDRINE ALKALOIDS 0.12 0.0002

696. 29394109 *OTHER EPHEDRINE & ITS SALTS 0.00 0.0000

697. 29394200 PSEUDO EPHEDRINE (INN) AND ITS SALTS 0.29 0.0005


- 255 -

698. 29394909 *OTHERS 3.21 0.0062 1.69 0.0028 -47.29


0.09 0.0002 0.39 0.0006 334.75

700. 29396101 *ERGOMETRINE 0.31 0.0006 0.09 0.0001 -70.35

701. 29396102 *METHYL ERRGOMETRINE 0.03 0.0001 0.02 0.0000 -18.02

702. 29396109 *OTHER 0.08 0.0002 0.01 0.0000 -82.82

703. 29396201 *ERGOTAMINE TARTARATE 0.05 0.0001 0.10 0.0002 102.10

704. 29396209 *OTHER 0.02 0.0000 0.00 0.0000 -91.49

705. 29396900 OTHER ALKALOIDS OF RYE ERGOT & DRVTVS 0.89 0.0017 0.61 0.0010 -31.58

706. 29397001 *NICOTINE ALKALOIDS 0.02 0.0000 0.00 0.0000 -98.11

707. 29397002 *NICOTINE SULPHATE 0.02 0.0000

708. 29397009 *SALTS AND DERIVATIVES OF NICOTINE 0.03 0.0001 0.08 0.0001 196.25

709. 29399001 *ATROPINE SULPHATE 0.25 0.0005 0.07 0.0001 -69.86

710. 29399002 *BERBERINE HYDROCHLORIDE 0.00 0.0000

711. 29399015 *BROMOHEXIN & ITS DRVTV (VASAK ALKALOID) 0.01 0.0000

712. 29399018 *PILOCARPINE 0.08 0.0002

713. 29399029 *OTHERS 0.86 0.0017 1.22 0.0020 41.14

714. 29400001 *DEXTROSE 0.15 0.0003 0.46 0.0008 212.08

715. 29400009 *OTHERS 0.47 0.0009 0.85 0.0014 81.01

716. 29411002 *AMPICILLINE & ITS SALTS 1.00 0.0019 4.82 0.0079 383.06

717. 29411003 *AMOXYCILLINE & ITS SALTS 1.89 0.0037 2.68 0.0044 41.59

718. 29411004 *CLOXACILLINE & ITS SALTS 0.14 0.0003 0.01 0.0000 -89.52

719. 29411005 *PENICILLINE 2.90 0.0056 23.36 0.0380 705.58

720. 29411006 *PENICILLIN PROCAINE !G! 0.09 0.0002 7.15 0.0116 8,308.82

721. 29411007 *PENICILLIN !G! POTASSIUM 70.19 0.1365 92.89 0.1513 32.35

722. 29411008 *PENICILLIN !G!SODIUM 5.53 0.0108 2.79 0.0046 -49.47

723. 29411011 *PENICILLIN V-POTASSIUM 4.26 0.0083 6.96 0.0113 63.29

724. 29411012 *BECAMPICILLIN & ITS SALTS 0.06 0.0001

725. 29411013 *PIPERACILLIN 0.05 0.0001 0.01 0.0000 -80.04

726. 29411014 *BENZATHIN PEN G. 0.05 0.0001

727. 29411016 *FLUCLOXACILLIN 0.00 0.0000

728. 29411017 *CARBENICILLIN 0.00 0.0000 0.00 0.0000 -25.96

729. 29411018 *OXACILLIN 0.02 0.0000 0.02 0.0000 -21.48

730. 29411021 *GRISEOFULVIN 0.89 0.0017 0.12 0.0002 -86.90

731. 29411022 *TOLNAFLATE 0.00 0.0000

732. 29411029 *OTHERS 6.52 0.0127 8.58 0.0140 31.61

733. 29412000 *STREPTOMYCINS & THR DRVTVS SLTS THEREOF 2.36 0.0046 2.44 0.0040 3.33

734. 29413001 *DOXYCYLIME & ITS SALTS 2.56 0.0050 3.96 0.0064 54.28

735. 29413002 *TETRACYCLINE &ITS SALTS 1.59 0.0031 2.88 0.0047 80.81

736. 29413003 *OXYTETRACYCLINE & ITS SALTS 0.16 0.0003 0.49 0.0008 198.39

737. 29413004 *MINOCYCLINE & ITS SALTS 0.07 0.0001

738. 29413009 *OTHER DERIVATIVES OF TETRACYCLINE AND SALTS THEREOF 0.55 0.0011 0.84 0.0014 51.50

739. 29414000 CHLORAMPHENICOL & ITS DRVTVS SLTS THEREOF 4.01 0.0078 3.39 0.0055 -15.49

740. 29415001 *ERYTHROMYCIN AND ITS SALTS 21.25 0.0413 33.72 0.0549 58.73

741. 29415003 *AZITHROMYCIN AND ITS SALTS 0.12 0.0002 0.05 0.0001 -63.44

742. 29415004 *CLARITHROMYCIN 0.13 0.0003 0.05 0.0001 -63.47

743. 29415009 *OTHERS 0.28 0.0005 2.98 0.0049 977.78


- 256 -

744. 29419001 *RIFAMPICIN & ITS SALTS 13.22 0.0257 23.86 0.0389 80.48

745. 29419002 *CEPHALEXIN & ITS SALTS 0.45 0.0009 0.24 0.0004 -46.86

746. 29419003 *CIPROFLOXACINE & ITS SALTS 0.59 0.0012 0.39 0.0006 -34.32

747. 29419004 *GENTAMYCIN & ITS SALTS 2.92 0.0057 1.38 0.0022 -52.85

748. 29419005 *NEOMYCIN 0.36 0.0007 0.20 0.0003 -45.07

749. 29419006 *CEFAZOLIN AND ITS SALTS 0.25 0.0005 0.19 0.0003 -23.04

750. 29419007 *CEFUROXIME AND ITS SALTS 4.96 0.0096 5.63 0.0092 13.49

751. 29419011 RIFAMPICIN 1.03 0.0020 0.53 0.0009 -47.90

752. 29419012 3 FORMYL RIFA S V (RIFA INT) 1.23 0.0024 1.06 0.0017 -13.35

753. 29419013 RIFA OR RIFA S SODIUM (RIFAINT) 0.08 0.0001 0.87 0.0014 1,060.46

754. 29419014 1 - AMINO -4 - METHYL PIPERAZINE (RIFAINT) 0.00 0.0000 0.06 0.0001 2,991.96

755. 29419015 *CEFIXIME AND ITS SALTS 0.25 0.0005 0.10 0.0002 -61.60


757. 29419018 *KANAMYCIN AND ITS SALTS 0.08 0.0002 0.10 0.0002 28.61

758. 29419021 *TOBRAMYCIN AND ITS SALTS 0.24 0.0005 0.17 0.0003 -29.60

759. 29419022 *SISOMYCIN 0.02 0.0000

760. 29419023 *NETILMYCIN AND ITS SALTS 0.02 0.0000

761. 29419024 *AMIKACIN AND ITS SALTS 0.59 0.0011 0.95 0.0015 60.79

762. 29419025 *NATAMYCIN AND ITS SALTS 0.03 0.0001 0.00 0.0000 -96.49

763. 29419026 *POLYMIXIN B AND ITS SALTS 0.20 0.0004 0.32 0.0005 61.54

764. 29419028 *VANCOMYCIN AND ITS SALTS 0.15 0.0003 0.06 0.0001 -61.37

765. 29419031 *FRAMYCETIN AND ITS SALTS 1.40 0.0027 0.16 0.0003 -88.84

766. 29419032 *BLEOMYCIN 0.04 0.0001

767. 29419033 *DOXORUBICIN 0.07 0.0001 0.09 0.0001 25.29

768. 29419034 *FLUXETINE 0.01 0.0000

769. 29419039 *OTHERS 26.47 0.0515 25.41 0.0414 -4.01

770. 29420001 *NORFLOXACIN & ITS SALTS 50.17 0.0976 90.79 0.1478 80.97

771. 29420002 *CEFADROXIL & ITS SALTS 0.45 0.0009 0.98 0.0016 115.99

772. 29420003 *IBUPROFANE 0.09 0.0002 0.09 0.0001 1.44

773. 29420004 *DIAZEPAM 0.21 0.0004 0.08 0.0001 -62.43

774. 29420005 *NIFEDIPINE 0.00 0.0000 0.00 0.0000 -8.70

775. 29420006 *RANITIDINE 0.12 0.0002 0.06 0.0001 -47.89

776. 29420007 *DANES SALT OF D (-) PHENYL GLYCINE 10.98 0.0214 4.74 0.0077 -56.87

777. 29420008 *D(-) PARA HYDROXY DANE'S SALTS 8.59 0.0167 5.09 0.0083 -40.73

778. 29420011 CEFADROXIL 0.00 0.0000 3.80 0.0062 112,396.80

779. 29420012 IBUPROFANE 0.00 0.0000

780. 29420013 NIFEDIPINE 1.57 0.0031 4.35 0.0071 176.97

781. 29420014 RANITIDINE 0.01 0.0000

782. 29420015 DANES SALT OF D (-) PHENYL GLYCINE 0.03 0.0000

783. 29420016 D(-) PARA HYDROXY DANE'S SALTS 0.10 0.0002

784. 29420017 *CYSTEANUNE HCL 1.56 0.0030 1.10 0.0018 -29.63

785. 29420021 TIMOLOL MALEATE 0.26 0.0005 0.23 0.0004 -13.36

786. 29420022 TERBUTOLINE SULPHATE 0.48 0.0009 0.23 0.0004 -51.25

787. 29420023 D(-) PHENYL GLYCIN CHLORIDE HCL (DPGCH) 0.34 0.0006

788. 29420024 IMIPRAMINE HCL 0.00 0.0000 0.00 0.0000 1,605.44

789. 29420026 CYSTEANUNE HCL 3.43 0.0067 5.16 0.0084 50.47

790. 29420027 ATENOLOL, PROPRONALOL 0.01 0.0000


- 257 -


791. 29420028 *ACYCLOVIR 0.33 0.0006 0.17 0.0003 -46.74

792. 29420031 DILOXANIDE FUROATE 1.10 0.0021 0.11 0.0002 -90.15

793. 29420032 CIMETIDINE 0.01 0.0000 0.01 0.0000 -1.23

794. 29420033 OXYCLOZANIDE 0.01 0.0000

795. 29420035 *ACETAZOLAMIDE 0.01 0.0000 0.07 0.0001 1,130.50

796. 29420036 *BETAXOLOL 0.03 0.0000

797. 29420046 *CAPTOPRIL 0.00 0.0000

798. 29420047 *CHLOROROMAZINE 0.01 0.0000 0.07 0.0001 451.37

799. 29420051 *CYCLOSPORIN 0.62 0.0012 0.23 0.0004 -63.62

800. 29420054 *DICLOFENAC SALTS 0.05 0.0001

801. 29420057 *5-FLUROURACIL 0.01 0.0000

802. 29420058 *FELODIPINE 0.03 0.0001

803. 29420066 *LISINOPRIL 0.00 0.0000

804. 29420073 *TRIPROLIDINE 0.08 0.0001

805. 29420079 *OTHERS 129.15 0.2512 182.20 0.2967 41.08

India's Total Import 51,413.29 61,412.13 19.45


- 258 -


Export: Commodity-wise all countries


Commodity: 30 PHARMACEUTICAL PRODUCTS Unit: S.No. Country Values in US$ Million Quntity in thousands

2001-2002 2002-2003 %Growth 2001-2002 2002-2003 %Growth

1. U S A 135.34 249.94 84.67

2. RUSSIA 92.36 98.95 7.14

3. NIGERIA 73.49 71.07 -3.29

4. U K 29.39 51.73 75.99

5. GERMAN F REP 36.79 44.92 22.10

6. BRAZIL 36.58 41.33 12.98

7. SRI LANKA 28.31 40.29 42.33

8. CHINA P RP 21.65 35.58 64.38

9. VIETNAM SOC REP 33.66 35.27 4.77

10. NEPAL 30.29 32.42 7.05

11. NETHERLAND 20.99 30.37 44.66

12. UKRAINE 22.20 29.67 33.65

13. MEXICO 9.51 22.50 136.48

14. CONGO P REP 10.57 18.80 77.83

15. SOUTH AFRICA 13.82 18.05 30.53

16. KENYA 18.92 17.73 -6.30

17. GUINEA 11.58 17.68 52.69

18. HONG KONG 24.99 15.71 -37.13

19. SINGAPORE 12.37 15.00 21.27

20. U ARAB EMTS 15.80 14.63 -7.38

21. PHILIPPINES 8.54 14.46 69.32

22. BENIN 7.67 14.36 87.10

23. UGANDA 10.39 13.83 33.14

24. GHANA 10.65 13.78 29.35

25. BANGLADESH 11.59 13.06 12.64

26. MAYANMAR 10.12 12.42 22.71

27. TURKEY 7.27 11.54 58.71

28. FRANCE 9.42 10.81 14.79

29. IRAN 10.71 10.39 -3.01

30. MALAYSIA 6.77 9.93 46.77

31. ITALY 4.88 9.85 102.06

32. IRELAND 7.53 8.45 12.29

33. THAILAND 10.34 8.27 -20.04

34. KOREA RP 8.02 8.14 1.45

35. TANZANIA REP 6.58 8.13 23.58


- 259 -

36. NIGER 3.88 8.13 109.32

37. CANADA 7.55 8.12 7.51

38. BELGIUM 6.46 8.10 25.32

39. YEMEN REPUBLC 8.47 8.08 -4.60

40. FINLAND 1.82 7.93 336.69

41. POLAND 4.96 7.89 58.95

42. CAMEROON 4.48 7.68 71.65

43. CAMBODIA 5.53 7.55 36.60

44. AUSTRALIA 8.66 7.25 -16.22

45. MOZAMBIQUE 2.47 7.17 190.40

46. DENMARK 6.55 6.93 5.79

47. SPAIN 7.41 6.86 -7.44

48. SUDAN 4.95 6.51 31.49

49. KAZAKHSTAN 1.94 6.46 232.99

50. ETHIOPIA 6.15 6.42 4.25

51. UNSPECIFIED 0.84 6.22 641.10

52. ANGOLA 4.15 6.21 49.61

53. JAPAN 5.15 6.20 20.44

54. HAITI 3.06 5.88 92.18

55. MAURITIOUS 3.77 5.49 45.83

56. PAKISTAN 4.87 5.22 7.08

57. ZIMBABWE 2.91 5.09 75.03

58. CHINESE TAIPEI 4.43 5.02 13.25

59. JORDAN 4.13 4.96 20.12

60. SAUDI ARAB 3.22 4.90 52.27

61. ZAMBIA 3.34 4.78 43.24

62. EGYPT A RP 5.74 4.73 -17.68

63. PERU 4.02 4.72 17.46

64. ISRAEL 1.94 4.55 134.88

65. SWITZERLAND 6.54 4.53 -30.74

66. HONDURAS 2.00 4.39 119.30

67. COLOMBIA 2.52 4.37 73.52

68. AFGHANISTAN 1.13 4.20 272.86

69. IRAQ 2.61 4.04 54.81

70. NEW ZEALAND 3.91 4.02 2.70


- 260 -

71. VENEZUELA 3.38 3.63 7.32

72. KOREA DP RP 0.80 3.60 351.04

73. SYRIA 3.19 3.57 12.10

74. ALGERIA 2.55 3.47 36.19

75. CHILE 4.00 3.38 -15.40

76. DOMINIC REP 2.07 3.37 62.27

77. TRINIDAD 2.00 3.19 59.62

78. MALI 1.40 2.91 106.95

79. ARGENTINA 5.45 2.59 -52.53

80. MALAWI 2.05 2.57 25.56

81. GUINEA BISU 1.38 2.35 70.30

82. SOMALIA 0.97 2.25 131.41

83. SENEGAL 1.57 2.21 41.07

84. BURKINA FASO 0.97 2.20 127.80

85. INDONESIA 1.35 2.18 61.23

86. COSTA RICA 1.55 2.14 38.15

87. IVORY COAST 1.78 2.10 18.00

88. MOLDVIA 0.94 2.10 123.79

89. CYPRUS 2.68 2.08 -22.18

90. URUGUAY 4.85 2.07 -57.27

91. CZECH REPUBLIC 1.99 2.06 3.61

92. GREECE 0.35 2.05 493.11

93. PAPUA N GNA 1.39 2.05 47.05

94. OMAN 2.01 2.03 0.96

95. FIJI IS 0.51 2.02 296.28

96. ROMANIA 1.27 2.02 59.26

97. HUNGARY 3.00 2.01 -32.84

98. MALDIVES 1.79 1.96 9.02

99. BELARUS 0.66 1.91 187.29

100. SIERRA LEONE 1.99 1.91 -4.43

101. MALTA 0.51 1.78 248.41

102. MALAGASY RP 1.40 1.78 26.78

103. UZBEKISTAN 1.21 1.76 46.11

104. BURUNDI 0.64 1.76 172.30

105. GUATEMALA 3.44 1.73 -49.56

106. MOROCCO 1.13 1.70 50.34

107. SLOVENIA 0.39 1.69 336.26

108. PORTUGAL 0.96 1.65 71.69

109. GUYANA 0.47 1.63 244.63

110. LITHUANIA 0.65 1.51 132.65

111. JAMAICA 1.07 1.33 24.51

112. TURKMENISTAN 1.26 1.32 5.26


- 261 -

113. DJIBOUTI 0.55 1.31 139.16

114. AUSTRIA 0.52 1.23 135.73

115. LIBERIA 1.11 1.20 8.70

116. AZERBAIJAN 0.41 1.19 189.03

117. ALBANIA 0.85 1.08 27.62

118. RWANDA 0.94 1.04 10.77

119. NETHERLANDANTIL 0.60 0.97 61.01

120. BOLIVIA 0.39 0.94 142.26

121. TAJIKISTAN 0.36 0.89 150.04

122. QATAR 0.32 0.84 160.77

123. LATVIA 0.71 0.72 1.80

124. SLOVAK REP 0.67 0.71 6.15

125. PANAMA REPUBLIC 1.09 0.70 -35.78

126. MACAO 0.22 0.70 211.40

127. YUGOSLAVIA F RP 0.51 0.69 35.06

128. ZAIRE REP 1.21 0.67 -44.47

129. CHAD 0.19 0.64 234.63

130. GEORGIA 0.49 0.63 28.06

131. BAHARAIN IS 0.97 0.59 -38.60

132. BOSNIA-HRZGOVIN 0.00 0.57 12,782.78

133. NAMIBIA 0.28 0.53 88.69

134. GAMBIA 0.35 0.48 38.16

135. TOGO 0.47 0.48 0.70

136. ECUADOR 0.33 0.45 37.68

137. REUNION 0.13 0.45 256.83

138. PANAMA C Z 0.21 0.43 110.21

139. DOMINICA 0.59 0.42 -29.00

140. KUWAIT 0.28 0.35 24.27

141. MAURITANIA 0.07 0.32 357.41

142. TUNISIA 0.54 0.29 -45.82

143. LAO PD RP 0.19 0.27 40.20

144. TURKS C IS 0.10 0.27 158.53

145. PARAGUAY 0.17 0.26 56.10

146. LEBANON 0.05 0.26 368.79

147. BULGARIA 0.21 0.26 21.55

148. SEYCHELLES 0.16 0.24 48.45

149. BAHAMAS 0.09 0.23 152.20

150. ICELAND 0.27 0.21 -21.69

151. WEST SAMOA 0.24 0.21 -12.57

152. MACEOERNIA 0.09 0.21 130.47

153. BRUNEI 0.00 0.18 19,275.41

154. PUERTO RICO 0.02 0.17 997.21

155. ARMENIA 0.11 0.17 50.55


- 262 -

156. GABON 0.28 0.16 -41.74

157. ANTIGUA 0.00 0.16 9,698.80

158. LIECHTENSTEIN 0.21 0.15 -29.53

159. GUAM 0.15 0.15 -2.25

160. EL SALVADOR 0.27 0.14 -47.74

161. FR GUIANA 0.10 0.14 37.11

162. SWEDEN 0.29 0.14 -52.73

163. KYRGHYZSTAN 0.55 0.12 -77.39

164. NICARAGUA 0.86 0.11 -86.78

165. KIRIBATI REP 0.04 0.11 175.89

166. BOTSWANA 0.11 0.10 -4.25

167. TONGA 0.10 0.09 -8.59

168. LUXEMBOURG 0.09

169. NORWAY 0.05 0.09 84.73

170. CUBA 0.43 0.09 -78.42

171. MONGOLIA 0.10 0.09 -13.03

172. SOLOMON IS 0.02 0.09 306.75

173. C AFRI REP 0.02 0.08 273.90

174. VIRGIN IS US 0.30 0.08 -73.32

175. CROATIA 0.04 0.08 114.41

176. VANUATU REP 0.01 0.07 518.94

177. ST LUCIA 0.04 0.06 48.01

178. ESTONIA 0.13 0.06 -52.41

179. ANDORRA 0.06

180. COMOROS 0.03 0.06 74.13

181. SURINAM 0.01 0.06 335.92

182. COCOS IS 0.11 0.05 -60.50

183. LIBYA 0.26 0.05 -82.86

184. SWAZILAND 0.05 0.04 -17.53

185. BARBADOS 0.03 0.04 33.72

186. MARSHALL ISLAND 0.03

187. LESOTHO 0.06 0.03 -52.51

188. CAYMAN IS 0.02 0.03 50.75

189. EQUTL GUINEA 0.06 0.03 -56.82

190. BELIZE 0.00 0.02 2,709.54

191. PITCAIRAN IS 0.01

192. FR POLYNESIA 0.01

193. BHUTAN 0.01

194. MONTSERRAT 0.02 0.01 -36.21

195. ST HELENA 0.01

196. ST KITT N A 0.01

197. WALLIS F IS 0.01 0.01 -40.98

198. MARTINIQUE 0.00 0.00 16.23


- 263 -

199. GRENADA 0.00

200. AMERI SAMOA 0.03 0.00 -97.42

201. CAPE VERDE IS 0.00 0.00 -81.07

202. GUADELOUPE 0.00 0.00 -88.10

203. ST VINCENT 0.00 0.00 -56.66

204. TOKELAU IS 0.00

205. SAO TOME 0.00

206. COOK IS 0.00

207. CANARY IS 0.00

208. BERMUDA 0.01

209. SAHARWI A.DM RP 0.16

210. NAURU RP 0.01


Documents

SOUTH-SOUTH TRADE PROMOTION PROGRAMME …s3.amazonaws.com/zanran_storage/ · SOUTH-SOUTH TRADE PROMOTION PROGRAMME INDIA ... presented in a report according to the broad outline given